Contents

1 About the institute
3 Director's and Chairman's report
5 Discovery
  8 Cancer and Haematology
  12 ACRF Stem Cells and Cancer
  16 Molecular Genetics of Cancer
  20 ACRF Chemical Biology
  24 Molecular Medicine
  28 Structural Biology
  32 Bioinformatics
  36 Infection and Immunity
  40 Immunology
  44 Cell Signalling and Cell Death
  48 Inflammation
  52 Molecular Immunology
  56 Systems Biology and Personalised Medicine
  59 Publications
  74 Awards

75 Translation
  76 Translating our research
  78 Developing our research
  80 Patents granted in 2011-2012

81 Education
  84 2011-12 graduates
  85 2011-12 PhD in progress
  88 Bachelor of Science (Honours) in progress
  89 2011-12 vacation scholars
  90 Seminars
  91 2011-12 institute speakers
  93 2011-12 visiting speakers
  96 2012 postgraduate lecture series
  98 Institute awards

99 Engagement
  101 Strategic partners
  102 Scientific and medical community
  104 Public engagement
  107 Donor and bequestor engagement
  109 Service to the scientific and wider community

118 Sustainability
  119 The Board
  123 Chief Operating Officer's report
  126 Supporters and donors
  131 Institute organisation
  132 Members of the institute
  133 Staff list
  136 Committees
  140 The year at a glance
  141 Financial statements
  168 Statistical summary
  169 Capital Funds
Acknowledgements

Produced by the institute’s Community Relations department
Managing editor: Penny Fannin
Editor: Liz Williams
Writers: Liz Williams and Vanessa Solomon
Design and production: Simon Taplin
Photography: Czesia Markiewicz and Cameron Wells

Cover image

A still taken from the WEHI.TV animation

X Inactivation and Epigenetics
www.wehi.edu.au/x_inactivation_and_epigenetics

Etsuko Uno and Drew Berry, WEHI.TV

X inactivation is a vital process that occurs in all DNA-containing cells of the female body. It is also an important research model and tool for studying epigenetics. Epigenetics refers to processes that tell our cells how, and when, to read the DNA blueprint. The epigenetic regulation of DNA is critical in both normal development and disease.
**About the institute**

**Our mission**
Mastery of disease through discovery

**Our vision**
To be an innovative medical research institute that engages and enriches society and improves health outcomes through discovery, translation and education

**Research themes**
Cancer
Chronic inflammatory disease
Infectious disease

**Key objectives**

**Discovery:** to make discoveries in medical biology that shape contemporary thinking and paradigms and enhance the understanding and treatment of disease

**Translation:** to convert our discoveries into improvements in disease diagnosis, prevention and treatment

**Education:** to develop and enrich the skills and experience of students and staff, allowing each person to realise their potential and contribute to a vibrant campus

**Engagement:** to engage with the community and develop support for medical research generally and the institute’s mission specifically

**Sustainability:** to build an infrastructure, funding and research capacity that enables the institute to fulfil its mission in a sustainable manner

An exterior view of the redeveloped Parkville campus.
The Walter and Eliza Hall Institute is home to more than 650 researchers who are working to understand, prevent and treat diseases including cancer, particularly blood, breast, lung, ovarian and colon cancers; chronic inflammatory diseases such as type 1 diabetes, rheumatoid arthritis and coeliac disease; and infectious diseases such as HIV and malaria.

We are committed to making fundamental discoveries about the way cells, particularly cancer and blood cells, behave and communicate and seeing these discoveries translated into benefits for patients.

The institute was founded in 1915 as a benevolence of the Walter and Eliza Hall Trust to be ‘the birthplace of discoveries rendering signal service to mankind in the prevention and removal of disease and the mitigation of suffering’.

We are affiliated with The University of Melbourne and The Royal Melbourne Hospital and offer postgraduate training as the Department of Medical Biology of The University of Melbourne.

Clinician-scientist Dr Kylie Mason, laboratory head Professor Don Metcalf, senior postdoctoral scientist Dr Catherine Carmichael and PhD student Mr Michael White (from left to right) from the institute’s Cancer and Haematology division are studying blood cells and their production, and what goes awry in the development of blood cancers such as leukaemias and lymphomas.
The past 12 months have been a landmark for the Walter and Eliza Hall Institute. We have completed a $185 million building project, which has seen construction of a new west wing and a complete renovation of the east wing of the institute.

The result is a doubling of our laboratory space and an integrated, state-of-the-art biomedical research facility that will continue to be a magnet for talented scientists who will make extraordinary discoveries.

Funding a project of this scale and completing it on time and under budget is a feat that took vision, professionalism and discipline.

▶ The vision of the Australian and Victorian Governments, Mr Chuck Feeney and The Atlantic Philanthropies, The Ian Potter Foundation, Australian Cancer Research Foundation and Drakensburg Trust who all contributed generously to funding the capital works.
▶ The professionalism of all those involved in design and construction at Denton Corker Marshall, S2F/SKM, Baulderstone and Aurecon.
▶ The discipline of our own management team, especially Mike Fitzpatrick and Tony Murphy who provided sage leadership of our new building sub-committee that has had oversight of the project for the board, as well as Maureen O’Keefe, Steve Droste and their teams in the institute who have managed the program day-to-day.

At this time, we should remember that the new building is not a fortress or an island, rather it is a magnificent base with which to interact with our partners in the Parkville precinct, and the wider community.

The institute could not be better positioned to perform world-class medical research. We are situated within a short distance of four major hospitals: The Royal Melbourne Hospital, Royal Women’s Hospital, Royal Children’s Hospital and Peter MacCallum Cancer Centre (which will soon relocate to the Victorian Comprehensive Cancer Centre building being erected on the...
old dental hospital site on Grattan Street). Each of these hospitals is a centre of excellence in patient care, research and education, and each is a highly valued partner as we work to translate the discoveries we make in the laboratory to improvements in disease prevention, diagnosis and treatment that benefit our community.

We are also situated opposite the world-class University of Melbourne, and have the privilege of being the Medical Biology department of the university while maintaining independent governance and management. This relationship allows intimate collaboration with colleagues in a range of departments and allows The University of Melbourne students, who are among the brightest young minds in Melbourne, to participate in the institute’s research as Undergraduate Research Opportunities Program (UROP) scholars, bachelor of science honours students and PhD students. We should remember that over the past 97 years, our students have made many of our standout discoveries.

Finally, with our building near the centre of Melbourne and at the crossroads of the city’s northern, eastern and western suburbs, we have been delighted to host an increasing number of discovery tours. At these tours members of the public get to know us and join the ever-growing institute family. To deliver the results that the investment in the new building merits, we need the community to be passionate advocates for medical research and to be passionate supporters of our own research effort. In our experiences, as president of the board and director of the institute, we could not ask for a more committed and engaged group of supporters. We thank you. The future is indeed rosy.

10 million and counting

Nearly 30 years ago, blood hormones called CSFs (colony stimulating factors) were discovered at the Walter and Eliza Hall Institute by a research team led by Professor Don Metcalf.

CSFs help to boost the numbers of infection-fighting white blood cells in the body, and are now commonly used to help cancer patients recover from the side-effects of chemotherapy. CSFs have also revolutionised stem cell donation and transplantation, being used in the collection of stem cells for bone marrow transplants.

In May 2012, the institute began running a series of advertisements in Melbourne and Sydney newspapers to promote awareness of this Australian research achievement. Since the early clinical trials of CSFs in Melbourne in the late 1980s, more than 10 million cancer patients worldwide have been treated with, and helped by, CSFs.

The 10 million and counting campaign aims to make contact with people across Australia, and internationally, who have benefited from CSFs and celebrate the improvements in cancer care that have arisen from the discovery of CSFs.

In the past two decades, many people who have received CSFs have contacted the institute to acknowledge its role in the success of their cancer treatment. Each of these people has their own story of what surviving cancer has meant for them, which in many cases includes how their lives after cancer treatment have benefited others in the community.

Kris and Juanjuan von Habsburg said CSFs gave their daughter Kim the best chance of recovery after her cancer treatment. “Our daughter Kim has neuroblastoma, a type of cancer,” Kris said. “The doctors said intensive chemotherapy, amongst other treatments, was her best chance of recovery, but that the treatment would destroy her bone marrow. Kim was given CSFs to collect her stem cells, which were given back to her after chemo to help her bone marrow grow back.”

Despite not receiving CSFs himself, Roland Caple said they helped save his life. “My stem cell donor had CSFs so I could have a bone marrow transplant,” Roland said. “I have myelodysplastic syndrome, a disease that stops my bone marrow making healthy blood cells. On three occasions, I was told to expect the worst. In 2007, I had a bone marrow transplant from a donor in Germany, which my doctor said was my best hope of survival.”

These are just two of the CSF stories we hope to share during our centenary celebrations in 2015 so others can be as inspired and motivated by them as we are.
Dr Ashley Ng (left) and Dr Maria Kauppi from the institute’s Cancer and Haematology division are studying how the cells of the blood system develop, with the hope of finding new treatments for blood cancers such as leukaemia and lymphoma.
Discovery

To stay at the forefront of modern medical research the Walter and Eliza Hall Institute assembles teams of outstanding researchers and provides them with access to the tools, infrastructure and support they need for scientific discovery.

Medical research is a rapidly evolving field, and the institute has judiciously established new technologies and facilities that will help our researchers solve important, and often complex, biological questions.

In the past year, the institute’s Systems Biology and Personalised Medicine division has become well established. The division incorporates proteomics and genomics facilities and supports research from across the institute that requires the integration of large biological data sets.

Investing in new technologies has delivered benefits across the institute’s research divisions. The ACRF Chemical Biology division is developing new high-throughput screening systems for discovering drugs to treat disease, and researchers in the Structural Biology division have identified a new strategy to more efficiently deliver therapeutic peptides into cells.

New image analysis and statistical strategies have enabled researchers in the Immunology division to determine how antibody-producing B cells decide their fate during an immune response. The Bioinformatics division remains at the forefront of mathematical analyses of complex biological phenomena. Researchers in the division have developed new systems to aid identification of the causes of complex genetic diseases, as well as determining the genome sequence of Australian marsupials including the Tasmanian devil and the tammar wallaby. Meanwhile, the Molecular Medicine division’s exploration of the field of epigenetics has revealed molecules that are important for brain and heart development.
Understanding disease through new preclinical models

The institute is committed to ensuring its research is relevant to human health and that promising laboratory discoveries are rapidly translated to clinical studies.

Advancing basic research towards clinical outcomes often requires the use of preclinical models that accurately reflect the complex features of a disease. Often these models involve human tissues, or use genetically modified cells that closely mimic patient samples.

In the past year, researchers in the institute’s ACRF Stem Cells and Cancer division have established new preclinical models of breast, lung and ovarian cancers. These models can be used to test promising new treatments or identify disease features that will help in refining or developing new therapies.

Already they have been used by the breast cancer research team to identify a new gene required for cancer initiation (see page 11).

Researchers in the Cancer and Haematology division have developed new models of T cell leukaemia, while potential new anti-cancer agents that showed promise in preclinical testing have now entered clinical trials.

A newly developed preclinical model of malaria has enabled researchers in the Infection and Immunity division to discover a combination of medications that has the potential to improve the survival of patients with severe malaria (see page 23). Progress in developing new models for studying hepatitis B and other chronic viral infections has also been made in the Infection and Immunity division.

Manipulating the immune system to treat disease

In 1957 the institute’s third director, Sir Frank Macfarlane Burnet, recognised the importance of immunology research and switched much of the institute’s resources to focus on studying the immune system.

Fifty-five years later, immunology is still a major research focus at the institute. In the past year, our immunology researchers have made many contributions to explaining how the immune system functions, and how it can be manipulated to treat disease.

A new class of T cells crucial for long-term immunity were identified by researchers from the Molecular Immunology division (see page 31). Researchers in the Immunology and Structural Biology divisions have identified new ways to target antigens to important immune system sentinels called dendritic cells, potentially enhancing the initiation of immune responses (see page 19).

In the Inflammation and Cell Signalling and Cell Death divisions, researchers have made advances in understanding which molecules and cell types are important for causing inflammation. This research could be the first step towards therapeutic interventions that prevent chronic inflammatory conditions such as type 1 diabetes, rheumatoid arthritis and coeliac disease. Other research from the Inflammation division has found that preventing inflammatory cell migration into the eye can prevent or treat uveitis, an inflammatory condition that is a major cause of adult blindness.

Combating parasitic diseases

Malaria is a major health problem in developing countries, causing significant disease and disability. For more than 25 years, the institute has been working to prevent and develop treatments for malaria.

This year, researchers in the Infection and Immunity division discovered a gene that is important for the malaria parasite to invade red blood cells, and have conducted preclinical and clinical testing of new combinations of medicines that could prevent or treat malaria (see page 23).

In recent years, researchers have also begun to study other significant parasitic diseases including toxoplasmosis. Researchers from the Infection and Immunity division and Systems Biology and Personalised Medicine division are collaborating on studies to determine which proteins are important for the invasion of the Toxoplasma and malarial parasites into host cells. This research has the potential to uncover potential targets for medications that stop infection or transmission of these parasitic diseases (see page 33).
Cancer and Haematology

The Cancer and Haematology division studies blood cells and the molecules that control their life-preserving functions.

With colleagues in the Molecular Medicine and Inflammation divisions, and through clinical and industry links, we aim to discover the fundamental processes regulating blood cell production and function to help devise new strategies for fighting diseases of the blood, such as leukaemias and immune disorders.

Dr Jeff Babon, Professor Nick Nicola and colleagues have significantly advanced our understanding of how blood cells control their response to hormone signals. They found that specialised proteins regulate the immune response to ensure sufficient numbers of blood cells are produced while also preventing chronic inflammation and excess blood cell production that can lead to diseases such as leukaemia. Recent results have shown a new and unexpected biochemical basis for controlling these hormone responses via SOCS3 (suppressor of cytokine signalling-3), paving the way for new therapeutic strategies for fighting blood diseases.

Platelets are small blood cells responsible for blood clotting, produced in vast numbers by cells in the bone marrow called megakaryocytes. Platelet numbers are often deregulated in leukaemias and myeloproliferative diseases (blood disorders caused by excess production of blood cells in the bone marrow). Chemotherapy causes significant loss of platelets, which can lead to severe risk of haemorrhage and compromise cancer treatment.

Our longstanding interest in improving management of platelets in disease continues, with recent discoveries from the laboratories of Professor Don Metcalf, Professor Warren Alexander and Dr Samir Taoudi that better define the identity and function of platelet-producing cells. Dr Emma Josefsson and Dr Benjamin Kile have also made important new insights into platelet production, defining the important role of cell death regulators in these cells (see opposite page).

The division continues to expand its program in leukaemia research, with initiatives that apply genetic and genomics tools to discover the mutations driving disease, and how these changes accumulate and cooperate in leukaemia progression. Dr Matt McCormack has developed powerful model systems for T cell leukaemia, while Professor Andrew Roberts is leading clinical studies and making breakthroughs applying new drugs to leukaemia and lymphoma treatment (see page 39).
Scientists discover link between chemo and platelet drop

Chemotherapy treatment can have a number of unwanted side-effects, including serious bleeding complications due to a drop in the number of platelets; tiny cells responsible for blood clotting.

Dr Emma Josefsson, Dr Chloé James, Dr Marlyse Debrincat and Mr Michael White from the institute’s Cancer and Haematology division are studying the mechanics of platelet formation, in the hope of finding new strategies to prevent chemotherapy-induced platelet deficiencies.

Dr Josefsson led a study that showed how survival of platelet-forming megakaryocytes is controlled at the molecular level, answering in the process a decade-old question about the formation of platelets.

“We wanted to find out whether the Bcl-2 family of proteins was necessary for platelet production,” Dr Josefsson said. “The Bcl-2 family controls programmed cell death, and includes ‘pro-death’ proteins that instruct cells to die, and opposing ‘pro-survival’ factions that keep the cells alive.

“We not only found that pro-death proteins were not required for platelet formation, as was previously thought, but in fact pro-survival proteins were required to keep megakaryocytes alive to make platelets.”

She said this discovery explained why patients have fewer platelets after chemotherapy. “Chemotherapy appears to kill platelet-forming megakaryocytes by activating pro-death proteins that instruct the cells to die,” she said.

Two additional studies published this year by division scientists also supported the finding that programmed cell death is not required for platelet production.

Collaborating organisations:
Australian Centre for Blood Diseases, Centre de Référence des Pathologies Plaquettaires, Peter MacCallum Cancer Centre, South Australian Pathology, The University of Melbourne, University of Adelaide.


Dr Emma Josefsson

Equipping blood cancer researchers
Leukaemia, lymphoma and myeloma are cancers that arise in blood cells. Blood cancers are responsible for more than 10 per cent of all cancers in Australia.

For the past 40 years, researchers from the Cancer and Haematology division have been studying how blood disorders, including blood cancers, are caused, and searching for new treatments for these often fatal diseases.

Professor Nick Nicola, joint head of the Cancer and Haematology division, said a $22,000 grant from The Angior Family Foundation was helping to fit out the division’s laboratories with equipment essential for the scientists to continue their work.

“Finding funding to buy laboratory equipment is often very difficult, as many grants provided through major funding sources do not allow you to purchase the equipment essential for research,” Professor Nicola said. “We are very grateful for the support of philanthropic trusts such as The Angior Family Foundation, who give generously to help us achieve this goal.”

The Angior Family Foundation grant supported the purchase of two new pieces of equipment that allow the researchers to grow large numbers of cells in a body-like environment and manipulate these cells under sterile conditions. “The equipment will allow seven different laboratories and more than 35 scientists within the division to further their research into the causes of, and treatments for, blood disorders,” Professor Nicola said.

The Angior Family Foundation was established in perpetuity in 2001 to raise funds to provide support for medical research, the arts and good works within the Anglican Church. The trust was established by Mr Leonard Angior who undertook, on behalf of his family, to form this trust upon his death.
Major national and international meetings

Stefan Glaser
Apoptosis and Cancer, Cambridge, United Kingdom, 06/12, Oral presentation
First Australian Workshop on Cell Death: Death on the Reef, Hamilton Island, Australia, 08/11, Oral presentation
New Directions in Leukaemia Research, Brisbane, Australia, 03/12, Oral presentation

Emma Josefsson
XXIIIrd Congress of the International Society of Thrombosis and Haemostasis, Kyoto, Japan, 07/11, Oral presentation

Benjamin Kile
XXIIIrd Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, 07/11, Invited speaker

Matthew McCormack
New Directions in Leukaemia Research, Twin Waters, Australia, 03/12, Oral presentation

Donald Metcalf
Victorian Stem Cell Network inaugural meeting, Melbourne, Australia, 02/12, Keynote speaker

James Murphy
Molecular Biology Conference: Biointeractions Satellite Queenstown, Queenstown, New Zealand, 08/11, Invited speaker
Third Australian Course in Macromolecular Crystallisation, Melbourne, Australia, 12/11, Invited speaker
12th Annual Protein Expression Workshop, Melbourne, Australia, 08/11, Invited speaker

Nick Nicola
Australian Technology Network of Universities-Group of Eight Symposium – Excellence in Innovation: Measuring the innovation dividend, Canberra, Australia, 11/11, Participant
Staff list

Sabine Kelly, BSc(Hons) Monash PhD Monash, scientific coordinator/alliance manager

Nick Nicola AO, BSc(Hons) Melbourne PhD Melbourne FAA

Stefan Glaser, PhD Germany

Nick Redpath, BSc Heriot-Watt PhD Bristol

Christine White, BSc(Hons) Adelaide PhD Monash

Jian-Guo Zhang, BSc Xinjiang PhD Melbourne (from 11/11 to 03/12)

Angelika Rutgersson, overseas research trainee (from 09/11 to 12/11)

Benjamin Kile, BSc(Hons) Melbourne LLB Monash PhD Melbourne

Catherine Carmichael, BBiomedSc(Hons) Melbourne PhD Melbourne

Stephane Chappaz, MSc Paris PhD Basel

Marlyse Debrincat, BSc(Hons) Melbourne PhD Melbourne

Irina Pleines, Dipl. Biol. Wuerzburg PhD Wuerzburg (from 10/11)

Janelle Collinge, BSc(Hons) LaTrobe PhD Monash

Katya Henley, BA Melbourne BSc Melbourne

Melissa Holmes, BSc(Hons) Melbourne PhD Melbourne (from 03/12)

Libby Kruse, BSc(Hons) Melbourne (to 07/11)

Rachael Lane, BSc Monash

Michael White, BBlus Swinburne BSc Swinburne BSc(Hons) Melbourne, PhD student

Matthew McCormack, BSc(Hons) Adelaide PhD Adelaide

Ben Shields, BSc(Hons) Melbourne PhD Melbourne (from 07/11)

Jacob Jackson, BSc(Hons) Melbourne GradDipArts Melbourne (from 03/12)

Hesham Abdulla, BAppSc RMIT, BSc(Hons) student

Raed Alserihi, BSc King Abdulaziz MSc RMIT, PhD student (from 08/11)

Don Metcalf AC, BSc(Med) Sydney MD Sydney FRACP HonDSc Sydney HonMD Oslo HonFRCPath London FRCPA FAA FRS, Carden Fellow

Ladina Di Rago

Sandra Mifsud, BAppSc RMIT

Andrew Roberts, MB BS Qld PhD Melbourne FRACP FRCPA

Seong Khaw, MBBS(Hons) Adelaide PhD Melbourne

Jessie Kiu, BBiomedSc(Hons) Melbourne PhD Melbourne (to 08/11)

Kylie Mason, MBBS Melbourne PhD Melbourne FRACP FRCPA

Louise Cengia, BSc UTAS

Mary Ann Anderson, MBBS Melbourne, visiting PhD student

Simon He, MBBS Melbourne, visiting MD student

Sophie Lee, MB ChB Auckland, PhD student (from 02/12)

Warren Alexander, BSc(Hons) Melbourne PhD Melbourne

Leigh Coultas, BSc(Hons) Adelaide PhD Melbourne

Maria Kauppi, PhD Helsinki

Rowena Lewis, BSc(Hons) Deakin PhD Deakin (to 02/12)

Ashley Ng, BMedSc Melbourne MBBS(Hons) Melbourne FRACP FRCPA

Sandra Pilat-Carotta, PhD Vienna

Bill Tang, BSc Nanjing MSc Auckland PhD Auckland (to 02/12)

Takashi Ushiki, MD Niigata PhD Niigata

Jason Corbin, BAppSc Swinburne Craig Hyland, BAppSc RMIT

Stanley Lee, BSc(Hons) Auckland

Janelle Lochland, BSc Deakin

Dina Stockwell, BSc LaTrobe

Evelyn Trousnon, BSc(Hons) VUT

Emma Watson, BSc Melbourne, BSc(Hons) student (from 02/12)

Jeff Babon, BSc(Hons) Melbourne PhD Melbourne

James Murphy, BSc(Hons) Canterbury PhD ANU

Artem Laktushin, BSc(Hons) LaTrobe

Eden Whitlock, BBiotech(Hons) LaTrobe

Leila Varghese, BSc(Hons) Melbourne PostGradDipArts Melbourne, PhD student

Anne Tripaydonis, UROP student

Emma Josefsson, MSc Gothenburg PhD Gothenburg

Ping Cannon, BSc Shanghai

Marion Lebois, BSc Marseille MSc Paris XI

Diane Moujalled, BMedSci(Hons) LaTrobe PhD LaTrobe (from 11/11 to 03/12)

Don Metcalf AC, BSc(Med) Sydney MD Sydney FRACP HonDSc Sydney HonMD Oslo HonFRCPath London FRCPA FAA FRS, Carden Fellow

Ladina Di Rago

Sandra Mifsud, BAppSc RMIT

Andrew Roberts, MB BS Qld PhD Melbourne FRACP FRCPA

Seong Khaw, MBBS(Hons) Adelaide PhD Melbourne

Jessie Kiu, BBiomedSc(Hons) Melbourne PhD Melbourne (to 08/11)

Kylie Mason, MBBS Melbourne PhD Melbourne FRACP FRCPA

Louise Cengia, BSc UTAS

Mary Ann Anderson, MBBS Melbourne, visiting PhD student

Simon He, MBBS Melbourne, visiting MD student

Sophie Lee, MB ChB Auckland, PhD student (from 02/12)

Warren Alexander, BSc(Hons) Melbourne PhD Melbourne

Leigh Coultas, BSc(Hons) Adelaide PhD Melbourne

Maria Kauppi, PhD Helsinki

Rowena Lewis, BSc(Hons) Deakin PhD Deakin (to 02/12)

Ashley Ng, BMedSc Melbourne MBBS(Hons) Melbourne FRACP FRCPA

Sandra Pilat-Carotta, PhD Vienna

Bill Tang, BSc Nanjing MSc Auckland PhD Auckland (to 02/12)

Takashi Ushiki, MD Niigata PhD Niigata

Jason Corbin, BAppSc Swinburne Craig Hyland, BAppSc RMIT

Stanley Lee, BSc(Hons) Auckland

Janelle Lochland, BSc Deakin

Dina Stockwell, BSc LaTrobe

Evelyn Trousnon, BSc(Hons) VUT

Emma Watson, BSc Melbourne, BSc(Hons) student (from 02/12)

Jeff Babon, BSc(Hons) Melbourne PhD Melbourne

James Murphy, BSc(Hons) Canterbury PhD ANU

Artem Laktushin, BSc(Hons) LaTrobe

Eden Whitlock, BBiotech(Hons) LaTrobe

Leila Varghese, BSc(Hons) Melbourne PostGradDipArts Melbourne, PhD student

Anne Tripaydonis, UROP student

Emma Josefsson, MSc Gothenburg PhD Gothenburg

Ping Cannon, BSc Shanghai

Marion Lebois, BSc Marseille MSc Paris XI

Diane Moujalled, BMedSci(Hons) LaTrobe PhD LaTrobe (from 11/11 to 03/12)

Don Metcalf AC, BSc(Med) Sydney MD Sydney FRACP HonDSc Sydney HonMD Oslo HonFRCPath London FRCPA FAA FRS, Carden Fellow

Ladina Di Rago

Sandra Mifsud, BAppSc RMIT

Andrew Roberts, MB BS Qld PhD Melbourne FRACP FRCPA

Seong Khaw, MBBS(Hons) Adelaide PhD Melbourne

Jessie Kiu, BBiomedSc(Hons) Melbourne PhD Melbourne (to 08/11)

Kylie Mason, MBBS Melbourne PhD Melbourne FRACP FRCPA

Louise Cengia, BSc UTAS

Mary Ann Anderson, MBBS Melbourne, visiting PhD student

Simon He, MBBS Melbourne, visiting MD student

Sophie Lee, MB ChB Auckland, PhD student (from 02/12)

Warren Alexander, BSc(Hons) Melbourne PhD Melbourne

Leigh Coultas, BSc(Hons) Adelaide PhD Melbourne

Maria Kauppi, PhD Helsinki

Rowena Lewis, BSc(Hons) Deakin PhD Deakin (to 02/12)

Ashley Ng, BMedSc Melbourne MBBS(Hons) Melbourne FRACP FRCPA

Sandra Pilat-Carotta, PhD Vienna

Bill Tang, BSc Nanjing MSc Auckland PhD Auckland (to 02/12)

Takashi Ushiki, MD Niigata PhD Niigata

Jason Corbin, BAppSc Swinburne Craig Hyland, BAppSc RMIT

Stanley Lee, BSc(Hons) Auckland

Janelle Lochland, BSc Deakin

Dina Stockwell, BSc LaTrobe

Evelyn Trousnon, BSc(Hons) VUT

Emma Watson, BSc Melbourne, BSc(Hons) student (from 02/12)

Jeff Babon, BSc(Hons) Melbourne PhD Melbourne

James Murphy, BSc(Hons) Canterbury PhD ANU

Artem Laktushin, BSc(Hons) LaTrobe

Eden Whitlock, BBiotech(Hons) LaTrobe

Leila Varghese, BSc(Hons) Melbourne PostGradDipArts Melbourne, PhD student

Anne Tripaydonis, UROP student

Emma Josefsson, MSc Gothenburg PhD Gothenburg

Ping Cannon, BSc Shanghai

Marion Lebois, BSc Marseille MSc Paris XI

Diane Moujalled, BMedSci(Hons) LaTrobe PhD LaTrobe (from 11/11 to 03/12)

Don Metcalf AC, BSc(Med) Sydney MD Sydney FRACP HonDSc Sydney HonMD Oslo HonFRCPath London FRCPA FAA FRS, Carden Fellow

Ladina Di Rago

Sandra Mifsud, BAppSc RMIT

Andrew Roberts, MB BS Qld PhD Melbourne FRACP FRCPA

Seong Khaw, MBBS(Hons) Adelaide PhD Melbourne

Jessie Kiu, BBiomedSc(Hons) Melbourne PhD Melbourne (to 08/11)

Kylie Mason, MBBS Melbourne PhD Melbourne FRACP FRCPA

Louise Cengia, BSc UTAS

Mary Ann Anderson, MBBS Melbourne, visiting PhD student

Simon He, MBBS Melbourne, visiting MD student

Sophie Lee, MB ChB Auckland, PhD student (from 02/12)
The ACRF Stem Cells and Cancer division studies the normal development of epithelial tissues and organs, and cancers arising within them.

Epithelial organs are those that primarily consist of epithelial cells, organs such as skin, breast, ovary and lung. Epithelial cancers account for approximately 80 per cent of all cancers and are major causes of death and disease worldwide, yet improved treatments have only resulted in modest increases in cancer survival.

The division focuses on breast, ovarian and lung cancers, with the key objective of understanding the normal development of these organs and which cell types within them are predisposed to cancer.

Our breast cancer research team has isolated breast stem cells and their daughter (progenitor) cells. Both cell types are likely to give rise to breast cancer. Gaining insights into the genes that control the normal regulation of these cells and deciphering how these genes go awry during tumour development will provide important clues on how to treat or even prevent breast cancer. Key proteins expressed by normal and cancerous cells could serve as tumour biomarkers or new therapeutic targets. We have developed powerful preclinical models in which to test novel anti-cancer agents. These models have revealed that agents that target the proteins Bcl-2 or c-kit show considerable promise for the treatment of an aggressive form of breast cancer. We have also discovered that a gene called GATA-3 is a critical regulator of tumour initiation through its ability to promote differentiation (see opposite page).

Similar approaches are being applied to studying ovarian and lung cancers. Ovarian cancer usually presents at a late clinical stage and is often resistant to existing therapies. We are using preclinical models of human high-grade serous ovarian cancer, the most aggressive form of the disease, to test the efficacy of agents that bind to cellular inhibitors of DNA repair.

The lung cancer laboratory has established a series of preclinical lung cancer models representing different cancer subtypes. Over the past year, we have made inroads into identifying new progenitor populations in normal lung tissue and how these are altered in cancer development and infection.
Predicting breast cancer development

Breast cancer is the most common cancer in Australian women, affecting more than 12,000 women each year.

Dr Marie-Liesse Asselin-Labat, Professor Jane Visvader and colleagues from the ACRF Stem Cells and Cancer division are looking for cellular ‘markers’ that could help in the early diagnosis of breast cancer, and help to determine cancer prognosis.

Breast cancers with high levels of a protein called GATA-3 generally have a good prognosis, with less chance that the tumour will spread to other places in the body. Dr Asselin-Labat said the research team was interested in finding out how GATA-3 affected the initiation of tumour growth and whether losing GATA-3 increased tumour growth and spread.

They found that luminal progenitor cells, the stem cell ‘daughters’ found to be at the origin of some hereditary breast cancers, were the cells affected by loss of GATA-3.

“In a mouse model of breast cancer, losing GATA-3 led to a marked increase in tumour development, while higher than normal levels of GATA-3 inhibited tumour growth,” Dr Asselin-Labat said.

In the study, the research team also looked at GATA-3 expression in tumour tissue from women who had DCIS (ductal carcinoma in situ) – an early-stage of breast cancer in which the cancer has not yet spread.

“GATA-3 appeared to be an important predictive marker for DCIS,” Dr Asselin-Labat said. “Given its value in prognosis, it may be possible to develop compounds that activate GATA-3 as potential therapies for preventing tumour development in these patients.”

Collaborating organisations: Peter MacCallum Cancer Centre and The Royal Melbourne Hospital.


Remembering Gillian Welshe (10 November 1950 - 12 March 1999)

A $2 million donation in perpetuity in memory of Mrs Gillian Welshe will support research into breast cancer at the institute.

In 2012, Gillian’s mother, Mrs Edith Qualtrough, set up the research fund in her daughter’s honour. “Gillian was 48 when she died of breast cancer,” Mrs Qualtrough said. “Her husband Greg died of cancer at 41. Both too young.”

The money from the sale of Gillian’s property in the UK prompted Mrs Qualtrough to think about how the funds could be used to remember her. “I started thinking about a donation towards breast cancer research,” she said.

In February 2012, the family established the Qualtrough Research Fund to improve understanding, treatment and prevention of breast cancer.

The family was aware of the work done at the Walter and Eliza Hall Institute, and decided to support the institute after reading a story about the innovative breast cancer research being done by Professor Jane Visvader and Professor Geoff Lindeman. “If this helps other women with breast cancer in some way I would be very pleased, and I’m sure Gillian would be too,” she said.

Born at Mooroopna, near Shepparton in Victoria, Gillian was a successful businesswoman. In the last two weeks of her life, Gillian set up an annual award for a female student at the International Institute for Management Development in Lausanne, Switzerland, where she had graduated with a Masters of Business Administration in 1984.

“Gillian advocated for recognition of women in the business world,” Mrs Qualtrough said. “The career challenges facing women scientists also struck a chord with me, because Gillian had long advocated for equal opportunities in the workplace.”

The family of Mrs Gillian Welshe has set up a research fund for breast cancer in her memory.
Major national and international meetings

Marie-Liesse Asselin-Labat
Australia-France Symposium, Canberra, Australia, 11/11, Oral presentation
Mater Medical Research Institute Stem Cell Symposium 2012, Brisbane, Australia, 05/12, Plenary speaker
Victorian Breast Cancer Research Centre Symposium 2011, Melbourne, Australia, 11/11, invited speaker

Geoff Lindeman
Amgen 2011 Breast Cancer scientific advisory board, San Antonio, United States, 12/10, Keynote speaker, invited speaker and participant on advisory board
Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) annual scientific meeting, Gold Coast, Australia, 07/11, Keynote speaker
Australian Society of Breast Disease annual scientific meeting, Melbourne, Australia, 10/11, Keynote speaker
Cancer Therapy & Research Center-American Association of Cancer Research San Antonio Breast Cancer Symposium, San Antonio, United States, 12/11, Invited session discussant and chair for oral poster session
EuroSyStem European Summer School ‘Hydra VII’, Hydra, Greece, 09/11, Keynote speaker
15th World Congress of Gynecological Endocrinology, Florence, Italy, 03/12, Invited speaker and session chair
Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) annual scientific meeting, Kingscliff, Australia, 08/11, Keynote speaker
The Copenhagen Bioscience Conference: The Stem Cell Niche - Development and Disease, Copenhagen, Denmark, 06/12, Keynote speaker
Victorian Breast Cancer Research Consortium: Fifteen Years of Progress in Breast Cancer Research, Melbourne, Australia, 03/12, Keynote speaker

Clare Scott
Australian Sarcoma Group 2011 annual scientific meeting, Melbourne, Australia, 10/11, Keynote speaker
Familial Aspects of Cancer: Research and Practice, Kingscliff, Australia, 08/11, Keynote speaker
Fifth p63/p73 Workshop, Lyon, France, 09/11, Keynote speaker
Fred Hutchinson/University of Washington Cancer Consortium’s Women’s Cancer Research Program (WCRP) Seminar, Seattle, United States, 06/12, Keynote speaker
Gynaecologic Cancer Inter-Group (GCIG) Meeting: Rare Tumor subgroup, Milan, Italy, 09/11, Keynote speaker
Gynaecologic Cancer Intergroup (GCIG) Translational Committee, Chicago, United States, 05/12, Invited speaker
Haematology and Oncology Targeted therapies (HOTT) Symposium, Melbourne, Australia, 04/12, Keynote speaker
Pfizer Oncology Forum, Sydney, Australia, 06/12, Keynote speaker
Victorian Comprehensive Cancer Centre Gynaecological Oncology Research Collaborative and the European Network for Translational Research in Ovarian Cancer (EUTROC), Melbourne, Australia, 08/11, Keynote speaker, invited speaker and session chair

Julie Sheridan
Victorian Breast Cancer Research Centre Symposium 2011, Melbourne, Australia, 11/11, Keynote speaker

François Vaillant
Victorian Breast Cancer Research Centre Symposium 2011, Melbourne, Australia, 11/11, Keynote speaker

Jane Visvader
American Association for Cancer Research annual meeting, Chicago, United States, 03/12, Keynote speaker, invited speaker and session chair
Australia-France Joint Symposium on Health Sciences and Biomedicine, Canberra, Australia, 11/11, Keynote speaker
Australian Academy of Science, Canberra, Australia, 4/12, Keynote speaker
Australian Academy of Science New Fellows and Medallist Symposium, Melbourne, Australia, 06/12, Keynote speaker
Breast Cancer Nobel Symposia, Stockholm, Sweeden, 06/12, Keynote speaker
Eighth International Symposium on Milk Genomics and Human Health, Melbourne, Australia, 11/11, Keynote speaker
EuroSyStem European Summer School ‘Hydra VII’, Hydra, Greece, 09/11, Keynote speaker
Frontiers in Cancer Science 2011, Singapore, Singapore, 11/11, Plenary speaker
Hinterzarten Kreis for Cancer Research meeting, Cadenabbia, Italy, 04/12, Keynote speaker
Human Genome Meeting 2012, Sydney, Australia, 03/12, Invited speaker
Ludwig Institute for Cancer Research Translational Oncology Conference, Melbourne, Australia, 10/11, Keynote speaker
The International Society for Stem Cell Research annual meeting, Yokohama, Japan, 06/12, Plenary speaker
Victorian Breast Cancer Research Consortium: Fifteen Years of Progress in Breast Cancer Research, Melbourne, Australia, 03/12, Keynote speaker
Staff list

Sally Cane, BSc Deakin, scientific coordinator
Audrey Partanen, BSc Washington, project coordinator
Kylie Shackleston, BSc(Nursing) Deakin, project officer (from 05/12)

Breast cancer laboratory
Geoff Lindeman, BSc(Med) Sydney MB BS(Hons) Sydney PhD Melbourne FRACP
Jane Visvader, BSc(Hons) Adelaide PhD Adelaide
Nai Yang Fu, BSc Xiamen MSc Sun Yat-sen PhD Singapore
Delphine Merino, MSc Dijon PhD Dijon (from 12/11)
Samantha Oakes, BSc(Hons) UNSW PhD UNSW (to 09/11)
Bhupinder Pal, MSc Kurukshetra PhD Melbourne
David Reynolds, BSc(Hons) Adelaide PhD Adelaide
Anne Rios, MSc Marseille PhD Marseille (from 12/11)
Julie Sheridan, BSc(Hons) Leeds PhD Edinburgh
François Vaillant, DEA Paris XI PhD Monash
Kelsey Breslin, BSc(Hons) Alberta Kun Jiang, BBiomedSc(Hons) QUT BBioSc LaTrobe (from 1/12)
Tamara McLennan, BAppSci(Hons) QUT BSc(Hons) La Trobe (from 1/12)
Emma Nolan, BSc(Hons) Otago (from 02/12)
Catherine To, BSc(Hons) Melbourne (from 04/12)
Teresa Ward, BSc(Hons) Massey (to 04/12)
Sarah Best, BSc(Hons) Melbourne, PhD student
Bianca Capaldo, BSc Monash BSc(Hons) Melbourne, PhD student
Lily Lee, BSc(Hons) Melbourne LLB(Hons) Melbourne, PhD student
Kate Voronova, overseas research trainee (to 10/11)
Chris Walter, UROP student (to 12/11)

Marie-Liesse Asselin-Labat, DEA Paris XI, PharmaD PhD Paris
Caitlin Filby, BBiomedSci(Hons) Monash PhD Monash
Kati Viltaniemi, MSc Jyvaskyla
Laura Galvis Vargas, UROP student
Clare Weedon, BA(Hons) UWA BSc(Hons) UWA, PhD student (from 03/12)

Clare Scott, MB BS Melbourne PhD Melbourne FRACP
Esther Moss, MB ChB Birmingham MSc Birmingham PhD Keele (from 01/12 to 02/12)
Rachael Rutkowski, BA Melbourne BSc(Hons) Melbourne PhD James Cook (from 08/11)
Phillip Moss BA Melbourne BSc Melbourne BMed Melbourne (from 8/11 to 10/11)
Michele Cock DipAppSci (Medical Laboratory Science) RMIT (from 3/12)
Lina Hoppo BBiomedSci(Hons) Melbourne PhD Melbourne (from 2/12)
Lynne Hartley, BSc(Hons) Melbourne GradDipAcc Monash Blazhe Nedanovski, BSc(Hons) Melbourne (to 07/11)
Elizabeth Lieschke, summer student (from 12/11 to 1/12)
Jenny Luong, UROP student
Monique Topp, visiting PhD student

15
Molecular Genetics of Cancer

Normal cells in our bodies have a limited lifespan. Those cells that are damaged, potentially dangerous or no longer needed are eliminated by a process of programmed cell death termed apoptosis.

A cell that develops a defect in its apoptosis machinery will fail to die when it should and may multiply to give rise to a cancer. Defective apoptosis makes the cancer cells resistant to chemotherapy drugs and radiation commonly used in cancer therapies.

The Molecular Genetics of Cancer division explores how apoptosis is controlled and how disruptions in this vital cellular process lead to cancer or resistance to cancer therapies. Our increased understanding of apoptosis has galvanised the search for novel anti-cancer drugs that directly trigger the apoptotic machinery to kill tumour cells.

Cellular ‘stress’ produces signals that trigger Bcl-2 family proteins inside the cell. The resulting tussle between the pro-survival family members (including Bcl-2 and Bcl-xL) and their pro-death relatives (Bak, Bax and the BH3-only signalling proteins) determines whether a cell lives or dies. Our researchers are helping to develop and test drugs that promote cell death by blocking pro-survival proteins. Our recent work reveals that one such promising drug is particularly effective at targeting Bcl-2 in lymphoid malignancies (see opposite page).

Cancer therapy should become more effective if we can establish which pro-survival protein is essential for the sustained survival and expansion of particular cancers, and develop treatments that target that specific protein. This year we showed that acute myeloid leukaemia cells depend on Mcl-1 for sustained survival both in tissue culture and in vivo. This points to Mcl-1 or its regulators as potential targets for therapeutic intervention for this incurable blood cell malignancy. Similarly, we found that the development of some lymphomas depends entirely on Bcl-xL. These findings emphasise the exciting potential of developing anti-cancer agents that attack specific Bcl-2 family members for cancer treatment and perhaps, ultimately, its prevention.
Defining the specificity of a new class of anti-cancer agents

Dr Bouillet said the finding was an important step towards tailoring anti-cancer treatments for individual patients. “It has been known that high levels of Bcl-2 or Bcl-x\textsubscript{L} can make certain leukemias and lymphomas resistant to conventional chemotherapy,” he said. “Our findings explain how BH3-mimetics function in cells, and identify high Bcl-2 expression as a marker of susceptibility to navitoclax.”

Collaborating organisations: Abbott, Genentech, a member of the Roche Group, Monash Medical Centre, The Royal Melbourne Hospital, The University of Melbourne.

Funding partners: Australian Research Council, Cancer Council Victoria, Leukaemia Foundation of Australia, Leukemia & Lymphoma Society (US), National Cancer Institute, National Health and Medical Research Council of Australia, The Lady Tata Memorial Trust and the Victorian Government.


Supporting outstanding Victorian science

In November 2011, Professor Andreas Strasser was awarded the 2011 Victoria Prize for his research into the control of cell death. The Victoria Prize, which includes a cash prize of $50,000 for the recipient, is awarded annually by the Victorian Government to a scientist whose discovery has significantly advanced knowledge.

Professor Strasser’s research into the control of cell death has shown that defects in cell death can lead to the development of cancer or autoimmune disease (where the immune system mistakenly attacks and destroys healthy body tissue), and can also render cancer cells resistant to chemotherapeutics.

As part of Professor Strasser’s award, the institute received an additional $100,000 through the Anne & Eric Smorgon Memorial Award. The Anne & Eric Smorgon Memorial Award is provided by the Jack & Robert Smorgon Families Foundation to the organisation supporting the work of the winner of the Victoria Prize.

The award celebrated its tenth anniversary in 2011, bringing the support it has provided to Victoria’s research community to $1 million.

Institute director Professor Doug Hilton said philanthropic funding provided by families such as the Smorgons was vital to the continued work of medical research organisations. “We are honoured to see the work of one of our outstanding researchers, Andreas Strasser, recognised with the Victoria Prize,” Professor Hilton said. “Even more so, we are delighted that the Smorgon family has recognised the importance of Andreas’ research, and that of other Victorian scientists, through their philanthropic support. This funding will allow Andreas and his team to continue to make discoveries that help in the treatment of diseases such as cancer and chronic inflammatory diseases, which are a significant health burden in Australia.”
Major national and international meetings

Jerry Adams
Human Genetics Society of Australasia
35th annual scientific meeting: Genetics in the Sun, Gold Coast, Australia, 08/11, Keynote speaker
Leukemia & Lymphoma Society SCOR progress review meeting, New York, United States, 10/11, Keynote speaker
European Molecular Biology Organization (EMBO) Workshop on Programmed Cell Death in Model Organisms, Ein-Gedi, Israel, 02/12, Keynote speaker

Rebecca Bilardi
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Philippe Bouillet
ComBio 2011, Cairns, Australia, 09/11, Invited speaker
Cold Spring Harbour Symposium on Cell Death, Cold Spring Harbour, United States, 10/11, Oral presentation
Second International Symposium on Carcinogenic Spiral: Infection, Immunity, and Cancer and seminar speaker, Kyoto, Japan, 01/12, Invited speaker

Suzanne Cory
Beaton International Cancer Conference: Cancer models and novel therapies, Glasgow, Scotland, 11/12, Keynote speaker
European Molecular Biology Organization (EMBO) Workshop on Programmed Cell Death in Model Organisms, Ein-Gedi, Israel, 02/12, Chairperson

Alexis Delbridge
RIKEN Research Center for Allergy and Immunology international summer program, Yokohama, Japan, 06/12, Oral presentation
24th Lorne Cancer Conference, Lorne, Australia, 02/12, Oral presentation

Stefan Glaser
Apoptosis and Cancer Conference, Cambridge, United Kingdom, 03/12, Oral presentation
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation
New Directions in Leukaemia Research, Sunshine Coast, Australia, 03/12, Keynote speaker

Daniel Gray
Keystone Symposium: Regulation of Lymphocyte Signalling, Keystone, United States, 03/12, Oral presentation

Ana Janic
24th Lorne Cancer Conference, Lorne, Australia, 02/12, Oral presentation

Ruth Kluck
Keystone Conference on Mitochondrial Dynamics and Function, Banff, Canada, 03/12, Invited speaker
Second Prato Conference on Pore Forming Proteins, Prato, Italy, 04/12, Keynote speaker

Delphine Mérino
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Lorraine O'Reilly
Beaton Institute for Cancer Research, Glasgow, United Kingdom, 10/11, Invited seminar
First Bio-Rheumatology Congress, Tokyo, Japan, 11/11, Keynote speaker

Clare Scott
Australian Sarcoma Group 2011 annual scientific meeting, Melbourne, Australia, 10/11, Keynote speaker
Australia and New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting 2012, Gold Coast, Australia, 02/12, Organiser and session chair

Haematology and Oncology Targeted therapies (HOTT) Symposium, Melbourne, Australia, 04/12, Keynote speaker
Gynaecologic Cancer Intergroup (GCIG) Translational Committee, Chicago, United States, 05/12, Invited speaker
Fred Hutchinson/University of Washington Cancer Consortium’s Women's Cancer Research Program (WCRP) seminar, Seattle, United States, 06/12, Keynote speaker
Pfizer Oncology Forum, Sydney, Australia, 06/12, Keynote speaker

Andreas Strasser
Australian and New Zealand Association for the Advancement of Science, Melbourne, Australia, 03/12, Invited seminar
Cold Spring Harbour Symposium on Cell Death, Cold Spring Harbour, United States, 10/11, Plenary speaker
IMB Academia Sinica Performance Review and Lecture Series, Taipei, Taiwan, 01/12, Keynote speaker
New Directions in Leukaemia Research Meeting, Sunshine Coast, Australia, 03/12, Keynote speaker
19th Euroconference on Apoptosis, Stockholm, Sweden, 09/11, Plenary speaker
Keystone Symposium: Regulation of Lymphocyte Signalling, Keystone, United States, 03/12, Invited speaker
Second Ludwig Institute of Cancer Research Translational Oncology Conference, Melbourne, Australia, 10/11, Keynote speaker
2011 Mitochondria, Apoptosis and Cancer Conference, Singapore City, Singapore, 10/11, Keynote speaker

Dana Westphal
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation
Staff list

Catherine McLean, BA Melbourne GradDipGenetCounsell Charles Sturt, scientific coordinator
Linda Scott, Executive assistant to Suzanne Cory

Jerry Adams, BSc Emory PhD Harvard FAA FRS

Suzanne Cory, BSc Melbourne MSc Melbourne PhD Cantab Hon DSc Syd, Hon DSc Oxon FAA, FRS
Rebecca Bilardi, BBiolSci(Hons) LaTrobe PhD LaTrobe Max Tailer, BSc Bordeaux 1 MSc Bordeaux 1 PhD Paris XI (from 01/12) Cassandra Vandenbergh, BSc(Hons) Otago PhD Otago Bin Wang, BSc Beijing PhD Beijing Dana Westphal, MSc Technical PhD Otago

Leonie Gibson, BAppSc RMIT Natasha Anstee, BSc(Hons) Melbourne, PhD student Marie Menard, overseas research trainee (from 01/12)

Andreas Strasser, MSc Basel PhD Basel FAA
Silvia Alvarez-Diaz, BSc Oviedo MSc Oviedo PhD Madrid (from 01/12) Stephanie Grabow, MSc Max Planck PhD Melbourne Daniel Gray, BBiomedSci(Hons) Monash PhD Monash Marco Herold, Dipl. Biol. Wuerzburg PhD Wuerzburg Ana Janic, BSc Belgrade PhD Barcelona (from 10/11) Gemma Kelly, BSc(Hons) Durham PhD Birmingham Lorraine O’Reilly, BSc Glasgow PhD London Ann Lin, BSc(Hons) Melbourne Antonia Policheni, BBiomedSci Monash BSc(Hons) Melbourne Lin Tai, BAppSc Swinburne MSc LaTrobe Michele Cook, Dip AppSc RMIT (to 03/12) Fiona Kupresanin, B BiomedSci Melbourne MDietetics Deakin Adam Bonner, overseas research trainee (to 08/11) Claire Bowtell, BSc Melbourne, BSc(Hons) student Alexis Delbridge, BBiomedSci(Hons) Melbourne, PhD student Reema Jain, MSc Auckland, PhD student (from 09/11) Francine Ke, BSc(Hons) Melbourne, PhD student Mathias Lang, BSc Innsbruck, overseas research trainee (to 10/11) Jun Low, BBiomedSci Melbourne, BSc(Hons) student (from 02/12) Elenora Ottina, BSc Milan MSc Milan, overseas research trainee (from 04/12) Leona Rohrbeck, BSc Maastricht MSc Maastricht, PhD student Liz Valente, BBiomedSci(Hons) LaTrobe, PhD student

Clare Scott, MBBS PhD Melb FRACP
Lina Happs BBiomedSci(Hons) Melb, PhD student (to 01/12)

Philippe Bouillet, PhD Louis Pasteur Delphine Mérimo MSc PhD Dijon (to 12/11) Maybelline Giam, BSc Melbourne PhD Melbourne (to 06/12) Bruno Helbert, MSc Paris-Sorbonne Mikara Robati, BSc Waikato Carley Young, BSc Melbourne Ryan Stuchbery, BSc Melbourne, BSc(Hons) student (to 11/11)

Ruth Kluck, BSc Qld PhD Qld Amber Alsop, BSc(Hons) Sydney PhD Cambridge Khastira Anwari, BBiomedSci Melbourne BSc(Hons) Melbourne PhD Monash (from 07/11) Ray Bartolo, BSc(Hons) Deakin PhD Deakin (from 01/12) Stephanie Fennell, BBiolSci(Hons) LaTrobe Colin Hockings, BA(Hons) Cambridge, PhD student Sweta Iyer, BSc India MSc Madurai Kamaraj, PhD student Vu Tran, BSc Melbourne, BSc(Hons) student (to 11/11)
ACRF Chemical Biology

The major focus of the ACRF Chemical Biology division is to discover, refine and apply state-of-the-art chemical approaches to address important biological questions and develop them into treatments for human diseases.

To achieve these goals, researchers in the division are developing agents that can specifically modulate the action of key proteins and enzymes that cause human diseases, such as cancers and malaria. The overactivity of the protein Bcl-2 enables the survival of some cancer cells. Chemical compounds that selectively target Bcl-2 have been developed and are showing promising results in clinical trials in patients with some forms of leukaemia and lymphoma.

Our research includes efforts to target other processes and pathways that drive and sustain cancers, including mutations that cause unregulated growth, leading to tumours. We are also using complementary approaches to search for new therapeutic agents. This includes taking alternative approaches such as testing and isolating chemical compounds that are shown to kill diseased cells, then identifying the specific molecular target.

The research undertaken covers a number of therapeutic areas. Together with scientists from the Infection and Immunity division, we are investigating the possibility of targeting malaria-infected red blood cells. Such an approach may allow the development of highly efficacious treatments for the millions of people worldwide affected by this disease.

To undertake these challenging and exciting projects, the division brings together world-class expertise in chemistry, molecular biology and high-throughput chemical screening, and strong collaborations with scientists in other research divisions. We have the unique capability to rapidly screen hundreds of thousands of compounds for those with desirable properties, placing us in a strong position to discover and develop chemicals that are extremely powerful as research tools or have great potential to be transformed into medications for treating diseases that currently have poor outcomes.

Laboratory heads
Dr Chris Burns
Professor David Huang
Division head
Dr Guillaume Lessene
Dr Ian Street

Research assistant Ms Freya Kahn (left) and division head Professor David Huang are looking for new treatments for cancers.
Discovering new drugs for treating leukaemias

Acute myeloid leukaemia (AML) is the most common type of acute leukaemia (aggressive blood cancer) in Australia, with up to 850 Australians diagnosed each year.

Dr Hendrik Falk and Dr Ian Street from the institute’s ACRF Chemical Biology division and Cancer Therapeutics CRC, and Dr Tim Thomas from the Molecular Medicine division, are collaborating to identify new drugs for treating AML.

The research team is looking for drugs that target MOZ, a protein known to be involved in the development of some types of AML.

Dr Thomas said the Moz gene was an excellent target for treating AML. “MOZ is a key regulator of genes that tell blood cells to renew, and has been implicated in leukaemia development,” Dr Thomas said. “People with AML linked to mutations in Moz have a very poor prognosis, with a mean survival time of less than five months. Identifying drugs that could bind to and inhibit this protein would give these people a much better treatment option.”

Dr Falk said the team had developed a new drug discovery system that better identifies small molecules that inhibit MOZ activity. “With the assay, we can assess a large number of compounds quickly and robustly to identify lead-like molecules as starting points for drug development; essentially sorting the ‘wheat from the chaff,’” Dr Falk said. “It also overcomes a number of significant technical challenges that have led other drug discoverers down the wrong track.”

Dr Street said the research team identified a compound that reversibly binds to and inhibits MOZ activity. “It is very exciting and, to the best of our knowledge, this is the first time that it has been achieved,” Dr Street said. “However drug discovery is a long and risky process and it could be more than five years before an agent that inhibits MOZ makes it into clinical trials.”

Collaborating organisations: Cancer Therapeutics CRC and CSIRO.

Funding partners: Australian Research Council, Cancer Therapeutics CRC, National Health and Medical Research Council of Australia and the Victorian Government.


ACRF support to help find new cancer drugs

In 2012 the Australian Cancer Research Foundation (ACRF) committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute.

The funding helped establish new laboratories for the institute’s ACRF Chemical Biology division and ACRF Stem Cells and Cancer division, allowing for the expansion of research into the causes of, and development of new treatments for, some of the most prevalent cancers in Australia, including breast cancer, ovarian cancer, lung cancer and leukaemia.

Professor David Huang, head of the ACRF Chemical Biology division, said the facilities would enable institute researchers to develop new medications for cancers including blood cancers such as leukaemia, and epithelial cancers including breast cancers. “The institute has many scientists investigating how cancers might be better treated,” Professor Huang said. “Our division will use this knowledge to develop medications that have the potential to be used as new anti-cancer agents.”

ACRF chairman Mr Tom Dery said the new funding agreement would further strengthen Australian cancer research efforts. “We have been proud to support successful research projects at the Walter and Eliza Hall Institute in the past,” Mr Dery said. “The ACRF’s support for these new research facilities will enable institute scientists to make discoveries about cancer biology, and then see them developed through to potential new anti-cancer treatments. This will undoubtedly improve the outlook for patients with some of the most common and deadly cancers in Australia.”
Major national and international meetings

David Huang
Institute for Research in Immunology and Cancer Symposium, Montreal, Canada, 9/11, Keynote speaker
Ludwig Institute for Cancer Research Translational Oncology Conference, Melbourne, Australia, 10/11, Invited speaker
Mitochondria, Apoptosis and Cancer, Singapore, Singapore, 10/11, Keynote speaker
12th Hunter Meeting – Australia’s Premier Cellular Biology Meeting, Pokolbin, Australia, 03/12, Keynote speaker

Kurt Lackovic
Screening Asia, Singapore, Singapore, 11/11, Invited speaker

Guillaume Lessene
Australia-France Symposium, Canberra, Australia, 11/11, Oral presentation

Brad Sleebs
Royal Australian Chemical Institute Biomolecular Division Conference, Torquay, Australia, 11/11, Oral presentation
Staff list

Kylie Aumann, BSc(Hons) Melbourne PhD Melbourne, scientific coordinator

David Huang, MBBS London PhD London MRCP London
Brooke Cody, BSc California PhD Wake Forest (to 02/12)
Lisa Lindqvist, BSc McGill PhD McGill (to 05/12)
Lei Liu, MSc China PhD China (from 01/12)
Kyle Mason, MBBS Melbourne PhD Melbourne
Toru Okamoto, BSc MSc Osaka PhD Osaka (to 01/12)
David Segal, BSc(Hons) UWA PhD ANU
Megumi Takiguchi, BSc Victoria PhD Oxford
Mark van Delft, BSc(Hons) McMaster PhD Melbourne (from 02/12)
Angela Georgiou, ADipAppSc RMIT Helen Ierino, BAppSc RMIT
Freya Kahn, BBiomedSci(Hons) Melbourne (to 12/11)
Kate McArthur, BSc(Hons) Melbourne (from 03/12)
Anuratha Srikumar, BSc Madras
Mary Ann Anderson, MBBS Melbourne, PhD student
Hui San Chin, BBiomedSci Melbourne, BSc(Hons) student (from 11/11)
Felanita Hutani, BBiomedSci Melbourne (to 12/11)
Douglas Tjandra, BBiomedSci Melbourne

Jonathan Baell, BSc(Hons) UTAS PhD Melbourne (to 04/12)
Brad Sleebs, BSc(Hons) LaTrobe PhD LaTrobe (to 04/12)
Ryan Brady, BSc(Hons) Melbourne PhD Melbourne (to 04/12)
Georgina Holloway, BAppSci(Hons) RMIT PhD Melbourne (to 04/12)
Kung Ban, BMedChem LaTrobe (to 04/12)
Dana Stachurska-Buczek, MSc Poland (to 04/12)
Michelle Gazdik, BMedChem(Hons) LaTrobe, visiting BSc(Hons) student (to 11/11)
Jelena Medan, BMedSci(Hons) LaTrobe, visiting PhD student (to 04/12)
Sarah Moawad, BMedChem LaTrobe, visiting BSc(Hons) student (to 11/11)
Silvia Teguh, BSc(Hons) Melbourne, PhD student (to 04/12)
Yen Vo, visiting MSc student (to 02/12)

Julie Sanchez, overseas research trainee (to 08/11)
Elliott Teston, overseas research trainee (to 08/11)

Chris Burns, BSc(Hons) Melbourne PhD Melbourne
Jo Alcindor, BSc(Hons) Hertfordshire PhD Cambridge
Ryan Brady, BSc(Hons) Melbourne PhD Melbourne (from 04/12)
Danny Ganame, BSc(Hons) LaTrobe PhD Melbourne
Bill Hawkins, BMedChem(Hons) Wollongong PhD Wollongong (to 06/12)
Georgina Holloway, BAppSci(Hons) RMIT PhD Melbourne (from 04/12)
Romina Lessene, BSc(Hons) Melbourne PhD Melbourne
George Nikolakopoulos, BAppSci(Hons) QUT PhD Monash
Louisa Phillipson, BSc Surrey PhD Reading
Paul Stupple, BA Oxford DPhil Oxford (from 01/12)

Kung Ban, BMedChem LaTrobe (from 04/12)
Wilco Kersten, BSc Netherlands Thao Nguyen, BSc VUT
Dana Stachurska-Buczek, MSc Poland (from 04/12)
Manal Ali, BMedChem LaTrobe, visiting BSc(Hons) student (from 03/12)
Duong Nhu, BSc LaTrobe, PhD student (from 03/12)
David Lee, visiting BSc student (from 03/12 to 06/12)

Guillaume Lessene, PhD Bordeaux 1
Chinh Bui, BSc(Hons) Griffith PhD Melbourne
Brad Sleebs, BSc(Hons) LaTrobe PhD LaTrobe (from 04/12)

Yelena Khakham, BSc(Hons) Monash Amelia Vom, BMedChem(Hons) Monash PhD Monash (from 02/12)
Michelle Gazdik, BMedChem(Hons) LaTrobe, PhD student (from 03/12)
Jelena Medan, BMedSci(Hons) LaTrobe, visiting PhD student (from 04/12)
Michael Roy, BSc(Hons) Melbourne LLB Melbourne, BSc(Hons) student (to 11/11)
PhD student (from 03/12)
Cyrus Tan, BA Melbourne BSc Melbourne, BSc(Hons) student (from 02/12)

Silvia Teguh, BSc(Hons) Melbourne, PhD student (from 04/12)
Simon Donck, overseas research trainee (to 08/11)
Sidney Louzoun, overseas research trainee (from 04/12)

Ian Street, BSc(Hons) Sussex PhD British Columbia
Tony Cardino, BSc Otago MSc Otago PhD Otago (to 03/12)
Hendrik Falk, BPPharm Halle PhD Berlin Ann Holmes, PhD London (from 07/11 to 08/11)

Kurt Lackovic, BAppSci(Hons) LaTrobe PhD LaTrobe
Karl Leuchowius, MSc Uppsala PhD Uppsala
Kym Lowes, BSc(Hons) UWA PhD UWA
John Parisiot, BSc(Hons) Monash PhD Melbourne (to 07/11)
Elizabeth Allan, BSc(Hons) Otago PhD Melbourne (from 12/11)
Lynda Allan, BSc(Hons) Dundee (to 08/11)
Melanie De Silva, BSc Melbourne (from 09/11)

Rebecca Moss, BAppSci(Hons) RMIT
Patrizia Novello, BBiolSci(Hons) LaTrobe Margaret Tiong, BSc(Hons) Melbourne (to 10/11)
Soo San Wan, BAgSci(Hons) LaTrobe
MAgSc LaTrobe
Hong Yang, PhD Norman Bethune

Andrew Wilks, BSc(Hons) Liverpool PhD Glasgow
Molecular Medicine

The Molecular Medicine division investigates the pathways that control normal differentiation of stem cells, in particular blood stem cells, and how these pathways are perturbed in diseases including leukaemia and lymphoma, and in inflammation.

Researchers use data from genetic, genomic, proteomic and computational analyses to place individual genes into the regulatory pathways, with the ultimate goal of working closely with clinicians and the private sector to translate our discoveries into improvements in the diagnosis and treatment of disease.

Major research themes in the division include the regulation of stem cells, blood cell production and function, and blood cancers. Researchers are also studying molecules that regulate the epigenome; chemical modifications to the chromatin (which is made up of DNA and proteins it binds to) that occur in response to environmental factors and tell genes to switch on or off.

The past 12 months have seen wonderful progress in understanding how an intriguing family of epigenetic regulators, the MYST acetyltransferases, work. Research headed by Dr Anne Voss and Dr Tim Thomas has shown that one MYST-family member, MOZ, regulates a number of genetic programs, including Tbx genes, needed for the proper formation of the heart and associated blood vessels. Congenital heart defects are present in approximately one per cent of live births, and this work provides a very rare insight into how an epigenetic regulator can combine both genetic and environmental cues to ensure proper formation of the heart (see opposite page).

The work of Mr Bilal Sheikh, a PhD student supervised by Dr Voss and Dr Thomas, has highlighted the importance of another MYST-family member, Querkopf, in maintaining a rare population of stem cells in the adult brain. This work highlighted the importance of Querkopf in maintaining stem cell features including self-renewal, and the ability to become many different cell types.

Together these studies, and other work in the division, emphasise the importance of epigenetic regulators in controlling stem cell function.

PhD student Ms Hannah Vanyai is looking at the role of epigenetic regulators in development and disease.
Gene ‘switch’ may explain DiGeorge syndrome severity

The discovery of a ‘switch’ that modifies a gene essential for normal heart development could explain the variations in severity of birth defects in children with DiGeorge syndrome.

DiGeorge syndrome is a common congenital disease, affecting approximately one in 4000 babies. Children with the syndrome exhibit a range of mild to severe birth defects, including heart and aorta defects.

Dr Anne Voss, Dr Tim Thomas and colleagues discovered the ‘switch’ while investigating foetal development in an animal model of DiGeorge syndrome.

“In DiGeorge syndrome the variation in symptoms is so prominent that even identical twins, with the exact same DNA sequence, can have remarkably different conditions,” Dr Voss said. “We hypothesised that environmental factors were probably responsible for the variation, via changes to the way in which genetic material is packaged in the chromatin.”

Chromatin is the genetic material that comprises DNA and associated proteins packaged together in the cell nucleus. Chemical marks that sit on the chromatin modify it to instruct when and where to switch genes on or off.

The research team found MOZ, a protein ‘switch’ involved in chromatin modification, was key to explaining the variation in birth defect severity in an animal model of DiGeorge syndrome. “MOZ makes marks on the chromatin that tell genes to switch on,” Dr Voss said. “We showed that MOZ regulates Tbx1, a major gene responsible for heart and aortic arch development. MOZ is crucial for normal activity of Tbx1, and variations in the level of MOZ activity may contribute to determining how severe the defects are in children with DiGeorge syndrome.”

The research team also showed reduced MOZ activity could conspire with excess retinoic acid (a type of vitamin A) to markedly increase the frequency and severity of DiGeorge syndrome. “In our mouse model, mice that had one normal copy of MOZ and one mutated copy looked completely normal. However if their mother’s diet during pregnancy was high in vitamin A, the offspring developed DiGeorge syndrome-like defects,” she said.

Collaborating organisations: University College London Institute of Child Health.

Understanding why some childhood leukaemias don’t respond to treatment

Acute lymphoblastic leukaemia (ALL) is an aggressive blood cancer and the most common childhood cancer, with approximately 175 children diagnosed each year in Australia.

Current ALL therapy begins with treatment using steroid hormones (glucocorticoids), which cause the leukaemia cells to undergo programmed cell death (apoptosis) and restore normal blood cell production. Approximately 80 per cent of patients are cured by current treatments, however the other 20 per cent often succumb to relapsed ALL that is glucocorticoid resistant.

PhD student Mr Matt Witkowski from the institute’s Molecular Medicine division was awarded a Leukaemia Foundation scholarship in 2011 to study how deletions in a gene called Ikaros are associated with resistance to conventional therapy in children with ALL.

“Mutations in the Ikaros gene are strongly associated with treatment failure and poor prognosis in ALL due to a lack of treatment options,” Mr Witkowski said. “Despite these breakthroughs in our understanding of the genetics of ALL, we still don’t understand how Ikaros suppresses tumour development and how its deletion contributes to leukaemia relapse.”

While Mr Witkowski was completing his honours project at the institute he was part of a team that showed Ikaros regulates the expression of an enzyme involved in activation of glucocorticoids, a class of steroid hormones that are the mainstay of ALL therapy.

The Leukaemia Foundation funding has allowed Mr Witkowski to undertake a PhD project at the institute using mouse models of ALL to investigate how this enzyme is controlled by Ikaros, and how its activity influences leukaemia therapy responses.

“Understanding how Ikaros deletions control therapy responses in normal lymphocytes and leukaemia cells will help in the design of new treatment strategies for patients with Ikaros-deleted ALL, who face a dismal prognosis with current treatments,” Mr Witkowski said.
Major national and international meetings

Marnie Blewitt
Annual Meeting of New Champions 2011, World Economic Forum, Dalian, China, 09/11, Invited speaker
Epigenetics Australia 2012, Fourth Australian Scientific Conference, Adelaide, Australia, 05/12, Keynote speaker
50 years of X inactivation research, Oxford, United Kingdom, 07/11, Oral presentation
New Directions in Leukaemia Research, Sunshine Coast, Australia, 03/12, Keynote speaker

Ross Dickins
New Directions in Leukaemia Research, Sunshine Coast, Australia, 03/12, Keynote speaker
34th Lorne Cancer Conference, Lorne, Australia, 02/12, Keynote speaker

Nick Seidenman
Australian Microarray and Associated Technologies Association (AMATA) 2011 Conference, Canberra, Australia, 10/11, Oral presentation

Bilal Sheikh
Lorne Genome Conference, Lorne, Australia, 02/12, Oral presentation

Samir Taoudi
New South Wales Stem Cell Network, Sydney, Australia, 09/11, Keynote speaker

Tim Thomas
New South Wales Stem Cell Network, Sydney, Australia, 8/2011, Invited speaker

Anne Voss
Molecular Pathways in Organ Development and Disease, Cold Spring Harbor, United States, 04/12, Oral presentation
### Staff list

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Degree</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etty Bonnici</td>
<td>Administration officer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fiona McGrath, BAppSc(Hons)</td>
<td>RMIT</td>
<td>PhD</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Doug Hilton, BSc(Hons)</td>
<td>Melbourne</td>
<td>BSc</td>
<td>Monash</td>
</tr>
<tr>
<td>Christine Biben, BSc(Hons)</td>
<td>Paris VI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rachel Burt, BSc Melborne</td>
<td>PhD Melborne</td>
<td>to 01/12</td>
<td></td>
</tr>
<tr>
<td>Marina Carpinelli, BSc(Hons)</td>
<td>Melbourne</td>
<td>PhD</td>
<td>Monash</td>
</tr>
<tr>
<td>Jarny Choi, BSc(Hons)</td>
<td>Melbourne</td>
<td>PhD</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Martin Pera, BA USA</td>
<td>PhD George Washington</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Owen Prall, BMedSci(Hons)</td>
<td>UTAS</td>
<td>MBBS(Hons)</td>
<td>Monash</td>
</tr>
<tr>
<td>Tracey Baldwin, BAppSc RMIT</td>
<td></td>
<td></td>
<td>Monash</td>
</tr>
<tr>
<td>Bette Borobokas, BBiolSc</td>
<td></td>
<td></td>
<td>LaTrobe</td>
</tr>
<tr>
<td>Anne Gooray, BSc Melbourne</td>
<td>(to 12/11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karry Ramsay, BSc(Hons)</td>
<td>Murdoch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nick Seidenman, systems</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lucy Bennett, vacation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Courtney Cameron, UROP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine Colman, vacation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caleb Dawson, vacation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anna Marneth, BBiomedSc</td>
<td>Groningen</td>
<td>overseas research trainee</td>
<td>(to 09/11)</td>
</tr>
<tr>
<td>Tim Thomas, BSc(Hons)</td>
<td>Melbourne</td>
<td>PhD</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Anne Voss, BVSch Hannover PD</td>
<td></td>
<td></td>
<td>Goettingen</td>
</tr>
<tr>
<td>Isobel Lawrenson, BSc (Hons)</td>
<td>Melbourne</td>
<td></td>
<td>Newcastle</td>
</tr>
<tr>
<td>Rose Cobb, BBiolSc(Hons)</td>
<td></td>
<td></td>
<td>LaTrobe</td>
</tr>
<tr>
<td>Natalie Downer, BSc(Hons)</td>
<td>Melbourne</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Kueh, BSc(Hons)</td>
<td>Melbourne</td>
<td></td>
<td>MBBS</td>
</tr>
<tr>
<td>Tamara McLennan BAAppSc(Hons)</td>
<td>QUT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisa Sampurno, BBiomedSc(Hons)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Farrah El-Saafin, BMedSc</td>
<td></td>
<td></td>
<td>LaTrobe</td>
</tr>
<tr>
<td>Hannah Vanyai, BA Melbourne</td>
<td></td>
<td></td>
<td>BSc(Hons)</td>
</tr>
<tr>
<td>Marnie Blewitt, BSc(Hons)</td>
<td>Sydney</td>
<td>PhD</td>
<td></td>
</tr>
<tr>
<td>Sarah Kinkel, BA Melbourne</td>
<td></td>
<td></td>
<td>BSc(Hons)</td>
</tr>
<tr>
<td>Hui San Leong, BBiomedSc(Hons)</td>
<td></td>
<td></td>
<td>Melbourne</td>
</tr>
<tr>
<td>Miha Pakusch, BSc(Hons)</td>
<td>Melbourne</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael Alexanian, BA</td>
<td></td>
<td></td>
<td>Florence</td>
</tr>
<tr>
<td>Darcy Butts, BSc Michigan</td>
<td></td>
<td></td>
<td>MSc Oxford</td>
</tr>
<tr>
<td>Kelan Chen, BSc(Hons)</td>
<td></td>
<td></td>
<td>Melbourne</td>
</tr>
<tr>
<td>Jamie Gearing, BSc(Hons)</td>
<td></td>
<td></td>
<td>Melbourne</td>
</tr>
<tr>
<td>Betty Kao, BAppSc</td>
<td></td>
<td></td>
<td>Otago</td>
</tr>
<tr>
<td>Joy Liu, UROP student</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ross Dickins, BSc(Hons)</td>
<td>Melbourne</td>
<td>PhD</td>
<td>Melbourne</td>
</tr>
<tr>
<td>Mutlu Kartal-Kaess, MD</td>
<td>Heidelberg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark McKenzie, BSc(Hons)</td>
<td>Melbourne</td>
<td>PhD</td>
<td></td>
</tr>
<tr>
<td>Megumi Takiguchi, BSc</td>
<td>Victoria PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laura Tuchey BMedSci</td>
<td></td>
<td></td>
<td>BIOTECH Charles Sturt</td>
</tr>
<tr>
<td>Tamara Huesser, BBiolSc</td>
<td>Zurich</td>
<td>overseas research trainee</td>
<td>(to 07/11)</td>
</tr>
<tr>
<td>Grace Liu, BBiomedSc(Hons)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew Witkowski, BSc</td>
<td></td>
<td></td>
<td>Melbourne</td>
</tr>
<tr>
<td>Samir Taoudi, BSc(Hons)</td>
<td>Westminster</td>
<td>PhD</td>
<td>Edinburgh</td>
</tr>
<tr>
<td>Andrew Jarratt, BSc(Hons)</td>
<td>York PhD</td>
<td>(from 02/12)</td>
<td></td>
</tr>
<tr>
<td>Adrienne Hilton, BAppSc RMIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathryn Potts, BSc</td>
<td></td>
<td></td>
<td>Melbourne</td>
</tr>
<tr>
<td>PhD student</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Researchers (from left) Dr Jian-Guo Zhang, Dr Mireille Lahoud, Dr Peter Czabotar and Professor Ken Shortman have discovered how a vital immune cell recognises dead and damaged body cells. The finding could modernise vaccine technology by ‘tricking’ cells into launching an immune response.
Manipulating the immune system for ‘next-gen’ vaccines

Dendritic cells are critical for raising the alarm about the presence of infectious invaders, as well as tumour cells and other dead or damaged cells.

Also known as antigen-presenting cells, dendritic cells digest and present molecules from damaged cells to immune system cells to launch the immune response.

The discovery of how this vital immune cell recognises dead and damaged body cells could modernise vaccine technology by “tricking” cells into launching an immune response, leading to next-generation vaccines that are more specific, more effective and have fewer side-effects.

Dr Peter Czabotar, Dr Jian-Guo Zhang, Dr Mireille Lahoud and Professor Ken Shortman made the discovery, through collaboration between the institute’s Structural Biology, Cancer and Haematology and Immunology divisions.

Dr Czabotar said the research team showed for the first time how a protein, called Clec9A, on the surface of dendritic cells recognises dangerous damage and trauma that could signify infection.

“Solving the structure of Clec9A allowed us to identify key parts of the protein that bind to the ligand,” Dr Czabotar said. “This helped us to discover that dendritic cells recognise and bind to internal cell fibres called actin via the Clec9A protein receptor.”

Actin is a highly conserved protein found in all cells of the body. It is only exposed when the cell is damaged or destroyed, so is a great method for immune cells to recognise potentially dangerous changes in the body.

Professor Shortman said exploiting Clec9A could be used to generate a new, more modern class of vaccines that are more effective and have fewer side-effects. “The Clec9A protein is one of the best targets currently known for improving immune responses,” he said. “By creating vaccines that bind to Clec9A, we can trick dendritic cells to think they have encountered a damaged cell and help to launch an immune response to the infectious agent of our choice.”

Collaborating organisations: Burnet Institute, Campbell Family Institute for Cancer Research/Ontario Cancer Institute, Monash University, National University of Singapore, New York Blood Center, Toronto General Research Institute/University Health Network and The University of Melbourne.

Funding partners: Australian Research Council, National Health and Medical Research Council of Australia and the Victorian Government.


CASS Foundation: supporting our early-career researchers

Travelling to conferences overseas to hear the latest research developments and meet possible future collaborators is an important opportunity for early-career researchers.

The CASS Foundation, a private philanthropic foundation, provides this opportunity by awarding travel grants to help early-career postdoctoral researchers attend overseas conferences, furthering their professional development and helping them to establish contact with their international peers.

Dr Geoffrey Kong from the institute’s Structural Biology division was awarded a CASS travel grant during the year to fund his attendance at the Gordon Research Conference on Three Dimensional Electron Microscopy, held in Switzerland in May 2012.

Dr Kong is studying the structure of the insulin receptor and the related type 1 insulin-like growth factor receptor (IGF-1R). Both receptors are of interest due to their link with diabetes and cancer.

“IGF-1R is over-expressed in many cancer types and is responsible for tumour growth, transformation and metastasis, while the insulin receptor is emerging as a link between obesity, diabetes and cancer,” Dr Kong said.

“Unravelling the details of how these receptors function normally is an important step in understanding their functions in the disease states and, in the longer term, the development of targeted therapeutics.”

Dr Kong is using cryo-electron microscopy to study the three-dimensional structures of the receptors, with and without insulin and insulin-like growth factor bound, which involves the direct imaging of protein molecules at cryogenic (liquid nitrogen) temperatures.

Dr Kong said the Gordon conference was regarded as the most important annual meeting dedicated to this field. “The use of cryo-electron microscopy for determining protein structures is an emerging field in Australia and few people are familiar with the techniques,” Dr Kong said. “The conference is attended by many major research groups worldwide, including leaders in the field, and is an ideal forum for learning about the latest and the best that the electron microscopy field has to offer.”

Dr Geoffrey Kong

Walter and Eliza Hall Institute
Annual Report 2011-2012
Supplementary information
Major national and international meetings

**Jeff Babon**
37th Lorne Conference on Protein Structure and Function, Lorne, Australia, 02/12, Keynote speaker

**Matthew Call**
Australia and New Zealand Society for Magnetic Resonance (ANZMAG) 2011 Conference, Torquay, Australia, 11/11, Invited speaker
17th International Biophysics Congress (International Union of Pure and Applied Biophysics), Beijing, China, 10/11, Invited speaker
IgV retreat, Geelong, Australia, 09/11, Invited speaker

**Peter Colman**
2011 Cold Spring Harbor Asia Conference on Protein Structure Based Drug Design, Suzhou, China, 09/11, Invited speaker
Australia-France Symposium, Canberra, Australia, 11/11, Invited speaker
Max Planck Institute, Huber 75th birthday symposium, Munich, Germany, 02/12, Invited speaker

**Peter Czabotar**
Erice Crystallography Conference, Erice, Sicily, 06/12
First Australian Workshop on Cell Death: Death on the Reef, Lindeman Island, Australia, 08/11, Oral presentation

**Doug Fairlie**
Cold Spring Harbor Cell Death Conference, New York, United States, 10/11, Invited speaker

**Jacqui Gulbis**
Australian Course in Advanced Neuroscience, North Stradbroke Island, Australia, 04/12, Invited speaker

**Geoffrey Kong**
Australian Research Council Centre of Excellence for Coherent X-ray Science Workshop: Facilitating imaging and biophotonics, Melbourne, Australia, 10/11, Invited speaker
Bio21 Biological Electron and Advanced Microscopy (BEAM) Workshop, Melbourne, Australia, 09/11, Invited speaker
IGF-Oz 2011: The IGF system and related proteins in development and disease, Melbourne, Australia, 10/11, Invited speaker

**Mike Lawrence**
Australian Synchrotron Users Meeting 2012, Melbourne, Australia, 12/11, Invited speaker
XXII Congress and General Assembly International Union of Crystallography, Madrid, Spain, 08/11, Oral presentation

**Shenggen Yao**
Australia and New Zealand Society for Magnetic Resonance (ANZMAG) 2011 Conference and Bruker Biospin NMR Users Meeting, Torquay, Australia, 11/11, Oral presentation
**Staff list**

Helen Barry, BA Melbourne, PostGradDipArts Melbourne, administrative officer
Pauline Drum, GradDipBus Swinburne, personal assistant (from 06/12)

**Peter Colman, BSc(Hons) Adelaide PhD**
Adelaide HonDSc Sydney FAA FTSE
Peter Czabotar, BSc Curtin PhD Curtin Mark Hinds, BSc Auckland MSc(Hons) Auckland PhD Auckland
Adeline Robin, MSc Louis Pasteur PhD Basel
Yilin Xu, BSc China MSc China PhD ANU

Shenggen Yao, MSc China PhD UNSW (to 05/12)
Geoff Thompson, BSc(Hons) Melbourne Ahmad Wardak, BSc(Hons) LaTrobe
Jason Brouwer, BBiomedSc(Hons) Monash, PhD student (from 02/12)
Keith Khoo, BBiomedSc(Hons) Melbourne, PhD student
Michael Roy, LLB Melbourne BSc(Hons) Melbourne, BSc(Hons) student (to 11/11)

**Jeff Babon, BSc(Hons) Melbourne PhD**
James Murphy, BSc(Hons) Canterbury PhD ANU
Artem Laktyushin, BSc(Hons) LaTrobe Eden Whitlock, BBiotech(Hons) LaTrobe
Leila Varghese, BSc(Hons) Melbourne PostGradDipArts Melbourne, PhD student

Tony Burgess, BSc(Hons) Melbourne PhD Melbourne AC FAA FTSE
Nadia Kershaw, MChem Oxford PhD Oxford (from 06/12)
Lauren King, BSc(Hons) Glasgow PhD Glasgow (from 05/12)
Chin Wee Tan, BECompEng(Hons) Singapore MBiomedEng Melbourne PhD Melbourne (from 05/12)
Nicole Church, BAppSc RMIT (from 06/12)
Melanie Condron, BSc(Hons) LaTrobe (from 06/12)
Yumiko Hirokawa, MVSc Japan (from 06/12)
Shabnam Khatibi, BSc Sharif, Visiting PhD student (from 06/12)
Pheng Wong, BSc Putra MSc Leicester, PhD student (from 06/12)
Kelvin Yip, BSc Hong Kong M.Phil Hong Kong, PhD student (from 06/12)

Matt Call, BSc Trinity PhD Harvard
Melissa Call, BSc Auckland MSc Auckland PhD Auckland
Pooja Sharma, BPharm IIT-BHU, India PhD Monash
Mariam Lufti, BSc Simon Fraser BSc(Hons) Melbourne (from 07/11)
Eamon Byrne, BA Melbourne BSc Melbourne, BSc(Hons) student (from 02/12)
Logeswaran Krishnan, BSc Melbourne, BSc(Hons) student (from 02/12)

Doug Fairlie, BSc(Hons) Monash PhD Monash
Erinna Lee, BSc Melbourne PhD Melbourne
Marco Evangelista, BBiotech(Hons) Adelaide
Anne Pettikiriarachchi, BSc(Hons) Monash
Nicholas Lim, BSc Melbourne, BSc(Hons) student (from 02/12)
Helen McRae, UROP student (from 11/11)

Jacqui Gulbis, BSc(Hons) LaTrobe PhD LaTrobe
Lukasz Kowalczyk, MSc Gdansk PhD Gdansk (from 08/11)
Kaaavya Krishna Kummar, BSc Madras MSc Madras, PhD Sydney (from 05/12)
Rasmus Linser, DipChem Gotting PhD Berlin (from 06/12 to 06/12)
Conny Ludwig, BSc(Hons) Edinburgh PhD Edinburgh (to 01/12)
David Miller, BSc(Hons) Wellington PhD Bristol (from 03/12)
Pauline Crewther, BSc(Hons) Melbourne MSc Melbourne
Cindy Luo, BEng Beijing
Agalya Periasamy, BBiomedSc(Hons) India MSc Flinders (from 11/11)
Katrina Black, UROP student (from 07/11)

Michael Lawrence, BSc(Hons) Cape Town PhD Cape Town
Geoffrey Kong, BSc(Hons) Melbourne PhD Melbourne
Colin Ward, BSc(Hons) UNSW PhD UNSW FAA
Mai Margetts, BAppSc RMIT
John Menting, BSc(Hons) Melbourne PhD LaTrobe
Bioinformatics

New genomic technologies are revolutionising biomedical research and the Bioinformatics division continues to be at the forefront of these developments.

The division develops new computational and statistical methods to analyse and interpret genomic data, and works collaboratively with other institute divisions to research a number of diseases including breast cancer, malaria and immune disorders.

The division has played a leading role in sequencing the genome of several iconic Australian animals. In the past year, Dr Tony Papenfuss, Professor Terry Speed and colleagues sequenced the complete genome of the tammar wallaby, drawing from it important insights into the evolution of mammalian reproduction and development. Dr Papenfuss also took part in a large collaboration to sequence the genome of the Tasmanian devil, and the devil facial tumour disease genome, with potential implications for controlling this devastating disease currently threatening Tasmanian devils’ survival.

In other developments, Dr Melanie Bahlo and colleagues discovered the genetic mutation that causes the hereditary disease adult onset neuronal lipofuscinosis. This discovery paves the way for genetic testing of some families, which might avoid invasive diagnostic brain biopsies. Dr Bahlo also showed that traditional identity-by-descent analyses could be readily applied to next-generation sequencing (NGS) data, leading to improved power for the discovery of disease-causing variants in family studies.

A number of important methodological contributions were also published in the past year. Professor Speed showed how to improve the quality of both microarray and NGS datasets. Professor Gordon Smyth developed tools to analyse changes in gene activity in complex biological experiments using NGS technologies (see opposite page).
Finding the cell changes that cause disease

High-throughput screening and next-generation sequencing are new technologies that are revolutionising medical research.

RNA-Seq is a recently developed high-throughput sequencing technology that is dramatically faster than standard DNA sequencing, and provides scientists with much more detail about how genes are regulated and expressed than any earlier technology.

New tools developed by Professor Gordon Smyth and colleagues from the institute’s Bioinformatics division are allowing researchers to use RNA-Seq technology to more accurately determine how gene expression is altered in the development of cancers and in response to cancer treatments. Professor Smyth said RNA-Seq allowed scientists to investigate the differences in expression of tens of thousands of genes at once in far more detail than ever before. “Next-generation sequencing is a revolutionary technology for science, however it is also enormously challenging because it generates vast amounts of data which require sophisticated mathematical and statistical algorithms to give meaning to the information,” he said. “We have developed new tools that will enable scientists around the world to analyse their complex experiments and correctly identify which genes are changing with greater powers of detection and with fewer errors.”

Professor Smyth said the statistical tools would be very useful in cancer research. “Using these tools, researchers will be able to more accurately determine whether gene expression is genuinely changing in response to a particular anti-cancer treatment, providing extremely valuable information about the treatment’s effectiveness,” he said. “They will also be able to compare normal, healthy tissues and cells that have transformed to become malignant cells to find the genes, molecular pathways and proteins that have changed to drive tumour growth.”

The tools allow researchers to estimate biological variability in studies where the sample sizes are necessarily small, which was previously not possible using RNA-Seq technologies, Professor Smyth said. “We refer to it as borrowing strength between genes; using sophisticated mathematics to get some idea of the overall variability from all genes, an idea of the gene-specific variability as well, and compromising between the two,” Professor Smyth said. “It allows researchers to identify genetic changes when they have only very small sample sizes, giving a reliable and complete picture about the cancer where before you may not have been able to do it at all.”

Statistics solving malaria questions

Each year more than 250 million people worldwide contract malaria, and up to one million people die, particularly children under five and pregnant women.

A generous donation of $10,000 supported a joint project between researchers from the Bioinformatics and Infection and Immunity divisions, with colleagues from the Swiss Tropical and Public Health Institute, Switzerland, to improve the understanding, prevention and treatment of malaria in Papua New Guinean children.

The donation from Professor Howard D’Aberne helped to fund a PhD student supervised by Bioinformatics division head Professor Terry Speed to analyse data from 264 children aged between one and three to understand how infection with different parasites affects a child’s chance of developing severe malaria.

“Children with severe malaria are often infected with two, or occasionally more, parasites at once,” Professor Speed said. “We wanted to answer the question: is a child more or less likely to develop severe malaria if they are infected by both the Plasmodium falciparum and Plasmodium vivax malaria parasites, in comparison with being infected by only one of the two?”

Professor Speed and PhD student Kathryn Benton are developing statistical approaches they hope will enable them to answer this question. “This is not entirely straightforward, as the child’s age, exposure to mosquitoes, and other factors such as use of insecticide-impregnated bed nets must be taken into account,” Professor Speed said.

Bioinformatics has become an increasingly sought-after research area to answer questions about cancer, malaria and many other diseases. “We work on a number of projects including searching for the cells at the origin of breast cancers, the genes that cause genetic and hereditary diseases and how cancers develop,” Professor Speed said. “Our collaborators tell us the questions they want to address and we take their data, and try to develop mathematical, statistical or computational methods that help us tease out the answers.”
Major national and international meetings

**Melanie Bahlo**

BioInfoSummer 2011, Melbourne, Australia, 12/11, Invited speaker
Conference for the International Federation of Operational Research Societies 2011, Melbourne, Australia, 07/11, Invited speaker
Genetics Society of Australia annual meeting, Melbourne, Australia, 07/11, Oral presentation
International Stroke Genetics meeting, Newcastle, Australia, 04/12, Keynote speaker

**Gordon Smyth**

Bioconductor Conference, Seattle, United States, 07/12, Invited speaker

**Terry Speed**

AEMC Seminar, New York, United States, 04/12, Invited speaker
Centre for Genomic Regulation annual symposium, Barcelona, Spain, 11/11, Invited speaker
Computational Biology Symposium, Los Angeles, United States, 04/12, Keynote speaker
Conference on New Statistical Methods for Next Generation Sequencing Data Analysis, Ames, United States, 05/12, Plenary speaker
Critical Assessment of Massive Data Analysis 2011, Vienna, Austria, 07/11, Invited speaker
European Molecular Biology Laboratory 2011, Heidelberg, Germany, 09/11, Distinguished lecture talk
Human Genome Meeting 2012, Sydney, Australia, 03/12, Invited speaker
Multiple Comparison Procedures 2011, Maryland, United States, 07/11, Keynote speaker

**Anthony Papenfuss**

Australian Society of Microbiology annual meeting 2011 Tasmanian devil workshop, Hobart, Australia, 04/07, Invited speaker
BioInfoSummer 2011, Melbourne, Australia, 05/12, Invited speaker
ComBio, Cairns, Australia, 09/11, Invited speaker
Genetics Society of Australia Annual Meeting, Melbourne, Australia, 11/07, Oral presentation
Next-generation deep sequencing technologies workshop, Sydney, Australia, 07/11, Invited speaker

**National Science Foundation Workshop for High-Dimensional Data, New Haven, United States, 06/12, Invited speaker**

Pao-Lu Hsu Lecture on Statistical Machine Learning and Applications, Beijing, China, 05/12, Lecture

Stanford School of Medicine, Workshop in Biostatistics, Stanford, United States, 02/12, Invited speaker
Staff list

Maria Markovic, BA RMIT DipEd LaTrobe, Administrative officer

Terry Speed, BSc(Hons) Melbourne DipEd Monash PhD Monash HonDSc UWA FAA

Kathryn Benton, BSc Colorado MSc Tulane (from 07/11 to 08/11)

Zhi-Ping Feng, BSc Peking MSc Tianjin PhD Tianjin

Rafael Irizarry, PhD Berkeley (to 08/11)

Jason Li, PhD Melbourne

Helen Lindsay, BSc Newcastle BSc(Hons) ANU PhD ANU (to 05/12)

Amsha Nahid, BSc Punjab PhD Punjab (from 07/11)

Martin O’Hely, BSc(Hons) Monash MA Minnesota PhD Minnesota

Moshe Olshansky, BSc Israel PhD Columbia

Mark Robinson, BSc(Hons) Guelph PhD British Columbia (to 07/11)

Matthew Wakefield, BSc(Hons) Melbourne PhD LaTrobe

Eugene Kapp, BSc(Hons) Rhodes MSc Rhodes, proteomics bioinformatics specialist

Ben Lansdell, BSc(Hons) Melbourne MSc Melbourne, visiting PhD student (to 08/11)

Joyce Lin, Visiting PhD student (to 05/12)

Alena Mysickova, BSc Humboldt MSc Humboldt, visiting PhD student (from 12/11 to 05/12)

Tom Taverner, BSc(Hons) Melbourne PhD Cambridge, visiting Masters student

Melanie Bahlo, BSc(Hons) Monash PhD Monash

Dimitar Azmanov (from 09/11 to 09/11)

Thomas Scerri, BSc UCL MSc Birbeck DPhil Oxford

Jim Stankovich, BA(Hons) Melbourne PhD Melbourne (from 02/12)

Natalie Thorne, BSc(Hons) Melbourne PhD Melbourne

Catherine Bromhead, BSc(Hons) Melbourne (to 11/11)

Luke Gandolfi, BA(Hons) Monash BSc(Hons) Monash MA Monash

Vesna Lukic, BEng(Hons) Melbourne BSc Melbourne MSc Melbourne (from 11/11)

Rick Tankard, BSc(Hons) Melbourne

Peter Hickey, BSc (Hons) Melbourne, DipArts(HPS) Melissa

Dineika Chandrananda, BSc(Hons) Auckland, MSc Auckland, PhD student

Peter Diakumis, BSc Athens, visiting Masters student (from 06/12)

Karen Oliver, visiting Masters student (from 07/11)

Katherine Smith, BSc(Hons) Melbourne MBioStat Melbourne, PhD student

Andrew Bennett UROP student (from 12/11)

David Wakeham, UROP student (from 07/11)

Anthony Papenfuss, BSc(Hons) Monash PhD Monash

Vincent Corbin, BSc Florida MSc Montana PhD Montana

Arthur Hau, BA Melbourne BE Melbourne PhD Melbourne

Jan Schroeder, MSc Christian-Albrechts PhD Melbourne (from 12/11)

Mark Kowarsky

Ehtesham Mofiz, BSc North South, PhD student

Xi Yao, visiting PhD student (from 02/12 to 06/12)

Lachlan McIntosh, UROP student (from 07/11)

Samuel Robinson, visiting PhD student (from 06/12)

Gordon Smyth, BSc(Hons) UWA PhD ANU

Matthew Ritchie, BAAppSc(Hons) Qld PhD Melbourne

Wei Shi, BCompEng Harbin MS Harbin PhD Harbin

Yifang Hu, BEsoftEng Melbourne BSc Melbourne, software engineer

Yang Liao, BCompSc Tsinghua MIT Melbourne

Cynthia Liu, BSc Melbourne

Keith Satterley, BSc Melbourne DipEd Melbourne DipCompSci LaTrobe, senior programmer

Andy Chen, BSc(Hons) Melbourne, PhD student

Joshy George, ME Bangalore, visiting PhD student

Charity Law, BSc(Hons) Melbourne, PhD student

Aaron Lun, BSc(Hons) Sydney, PhD student (from 02/12)

Davis McCarthy, BA Melbourne BSc(Hons) Melbourne, visiting PhD student (from 06/12 to 06/12)

Belinda Pipson, BSc(Hons) KwaZulu-Natal MSc KwaZulu-Natal, PhD student
Infection and Immunity

Infectious diseases caused by parasites, bacteria and viruses are a major health burden and can result in death, disability, and social and economic disruption for millions of people globally.

Malaria, tuberculosis and HIV cause significant death and disease, particularly in developing countries. In the Infection and Immunity division, we aim to understand how infectious agents cause human disease and use this knowledge to develop new treatments.

A highlight in the division this year has been work identifying novel avenues for treating malaria. In a newly designed mouse model, we showed that combination treatment with antimalarial drugs and synthetic anti-inflammatory compounds based on natural host defence (innate defence regulator or IDR) peptides can increase the survival of mice with cerebral malaria (see opposite page).

In a human clinical trial based in Papua New Guinea (PNG) we showed that the use of intermittent preventive treatment with a combination of antimalarial drugs significantly improved the prevention of malaria and anaemia in infants living in a region of PNG highly endemic for *Plasmodium falciparum* and *Plasmodium vivax* malaria (see opposite page).

The malaria parasite infects humans by invading red blood cells where it can access the nutrients it requires for survival. An important aim of the division has been to understand how the parasite evades the host immune system, as this has important implications for the development of new treatments. We identified a new protein called PfSET10 in *P. falciparum* that is central to the parasite’s ability to evade host immune responses by varying proteins recognised and targeted by the immune system.

Our work on chronic infectious diseases has progressed significantly with the development of preclinical models of hepatitis B that will allow us to test new therapeutics. We are also in the process of developing mouse models with human immune systems that will more accurately reflect human disease states, aiding development of new therapies for treating HIV and malaria.

Laboratory heads

Dr Alyssa Barry  
Dr Jake Baum  
Dr Justin Boddey  
Professor Alan Cowman  
Division head  
Dr Diana Hansen  
Professor Ivo Mueller  
Dr Marc Pellegrini  
Professor Louis Schofield  
Dr Chris Tonkin

Professor Ivo Mueller led the team that showed malaria infections among Papua New Guinean infants could be cut by 30 per cent by giving the infants a combination of antimalarial drugs intermittently over 12 months.
Improving malaria survival and treatment

Malaria kills up to one million people worldwide every year, particularly children under five and pregnant women.

Two research teams from the institute’s Infection and Immunity division are looking for ways to improve treatment for, and survival from, malaria infection and its complications.

A study led by Professor Ivo Mueller showed malaria infections could be cut by up to 30 per cent among Papua New Guinean infants given a combination of antimalarial drugs intermittently over 12 months.

The three-year clinical trial showed the most effective treatment was a combination of long-lasting antimalarials sulfadoxine/pyrimethamine and amodiaquine (SP-AQ). The treatment decreased infant infections with Plasmodium falciparum malaria by 35 per cent and Plasmodium vivax malaria by 23 per cent; the first time antimalarial drugs have been shown to prevent infections by both malaria species.

Infants were protected for at least six weeks after the end of treatment, showing that the drugs had an ongoing protective effect and did not hinder natural immunity. “This treatment is a cheap and easy way to decrease the burden of malaria in those most susceptible to clinical illness, such as young infants and pregnant women,” Professor Mueller said.

In another study, researchers Dr Ariel Achtman, Dr Sandra Pilat-Carotta and Professor Louis Schofield showed that a new class of anti-inflammatory agents called IDR (innate defence regulator) peptides could help to increase survival from severe clinical malaria when used in combination with antimalarial drugs.

IDR peptides were developed at the University of British Columbia, Canada, and enhance the beneficial aspects of the initial immune response, while dampening harmful inflammation.

Dr Achtman said IDR peptide treatment, when used with standard antimalarial drugs, improved survival in mouse models of cerebral malaria infection. “Cerebral malaria, which causes brain damage, is actually the result of the immune system trying to fight infection and causing collateral damage. IDR peptides help to improve survival by preventing the immune system from causing this irrevocable brain and tissue damage,” she said.

Gates Foundation supports world-first malaria vaccine

Malaria is a major disease and economic burden in developing nations. More than half the world is at risk from malaria, a parasitic disease that infects more than 225 million people per year, resulting in up to one million deaths.

The Bill & Melinda Gates Foundation, through its Grand Challenges Explorations program, is supporting malaria researcher Professor Louis Schofield in a project to develop the world’s first carbohydrate-based malaria vaccine.

The vaccine targets an essential Plasmodium parasite carbohydrate called GPI (glycosylphosphatidylinositol). Professor Schofield said GPI was a parasite toxin that had previously been identified as a major determinant in the severity and fatality of malaria disease.

“The anti-GPI vaccine is novel in that it is the first potential antimalarial vaccine that targets a parasite carbohydrate, rather than a protein,” Professor Schofield said. “Malaria parasites invest considerable effort in evading the immune system, continuously modifying their proteins to avoid detection, which is why a malaria vaccine has continued to be elusive. A vaccine that targets a highly conserved carbohydrate target could be especially effective in treating malaria.”

The US$1 million funding will allow the team to advance development and preclinical trials that will test the ability of the vaccine to interrupt transmission of the parasite, and decrease the severity of the disease.

“We generated some very encouraging results from a phase I project, also supported by the Grand Challenges Explorations program, that indicated the anti-GPI vaccine could be very useful in both preventing and treating malaria,” Professor Schofield said. “The use of a vaccine with anti-toxin properties could help to diminish the disease burden in countries where malaria is endemic, particularly if used in combination with other prevention and treatment strategies.”

Collaborating organisations: Barcelona Centre for International Health Research, Burnet Institute, Case Western University, Papua New Guinea Institute of Medical Research, Simon Fraser University, Swiss Tropical and Public Health Institute, The Irish Agriculture Food Development Authority, The University of Melbourne, University of Basel and University of British Columbia.

Funding partners: Grand Challenges in Global Health Research program through the Foundation for the National Institutes of Health and Canadian Institutes of Health Research, National Health and Medical Research Council of Australia, The Bill & Melinda Gates Foundation and the Victorian Government.


Professor Louis Schofield (centre), Dr Sandra Pilat-Carotta (left) and Dr Ariel Achtman.
Major national and international meetings

Jake Baum
Ninth Protein Island Matsuyama Symposium, Matsuyama, Japan, 09/11, Keynote speaker
12th Hunter Cellular Biology Meeting, Pokolbin, Australia, 03/12, Keynote speaker
Creative Innovation Ci2011, Melbourne, Australia, 11/11, Invited speaker
Gordon Research Conference on Proteolytic Enzymes and their Inhibitors, Lucca, Italy, 06/12, Keynote speaker
International Young Researcher Symposium in Zoonosis Control, Sapporo, Japan, 09/11, Invited speaker

Alan Cowman
Australia-France Symposium, Canberra, Australia, 11/11, Plenary speaker
International Meeting of Pathogens, Sao Paulo, Brazil, 08/11, Plenary speaker
Molecular Approaches to Malaria, Lorne, Australia, 02/12, Keynote speaker
12th Hunter Cellular Biology Meeting, Pokolbin, Australia, 03/12, Plenary speaker

Louis Schofield
Australasian Vaccines and Immunotherapeutics Development Conference, Brisbane, Australia, 07/11, Keynote speaker
Australian College of Tropical Medicine, Cairns, Australia, 07/11, Plenary speaker
Culture Systems for Malaria, Tampa, United States, 03/12, Invited speaker
Emory Systems Biology Workshop, Atlanta, United States, 04/12, Invited speaker
Molecular Approaches to Malaria, Lorne, Australia, 02/12, Keynote speaker
Staff list

Joan Curtis, scientific coordinator

Alan Cowman, BSc(Hons) Griffith PhD Melbourne FAA
Dejan Bursac, BAppSc RMIT BSc(Hons) Melbourne PhD Monash
Teresa Carvalho, PhD Paris (to 12/11)
Lin Chen, PhD LaTrobe
Sara Erickson, BSc Iowa MSc Iowa PhD Wisconsin (from 10/11)
Julie Healer, BSc(Hons) Glasgow M.Phil London PhD Edinburgh
Tony Hodder, BSc(Hons) Monash PhD Monash
Nata Riegev-Rudzki, MSc Jerusalem PhD Jerusalem
Melanie Rug, PhD Heidelberg (to 11/11)
Xavier Sanguella Duran, BSc Barcelona MSc Barcelona PhD Barcelona (from 01/12)
Wai-Hong Tham, BA California PhD Princeton
Tony Triglia, BSc(Hons) Melbourne MSc Melbourne
Shiela Unkles, BSc Glasgow MSc Glasgow PhD St Andrews (from 10/11 to 01/12)
Danny Wilson, BSc(Hons) NTU PhD Melbourne
Sash Lopaticki, BSc(Hons) VUT Jennifer Thompson, MSc Melbourne
Brendan Ansell, BA Melbourne BSc Melbourne, BSc(Hons)student (to 11/11)
Michelle Boyle, BA Melbourne BSc(Hons) Melbourne, PhD student (to 06/12)
Hayley Bullen, BBiomedSc(Hons) Melbourne, PhD student (to 02/12)
Jo-Anne Chan, BBiomedSc(Hons) Melbourne, PhD student (to 06/12)
Wieteke Faber-Hoeijmakers, BSc Radboud MSc Radboud, visiting PhD student (from 01/12 to 02/12)
Claire Lin, BBiomedSc Melbourne BSc(Hons)Melbourne, PhD student (from 04/12)
Tana Taechalerptaisarn, BSc(Hons) Chulalongkorn, visiting PhD student (to 03/12)
Alan Yap, BBiomedSc(Hons) Melbourne, PhD student
Hayley Stratton, UROP student (from 02/12)

Alyssa Barry, BSc(Hons) UTAS PhD Melbourne
Alicia Arnott, BBiomedSc(Hons) Deakin PhD Monash (from 02/12)
Mark Schultz, BSc(Hons) Deakin PhD CDU (to 03/12)
Charlie Jennison, BSc Leeds MSc London (from 08/11)
Valentine Siba (from 07/11 to 09/11)

Jacob Baum, BA(Hons) Oxford MA Oxford MSc London PhD London
Paisuke Ito, PhD Ehime (from 02/12 to 02/12)
Danushka Marapana, BBiomedSc Melbourne
Yan Hong Tan, BSc(Hons) Melbourne
Wilson Wong, BBiomedSc(Hons) Monash
Fiona Angrisano, BBiomedSc(Hons) LaTrobe, PhD student
Maya Oshina, BSc(Hons) Melbourne, PhD student
Noa Pasternak-Dahan, BA Hebrew MSc Hebrew, visiting PhD student (from 02/12 to 05/12)
David Riglar, BSc(Hons) Melbourne, PhD student
Elizabeth Zuccala, BSc(MSc) Melbourne, PhD student

Justin Boddey, BBiomedSc(Hons) Griffith PhD Griffith
Matthew O’Neill, BSc(Hons) Melbourne
Michelle Gazdik, BMedChem(Hons) LaTrobe, PhD student (from 03/12)
Pravin Rajasekaran, BSc(Hons) Melbourne, PhD student (from 01/12)

Diana Hansen, BBiolSc Buenos Aires PhD Upsaaal
Lisa Ioannidis, BSc(Hons) Melbourne (from 04/12)
Chris Chiu, BSc(Hons) Adelaide, PhD student (from 07/11)
Victoria Ryg-Cornejo, BSc Montpellier BSc(Hons) Melbourne, PhD student

Ivo Mueller, MSc Basel PhD Basel
Celine Barnadas, MSc Lyon PhD Lyon
Cristian Koepfl, BSc Zurich MSc Zurich PhD Basel (from 02/12)
Suparat Phuankrkonin, BSc Thailand MSc QUT PhD Qld
Holger Unger, BSc(Hons) Edinburgh MB ChB Edinburgh MSc LSHTM DTM&H LSHTM (from 12/11)
Raksmei Keo, BAppSc RMIT (from 01/12)
Connie Li Wai Suen, BSc(Hons) LaTrobe (from 04/12)
Elishba Malau, visiting GradDip student (to 11/11)
Andreea Walmann, BA Monash BSc(Hons) Monash, PhD student (from 11/11)

Marc Pellegrini, BSc Melbourne MB BS Melbourne PhD Melbourne FRACP
Cody Allison, BAppSc QUT BSc(Hons) Monash PhD Monash (from 01/12)
Kate Coles, BSc(Hons) UWA MB BS Melbourne PhD UWA (from 02/12 to 06/12)
Gail Cross, BSc UNSW MB BS Monash (from 02/12 to 06/12)
Gregor Ebert, Dipl. Biol. Munich PhD Munich
Hamish Scott, BSc(Hons) UTAS
James Cooney, BBiotech(Hons) Flinders (from 04/12)
Simon Preston, BBiomedSc(Hons) Monash, PhD student
Jesse Toe, BSc(Hons) Melbourne, PhD student

Louis Schofield, BSc London MSc London PhD Qld
Ariel Achtmann, MSc Freiburg PhD London
Emily Eriksson, MSc Malmoe PhD Melbourne (from 08/11)
Krystal Evans, BMedChem(Hons) Wollongong PhD Melbourne
Ramin Mazhari, BSc(Hons) Justus-Liebig MSc Philips PhD Philips
Willie Pomat, PhD UWA (from 10/11 to 10/11)
Pilar Requena Mandez, BSc Granada MSc Granada PhD Granada (from 01/12 to 02/12)
Amandine Carmagnac, BSc France
Wasan Forsyth, BSc(Hons) Auckland (from 02/12)
Thuan Phuong, BSc(Hons) LaTrobe
Danika Hill, BBiomedSc(Hons) Adelaide, PhD student
Natalia Sampaio, BSc(Hons) UWA, PhD student (from 01/12)
Stephanie Tan, BBiomedSc(Hons) Qld, PhD student (from 02/12)

Chris Tonkin, BSc(Hons) Melbourne PhD Melbourne
Carolina Agop-Nersesian, PhD Heidelberg (to 09/11)
Alex Uboldi, BSc(Hons) Witwatersrand PhD Witwatersrand
James McCoy, BA Melbourne BBiomedSc(Hons) Melbourne, PhD student
Rebecca Stewart, BSc(Hons) UWA, PhD student
Melanie Williams, BBiomedSc RMIT BSc(Hons) Melbourne, PhD student (from 12/11)
Immunology

Our immune systems play a vital role in protecting us from infectious diseases through the coordinated activity of many cell types.

This remarkable collection of cells detects new infections and remembers those we have seen before to provide long-term, even lifetime, protection. There is a cost, however, to having an active immune system. In some people, the immune system attacks its own tissues, leading to autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis. Allergies too are an overreaction of the immune system to harmless materials found in our environment.

Every cell of the immune system must continuously make decisions that affect the health of an individual. Researchers in the Immunology division are committed to understanding how these cellular decisions are made. Understanding these processes will allow us to dampen over-reactive autoimmune and allergic responses, or enhance immunity to boost, where necessary, vaccines for infectious disease or cancers.

Three cell types – T cells, B cells and dendritic cells – are the primary focus of research in the division. Methods to remove the specific auto-reactive T cells that cause type 1 diabetes and coeliac disease have been developed and hold promise in the clinic. Other strategies to prevent tissue graft rejection by targeting molecules on T cells that inhibit their activity are yielding promising results.

This year we also gained new insights into how T and B cells communicate to regulate the antibody response and remember past infections. A novel method for enhancing vaccine efficacy by targeting foreign material directly to dendritic cells (the primary cells responsible for alerting the immune system to infection) was also identified. Catching cells in the act of deciding between fates provided a major insight into how autonomous individual cell decisions can lead to a predictable, reliable and effective immune response (see opposite page).

Together these advances greatly enhance our understanding of immune regulation and progress our goal of developing a computer-based model of immunity that can be used to optimise therapies to promote health.
Research shows cells influence their own destiny

B cells, immune cells that make antibodies, can have multiple fates. Some of the more common fates are to die, divide, become antibody-secreting cells or change the antibody they make.

Researchers from the institute’s Immunology division have shown B cells have some control over their own destiny, challenging the commonly-held view that a cell’s fate is determined by external cues such as hormones or cell signalling molecules.

Professor Phil Hodgkin, Dr Mark Dowling and colleagues from the institute’s Immunology division led the research, in collaboration with mathematician Dr Ken Duffy from the Hamilton Institute, National University of Ireland, Maynooth, and Dr John Markham from National Information and Communications Technology Australia.

The research team recreated the conditions required for 2500 B cells to develop into different cell types and filmed the cells, developing new technology, image analysis and mathematical methods to analyse their behaviour and decisions.

Professor Hodgkin said the cells behaved as though they had internal machines governing their fate. “Each internal machine is like a little clock or timer for each potential fate,” he said.

Dr Dowling explained the different fate outcomes resembled a competition. “The cell has internal clocks that ‘count down’ to each potential outcome, and whichever clock goes off first is the decision the cell makes,” he said.

Professor Hodgkin said the external signals did not tell the cells what to do, but did alter the probability of the cell’s final fate ‘decision’. “We hope to create mathematical models that accurately predict how these external signals interact with internal clocks to alter cell fate, which would help in the design of new immune therapies for autoimmune diseases and improved vaccines,” he said.

Coeliac Australia appeal to support new treatment search

Coeliac disease, which affects more than one per cent of the population, is caused by an abnormal immune response to gluten. Treatment involves a strict, lifelong, gluten-free diet. Without treatment, patients with coeliac disease have an increased risk of other immune diseases, osteoporosis and some types of cancer.

Coeliac Australia and the Walter and Eliza Hall Institute have formed a three-year, $570,000 partnership to support critical research required for new treatments and diagnostic tests for coeliac disease.

Funded by an ongoing Coeliac Australia appeal, the partnership aims to develop better treatments for children with coeliac disease, effective treatments following accidental gluten consumption, and a diagnostic test for people already following a gluten-free diet.

Coeliac Australia president Mr Hugh Sheardown praised the research efforts of Dr Bob Anderson and Dr Jason Tye-Din, who lead the institute’s coeliac disease research team.

“The research being undertaken is critical to unlocking a greater understanding of coeliac disease, particularly in the under-researched area of children. This is the largest research funding project Coeliac Australia has ever undertaken, and we are very happy to partner with the Walter and Eliza Hall Institute to improve the understanding, diagnosis and treatment of coeliac disease,” Mr Sheardown said.

Dr Anderson and Dr Tye-Din’s research at the institute has already led to the development of a potential coeliac vaccine, Nexvax2®, currently in clinical trials.

Dr Tye-Din said the Coeliac Australia partnership was very exciting. “We are thrilled that Coeliac Australia is supporting the institute’s research. A major focus is understanding the immune response that causes disease in young people, in the hope of developing a treatment for children similar to Nexvax2®. We are grateful for the opportunity to translate these research projects into meaningful outcomes for people with coeliac disease,” Dr Tye-Din said.

Collaborating organisations:
Hamilton Institute at the National University of Ireland, National Information and Communications Technology Australia, Peter MacCallum Cancer Centre.

Funding partners: National Health and Medical Research Council of Australia, Science Foundation Ireland and the Victorian Government.

Major national and international meetings

Maria Esther Bandala Sanchez
8th Congress of Autoimmunity, Granada, Spain, 05/12, Oral presentation

Jamie Brady
Transplant Society of Australia and New Zealand (TSANZ), Canberra, Australia, 06/11, Oral presentation

Mark Chong
Immunology Group of Victoria Annual Scientific Meeting, Geelong, Australia, 09/11, Invited speaker
International Symposium of Aging and Autoimmunity, Seoul, South Korea, 12/11, Invited speaker
Fourth Australasian Vaccines and Immunotherapeutics Development Meeting, Brisbane, Australia, 05/12, Invited speaker
Novo Nordisk Type 1 Diabetes Research and Development Center, Opening Scientific Symposium, Seattle, United States, 06/12, Invited speaker
12th Immunology of Diabetes Society Scientific Meeting, Victoria, Canada, 06/12, Invited speaker

Len Harrison
Australian Diabetes Society annual scientific meeting, Perth, Australia, 08/11, Oral presentation
41st Australasian Society of Immunology annual scientific meeting, Adelaide, Australia, 12/11, Invited speaker
Fourth Australasian Vaccines and Immunotherapeutics Development Meeting, Brisbane, Australia, 05/12, Invited speaker

Phil Hodgkin
British Society of Immunology Congress, Liverpool, United Kingdom, 12/11, Invited speaker
Cambridge Immunology forum: Systems Immunology: datasets and discovery in the immune system, Cambridge, United Kingdom, 09/11, Invited speaker
Computational Immunology Conference, Melbourne, Australia, 04/12, Invited speaker
41st Australasian Society of Immunology Annual Scientific Meeting, Adelaide, Australia, 12/11, Invited speaker
ICT for Life Sciences forum, Melbourne, Australia, 05/12, Invited speaker
Models and Methods for Analysis of Lymphocyte Repertoire Generation, Development, Selection and Evolution research workshop, Jerusalem, Israel, 02/12, Invited speaker
12th Hunter Cellular Biology Meeting, Hunter Valley, Australia, 03/12, Invited speaker
2011 International Nanomedicine Conference, Sydney, Australia, 07/11, Invited speaker

Andrew Lew
19th Immunology Group of Victoria annual scientific meeting, Geelong, Australia, 09/11, Keynote speaker
29th Transplantation Society of Australia and New Zealand annual scientific meeting, Canberra, Australia, 07/11, Invited speaker

Staff list
Kim McIntosh, BSc(Hons) Monash
MEvSc Monash, scientific coordinator

Phil Hodgkin, BSc(Hons) UWA PhD ANU
Mark Dowling, BA Qld BSc(Hons) Qld PhD Qld
Melinda Hardy, BSc(Hons) Qld PhD Qld
Jhagvaral Hasbold, PhD Budapest (to 07/11)
Susanne Heinzel, BSc(Hons) Tuebingen PhD Tuebingen
Mike Inouye, BSc Washington MSc California PhD Leiden (to 03/12)
John Markham, BEng Swinburne BSc(Hons) Melbourne PhD Melbourne
Nadine Taubenheim, PhD Albert-Ludwigs
Jason Tye-Din, MB BS Melbourne PhD Melbourne FRACP
George Varigos, MB BS Melbourne PhD Melbourne
Cameren Wellard, BSc(Hons) Melbourne PhD Melbourne
Adam Girardin, BSc British Columbia (from 04/12)
Julia Marchingo, BBiomedSc(Hons) Melbourne, PhD student

Jessica Moffat, BSc(Hons) Melbourne, PhD student
Scott Ritchie, BCompSc Melbourne, visiting Masters student (from 08/11 to 03/12)
Jeigh Tiu, BBiomedSc Melbourne, BSc(Hons) student (from 02/12)
Jie Zhou, BBiomedSc Melbourne, BSc(Hons) student

Bob Anderson, BMedSc Otago MB ChB Otago PhD Otago FRACP
Noe Ontiveros-Apoda, overseas research trainee (to 10/11)

Robyn Sutherland
Cell Transplant Society - International Xenotransplantation Association 2011 Joint International Congress, Miami, United States, 10/11, Invited speaker
30th Transplant Society of Australia and New Zealand (TSANZ) annual scientific meeting, Canberra, Australia, 06/12, Oral presentation

David Tarlinton
Australasian Society for Immunology NSW/ACT branch retreat, Bowral, Australia, 08/11, Keynote speaker
Berlin Life Science Colloquium, Max Planck Institute for Infection Biology, Berlin, Germany, 09/11, Invited speaker
41st Japanese Society for Immunology, Chiba, Japan, 11/11, Plenary speaker
Gordon Research Conference on Immunohistochemistry and Immunobiology, Les Diablerets, Switzerland, 06/12, Plenary speaker
Keynote Symposium: HIV Vaccines and Viral Immunity, Kingston, United States, 03/12, Plenary speaker
Sixth Chiba University Global Center of Excellence Symposium, Chiba, Japan, 11/11, Plenary speaker
17th International Conference on Lymphatic Tissues and Germinal Centres in Immune Reactions, West Midlands, United Kingdom, 09/11, Plenary speaker

Jason Tye-Din
Fifth Autoimmunity Conference Asia, Singapore, Singapore, 11/11, Oral presentation
Len Harrison, MB BS UNSW DSc Melbourne MD Melbourne FRACP FRCPA
Petra Augustin, BSc Ernst-Moritz-Arndt PhD Ernst-Moritz-Arndt (to 10/11)
Ilia Banakh, BSc(Hons) Monash PhD Monash
Esther Bandala Sanchez, BSc(Hons) LaTrobe MSc LaTrobe PhD LaTrobe
Mark Chong, BA Melbourne BSc(Hons) Melbourne PhD Melbourne
Diana Mittag, MSc Technical PhD Johann Wolfgang Goethe (to 01/12)

Petra Augustin, BSc Ernst-Moritz-Arndt PhD Ernst-Moritz-Arndt (to 10/11)
Ilia Banakh, BSc(Hons) Monash PhD Monash
Esther Bandala Sanchez, BSc(Hons) LaTrobe MSc LaTrobe PhD LaTrobe
Mark Chong, BA Melbourne BSc(Hons) Melbourne PhD Melbourne
Diana Mittag, MSc Technical PhD Johann Wolfgang Goethe (to 01/12)

John Wentworth, MB BS Qld PhD Cambridge
Yuxia Zhang, PhD IMCAS

Michelle Low, MSc Melbourne, visiting Masters student (from 07/11)
Cathy Qian, overseas research trainee (from 01/12 to 02/12)
Maryam Rashidi, MD Yazt Azad, PhD student
Janet Yeo, BSc(Hons) Melbourne, PhD student

Andrew Lew, BVSc Melbourne MVSc Melbourne PhD London
Emma Carrington, BSc(Hons) Melbourne PhD Melbourne
Sophie Ko, MSc Sungkyunkwan University PhD Monash
Robyn Sutherland, BSc(Hons) Melbourne PhD Melbourne
Yifan Zhan, BMedSci Jiangxi MMedSc Beijing PhD Melbourne
Jiao Zhijun, PhD Shanghai (to 10/11)
Jamie Brady, BSc(Hons) LaTrobe MSc Adelaide
Manuela Hancock, BAppSc RMIT
Kevin Chow, MB BS(Hons) Melbourne, PhD student (from 04/12)
Tim Johanson, BSc(Hons) Melbourne, PhD student
Shirley Seah, BSc(Hons) Melbourne, PhD student

Ken Shortman, BSc(Hons) Sydney PhD Melbourne FAA
Irene Caminschi, BSc(Hons) Murdoch PhD UWA (to 12/11)
Mireille Lahoud, BSc Monash BSc(Hons) Melbourne PhD Monash (to 12/11)

Hae Park, MD Dong-A PhD Dong-A (from 01/12)
Fatma Ahmet, BSc(Hons) Melbourne (to 12/11)
Lauren Cox, BBiomedSc LaTrobe (from 02/12)
Susie Kitsoulis, BSc Monash (to 12/11)
Priyanka Sathe, BSc Sydney BSc(Hons) Melbourne (to 08/11)
David Vremec, BAppSc RMIT

David Tarlinton, BSc(Hons) Sydney PhD Stanford
Simona Infantino, MSc Switzerland PhD dell’Insubria
Kim Jacobson, BBiomedSc(Hons) UTS PhD Sydney
Katja Luethje, PhD Hamburg
Victor Peperzak, MSc Amsterdam PhD Netherlands

Ken Smith, BMedSc Melbourne MB BS Melbourne PhD Melbourne (from 02/12 to 02/12)
Ingelina Vikstrom, MSc Ume PhD Ume
Dimitra Zotos, BBiomedSc Melbourne (from 03/12)
Lingli Li, BSc Hunan MSc Hunan (from 01/12)
Amanda Light, BAppSc RMIT
Kristy O’Donnell, BAppSc RMIT BSc(Hons) Melbourne
Ivan Fung, BSc(Hons) Melbourne, PhD student (from 02/12)
Cell Signalling and Cell Death

Some of the pathways that tell a cell whether to continue to survive or to self-destruct also control innate immune responses to viruses and other pathogens.

Drugs that target these proteins have been designed to cause the death of cancer cells, but might also be used to reduce inflammation in autoimmune disease. The Cell Signalling and Cell Death division studies two families of proteins that inhibit cell death, the Bcl-2 family and IAP (inhibitor of apoptosis) family.

Dr Grant Dewson is studying how Bax and Bak, the two essential pro-death members of the Bcl-2 family, are activated. Dr Dewson and Dr Ruth Kluck, from the Molecular Genetics of Cancer division, have found that these proteins first bind to each other, then bind in higher numbers to form higher-order oligomers. This is the first step in the search for novel drugs that can block cell death when it occurs inappropriately, such as in heart attacks or stroke.

In healthy cells, activation of the Bcl-2 family pro-death molecules Bax and Bak is governed by other Bcl-2 family proteins, which are in turn controlled by a network of signalling pathways. Associate Professor Paul Ekert is investigating such pathways in blood cells that respond to growth factors. He has found that, rather than being simple linear pathways, there is unexpected communication between the pathways controlled by cell signalling hormones (cytokines) involved in inflammation, and those that respond to DNA damage.

Dr John Silke and Professor David Vaux are studying signalling pathways that regulate cell survival independently of the Bcl-2 family. In these pathways the key killers are RIP (receptor-interacting protein) kinases and the enzyme caspase 8. Both classes of proteins are regulated in large part by the IAPs. They have carried out genetic studies to determine the role of IAP proteins during embryo development, and to validate the effects of IAP-antagonist drugs that are undergoing clinical trials for the treatment of cancer. Drs James Vince, Ueli Nachbur and Kate Lawlor have discovered that the IAPs not only regulate cell survival, but also control the level of inflammation in immune responses.

Laboratory heads
Dr Grant Dewson
Associate Professor Paul Ekert
Associate Professor John Silke
Professor David Vaux
Division head

Dr James Vince is studying inhibitor of apoptosis (IAP) proteins and their role in inflammation.
Cancer, development and cell death

Most of our cells contain mechanisms that enable them to self-destruct.

This process, called programmed cell death or apoptosis, can cause disease when activated inappropriately such as in heart or brain cells during heart attack or stroke. However if cells fail to kill themselves when they should, they can lead to cancers.

Inhibitor of apoptosis proteins (IAPs) are important for cell survival and the response to certain cell signalling hormones, such as tumour necrosis factor (TNF), involved in immunity. IAP genes are also frequently amplified in cancers. Anti-cancer agents called smac-mimetics that kill cancer cells by targeting and binding the IAPs are currently in clinical trials.

Professor David Vaux and colleagues from the institute’s Cell Signalling and Cell Death division are studying how IAPs keep tumour cells alive, as well as looking at the role of IAPs in healthy cells.

Professor Vaux said the research team had identified three IAPs involved in inhibiting cell death. “We don’t yet understand precisely what role the IAPs play in the cells of adult organisms, or in the developing embryo,” Professor Vaux said. “A better understanding of how IAPs function will help us to reveal the susceptibility of tumour cells to treatment with smac-mimetic agents, and help predict the potential side effects.”

The research team looked at mouse models that had different combinations of the IAP genes missing to investigate how the genes function during embryonic development. They found that deleting the gene for one IAP did not significantly affect development. However deleting genes for two IAPs was fatal, proving that they do have some overlapping roles but are essential for normal development.

“We also found IAPs are critical regulators of TNF signalling, and they act in large part by limiting activity of associated proteins called RIP kinases that, left unchecked, cause cell death at the wrong time,” Professor Vaux said. “Unravelling the overlapping roles of these proteins will give us a better understanding of how they are involved in diseases such as cancers, trauma and chronic inflammation, and lead to better, more targeted, therapies.”

Collaborating organisations:
La Trobe University.

Funding partners: The Leukemia & Lymphoma Society (US), National Health and Medical Research Council of Australia and the Victorian Government.


Finding new treatments for childhood cancers

Neuroblastoma is a rare childhood cancer in which malignant tumour cells form in the nerve tissue of the glands above the kidneys, spinal cord, neck or chest. Approximately 40 children per year are diagnosed with neuroblastoma in Australia, mostly children under five.

In September 2011 The Scobie and Claire Mackinnon Trust made a grant of $75,000 payable over three years to Associate Professor Paul Ekert for genetic studies into neuroblastoma. Associate Professor Ekert is a clinician-scientist from the institute’s Cell Signalling and Cell Death division, who also has an appointment at Melbourne’s Royal Children’s Hospital.

The Trustees of The Scobie and Claire Mackinnon Trust said they had endeavoured to pursue themes to which Scobie and Claire were particularly sympathetic. “One of our main themes has been child health and welfare and, for this reason, we were particularly attracted to Professor Ekert’s neuroblastoma project,” they said.

Associate Professor Ekert said the advent of new genetic technologies had begun to shed light on the underlying nature of this disease and the molecular variations that influence response to treatment.

“The project will focus on understanding how different genetic profiles of neuroblastoma can be used to diagnose patients and guide treatment,” Associate Professor Ekert said. “Tumours will be profiled for genetic changes that predict better or worse outcomes that may be helpful in guiding treatment for the child. This is a type of personalised medicine which helps each child to have the best possible treatment applied to their particular type of cancer.”

The project is a collaboration between Associate Professor Ekert and Dr Francoise Machinaud and Dr Elizabeth Algar from the Children’s Cancer Centre at the Royal Children’s Hospital. Associate Professor Ekert said it was an exciting project, bringing together expertise from the institute and the hospital to gain a better understanding of a serious childhood cancer.

“Children with neuroblastoma require multiple invasive surgeries, as well as intensive chemotherapy, and still the outcome is often very poor,” Associate Professor Ekert said. “New treatments for this disease are desperately needed, and we look forward to opportunities that will permit the early and realistic trial of new drugs and a more rapid transition to treatments.”
Major national and international exchanges

Gabriela Brumatti
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Paul Ekert
Eighth European Workshop on Cell Death (EWCD), Monetier-les-Bains, France, 06/12, Session chair
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Session chair
New Directions in Leukaemia Research, Sunshine Coast, Australia, 03/12, Oral presentation

Joe Evans
Eighth European Workshop on Cell Death, Monetier-les-Bains, France, 06/12, Oral presentation

Anissa Jabbour
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Najoua Lalaoui
Eighth European Workshop on Cell Death, Monetier-les-Bains, France, 06/12, Oral presentation
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Kate Lawlor
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Donia Moujalled
Apoptosis and Cancer Conference, Cambridge, United Kingdom, 06/12, Oral presentation
Eighth European Workshop on Cell Death, Monetier-les-Bains, France, 06/12, Oral presentation
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Ueli Nachbur
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

James Rickard
Eighth European Workshop on Cell Death, Monetier-les-Bains, France, 06/12, Oral presentation
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

Jarrod Sandow
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation

John Silke
Cytokine Interest Group Symposium - TNF Family Cytokine Biology and Signalling, Bethesda, United States, 04/12, Keynote speaker
Eighth European Workshop on Cell Death, Monetier-les-Bains, France, 06/12, Keynote speaker and session chair

Fifth Barossa Meeting on Cell Signalling and Molecular Medicine (Science Among the Vines), Barossa Valley, Australia, 11/11, Keynote speaker
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Session chair
2011 Genes and Cancer Meeting, Warwick University, England, 12/11, Keynote speaker

David Vaux
Annual Meeting of the Committee of Freedom and Responsibility in the Conduct of Science, Paris, France, 03/12, Invited participant
Committee on Publication Ethics meeting, Melbourne, Australia, 10/11, Invited speaker
CSIRO Clayton, Melbourne, Australia, 05/12, Invited speaker

James Vince
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation
TLROZ 2012, Melbourne, Australia, 05/12, Oral presentation

Lynn Wong
First Australian Workshop on Cell Death: Death on the Reef, Lindemann Island, Australia, 08/11, Oral presentation
Staff list

Catherine McLean, BA Melbourne
GradDipGenetCounsell Charles Sturt, Scientific Coordinator

Dave Vaux, BMedSc Melbourne MBBS Melbourne PhD Melbourne FAA
Kate Lawlor, BSci(Hons) Melbourne PhD Melbourne
Lisa Lindqvist, BSci(Hons) McGill PhD McGill
Donia Moujalled, BMedSci(Hons) LaTrobe PhD LaTrobe
James Vince, BSci(Hons) Melbourne PhD Melbourne
Catherine Hall, BSc LaTrobe
Boon Chai, BSc Melbourne, BSc(Honours) student (from 02/12)

Grant Dewson, BSc Nottingham
PhD Leicester
Stephen Ma, BBiomedSci(Hons) Melbourne
Robert Ninnis, BBiolSci(Hons) LaTrobe
Iris Tan, BSci(Hons) Melbourne PhD Melbourne
Laura Raiti BSc Melbourne (to 02/12)

Paul Ekert, MBBS Melbourne
PhD Melbourne
Gabriela Brumatti, BSc(Hons) Sao Paulo
PhD Sao Paulo
Anissa Jabbour, BSc(Hons) Melbourne
PhD Melbourne
Jarrod Sandow, BBiotech Adelaide BSc(Hons) Adelaide PhD Adelaide
Carmel Daunt, BSc(Hons) Melbourne
Chris Riffkin, BSc(Hons) LaTrobe
Natasha Silke, DipLabTech University of Zürich
Mimi Bandopadhyay, BBiomedSci(Hons) Monash MB BS(Hons) Monash FRACP, PhD student (to 08/11)
Stephanie Conos, BA Melbourne BSc Melbourne, BSc(Honours) student (from 02/12)
Gerda de Vries, BSc Groningen, overseas research trainee (from 12/11 to 06/12)
Ben Green, BSc(Hons) Melbourne, PhD student (to 03/12)
Ashod Kherlopian, BSc Monash, BSc (Honours) student (from 02/12)
Dimitra Masouras, BSc(Hons) Melbourne, PhD student
Nisha Narayan, BBiomedSc Melbourne BSc(Hons) Melbourne, PhD student (from 03/12)
Manika Salmonidis, BSc(Hons) Melbourne, PhD Student
Jolanda Visser, BSc Groningen, overseas research trainee (from 12/11 to 06/12)

John Silke, BA(Hons) Cantab LLB
London PhD Zurich
Joanne Hildebrand, BBiomedSci(Hons) Melbourne PhD Melbourne (from 02/12)
Najoua Lalaoui, PhD France
Ueli Nachbur, PhD Berne
Lynn Wong, BSc Guelph PhD Toronto (to 08/11)
Holly Anderton, BA Canterbury
BSc(Hons) Canterbury
Aleksandra Bankovacki, BSci(Hons) LaTrobe
Diep Chau, BSc Melbourne
Sukhdeep Spall, BSc India MSc LaTrobe
Nima Etemadi, BSc Iran MSc LaTrobe, PhD student
Joseph Evans, BBiomedSci(Hons) LaTrobe, visiting PhD student
Timothy Liemar, BSc Adelaide, BSc (Hons) student (from 02/12 to 03/12)
James Rickard, BSc LaTrobe MSc LaTrobe, PhD student
Richelle Spanjers, overseas research trainee (to 07/11)
Inflammation

Inflammation is a rapid, protective response that forms part of the body’s first line of defence against noxious stimuli.

Although short-term inflammation is usually beneficial to the host, prolonged inflammation can be harmful and contribute to the development of disease. In the Inflammation division, we aim to understand the biological and molecular mechanisms underlying inflammatory diseases in order to improve prevention, diagnosis and treatment. We use a wide range of experimental techniques to study immune cells, molecular regulators of inflammation, and responses to cell signalling proteins (cytokines).

Neutrophils are white blood cells that play a key role in inflammation and are essential for the immune response, however too many activated neutrophils can lead to inflammatory diseases. Little is known about the control of neutrophil lifespan during infection and inflammation. We have developed software to study the survival of neutrophils and are using this to investigate how molecular regulators control inflammation.

We are interested in two families of proteins that control the inflammatory response to infection, the SOCS (suppressors of cytokine signalling) and TRIM (tripartite motif) proteins. Defining the complexes these proteins interact with will help us to understand how the immune response is regulated. We have solved the crystal structure of the TRIM25 SPRY domain and now seek to understand how it interacts with its binding partners. We have also demonstrated, using a mouse influenza model, the importance of SOCS4 and SOCS5 proteins during viral infection.

Uveitis is a major cause of adult blindness. In collaboration with CSL, we have shown that blocking G-CSF (granulocyte colony stimulating factor), an important neutrophil growth factor, decreases the incidence and severity of uveitis by markedly decreasing migration of neutrophils to the site of inflammation.

Chondrocytes are the resident cells in cartilage and are thought to play a passive role in diseases such as osteoarthritis and rheumatoid arthritis. Our research, however, has shown that they are actively involved in joint inflammation, producing cytokines and chemokines, as well as enzymes that degrade the cartilage matrix. SOCS molecules control these responses.

Laboratory heads
Dr Ben Croker
Dr Seth Masters
Dr Sandra Nicholson
Professor Ian Wicks
Division head

Dr Seth Masters is studying the role of micro-RNAs in inflammation and in viral infections.
Switching off free radicals to control inflammation

The immune system has evolved to rapidly detect and respond to ‘invasion’ by infectious agents through the inflammatory response. A number of complex ‘brakes’ or control systems have also evolved in immune cells to ensure that inflammation is short-lived and prevent long-term inflammatory responses that could cause collateral damage and lead to severe or chronic inflammatory diseases.

Inflammation division researchers are studying the cellular production of nitric oxide, a ‘free radical’ which is a potent frontline killer of infectious agents such as bacteria and viruses. Inducible nitric oxide synthase (iNOS) is an enzyme that is crucial for the production of nitric oxide.

Dr Sandra Nicholson and colleagues have identified a protein, called SPSB1, as a key regulator of the iNOS enzyme. "Nitric oxide is a potent inflammatory molecule that can cause severe tissue damage and toxicity," Dr Nicholson said. "If unregulated, you can end up with inflammation that can be fatal, such as in acute infections which result in sepsis. So nitric oxide production is very tightly monitored and controlled by the cell."

Dr Nicholson said the research team found both iNOS and SPSB1 were rapidly upregulated early in the inflammatory response. "We found that SPSB1 acts as a switch to turn off nitric oxide production by making marks on the iNOS enzyme that label it for degradation," Dr Nicholson said. “SPSB1 and iNOS are produced at the same time by the cell, and SPSB1 acts in a negative feedback loop to modulate the level of iNOS."

The research team is now looking at how targeting this pathway could enhance the anti-infectious action of nitric oxide, while minimising the effects of damaging inflammatory responses. "By disrupting the SPSB1 interaction with iNOS, the effects should only be seen in the target cell where iNOS is produced in response to infection. This strategy would limit the toxicity associated with excessive systemic nitric oxide," Dr Nicholson said.

Funding partners: National Health and Medical Research Council of Australia and the Victorian Government.


Funding better diagnostics for acute rheumatic fever

Acute rheumatic fever is an inflammatory disease caused by an immune reaction to streptococcal bacteria that leads to damage of heart valves and rheumatic heart disease. Indigenous Australians have one of the highest rates of rheumatic heart disease in the world, a disease that affects more than 15 million people worldwide and kills more than 200,000 annually. More than 80 per cent of rheumatic fever cases occur in developing countries.

Researchers from the institute’s Inflammation division and the Menzies School of Health Research in Darwin were awarded almost $60,000 by the H & L Hecht Trust to develop a better diagnostic test for acute rheumatic fever (ARF), the illness which follows certain streptococcal infections and eventually leads to rheumatic heart disease (RHD).

Professor Ian Wicks, head of the institute’s Inflammation division, said despite the global significance of ARF, a simple and effective diagnostic test for the disease does not currently exist. “Prevention of RHD is dependent on the timely diagnosis and treatment of ARF in high-risk groups,” Professor Wicks said. “However, a simple and effective diagnostic test for ARF does not currently exist. We will use new technological platforms to find blood markers for the disease. Hopefully, the generous funding from the H & L Hecht Trust will also enable more targeted therapeutic interventions to improve outcomes for patients and help to diminish the global impact of this preventable disease.”

Professor Ian Wicks

Dr Sandra Nicholson
Major national and international meetings

Simon Chatfield
European League Against Rheumatism
Annual European Congress of Rheumatology, Berlin, Germany, 6/12, Oral presentation

Ben Croker
Keystone Symposia: Cell Death Pathways: Beyond Apoptosis, Banff, Canada, 03/12, Plenary speaker
Keystone Symposia: Innate Immunity, Keystone, United States, 03/12, Plenary speaker
Lorne Infection and Immunity Conference, Lorne, Australia, 02/12, Invited speaker
Salk Symposium on Biological Complexity: Immunity and Inflammation, San Diego, United States, 01/12, Oral presentation
TLROZ 2012, Melbourne, Australia, 05/12, Invited speaker

Gabrielle Goldberg
Eighth International Congress on Autoimmunity, Granada, Spain, 5/12, Oral presentation

Xiao Liu
Australian Rheumatology Association annual scientific meeting, Canberra, Australia, 5/12, Oral presentation

Seth Masters
Australian Society of Immunology (Special Interest Group), Adelaide, Australia, 12/11, Invited speaker
Australian Society of Immunology annual scientific meeting, Adelaide, Australia, 12/11, Oral presentation
French Society of Immunology, Montpellier, France, 11/11, Invited speaker
Lorne Infection and Immunity, Lorne, Australia, 03/12, Oral presentation
TLROZ 2012, Melbourne, Australia, 05/12, Invited speaker

José Villadangos
Congress of the Brazilian Society of Immunology, Iguaçu, Brazil, 10/12, Invited speaker
Fifth Barossa Meeting: Science Amongst the Vines, Barossa Valley, Australia, 11/12, Invited speaker

Ian Wicks
European Phagocyte Workshop, Budapest, Hungary, 3/12, Keynote speaker

Annemarie van Nieuwenhuijze
Australian Rheumatology Association annual scientific meeting, Canberra, Australia, 5/12, Oral presentation
Staff list

Rhiannon Jones, BSc(Hons) Adelaide PhD Adelaide, scientific coordinator

Ian Wicks, MB BS Sydney PhD Melbourne FRACP
Gabby Goldberg, BSc(Hons) Monash PhD Monash
Rowena Lewis, BSc(Hons) Deakin PhD Deakin (from 02/12)
Willy-John Martin, BSc Waikato MSc Waikato PhD Wellington
Jacinta Grayden, BSc(Hons) Monash
Jane Murphy, BSc(Hons) Adelaide
Annemarie van Nieuwenhuijze, BSc Amsterdam MSc Amsterdam
Simon Chatfield, MB BS Melbourne, Reid Translational Scholar
Tommy Liu, BSc Otago MSc VUT, PhD student
Shereen Oon, BMedSc Melbourne MB BS Melbourne, PhD student (from 02/12)
Bart Pieters, overseas research trainee (from 11/11)

Ben Croker, BSc(Hons) UNSW PhD Melbourne
Motti Gerlic, BBiomedSc Ben Gurion PhD Ben Gurion (from 07/11)
Man Lyang Kim, BSc Gyeongsang MSc Gyeongsang PhD Basel (from 07/11)
Kate MacArthur, BSc Melbourne, BSc(Hons) student (to 11/11)
Jo O’Donnell, BSc(Hons) Melbourne, PhD student

José Villadangos, PhD Madrid (to 11/11)
Wan Shoo Cheong, PhD Monash (to 12/11)
Nishma Gupta, MSc Madural PhD Madural (to 12/11)
Simone Meuter, PhD Berne (to 12/11)
Justine Mintern, BSc(Hons) Melbourne PhD Melbourne (to 12/11)
Sanduro Prato, BSc(Hons) Lausanne PhD Melbourne (to 12/11)
Javier Vega Ramos, BSc(Hons) Barcelona PhD Barcelona (to 12/11)
Linda Wakim, BSc(Hons) Melbourne PhD Melbourne (to 12/11)
Yuekang Xu, BA China BM China PhD Melbourne (to 12/11)
Wei Jin Chin, BSc(Hons) Melbourne (to 12/11)

Ben Masters, BSc(Hons) Melbourne PhD Melbourne (from 09/11)
Motti Gerlic, BBiomedSc Ben Gurion PhD Ben Gurion
Man Lyang Kim, BSc Gyeongsang MSc Gyeongsang PhD Basel

Seth Masters, BSc(Hons) Melbourne PhD Melbourne (from 09/11)
Motti Gerlic, BBiomedSc Ben Gurion PhD Ben Gurion
Man Lyang Kim, BSc Gyeongsang MSc Gyeongsang PhD Basel

Sandra Nicholson, BSc Monash MSc UNSW PhD Melbourne
Lukasz Kedzierski, BSc(Hons) Monash PhD Monash
Tatiana Kolesnik, BSc(Hons) Nizhni Novgorod MSc Nizhni Novgorod PhD Moscow
Sarah Freeman, BSc Melbourne
Akshay D’Cruz, BBiomedSc(Hons) Melbourne, PhD student
Eddie Linossi, BSc(Hons) Melbourne, PhD student

Nishma Gupta, MSc Madurai PhD Madurai (to 12/11)
Simone Meuter, PhD Berne (to 12/11)
Justine Mintern, BSc(Hons) Melbourne PhD Melbourne (to 12/11)
Sanduro Prato, BSc(Hons) Lausanne PhD Melbourne (to 12/11)
Javier Vega Ramos, BSc(Hons) Barcelona PhD Barcelona (to 12/11)
Linda Wakim, BSc(Hons) Melbourne PhD Melbourne (to 12/11)
Yuekang Xu, BA China BM China PhD Melbourne (to 12/11)
Wei Jin Chin, BSc(Hons) Melbourne (to 12/11)

Elisa Crisci, overseas research trainee (to 07/11)
Natalie Patterson, BSc(Hons) Melbourne, PhD student (to 12/11)
Gabriela Segal, BEng Chile BSc Chile, PhD student (to 12/11)
Jaris Valencia, BBiolSc Madrid, overseas research trainee (from 10/11 to 01/12)
Peter Zeller, MSc Albert-Ludwigs, overseas research trainee (to 07/11)
Molecular Immunology

Our immune system has the complex task of defending us against potentially harmful microorganisms in our environment, while allowing us to live in harmony with the multitudes of beneficial microbes that occupy our bodies.

This harmony depends on a network of immune cells whose many and diverse functions provide the checks and balances necessary to control the immune response. The goal of the Molecular Immunology division is to understand how our immune network functions normally and what goes wrong in conditions such as chronic inflammatory (autoimmune) disease and cancers such as leukaemia.

Just when we think that we know all the players in the immune system, immunologists find another. This year much of our attention has focused on a newly identified cell type, T follicular helper cells, which are specialised in promoting antibody responses. In a collaborative project involving members of the Molecular Immunology and Immunology divisions, we discovered that not all T follicular helper cells are alike and some have the ability to persist for long periods after an encounter with a virus, in this case influenza, and to provide immunological memory, the central feature of vaccination and immunity (see opposite page). A related study, led by Associate Professor Lynn Corcoran, examined how T follicular helper cells achieve their function and found that blood hormones (cytokines) IL-6 and IL-21 have an important role.

Researchers in the Molecular Immunology division are also trying to understand how immune cells from a common ancestor are programmed differently to maintain their distinct functions. Dr Gabrielle Belz and Dr Sebastian Carotta are investigating the function of inhibitory molecule Id2 in producing killer T cells and natural killer cells, which fight virus-infected and cancerous cells. Dr Axel Kallies is asking similar questions with regard to another cell programmer, Blimp1. Finally, we are actively translating our fundamental findings to improve health outcomes, highlighted by Dr Li Wu, whose research is deciphering the complexities of human dendritic cell biology.

Laboratory heads

Dr Gabrielle Belz  
Dr Sebastian Carotta  
Associate Professor Lynn Corcoran  
Dr Axel Kallies  
Dr Stephen Nutt  
Division head  
Dr Li Wu

Associate Professor Lynn Corcoran is studying the role of blood hormones in the function of specialised immune cells.
Rare immune cells could hold key to treating immune disorders

T follicular helper cells represent less than half of one per cent of all immune cells, but play a critical role in antibody production and developing long-lasting immunity.

Dr Stephen Nutt, Dr Katja Lüthje and Associate Professor David Tarlinton from the institute’s Molecular Immunology and Immunology divisions have found T follicular helper cells can ‘remember’ infectious agents. Exploiting these cells could help to improve vaccination and lead to new treatments for immune disorders such as chronic inflammatory (autoimmune) diseases.

Dr Nutt said the study showed T follicular helper cells were essential for developing strong and specific antibody responses to infectious agents and could ‘remember’ being exposed to infectious agents, allowing them to rapidly react to subsequent attacks.

“The success of vaccines relies on antibody production and long-term immune ‘memory’. It is well established that antibody-producing B cells can remember a particular infectious agent and rapidly respond when exposed again. Our study shows, for the first time, that T follicular helper cells also develop memory to rapidly respond to infection. This finding is incredibly important for the development of vaccines, which rely on immune memory to prevent subsequent infections,” Dr Nutt said.

Associate Professor Tarlinton said the team discovered T follicular helper cells were tightly controlled by the immune system, which might explain why increases in their numbers are associated with chronic inflammatory diseases such as rheumatoid arthritis and lupus. “In some disease models, large numbers of T follicular helper cells are associated with the development of chronic inflammatory diseases and can actually cause autoimmune disease very much like lupus in humans. This suggests that modulating these cells could be a potential treatment for autoimmune conditions.”

Funding partners: Australian Research Council, German Academic Exchange Service, National Health and Medical Research Council of Australia, Pfizer Australia, Sylvia and Charles Viertel Foundation and the Victorian Government.


$200,000 support for studying genetic causes of myeloma

Myeloma is one of the most common types of blood cancer, with more than 1000 Australians diagnosed each year. The risk of developing myeloma increases with age, with almost 80 per cent of new cases in people over 60.

Myeloma results from mutations that cause uncontrolled growth of plasma cells, rare and highly specialised cells that produce the antibodies essential for protection against infection and immunity after vaccination.

Dr Julie Tellier and Dr Stephen Nutt have been awarded a $200,000 Multiple Myeloma Research Foundation (US) grant to study key plasma cell genes and their role in development of myeloma.

Dr Tellier said the research team would look at the function of molecules called transcription factors which control the development, differentiation and function of immune cells.

“Modern genomics technologies have revealed that altered transcription factor functions are at the heart of most blood cell cancers,” Dr Tellier said. “Our research aims to understand how plasma cells are formed and what causes these cells to become cancerous,” she said.

Dr Nutt said Irf4 and Blimp1, two particularly important transcription factors for the development of plasma cells, would be the first investigated.

“We will use sophisticated DNA screening technologies to understand how Irf4 and Blimp1 control the activity of the plasma cell genome. There is evidence to suggest these proteins are essential for myeloma development, and we are interested in seeing whether inhibiting Irf4 or Blimp1 function impairs cancer growth,” he said.

Dr Nutt said although myeloma could be treated with chemotherapy, there was at present no therapy specific for this type of cancer, and no cure. “Our studies, if successful, will highlight Irf4 and/or Blimp1 as important therapeutic targets for this difficult-to-treat blood cancer,” he said.
Major national and international meetings

**Rhys Allan**

Australian Epigenetics Conference, Adelaide, Australia, 04/12, Oral presentation

41st Australasian Society of Immunology annual scientific meeting, Adelaide, Australia, 12/11, Oral presentation

**Gabrielle Belz**

Australasian Vaccines and Immunotherapeutics Development, Brisbane, Australia, 05/12, Session chair

41st Australasian Society of Immunology annual scientific meeting, session chair, Adelaide, Australia, 12/11, Invited speaker

**Sebastian Carotta**

New Directions in Leukemia 2012, Sunshine Coast, Australia, 03/12, Oral presentation

45th Annual Congress Of The German Society Of Transfusion Medicine, Graz, Austria, 06/12, Plenary speaker

XIX Modern Trends in Human Leukaemia and Cancer, Wilsede, Germany, 06/12, Oral presentation

**Erika Cretney**

World Immune Regulation Meeting-VI, Davos, Switzerland, 03/12, Oral presentation

**Renee Gloury**

19th Annual Conference of the Immunology Group of Victoria (IgV), Geelong, Australia, 09/11, Oral presentation

**Nick Huntington**

The Society for Natural Immunity Meeting, Pacific Grove, United States, 04/12, Invited speaker

**Axel Kallies**

41st Australasian Society of Immunology annual scientific meeting, Adelaide, Australia, 12/11, Plenary speaker

Seventh RIKEN Research Center for Allergy and Immunology International Summer Program, Yokohama, Japan, 06/12, Invited lecturer

**Stephen Nutt**

Sixth Gene Expression and Signalling in the Immune System, Cold Spring Harbor, United States, 04/12, Invited speaker

10th German B Cell Forum, Kloster Banz, Bavaria, Germany, 03/12, Keynote speaker

Thomson Reuters Systems Biology Symposium, Melbourne, Australia, 07/11, Keynote speaker

University of Erlangen-Nuremberg Graduate program in Molecular Immunology Symposium, Erlangen-Nuremberg University, Germany, 03/12, Keynote speaker

**Li Wu**

22nd Nikolas Symposium on Histiocytosis, Corinth, Greece, 05/12, Invited speaker
Staff list

Kim McIntosh, BSc(Hons) Monash
MEnvSc Monash, scientific coordinator

Stephen Nutt, BSc(Hons) Sydney
PhD Vienna

Rhys Allan, BSc(Hons) Melbourne
PhD Melbourne
Michael Chopin, PhD Dresden
Erika Cretney, BSc(Hons) Melbourne
PhD Melbourne
Aleksandar Dakic, BSc(Hons) Melbourne
PhD Melbourne
Sheila Dias Dos Santos, BSc Lisbon PhD Paris VI
Yoko Shimohakamada, MD Tokyo PhD Yamaguchi (to 01/12)
Julie Tellier, PhD France (from 12/11)
Simon Willis, BSc(Hons) Melbourne
PhD Melbourne
Rebecca Thong, BBiomedSc(Hons) Melbourne

Gabrielle Belz, BV Biol Qld BVSc Qld
PhD Qld
Jo Groom, BAppSc Charles Sturt
BSc(Hons) Melbourne PhD UNSW
(from 11/11)
Frederic Masson, BSc(Hons) France MSc France PhD Geneva
Lisa Mielle, BSc Melbourne PhD Melbourne (from 01/12)

Adele Mount, BSc(Hons) Melbourne
PhD Melbourne
Cyril Seillet, MSc France PhD France
(from 12/11)
Mary Camillari
Dane Newman, BEng(Hons) Deakin
PhD Deakin
Janina Findeis, overseas research trainee
(from 10/11 to 12/11)
Lucille Rankin, BA Melbourne BSc(Hons)
Melbourne, PhD student
Simone Farrow, BSc(Hons) Monash MSc
Melbourne, editorial assistant

Sebastian Carotta, PhD Vienna
Nick Huntington, BSc(Hons) LaTrobe PhD
Melbourne (from 10/11)
Pradnya Gangatirkar, MSc Nagpur
Louisa Hill, BSc Germany, overseas research trainee
(from 09/11 to 12/11)

Lynn Corcoran, BSc(Hons) Melbourne
PhD Melbourne
Stephane Chevrier, PhD Lausanne
Dianne Emslie, BSc(Hons) VUT PhD VUT
Tobias Kratina, BSc(Hons) Deakin

Axel Kallies, PhD Free
Mia Miasari, BSc(Hons) LaTrobe PhD
LaTrobe (to 12/11)
Klaas van Gisbergen, PhD Netherlands
(from 04/12)
Ajithkumar Vasanthakumar, BSc Madurai Kamaraj MSc Madurai Kamaraj PhD
Madurai Kamaraj (from 11/11)
Shoukat Afshar-Sterle, PhD Adelaide
Renee Gloury, BSc(Hons) Melbourne
(from 12/11)
Ellen Doorduin, overseas research trainee (to 08/11)
Kevin Man, BSc Melbourne LLB
Melbourne, PhD student
Anna Scherger, overseas research trainee
(from 11/11)

Li Wu, MB Beijing MMedSc Beijing PhD
Melbourne
Angela D’Amico
Anna Proietto, BSc(Hons) PhD Melbourne
Chin Nien Lee, MSc Taiwan
Milon Pang, BSc Murdoch BSc(Hons)
Melbourne, PhD student

Walter and Eliza Hall Institute
Annual Report 2011-2012
Supplementary information
The Systems Biology and Personalised Medicine division is gaining new insights into how biological systems work by sifting through complex biological data that has been generated using high throughput technologies, and then using this data to identify the most appropriate treatment strategies for patients.

The goal of the division is to understand how complex biological systems work. Our researchers use large-scale technologies such as genome sequencing and quantitative tandem mass spectrometry to develop this understanding. The very large datasets generated by these technologies are transforming biology into an information-based discipline and forcing us to re-examine how we think about biology.

The emergent field of personalised medicine uses high-throughput biology to drive better therapeutic outcomes for patients. We are using highly specialised equipment to identify molecular patient profiles that will predict which patients are likely to do well and which will do poorly in response to existing therapies. These profiles can then be used to design the best treatment plan for each patient. We have already embarked on a pilot-scale genomic study in which we are analysing the gene sequences of patients with colon cancer (some of whom respond well to chemotherapy and some poorly) to see if we can discover the reasons for this range of responses.

We are currently asking such questions as:

▶ What are the global changes in biological pathways during tumor formation, maintenance and spread?
▶ Can cancer patients be stratified into treatment groups based on their genomic profiles?
▶ Are there genomic changes in tumors that will allow us to predict disease outcomes more accurately?

In our first year of operation, we have established quantitative proteomics through the formation of the WEHI Proteomics Laboratory and are building our capacity in genome-scale DNA sequencing through the institute’s genomics laboratory, which will form the nucleus of the newly established Ian Potter Centre for Genomic and Personalised Medicine (see opposite page).

Laboratory head
Professor Liam O’Connor
Division head

Dr Tom Nebl (right) from the institute’s Systems Biology and Personalised Medicine division and Dr Chris Tonkin from the Infection and Immunity division are studying the cell motor in Toxoplasma parasites.
Pinpointing the ‘on’ switch for parasite entry

Parasitic infections such as malaria and toxoplasmosis affect hundreds of millions of people worldwide each year, killing millions and causing severe disease and debilitating illness.

*Plasmodium* and *Toxoplasma* species, which cause malaria and toxoplasmosis respectively, are closely related parasites that must invade the host cell to reproduce and live. Dr Chris Tonkin and Dr Tom Nebl are working to understand the machinery used by the parasites to enter the cell.

Dr Tonkin said both *Plasmodium* and *Toxoplasma* parasites activate a molecular ‘motor’ to burrow into the host cell. “We are studying this invasion motor complex in *Toxoplasma* in the hope we will be able to identify important ‘motor’ proteins that could be a potential target for drug treatments for malaria,” he said.

Dr Nebl said proteomics technology and techniques were enabling the research team to identify crucial proteins involved in ‘flicking the switch’ on the parasite motor.

“Proteomics allows us to look at the proteins in the motor complex and see the changes that are made to the proteins after cell signals stimulate the motor and ‘flick the switch’ to invade a host cell,” Dr Nebl said. “Using state-of-the-art proteomics technologies, we were able to compare the motor complex in parasites that are stimulated via a signalling pathway to those that have not been, to see which proteins are altered when the parasite is attempting to invade the cell. It’s a really powerful tool to look at how cell proteins behave in a situation that most closely resembles the real cellular environment.”

Dr Tonkin said the team identified several proteins that are altered during the motor signalling process. “We’ve determined a number of proteins that are involved in switching on the invasion motor complex, and we are now looking at the pathways involved to identify potential therapeutic targets for treating malaria and toxoplasmosis,” Dr Tonkin said.

Matching disease treatments to genetic makeup

The Ian Potter Centre for Genomics and Personalised Medicine is Australia’s first research centre devoted to matching disease treatments to a person’s genetic makeup. The centre is a collaboration between the Walter and Eliza Hall Institute of Medical Research and Murdoch Childrens Research Institute and is supported by a $3 million grant from The Ian Potter Foundation.

The centre will offer new insights into childhood and adult diseases with a focus on immune disorders and cancer. In particular, projects will use genomics to examine food allergy in children, juvenile arthritis, leukaemia, neural tumours and colon cancer.

Professor Liam O’Connor, head of the institute’s Systems Biology and Personalised Medicine division, said the centre would make discoveries that will allow personalised therapies to be delivered to patients, improving their clinical outcomes.

“One of the first projects at the centre will look at colorectal cancer, which is among the most commonly diagnosed cancers, with more than 1.2 million new cases and 608,700 deaths estimated worldwide per year,” Professor O’Connor said. “The goal of this study is simple – to identify a molecular fingerprint by sequencing patients’ own (non-cancer) DNA. DNA from tumours, and resulting RNA and proteins, that can predict which patients will do well and which patients will do poorly in response to chemotherapy.”

Mrs Janet Hirst, chief executive officer of The Ian Potter Foundation, said the centre would hold a unique place in Australia, offering patients access to the large-scale technologies that have made personalised medicine possible. “We are delighted that Australians will be able to benefit from these pivotal new technologies,” Mrs Hirst said. “These new methods provide a window into the micro world of our bodies and we expect they will have a profound impact on the pace of research into cancer and other major health conditions.”

Professor Doug Hilton (left) and Mrs Janet Hirst (centre) with Professor Andrew Sinclair from the Murdoch Childrens Research Institute at the centre opening.
Staff list

Lisa Connolly, BSc(Hons) Melbourne, scientific coordinator (from 07/11)

Liam O’Connor, BSc(Hons) UWA PhD Melbourne
Nishma Gupta, MSc Madurai Kamaraj PhD Madurai Kamaraj (to 04/12)
Sam Wormald, BSc(Hons) Melbourne PhD Melbourne (from 02/12)
Doreen Agyapomaa, BAppSc(Hons) RMIT (from 11/11)
Liz Milla, BSc Deakin BBiolSc LaTrobe (from 11/11)

Proteomics laboratory
Giuseppe Infusini, BSc Naples PhD Naples (from 07/11)
Thomas Nebl, PhD LaTrobe
Andrew Webb, BSc Monash PhD Melbourne (from 07/11)
In 2011-12, the Walter and Eliza Hall Institute again published a record number of scientific papers, with 284 papers published by our researchers.

As in previous years, a number of institute scientists published in top-tier journals including Cell, Science, and Nature, and associated publications.

In 2011-12, 35 per cent of papers published were in the top 10 per cent of their field, and nine per cent in the top one per cent, according to Thomson Reuters Web of Knowledge, which ranks the impact of journal papers around the world.

A full list of publications produced by the institute in 2011-12 can be found on the accompanying CD.

Some of our highest impact papers for the year were:

**Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria.**


Although antimalarial drugs can be effective in killing malaria parasites, they do nothing to ameliorate the sometimes life-threatening inflammatory response to malaria infection.

In this paper the authors use a mouse model of cerebral malaria to show that a combination of antimalarial drugs and synthetic anti-inflammatory compounds based on natural host defence peptides (innate defence regulatory (IDR) peptides) increases survival by reducing host inflammation.

**PfSET10, a Plasmodium falciparum methyltransferase, maintains the active var gene in a poised state during parasite division.**


Malaria parasites express a protein, PfEMP1, on the surface of infected red blood cells that allows them to adhere to blood vessels and contributes to disease progression. The var genes encoding this protein come in 60 different varieties, and the parasite switches the gene used in each infected cell to enable the parasite to evade detection by the immune system.

In this paper, a new protein called PfSET10 is identified that acts on these var genes to keep them in a state where rapid switching is possible. This protein may be a potential target for drugs that prevent this form of immune evasion.

**The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.**


Dendritic cells recognise dead or damaged cells and present antigens from them to the immune system to generate an appropriate immune response. Clec9A is a lectin-like protein expressed on dendritic cells that recognises dead cells and powerfully enhances antibody production. This paper reveals that Clec9A recognises a protein complex – filamentous actin – present in all cells but which only becomes exposed after cell death. This may pave the way to improved vaccination methods.
Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.


SOCS3 (suppressor of cytokine signalling 3) is a critical natural suppressor of inflammatory responses caused by the action of a variety of cytokines. However its precise mechanism of action and the reason for its specificity for only some cytokines was unknown.

In this paper, detailed studies show that SOCS3 has distinct sites for binding different cytokine receptors. At the same time, SOCS3 binds and inhibits receptor-associated tyrosine kinases, which are required to mediate the biological actions of the cytokine.

Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.


Interleukin-1 (IL-1) is a major mediator of inflammatory diseases. Its production in response to infection is regulated by the activation of enzymes that alter (via proteolytic cleavage) the biologically inactive precursor form of IL-1 to make it active.

In this paper, the researchers show that cleavage of pro-IL-1 is constrained by proteins known as inhibitors of apoptosis proteins (IAPs). The study suggests that activators of IAPs could be useful in helping to treat some forms of inflammatory disease.

The development and fate of follicular helper T cells defined by an IL-21 reporter mouse.


Follicular helper T cells (TFH cells) are required for B cell maturation and proliferation. By studying mice in which the TFH cell cytokine IL-21 (interleukin-21) is linked to a fluorescent tag, this paper shows that TFH cells are not terminally differentiated but can give rise to memory T-cells and effector T-cells. This study expands the potential role TFH cells play in immune reactions.

Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer.


The Tasmanian devil population is currently endangered due to an unusual facial tumour that is transmissible through biting. In this paper whole genome sequencing is used to define the mutations that occur in the tumour and to trace the evolution of the disease within the Tasmanian devil population. This work may help to define the different sub-types of the tumour and the nature of its spread.

The current edition of this report is divided into the following sections:

**Publications**

- Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.
- Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation.
- The development and fate of follicular helper T cells defined by an IL-21 reporter mouse.
- Genomic sequencing and analysis of the Tasmanian devil and its transmissible cancer.
- Activation-induced B cell fates are selected by intracellular stochastic competition.
- The current edition of this report is divided into the following sections:
Publications

ART Advanced Research Technologies
BIO Bioinformatics division
CBD ACRF Chemical Biology division
CHD Cancer and Haematology division
CSCD Cell Signalling and Cell Death division
INF Infection and Immunity division
INFL Inflammation division
IMM Immunology division
MGC Molecular Genetics of Cancer division
MIMM Molecular Immunology division
MMD Molecular Medicine division
SBPM Systems Biology and Personalised Medicine division
SCC ACRF Stem Cells and Cancer division
SBD Structural Biology division

Number of publications
Primary: 203
Reviews: 70
Edited book: 1
Book chapters: 10
Total: 284

Primary


58. Gray DH, Kupresanin F, Berzins SP, Herold MJ, O'Reilly LA, Bouillet P, Strasser A. The BH3-only proteins Bim and Puma cooperate to impose deleterious effects to organ-specific antigens. *Immunity.* (in press) MGC


Kelly PN, Grabow S, Delbridge AR, Adams JM, Strasser A. Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. Cell Death and Differentiation. (in press) MGC


124. Merino D, Strasser A, Bouillet P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. *Oncoogene.* 2011 31(28):3392-3396. MGC


126. Moujalled DM, Cook WD, Luiss JM, Khan NR, Ahmed AU, Callus BA, Vaux DL. In mouse embryonic fibroblasts, neither caspase-8 nor cellular FasL-like inhibitory protein (FLIP) is necessary for TNF to activate NF-kappaB, but caspase-8 is required for TNF to cause cell death, and induction of FLIP by NF-kappaB is required to prevent it. *Cell Death and Differentiation.* 2011 19(8):808-815. OSCD


134. Nguyen NH, Sleebes BE, White JM, Hughes AB. Diastereoselective synthesis of highly functionalized 2,2,3-substituted amino acids from 4-substituted-1,3-oxazinan-6-ones. *Tetrahedron.* 2012 68(24):4745-4756. CBD


Reviews and Book Chapters


206. Allan RS. From little things big things grow; a new role for onz in contact hypersensitivity responses. Immunology and Cell Biology. 2012 Jan 24. (epub ahead of print) MIMM


229. Good-Jacobson KL, Tarlton DM. Multiple routes to B-cell memory. International Immunology. 2012 24(7):403-408. IMM


Awards

The Victoria Prize, the Milstein Award and an Australian Academy of Science fellowship are just some of the national and international awards and fellowships received this year by institute staff and students.

Honours and awards received by staff at the institute in the past 12 months include:

In 2012, Professor Jane Visvader was elected a fellow of the Australian Academy of Science. Professor Visvader’s fellowship recognised her research achievements, which over the past decade have included: discovering rare “breast stem cells”, which give rise to all cell types in the breast, and identifying the breast stem cell daughters from which some types of breast cancer arise.

Professor Andreas Strasser was awarded the 2011 Victoria Prize for his research into the control of cell death. The $50,000 Victoria Prize is awarded annually by the Victorian Government to a scientist whose discovery has significantly advanced knowledge. Professor Strasser’s research has shown that defects in cell death can lead to the development of cancer or autoimmune disease, and render cancer cells resistant to chemotherapy.

Professor David Vaux as a organisation member in 2012, in recognition of his contribution to cell death research. In the 1980s, Professor Vaux made the landmark discovery that the Bcl2 gene prevented cells from dying. His findings launched the field of programmed cell death (apoptosis) research, and led to development of novel anti-cancer agents such as BH3-mimetics, which promote death of cancer cells.

In 2011, institute director Professor Doug Hilton became the first Australian to receive the Milstein Award, established in 1988 by US philanthropists Seymour and Vivian Milstein to recognise scientists who have made exceptional contributions to cytokine and interferon research.

Professor Hilton also received the Research Australia Leadership and Innovation Award in 2011 for his achievements, including leadership in promoting the value of health and medical research to the Australian community following the ‘Discoveries Need Dollars: Protect Medical Research’ campaign he initiated.

Dr Seth Masters was awarded a $150,000 Victorian Endowment for Science, Knowledge and Innovation (VESKI) Fellowship by the Victorian Government to identify the role of tiny molecules, called micro-RNAs, in the development of cancer and chronic inflammatory disease. He is investigating whether these molecules could be a therapeutic target for treating disease.

Discovering the cellular ‘link’ between female hormones and breast cancer development earned Dr Marie-Liesse Asselin-Labat the inaugural $25,000 Lawrence Creative Prize from the Centenary Institute in 2011.

Tackling ovarian cancer at the source

Ovarian cancer researcher Associate Professor Clare Scott (pictured) has been awarded the Cancer Council Victoria’s Edward ‘Weary’ Dunlop Fellowship, which will allow her to develop better experimental models of epithelial ovarian cancer with the aim of improving patient outcomes.

Epithelial ovarian cancer is the most lethal type of ovarian cancer. Despite efforts to develop better screening tools, 80 per cent of these cancers are diagnosed after they have spread beyond the ovary and 70 per cent are generally incurable.

The funding provided by the Dunlop Fellowship – $1.5 million over five years – will enable Associate Professor Scott to develop new experimental models of ovarian cancer to explore the genetic factors driving the subtypes of this lethal disease.

Her work will build on research from the Australian Ovarian Cancer Study, which has identified several different molecular subtypes of high-grade epithelial ovarian cancer.

“At the moment, appropriate preclinical models to identify and test targeted therapies for subtypes of high-grade epithelial ovarian cancer are simply not available,” Associate Professor Scott said. “These new models are essential in order to change clinical outcomes for women with ovarian cancer, from what is currently a very frightening outlook to one of targeted treatment options. Using preclinical models to test new therapies has produced some great successes in understanding related cancers, such as breast cancer. We are hopeful it will also be successful for ovarian cancer patients,” she said.

Associate Professor Scott said the Cancer Council Victoria funding was crucial to the project. “This type of work would simply not be possible without the significant, long-term funding available through the Dunlop Fellowship,” she said.
Dr Jason Tye-Din (right) is a clinician-scientist at the institute and a gastroenterologist at The Royal Melbourne Hospital. He is researching the factors that lead to development of coeliac disease in the hope of developing new treatments for this immune disorder.
Translating our research

The institute’s Clinical Translation Centre facilitates translational research being undertaken across the institute.

The institute currently has 14 clinician-scientists and nine medically-qualified PhD students undertaking medical research into blood, breast and ovarian cancers, type 1 diabetes, coeliac disease, rheumatoid arthritis, rheumatic fever, HIV, hepatitis and malaria. Recent developments in translational research across the institute include:

- identification of new classes of anti-inflammatory drugs for treating malaria;
- dendritic cell research to boost the effectiveness of vaccines; and
- ongoing testing of a potential vaccine for coeliac disease.

The institute’s clinician-scientists are committed to linking discoveries from within their laboratory to the clinic, supported through their collaborations with Melbourne Health, Peter MacCallum Cancer Centre, St Vincent’s Hospital Melbourne, The Royal Women’s Hospital, Menzies School of Health Research and the Royal Children’s Hospital, as well as other health facilities throughout Australia and internationally. The institute’s research discoveries are associated with more than 100 current national and international clinical trials.

The Clinical Translation Centre has been fully operational since late 2011, offering clinical and laboratory services as well as human ethics advice. The coeliac disease research group, led by Dr Jason Tye-Din, is one of the first to be located within the Clinical Translation Centre. Research nurse Ms Cathy Pizzey monitors research participants and healthy volunteers in the effort to discover better treatments for coeliac disease. This is the first time in decades that the institute has had direct clinical interaction with participants of research projects and is a big step towards aligning clinical and laboratory research goals.

In collaboration with Melbourne Health, the Clinical Translation Centre recently established a Volunteer Blood Donor Registry to facilitate the availability of volunteer blood samples for ethically approved translational research projects throughout the wider Parkville precinct. The registry is a not-for-profit service for obtaining blood samples from healthy individuals as ‘controls’ for comparison with people who have developed disease and identify what has changed, whilst maintaining the respect and privacy of volunteer donors.

In May 2012 the Clinical Translation Centre held its biennial PhD research opportunities forum for clinicians interested in undertaking laboratory research. This event showcased the institute’s translational research and career opportunities and attracted a number of Victorian and interstate clinicians.
New anti-cancer agent shows promise for chronic leukaemias

Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in Australia, with approximately 1000 new cases diagnosed each year, mostly in people over 60.

While many people with CLL either require no treatment or respond well to standard treatments, around 300 Australians die of the disease every year.

A clinical trial led by Professor Andrew Roberts from the institute’s Clinical Translation Centre has found that a potential new anti-cancer agent called navitoclax may improve the symptoms and extend the survival of patients with CLL who have failed current standard therapies.

Navitoclax (ABT-263) is a so-called BH3-mimetic compound that blocks the function of the proteins Bcl-2 and Bcl-xL, which are found at high levels in CLL cells. The ‘pro-survival’ role of Bcl-2 in allowing leukaemia cells to become long-lived was discovered at the Walter and Eliza Hall Institute.

It is now known that high levels of Bcl-2 are an important contributor to the development of several types of cancer, and resistance to anti-cancer treatments. The phase I trial was sponsored by two companies – Abbott and Genentech, a member of the Roche Group. Navitoclax was discovered by Abbott as a potential anti-cancer agent and works by rapidly neutralising the ‘pro-survival’ effects of Bcl-2 in CLL and other cancers, killing the cancer cells.

The 29 patients in the trial who received navitoclax had CLL that had not responded to multiple standard treatments, or their cancer had returned after treatment. Professor Roberts said although the phase I trial was designed to determine the safety and best dose of the agent, the patients had shown major reductions in leukaemic cells in their blood and substantial improvements in their symptoms.

“The trial has shown that navitoclax can be safely delivered,” Professor Roberts said. “Further, in a group of patients who, without treatment, would be expected to have only six to 12 months to live, many of the trial participants have survived for more than two years. This suggests that navitoclax may be an advance in treatment of poor prognosis CLL.”

Professor Roberts said it was pleasing to see the trial participants respond well to navitoclax, but there were still many years of testing ahead to determine whether it could improve the outlook for CLL patients.

“This trial was only the first step in determining whether navitoclax is a safe treatment for CLL,” he said. “The results of a larger phase II clinical trial will determine more precisely whether this agent will be of real benefit for CLL patients more broadly.”

The trial was a collaboration between Australian and US researchers including Professor Roberts, who is also a clinical haematologist at The Royal Melbourne Hospital, Professor David Huang from the institute’s ACRF Chemical Biology division and Professor John Seymour from the Peter MacCallum Cancer Centre. The trial was conducted at The Royal Melbourne Hospital, the Peter MacCallum Cancer Centre - coordinated locally by Cancer Trials Australia - and at three and at three centres in the United States.

Collaborating organisations:
Abbott Laboratories, ACRF Centre for Therapeutic Target Discovery. Dana-Farber Cancer Institute, MD Anderson Cancer Center, Moores University of California at San Diego Cancer Center, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital and The University of Melbourne.

Funding partners: Supported by Abbott and Genentech, a member of the Roche Group. Additional support for correlative studies was provided by Australian Cancer Research Foundation, Leukaemia Foundation of Australia, Leukemia & Lymphoma Society (US), National Health and Medical Research Council of Australia, Victorian Cancer Agency and the Victorian Government.


Professor Andrew Roberts
Developing our research

In an increasingly difficult commercialisation environment, the business development office is engaged in a wide range of activities designed to enhance translation of the institute’s research activities. These activities were underpinned by more than 320 material transfer agreements, 86 commercial and collaboration agreements, 22 invention disclosures and eight new provisional patent applications.

Major outcomes this year included:
- commercialisation of two anti-cancer drug discoveries;
- commencement of two major stem cell initiatives;
- new collaborations targeting breast cancer and infectious disease;
- a start-up company raising significant capital in the US to progress a potential coeliac disease vaccine; and
- contributing to major changes in protecting intellectual property.

New collaborations target breast cancer and infectious disease

A major consortium involving 14 participants was established with $5.7 million from the National Breast Cancer Foundation, with the possibility of extension after three years.

The consortium will focus on treating and preventing breast cancer recurrence through development of small molecule therapeutics targeting epithelial-mesenchymal plasticity, a newly-recognised process involved in cancer metastasis. The institute’s role in the consortium specifically relates to compound screening and medicinal chemistry. The Cancer Therapeutics Cooperative Research Centre has a right to commercialise candidate compounds.

The business development office helped establish a strategic program between the institute and the University of Otago to exploit new technologies targeting, for example, HIV and fungal infections. Together with Otago Innovations at the University of Otago, a productive technology transfer relationship has been developed which sets the foundation for two drug discovery programs; one aimed at developing novel anti-HIV drugs targeting a critical viral strategy called ribosomal frameshift, the other focused on developing anti-fungal compounds.

The combined research teams bring complementary skill sets and pooled intellectual property, exemplifying the multidisciplinary approach required to achieve translation of new technologies.

Dr Julian Clark (left) with Ms Carmela Monger.
Start-up company raises capital to progress coeliac disease vaccine

A major milestone was achieved by ImmusanT, a US-based biotech company created to commercialise Nexvax²®, the world’s first potential therapeutic vaccine for coeliac disease. The vaccine is based on research conducted by Dr Bob Anderson at the institute, The Royal Melbourne Hospital and the University of Oxford. In 2012, Dr Anderson took up the position of chief scientific officer of ImmusanT, based in Boston.

In a tough economic environment, ImmusanT succeeded in raising more than $20 million to fund further clinical development of Nexvax²®. Research activities into the immune response to gluten, which is responsible for coeliac disease, continue at the institute under the guidance of Dr Jason Tye-Din and in collaboration with ImmusanT.

Two major stem cell initiatives

The business development office facilitated establishment of two major stem cell initiatives, building on the institute’s long history of research into blood cells. Both initiatives aim to translate basic understanding of blood cells into more effective sources for transfusion and therapy.

Based on funding secured from the CSIRO Science Industry and Endowment Fund, CSIRO, CSL and the institute, we embarked on a program to identify novel drug targets in blood stem cells using a systems biology approach. The goal is to develop agents for mobilising blood stem cells and develop methods for in vitro platelet production.

The institute also entered into a major consortium agreement to create Stem Cells Australia, a collaboration between nine organisations supported by $21 million from the Australian Research Council. The initiative will expand on the institute’s investment in a systems biology approach to understanding blood stem cells and will complement the collaboration with CSIRO and CSL.

Protecting intellectual property

The year witnessed strong growth in the institute’s intellectual property (IP) portfolio with 35 complete patent applications being filed, and a nearly four-fold increase in patents granted. The business development office continued to engage and educate scientists in IP and translation through its training programs, focusing on IP capture. The annual institute laboratory notebook audit revealed an increased and high degree of compliance with international IP requirements. This was the third year of successive improvement across all research divisions. Through our education initiatives, the business development office continued to mentor its business development interns in IP translation, providing assistance and guidance in agreement drafting and negotiation (see page 42).

The business development office was also active in providing detailed input and evidence into a number of national intellectual property initiatives including assisting IP Australia in developing and promoting the Intellectual Property Laws Amendment (Raising the Bar) Bill 2012, and informing the Australian Council on Intellectual Property in its enquiry into ‘Collaborations between public and private sectors: the role of intellectual property’.

Catalyst Fund accelerates two discoveries into development

Modest investments from the business development office’s Catalyst Fund have accelerated development of two potential targeted anti-cancer therapies.

The therapies were developed in a collaboration between Professor Tony Burgess, who recently joined the institute’s Structural Biology division from the Ludwig Institute for Cancer Research, and Dr Guillaume Lessene from the institute’s ACRF Chemical Biology division.

The joint research team discovered a novel family of chemical compounds targeting a protein called Src kinase, high levels of which are associated with several types of cancer and poor prognosis. An investment from the Catalyst Fund resulted in critical in vivo efficacy data that helped secure a National Health and Medical Research Council of Australia Development Grant and led to the development of a series of lead compounds, which will be developed further and commercialised in collaboration with an Australian biotech company.

The same team discovered that a new series of small molecules were strong mitotic inhibitors in a range of tumour cell lines. Anti-mitotic agents inhibit cell division, which is important for stopping cancer progression. An investment from the Catalyst Fund enabled further medicinal chemistry and the discovery of a novel cancer target and mechanism of action that stopped cancer cells dividing. Importantly, the compounds were active against cancer cells resistant to common chemotherapeutic agents such as the taxanes. The project was successfully partnered.

These two major translational events in the journey to develop novel targeted anti-cancer therapies illustrate the importance of collaboration between multidisciplinary teams and the significance of investments in ‘killer experiments’ that lead to proof-of-concept and result in further investment from public and commercial sources. Future development of both classes of compounds will focus on major types of solid tissue tumours.

Professor Tony Burgess
A method of cell isolation
Inventors: G Lindeman, J Visvader, M Shackleton, F Vaillant
Australia and Japan

A method of diagnosis and treatment and agents useful for same
Inventors: G Lindeman, J Visvader, E Sum, L O’Reilly
New Zealand, France, United Kingdom and Germany

A method of treatment and prophylaxis
Inventors: I Wicks, I Campbell, K Lawlor, A Roberts, D Metcalf
Israel

Alpha-helical mimetics
Inventors: J Baell, G Lessene
Australia and Japan

Arylsulfonamide compounds
Inventors: J Baell, W Fairbrother, J Flygare, M Kohler, G Lessene, B Sleebs
New Zealand

Compounds and methods of use
United States

Compounds and methods of use
United States

Immunogenic compositions
Inventors: W Heath, G Belz
New Zealand and Cuba

Immunogenic compositions and uses thereof
Inventors: L Schofield
United States

Immunogenic compositions and uses thereof
Inventors: L Schofield
United States and China

Live genetically attenuated malaria vaccine
Inventors: A Cowman, S Kappe, K van Buskirk
Australia and United States

Modified cells that co-express Blimp1 and a reporter molecule and methods of using the same
Inventors: S Nutt, A Kallies, J Hasbold, D Tarlinton, L Corcoran, P Hodgkin
Japan, France, United Kingdom and Germany

Novel aryl potassium channel blockers and uses thereof
Inventors: A Harvey, B Flynn, D Grobelny, J Mould, G Gill, J Chaplin, J Baell, D Paul
Australia and New Zealand

Novel benzofuran potassium channel blockers and uses thereof
Inventors: J Baell, J Chaplin, B Flynn, A Harvey, J Mould, D Paul
United States

Novel chromone potassium channel blockers and uses thereof
Inventors: J Baell, J Chaplin, B Flynn, A Harvey, J Mould, D Paul
United States

Novel potassium channel blockers and uses thereof
Inventors: J Baell, A Harvey, H Wulff
United States

Structure of the insulin receptor ectodomain
Inventors: M Lawrence, C Ward, N McKern, G Lovrecz, T Adams, L Sparrow, V Streltsov, T Garrett, M Lou
United States

Therapeutic and diagnostic agents
Inventors: L Harrison, S Manneing, A Purcell, N Williamson
Australia, United States and China

Therapeutic molecules and methods for generating and/or selecting same
Inventors: P Colman, D Huang, E Lee, W Fairlie
Australia and China

Business development interns deliver

As the business development internship program designed and run by the business development office nears its third anniversary, the program continues to be a drawcard for early-career researchers.

The program provides real-life experience of working in a technology transfer office, with the interns spending up to 20 per cent of their time as part of the business development team and contributing to projects active in the office at that time. Up to 10 interns take part in the program at any one time. As a result of its success, the program has been extended to senior postdoctoral researchers and experienced research technicians.

Twenty interns have graduated from the program since its inception, the majority having strengthened their position as a career research scientist and developing skills in five core areas of technology transfer and business development: opportunity identification and analysis, intellectual property management, technology marketing communication, agreements and technology transfer administration.

The program offers researchers the opportunity to gain skills in an area outside of, but complementary to, their research, as well as developing an understanding of the process, drivers and players involved in translation of research bench innovations to bedside applications.

During the year the interns made significant contributions towards market analysis, grant and proposal preparation, marketing communication materials, consulting and a review of the institute’s high-throughput chemical screening facility.

Dr Grant Dewson, a laboratory head from the institute’s Cell Signalling and Cell Death division, recently completed the business development internship.

“Since establishing my own laboratory, I have found the experience gained with the business development office extremely useful for the identification, critical assessment and management of collaborative research opportunities, strategic planning, and for understanding the process and importance of securing intellectual property,” Dr Dewson said. “The program also served to reinforce my understanding of the key role for business development in establishing a clinically relevant research program.”

Dr Grant Dewson (left) with Dr Julian Clark.
Institute director Professor Doug Hilton (left) with Undergraduate Research Opportunities Program (UROP) student Mr Doug Tjandra from the institute’s Structural Biology division.
The Education Committee is pleased to report on a productive and rewarding year.

The institute currently has 87 PhD students and 15 honours students. In the past 12 months the institute has hosted 21 Undergraduate Research Opportunities Program (UROP) students and 13 visiting students.

Eighteen PhD students completed their postgraduate degrees during the financial year, and we congratulate them on this wonderful effort. Five PhD students were also awarded PhD scholarships in the past 12 months, including National Health and Medical Research Council of Australia (NHMRC) Medical and Dental Postgraduate Research Scholarships and NHMRC Dora Lush Biomedical Postgraduate Research Scholarships. The institute’s Harold Mitchell Foundation Travel Awards were awarded to PhD student Mr David Riglar and postdoctoral scientist Dr Mike Inouye, enabling them to attend international conferences and tour prospective laboratories in the US, Canada and Germany.

We were once again privileged to host an exceptional cohort of honours students in 2011. All 14 students achieved first-class honours.

One of the Education Committee’s specific aims is engagement with our partner institutions and, with respect to education in particular, with Melbourne-based universities. In the past 12 months, institute faculty members Dr Marnie Blewitt, Dr Chris Burns, Dr Matthew Call, Associate Professor Lynn Corcoran, Dr Guillaume Lessene, Professor Andreas Strasser, Associate Professor David Tarlinton and Professor David Vaux have delivered lectures and participated in the assessment of students at The University of Melbourne, La Trobe University and RMIT.

In 2011-12 we also ran a pilot mentoring program between the institute’s postdoctoral scientists and undergraduate students from The University of Melbourne, organised by Professor Dick Strugnell from The University of Melbourne and Walter and Eliza Hall Institute researcher Dr Krystal Evans.

In July 2011, the institute appointed a scientific education officer, Dr Keely Bumsted-O’Brien. Dr Bumsted-O’Brien initiated and facilitated a new Advanced Honours Coursework element designed to instruct students in critical reading and discussion of scientific literature, as well as workshops to increase the skills of our students in areas such as journal article writing. Aspects of the Advanced Honours Coursework offered jointly with The University of Melbourne for the first time in 2011 were successful and this arrangement continued in 2012.

Encouraging medical professionals to participate in laboratory-based research is an important aspect of translational research, which is a key strategic pillar of the institute. Together with the institute’s clinician-scientists, we have mapped potential paths for becoming a clinician-scientist, and this information is now available on the institute website.

Prospective honours and PhD students attended the institute’s Open Days in September 2011.
Discovering new treatments for deadly parasites

Schistosomiasis is a deadly parasitic disease in the developing world. More than 200 million people are infected with schistosomiasis, and an estimated 200,000 people die from the disease each year.

Honours student Mr Nicholas Lim has been studying the programmed cell death pathway that was recently discovered in parasitic worms by researchers Dr Doug Fairlie and Dr Erinna Lee from the institute’s Structural Biology division.

Mr Lim said the research team was looking for proteins similar to the Bcl-2 family of cell death proteins found in humans. “The Bcl-2 protein family includes ‘pro-survival’ and ‘pro-death’ proteins that are responsible for telling the cells whether to live or die,” Mr Lim said. “My honours project has been focused on characterising components of the cell death pathway in parasitic worms called schistosomes to try to identify new pro-survival or pro-death proteins that are part of this process.”

Mr Lim has already potentially identified a previously unknown pro-death protein in schistosomes as part of his project. “I found a pro-death protein that binds to and interacts with a previously identified pro-survival protein, giving us another ‘link’ in the pathway,” he said. “As researchers continue to understand the components of this pathway they will be able to determine whether targeting these proteins with drugs will be helpful in treating this devastating disease.”

Mr Lim said the Walter and Eliza Hall Institute’s honours program had been a great experience. “The honours program really gives you practical experience and helps you to develop a lot of skills that will be very useful in any future workplace,” he said.

Honours student Mr Nicholas Lim

New genetic clue to dementia puzzle

Fronto-temporal lobar degeneration (FTLD) is the second-most common cause of dementia, a degenerative brain disease for which there is currently no treatment or cure, in people aged under 65.

Approximately 40 per cent of people who develop FTLD have a family history of the disease. Now, institute researchers have made a genetic discovery that may lead to a deeper understanding of this inherited form of dementia.

The research is a joint project between PhD student Ms Katherine Smith and her supervisors Dr Melanie Bahlo, from the institute’s Bioinformatics division, and Professor Sam Berkovic from the Epilepsy Research Centre at Austin Health.

Ms Smith said the research team made the discovery while investigating the genetic cause of a very rare, but fatal, neurodegenerative disease. “Our work is a bit like detective work. We look at the DNA of people who have particular inherited diseases and use sophisticated mathematical and statistical methods to find the genes that have mutations or changes that cause these diseases,” Ms Smith said.

The researchers found that two abnormal copies of a gene called progranulin caused very different disease compared to that seen with one abnormal copy. While a single abnormal copy of progranulin causes FTLD, a condition that begins in middle to late life, two abnormal copies cause a rare and devastating disease, which causes blindness, seizures, and mental decline in young adults in their early twenties.

Ms Smith said the link between these two disorders was not previously suspected. “We had no idea that this mutation, which causes a well-known type of dementia when it affects a single gene copy, would cause this very rare neurodegenerative disease when it affects both gene copies,” she said. “The discovery will help us to better understand how mutations in the progranulin gene cause severe neurological disease.”

Collaborating organisations: Austin Health, Carlo Besta Neurological Institute, Center for Human Genetic Research, Hospital São João, Mayo Clinic, The University of Melbourne, University College London, University of Florida.

Funding partners: Australian Research Council, National Health and Medical Research Council of Australia, The Pratt Foundation and the Victorian Government.


PhD student Ms Katherine Smith
2011-12 graduates

The following students successfully completed their studies in the past year:

**Doctor of Philosophy, The University of Melbourne**

**Dr Julia Cutts**
The innate immune response and human severe malaria. 
Professor Louis Schofield, Professor Alan Cowman

**Dr Hayley Bullen**
Novel membrane proteins of Plasmodium falciparum. 
Professor Alan Cowman, Dr Brendan Crabb, Dr Paul Gilson, Dr Jacob Baum

**Dr Oliver Clarke**
Structural investigations of the Bk potassium channel assembly. 
Dr Jacqui Guilbis, Dr Brian Smith

**Dr Felix Ellett**
Zebrafish models for studying macrophage function and fungal infection. 
Dr Graham Lieschke, Dr Benjamin Kile

**Dr Maybelline Giam**
Functional characterisation of Bcl-G. 
Professor Andreas Strasser, Dr Philippe Bouillet

**Dr Alexander Gout**
Plasmodium falciparum transcriptional regulation of gene expression. 
Professor Terry Speed, Dr Tony Rapenfuss, Dr Brendan Crabb

**Dr Stephanie Grabow**
Which pro-survival Bcl-2 family members are required for lymphoma development or sustained lymphoma growth? 
Professor Andreas Strasser, Dr Philippe Bouillet

**Dr Lina Happo**
The impact of BH3-only genes on the response of murine lymphoma to anti-cancer therapy. 
Professor Andreas Strasser, Associate Professor Clare Scott

**Dr Peter Hughes**
The pro-apoptotic protein Bim and its role in the immune system and polycystic kidney disease. 
Dr Philippe Bouillet, Professor Andreas Strasser

**Dr Seong Khaw**
Translational and mechanistic studies with BH3-minetics in haematological malignancies. 
Professor Andrew Roberts, Professor David Huang

**Dr Elizabeth Kruse**
Regulation of haematopoiesis by ETS transcription factors. 
Dr Benjamin Kile, Professor Warren Alexander

**Dr Huei Leong**
The role of Smad1 in cancer. 
Dr Marnie Blewitt, Professor Doug Hilton

**Dr Shu Louie**
Targeting alternative enzymes in malaria. 
Dr Keith Watson, Associate Professor Jonathan Baell

**Dr Ashley Ng**
The role of Erg in haematopoiesis. 
Professor Warren Alexander, Dr Benjamin Kile

**Dr Priyanka Sathe**
The development pathways of splenic dendritic cells. 
Professor Ken Shortman, Dr Li Wu

**Dr Di Wu**
Finding hidden relationships between gene expression profiles with application to breast cancer biology. 
Professor Terry Speed, Professor Gordon Smyth

**Dr Dmitra Zotos**
The regulation of germinal centre B cell differentiation. 
Associate Professor David Tarlinton, Professor Phil Hodgkin

**Dr Yi Xin**
Understanding transcriptional regulation of terminal T cell differentiation: a focus on Blimp1. 
Dr Stephen Nutt, Dr Axel Kallies

**Bachelor of Science (Honours), The University of Melbourne**

**Mr Brendan Ansell**
Understanding malarial invasion from a structural perspective. 
Professor Alan Cowman, Dr Wai-Hong Tham

**Ms Renee Gloury**
Unravelling the distinct roles of transcription factors in B cell leukaemia development. 
Dr Axel Kallies, Professor Phil Hodgkin

**Mr Nicholas Liu**
Understanding the interplay between JAK2 and SOCS3 in myeloproliferative disease. 
Dr Jeff Babon, Professor Nick Nicola

**Ms Clara Lin**
Function and structure of MSP-DBL2 – an MSP3-like protein peripherally associated with the merozoite surface of P. falciparum. 
Professor Alan Cowman, Dr Tony Hodder

**Mr Edmond Linossi**
SOCS4 structure/function studies and detection of interacting proteins. 
Dr Sandra Nicholson, Dr Lukasz Kedzierski

**Mr Michael Manning**
Investigation of the genetics of hearing loss. 
Dr Rachel Burt, Dr Marina Carpinelli

**Miss Kate McArthur**
Phenotypic cell-based chemical screening. 
Dr Kurt Lackovic, Professor David Huang, Dr Ben Croker

**Ms Antonio Policheni**
Biological characterisation of Clec9A function. 
Dr Mireille Lahoud, Dr Jian-Guo Zhang, Dr Peter Czabotar

**Ms Kathryn Potts**
Investigating the lineage interactions that facilitate transcriptional control of haematopoietic development and stem cell formation in the embryo. 
Dr Sanir Taoudi, Dr Christine Biben

**Mr Michael Roy**
Design and structural characterisation of Bcl-2 inhibitors. 
Dr Guillaume Lessene, Dr Peter Czabotar

**Mr Ryan Stuchbery**
Acute deletion of the pro-apoptotic protein Bim in mice. 
Dr Philippe Bouillet, Dr Delphine Merino

**Mr Vu Tran**
Mitochondrial permeabilisation by Bak and Bax during apoptotic cell death. 
Dr Ruth Kluck, Dr Grant Dawson

**Ms Melanie Williams**
Molecular characterisation of signal transduction pathways mediating apicomplexan parasite-host cell invasion. 
Dr Chris Tonkin, Dr Jacob Baum

**Mr Matthew Witkowski**
Characterising essential genes in B cell leukaemia using RNAi. 
Dr Ross Dickins, Dr Mark McKenzie

**Bachelor of Science (Honours), visiting students**

**Ms Michelle Gazdik**
Design and synthesis of pyridylbenzamides as novel agents active against Trypanosoma brucei. 
Associate Professor Jonathan Baell, Dr Brad Sleebs, Dr Andrew Hughes

**Ms Sarah Moawad**
Design and synthesis of acyguanidines as novel agents active against Trypanosoma brucei. 
Associate Professor Jonathan Baell, Dr Brad Sleebs, Dr Andrew Hughes

**Mr Digjaya Utama**
Diversity of the major surface antigen of Plasmodium falciparum, PfEMP1. 
Dr Alyssa Barry
Scholarships to support training

APA  Australian Postgraduate Award
BPS  National Health and Medical Research Council (NHMRC) Biomedical Postgraduate Scholarship
CCV  Cancer Council of Victoria
CSL  CSL Scholarship
Dora Lush  NHMRC Dora Lush
DSO  DSO National Labs, Scholarship, Singapore
IPRS  International Postgraduate Research Scholarship
LFA  Leukaemia Foundation Australia Scholarship
MIFRS  Melbourne International Fee Remission Scholarship
MIRS  Melbourne International Research Scholarship
MPS  NHMRC Medical Postgraduate Scholarship
MRS  Melbourne Research Scholarship
NBC  National Breast Cancer Foundation Scholarship
Pearl  Pearl Scholarship
Pratt  Pratt Foundation
RCS  Reid Foundation Scholarship
WEHI  Walter and Eliza Hall Institute Scholarship

Raed Alserihi  
Targeting self-renewal mechanisms in T-cell acute lymphoblastic leukaemia.  
Dr Matthew McCormack, Professor Warren Alexander, Professor David Huang SACM

Fiona Angrisano  
The molecular basis for motility in the malaria parasite insect stages.  
Dr Jake Baum, Professor Alan Cowman WEHI

Natasha Anstee  
Impact of Mcl-1 on the development of acute myeloid leukaemia and its resistance to therapy.  
Professor Suzanne Cory, Dr Cassandra Vandenberg LFA

Priscilla Auyeung  
Cellular immune mechanism in chronic idiopathic urticaria.  
Professor Len Harrison, Dr Diana Mittag MPS

Sarah Best  
Identification of master regulators of the mammary hierarchy.  
Professor Jane Visvader, Professor Geoff Lindeman Dora Lush

Julian Bosco  
Mechanism and function of CD52 in immune regulation.  
Professor Len Harrison, Dr John Wentworth Dora Lush

Michelle Boyle  
Plasmodium falciparum merozoite invasion mechanisms and inhibitors of invasion.  
Professor James Beeson, Dr Jake Baum APA

Jason Brouwer  
Structural and biochemical analysis of the pro apoptotic protein Bak.  
Dr Peter Czabotar, Professor Peter Colman APA

Darcy Butts  
An shRNA screen for novel epigenetic regulators of neural stem cell proliferation, differentiation and survival.  
Dr Marnie Blewitt, Professor Doug Hilton, Professor Chris Parish IPRS

Bianca Capaldo  
Functional screens to identify mammary epithelial regulators.  
Professor Jane Visvader, Professor Geoff Lindeman APA

Jo-Anne Chan  
Targets of antibodies to the surface of Plasmodium falciparum-infected erythrocytes that mediate protective immunity to human malaria.  
Professor James Beeson, Professor Alan Cowman, Dr Freya Fowkes MRS

Dineika Chandrananda  
Impact of Mcl-1 on the development of acute myeloid leukaemia and its resistance to therapy.  
Dr Melanie Bahlo, Professor Terry Speed APA

Simon Chatfield  
Human neutrophil activation in inflammatory arthritis.  
Professor Ian Wicks, Dr Ben McKenzie RCS

Kelan Chen  
Structural and functional characterisation of a novel epigenetic regulator SmcHD1.  
Dr Marnie Blewitt, Dr James Murphy, Professor Doug Hilton MIFRS/MIRS

Andy Chen  
Statistical analysis of RNA-Seq data.  
Professor Gordon Smyth, Professor Terry Speed APA

Chris Chiu  
Defining antigenic targets of immunity to malaria.  
Dr Diana Hansen, Professor Alan Cowman WEHI

Kevin Chow  
The regulation of monocyte-derived cells during allograft rejection.  
Associate Professor Andrew Lew, Dr Yuxia Zhang KHA

Akshay D’Cruz  
Investigation of SPRY domain-containing SOCS box proteins.  
Dr Sandra Nicholson, Dr Jeff Babon, Professor Nick Nicola APA

Alexis Delbridge  
Investigating the binding specificity of the SPRY domain.  
Professor Andreas Strasser, Dr Philippe Bouillet APA

Farrah El-Saaffin  
Investigating the molecular and cellular role of TRN.  
Dr Tim Thomas, Dr Anne Voss APA

Nima Etemadi  
Regulation of lymphotoxin β receptor signalling.  
Associate Professor John Silke, Professor David Vaux WEHI

Ivan Fung  
Regulation of early B cell differentiation in response to antigen.  
Associate Professor David Tarlinton, Professor Phil Hodgkin APA
Michelle Gazdik  
The design of small molecule inhibitors of Plasmepsin V for intervention against malaria.  
Dr Justin Boddey, Dr Brad Sleebs, Professor Alan Cowman APA

Jamie Gearing  
An RNA interference-based screen for epigenetic modifiers of X chromosome inactivation.  
Dr Marnie Blewit, Professor Doug Hilton APA

Danika Hill  
Analysis of immunological memory to malaria.  
Professor Louis Schofield, Professor Alan Cowman APA

Colin Hocking  
The Bak:Mcl-1 complex – a mechanism of resistance to apoptosis.  
Dr Ruth Kluck, Professor Jerry Adams APA

Sweta Iyer  
Membrane topology of the mitochondrial apoptosis pore.  
Dr Ruth Kluck, Dr Brian Smith, Professor Peter Colman MIFRS

Reema Jain  
Thymic epithelial cell differentiation and apoptosis.  
Dr Daniel Gray, Professor Andreas Strasser MIFRS

Timothy Johanson  
The role of micro RNAs in dendritic cells. Associate Professor Andrew Lew, Dr Yuxia Zhang, Dr Mark Chong APA

Eugene Kapp  
Improved bioinformatics tools for the analysis of mass spectrometry based on peptidomics data.  
Professor Terry Speed, Professor Gordon Smyth N/A

Francine Ke  
Determining the role of Bak in development and apoptosis.  
Professor Andreas Strasser, Professor Jerry Adams LFA

Keith Khoo  
Characterisation of helical peptide toxins and their analogues.  
Professor Ray Norton, Dr Jonathan Baell IPRS

Andrew Kueh  
The role of HBO1 during embryonic development.  
Dr Tim Thomas, Dr Anne Voss IPRS

Charity Law  
Statistics for next-generation sequencing.  
Professor Gordon Smyth, Professor Terry Speed MRS

Chin-Nien Lee  
Functional studies of dendritic cells in type 1 diabetes: Non-Obese Diabetic (NOD) mouse model.  
Dr Li Wu, Professor Ken Shortman, Associate Professor Andrew Lew MIFRS/MIRS

Stanley Lee  
The role of polycomb group genes in cancer.  
Professor Warren Alexander, Dr Ian Majewski APA

Lily Lee  
Cell types in normal breast and human breast cancers: when do they express the oestrogen receptor?  
Professor Jane Visvader, Professor Geoff Lindeman NBCF

Sophie Lee  
The biological and functional characterisation of how the Erg transcription factor contributes to the development of human leukaemia.  
Professor Warren Alexander, Dr Ashley Ng APA

Clara Lin  
Functions of proteins involved in invasion of Plasmodium falciparum merozoites into human red blood cells.  
Professor Alan Cowman, Dr Tony Hodder MIRS

Edmond Linossi  
Characterising the suppressor of cytokine signalling 4.  
Dr Sandra Nicholson, Professor Nick Nicola APA

Grace Liu  
Investigating the interactions between critical molecular pathways in cancer using RNAi.  
Dr Ross Dickins, Dr Lorraine Robb LFA

Tommy Liu  
The role of suppressor of cytokine signalling-3 (SOCS3) in chondrocytes during development and in inflammatory arthritis.  
Professor Ian Wicks, Dr Ben Croker, Dr Kate Lawlor APA

Aaron Lun  
Systems biology for chromatin interaction using ChiA-PET.  
Professor Gordon Smyth, Dr Stephen Nutt APA

Kevin Man  
The role of IRF4 in CD8 T cell effector and memory differentiation.  
Dr Axel Kallies, Dr Stephen Nutt APA

Julia Marchingo  
Regulation of T cell activation and survival.  
Professor Phil Hodgkin, Dr Susanne Heinzel APA

Dimitra Masouras  
Establishing the role of Ikk in the regulation of BH3-only pro-apoptotic proteins.  
Dr Anissa Jabbour, Associate Professor Paul Ekert APA

James McCoy  
Activation of the Toxoplasma invasion motor.  
Dr Chris Tonkin, Dr Jake Baum, Professor Alan Cowman APA

Jessica Moffat  
Specialising of antigen presentation in the dendritic cell network.  
Dr Jose Villadangos, Dr Justine Mintern APA

Ehtesham Mofiz  
Scabies mite genome project.  
Dr Tony Papenfuss, Professor Terry Speed APA

Nisha Narayan  
Defining how HoxB8 functions to regulate cell survival and differentiation.  
Associate Professor Paul Ekert, Dr Anissa Jabbour APA

Duong Nhu  
Rocaglamide congeners as novel anti-cancer agents.  
Dr Chris Burns, Dr Guillaume Lessene MIFRS/MIRS

Joanne O’Donnell  
Molecular regulation of inflammatory cell death.  
Dr Ben Croker, Professor Andrew Roberts, Dr Motti Gerlic Dora Lush

Maya Olshina  
In vivo and in vitro investigation of actin regulation in the malaria parasite.  
Dr Jake Baum, Dr Jacqui Gubbris, Professor A Cowman Dora Lush

Shereen Oon  
A novel approach to cytokine blockade for the treatment of systemic erythematosus.  
Professor Ian Wicks, Dr Nicholas Wilson MPS
Milon Pang
The role of PU.1 in early lymphocyte development and leukaemogenesis.
Dr Li Wu, Dr Stephen Nutt LFA

Kathryn Potts
Generation of inter-lineage cross-talk model of haematopoietic stem cell development.
Dr Samir Taoudi, Professor Doug Hilton APA

Simon Preston
The role of signal transducer and activator of transcription (STAT)-related proteins in dendritic cells during chronic active infection.
Dr Marc Pellegrini, Dr Gabrielle Belz Dora Lush

Pravin Rajasekaran
Characterising Plasmodium–hepatocyte interactions during liver-stage malaria.
Dr Justin Boddey, Professor Alan Cowman APA

Lucille Rankin
Investigating the transcriptional regulation of lymphoid tissue inducer (LTI) cells by inhibitor of differentiation (Id2) and retinoid-related orphan receptor gamma T (Ror-Gamma-T).
Dr Gabrielle Belz, Dr Stephen Nutt Dora Lush

Maryam Rashidi
Innate immunity and inflammation in diabetes.
Professor Len Harrison, Dr John Wentworth MIFRS/MIRS

James Rickard
Sharpin regulation of TNF signalling in chronic proliferation dermatitis.
Associate Professor John Silke, Professor David Vaux APA

David Riglar
Dissection of the coordinated events during Plasmodium falciparum infection of the human erythrocyte.
Professor Alan Cowman, Dr Jake Baum APA

Leona Rohrbeck
Regulation of BH3-only protein in vivo.
Professor Andreas Strasser, Dr Philippe Bouillet MIFRS/MIRS

Michael Roy
Design and characterisation of Bcl-xL and Mcl-1 inhibitors.
Dr Guillaume Lessene, Dr Peter Czabotar, Professor Peter Colman APA

Victoria Ryg-Cornejo
Understanding generation of high-affinity antibody responses to malaria.
Dr Diana Hansen, Professor Louis Schofield APA

Natalia Sampaio
Suppression of malaria by the malaria parasite antigen Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1).
Professor Louis Schofield, Dr Krystal Evans Dora Lush

Shirley Seah
Costimulatory requirements of help-independent anti-influenza CTL.
Associate Professor Andrew Lew, Dr Yuxia Zhang DSO

Bilal Sheikh
The independent and overlapping roles of chromatin regulators MOZ, QKF and BMI1.
Dr Anne Voss, Dr Tim Thomas Dora Lush

Katherine Smith
Developing statistical analysis methods robust to heterogeneity for the discovery of disease variants.
Dr Melanie Bahlo, Professor Terry Speed Pratt

Rebecca Stewart
Functional characterisation of phosphorylation of the Toxoplasma invasion motor.
Dr Chris Tonkin, Dr Jake Baum, Professor Alan Cowman APA

Stephanie Tan
Glycosphosphatidylinositol as a multi-stage, pan-species surface antigen in malaria.
Professor Louis Schofield, Dr Diana Hansen MIRS/MIFRS

Jesse Toe
Clearing chronic infectious diseases – enhancing host immune effector function.
Dr Marc Pellegrini, Dr Gabrielle Belz Dora Lush

Elizabeth Valente
Pro-apoptotic BH3-only proteins Puma, and to a lesser extent Noxa, are critical for the therapeutic effects of the p53-activating compound Nutlin-3a in normal and malignant lymphoid cells.
Professor Andreas Strasser, Dr Philippe Bouillet CCV

Hannah Vanyai
The role of monocytic leukaemia zinc finger protein in embryonic development.
Dr Anne Voss, Dr Tim Thomas APA

Leila Varghese
Janus kinase activity and regulation of haematopoiesis and disease.
Dr James Murphy, Professor Doug Hilton, Dr Jeff Babon LFA

Andreea Waltmann
The molecular epidemiology of malaria transmission in the South West Pacific.
Professor Ivo Mueller, Dr Alyssa Barry WEHI

Clare Weeden
Preclinical validation of new combination therapies in xenograft mouse models of lung cancer.
Dr Marie-Liesse Asselin-Labat, Professor Geoff Lindeman APA

Michael White
Functional characterisation of caspase-9 in haematopoiesis.
Dr Ben Kile, Professor David Huang LFA

Melanie Williams
Structural and functional analysis of host cell invasion motor in toxoplasma parasites.
Dr Chris Tonkin, Professor Alan Cowman APA

Matthew Witkowski
The role of transcription factor, Ikaros, in acute lymphoblastic leukaemia pathogenesis and therapy-resistance.
Dr Ross Dickins, Dr Mark McKenzie APA

Alan Yap
Molecular mechanisms of remodelling and invasion of malaria parasites.
Professor Alan Cowman, Dr Jake Baum Pearl

Kelvin Yip
Responses of normal and cancerous intestinal stem cells to regulatory signals.
Professor Tony Burgess MIFRS/MIRS

Janet Yeo
Alternative pathways to miRNA biogenesis.
Dr Mark Chong, Dr Gabrielle Belz MIFRS/MIRS

Sook Pheng Wong
Notch signalling in colorectal cancer.
Professor Tony Burgess MIFRS/MIRS

Elizabeth Zuccala
Molecular dissection of malaria parasite interactions with the human erythrocyte.
Dr Jake Baum, Professor Alan Cowman APA
Visiting PhD students

Mary Ann Anderson
Anti-lymphoma therapy.
Professor David Huang, Professor Andrew Roberts

Pratiti Bandopadhayay
Oncogenic functions of the EWS-WT1 translocation in desmoplasic small round cell sarcoma.
Associate Professor Paul Ekert, Dr Elizabeth Algar, Dr David Ashley

Joseph Evans
TNF superfamily signalling in tumourigenesis and discovery of therapeutic applications.
Associate Professor John Silke, Professor David Vaux

Benjamin Green
The role of AKT in IL-3 receptor survival signalling.
Associate Professor Paul Ekert, Dr Richard Pearson

Marika Salmanidis
Molecular mechanisms of HoxB8 function in myeloid cells.
Associate Professor Paul Ekert, Dr Lavinia Gordon

Sylvia Teguh
Artemisinin study for mechanisms of actions and investigation of novel potential antimalarial compounds: conjugated-indole dye and triazine.
Dr Guillaume Lessene, Dr Leann Tilley

Monique Topp
Novel xenograft mouse model of human high-grade serous epithelial ovarian cancer for preclinical analysis.
Associate Professor Clare Scott, Dr Karla Hutt

Bachelor of Science (Honours) in progress

Walter and Eliza Hall Institute honours students are supported by funding from the Alan W Harris Scholarship program.

Hesham Abdulla
Modelling the multi-step pathogenesis of T cell leukaemia.
Dr Matthew McCormack, Professor Warren Alexander

Claire Bowtell
Using RNA interference to uncover novel regulators of apoptosis.
Professor Andreas Strasser, Dr Marco Herold

Eamon Byrne
How do immune regulatory enzymes recognise substrates inside the lipid bilayer?
Dr Melissa Call, Dr Matthew Call

Boon Kheng Chai
Analysis of CARP1 and CARP2 knockout mice.
Professor David Vaux, Dr Najoua Lalaoui, Dr James Vince

Hui San Chin
Regulation of apoptosis in Mcl-1-dependent cells.
Professor David Huang, Dr Seong Lin Khaw, Dr David Segal

Stephanie Conos
Cytokine signalling in myeloid leukaemia.
Associate Professor Paul Ekert, Dr Anita Jabbour

Ashleigh Keown
The role of cytoskeletal regulatory proteins in T cell development.
Dr Mark Chong, Dr Sheila Dias

Ashod Kherlopian
Cytokine signalling in myeloid leukaemia.
Dr Anissa Jabbour, Associate Professor Paul Ekert

Logesvaran Krshnan
Mechanisms of transmembrane signalling in the immune system.
Dr Matthew Call, Dr Melissa Call

Nicholas Lim
Targeting cell death pathways in parasites.
Dr Doug Fairlie, Dr Erinna Lee

Jun Ting Low
The role of NF-κB in the development of autoimmunity and cancer in FasL-Fas mutant mice.
Dr Lorraine O'Reilly, Professor Andreas Strasser

Cyrus Tan
Discovering new treatments for debilitating parasitic diseases using medicinal chemistry.
Dr Jonathan Baell, Dr Brad Sleebs

Jeigh Tiu
Improving drug therapies for immune diseases.
Professor Phil Hodgkin, Dr Susanne Heinzel

Emma Watson
Programmed cell death and angiogenesis.
Dr Leigh Coultas, Professor Andreas Strasser

Jie Zhou
Exploring cellular calculation with the B lymphocyte model.
Professor Phil Hodgkin, Associate Professor David Tarlinton

Visiting Honours students

Manal Ali
Design and synthesis of selective kinase inhibitors.
Dr Chris Burns, Dr Brian Smith
2011-12 vacation scholars

UROP students and overseas research trainees

The institute hosted eight university undergraduates as vacation scholars mainly between November 2011 and March 2012, for periods from two weeks up to four months.

Another 21 students participated in the University Research Opportunities Program (UROP), which is administered through the Bio21 Cluster and gives university students an opportunity to participate in research.

In addition, the institute hosted 12 overseas undergraduates to undertake short-term research training placements from Austria, China, France, Germany, The Netherlands, Spain and Sweden.

Mr Aaron Bagnato
UROP student
Dr Guillaume Lessene

Mr Andrew Bennett
UROP student
Dr Melanie Bahlo

Ms Lucy Bennett
Vacation scholarship student
Professor Doug Hilton

Ms Katrina Black
UROP student
Dr Jacqui Gulbis

Ms Courtney Cameron
UROP student
Professor Doug Hilton

Ms Hui Chin
Vacation scholarship student
Professor David Huang

Ms Bethany Clark
UROP student
Professor Warren Alexander

Ms Katherine Colman
Vacation scholarship student
Professor Doug Hilton

Mr Caleb Dawson
Vacation scholarship student
Professor Doug Hilton

Ms Gerda de Vries
Overseas research trainee
(The Netherlands)
Associate Professor Paul Ekert

Ms Janina Findeis
Overseas research trainee (Germany)
Dr Gabrielle Belz

Ms Laura Galvis Vargas
UROP student
Dr Marie-Liesse Asselin-Labat

Ms Sally Higgins
UROP student
Dr Alyssa Barry

Ms Louisa Hill
Overseas research trainee (Germany)
Dr Sebastian Carotta

Ms Felanita Hutani
UROP student
Dr Chris Burns

Mr Sean Ivory
UROP student
Dr Ross Dickens

Ms Ashleigh Keown
UROP student
Professor Len Harrison

Mr Logesvaran Krishnan
UROP student
Dr Melissa Call, Dr Matthew Call

Mr Mark Kowarsky
UROP student
Dr Tony Papenfuss

Mr Matthias Lang
Overseas research trainee
Professor Andreas Strasser

Ms Elizabeth Lieschke
Vacation scholarship student
Associate Professor Clare Scott

Ms Joy Liu
UROP student
Dr Marnie Blewitt

Mr Sidney Louzoun
Overseas research trainee (France)
Dr Guillaume Lessene

Ms Hang Luong
UROP student
Associate Professor Clare Scott

Mr Davis McCarthy
UROP student
Professor Gordon Smyth

Mr Lachlan McIntosh
UROP student
Dr Tony Papenfuss

Ms Helen McRae
UROP student
Dr Doug Fairlie

Ms Marie Menard
Overseas research trainee (France)
Professor Suzanne Cory, Professor Jerry Adams

Ms Elenora Ottina
Overseas research trainee (Austria)
Professor Andreas Strasser

Mr Bartija Pieters
Overseas research trainee
(The Netherlands)
Professor Ian Wicks

Ms Junyan Qian
Overseas research trainee (China)
Professor Len Harrison

Mr Michael Roy
Vacation scholarship student
Dr Guillaume Lessene

Ms Angelika Rutgersson
Overseas research trainee (Sweden)
Dr Emma Josefsson

Mr Douglas Tjandra
UROP student
Professor David Huang

Ms Jaris Valencia
Overseas research trainee (Spain)
Professor Jose Villadangos

Ms Jolanda Visser
Overseas research trainee
(The Netherlands)
Associate Professor Paul Ekert

Ms Andrea Waltman
Vacation scholarship student
Professor Ivo Mueller

Mr David Wakeham
UROP student
Dr Melanie Bahlo

Mr Jeremy Wong
Vacation scholarship student
Dr Matthew McCormack

Mr Clarence Wong
UROP student
Professor Phil Hodgkin

Mr Nicholas Yee
UROP student
Associate Professor Mike Lawrence
The 2012 seminar program at the Walter and Eliza Hall Institute featured more than 100 researchers from around the world presenting the latest scientific knowledge and discoveries.

The Walter and Eliza Hall Institute runs two regular seminar programs, the Monday postgraduate lecture series, and Wednesday seminar series, which are both open to the public.

The Monday postgraduate lecture series features the ‘who’s who’ of national researchers providing insights on major questions in their field of expertise. In 2012, the postgraduate series focused on infectious diseases and the immune response to infection.

Prominent Australian and international researchers were invited to share their research and views on microbe biology, disease pathogenesis and the epidemiology of preventing transmission.

Some highlights from the series included: Professor Tania Sorell from the University of Sydney, Westmead, discussing the impact of fungal infections on human health; Dr Jake Baum from the Walter and Eliza Hall Institute on the complexity of tackling malaria; Professor Paul Young from the University of Queensland, who highlighted the threat that dengue fever virus poses in Australia; and Professor Lindsay Grayson from the Austin Hospital in Melbourne, providing an insightful study of how simple hygiene can have a massive effect on the transmission of superbugs.

The institute’s Wednesday seminar series features the best, ‘hot-off-the-press’ research and includes presentations from across the institute’s research community, including PhD students, laboratory heads and division heads.

The quality of the research presented by institute scientists was underscored by the numerous high profile publications that followed. Dr Emma Josefsson discussed how cell death programs regulate platelet production, Dr Erika Cretney presented data on the biological programming of regulatory T cells, Dr Katja Lüthje showed us how the fate of certain T cells could be tracked, and Dr James Vince presented his work investigating the role of cell death regulators in inflammation.

A number of special seminars were also held at the institute. Professor Nadia Rosenthal, director of the Australian Regenerative Medicine Institute at Monash University, presented her work on how the immune system may impact on our body’s regenerative capacity. Professor Rosenthal was our first ‘Women in Science’ guest speaker for 2012.

Our ‘Clinical Translation’ guest seminars match basic science researchers with hospital clinicians, demonstrating how disease-focused research is providing valuable insights in medicine. Clinician-scientist Dr John Wentworth from the institute and The Royal Melbourne Hospital partnered with Professor Paul O’Brien from Monash University to discuss obesity, its impact on biological processes and its management.

A full list of institute seminars held in 2011-12 can be found on the accompanying CD.

Nobel Laureate Professor Elizabeth Blackburn presented Hooked on Science, a lecture to inspire junior and middle high school students to study science, medicine or engineering.
<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 July 2011</td>
<td>The comparative epidemiology of <em>P. falciparum</em> and <em>P. vivax</em>: lessons from population-based studies in Papua New Guinea.</td>
<td>Professor Ivo Mueller, Infection and Immunity division.</td>
</tr>
<tr>
<td>13 July 2011</td>
<td>Bim isoforms: three bullets to kill a cancer cell.</td>
<td>Dr Delphine Merino, Molecular Genetics of Cancer division.</td>
</tr>
<tr>
<td>27 July 2011</td>
<td>Weight loss surgery provides insights into immune mechanisms of metabolic disease.</td>
<td>Dr John Wentworth, Immunology division.</td>
</tr>
<tr>
<td>3 August 2011</td>
<td>The impact of BH3-only genes on the response of murine lymphoma to anti-cancer therapy.</td>
<td>Ms Lina Happo (PhD student), Molecular Genetics of Cancer division.</td>
</tr>
<tr>
<td>8 August 2011</td>
<td>Clinical translation: developing targeted therapies in haematological cancers.</td>
<td>Professor Andrew Roberts, Clinical Translation.</td>
</tr>
<tr>
<td>10 August 2011</td>
<td>The identification of an epigenetic lock that maintains Th2 lineage fidelity.</td>
<td>Dr Rhys Allan, Molecular Immunology division.</td>
</tr>
<tr>
<td>17 August 2011</td>
<td>Dissecting the molecular mechanisms behind actin filament disassembly – an essential process in malaria parasite cell movement.</td>
<td>Mr Wilson Wong, Infection and Immunity division.</td>
</tr>
<tr>
<td>24 August 2011</td>
<td>Development of the haematopoietic system during embryogenesis.</td>
<td>Dr Samir Taoudi, Molecular Medicine division.</td>
</tr>
<tr>
<td>31 August 2011</td>
<td>Living on the edge: releasing Arh2’s stranglehold on immunity.</td>
<td>Dr Marc Pellegrini, Infection and Immunity division.</td>
</tr>
<tr>
<td>7 September 2011</td>
<td>Inside the plasma membrane: how lipid-embedded protein domains participate in immune regulation.</td>
<td>Dr Matthew Call, Structural Biology division.</td>
</tr>
<tr>
<td>21 September 2011</td>
<td>A modern high-throughput screening approach to a 20-year-old drug target.</td>
<td>Dr Tony Cardno, Chemical Biology division.</td>
</tr>
<tr>
<td>28 September 2011</td>
<td>Restraint of apoptotic cell death, not its activation, is essential for megakaryocytes to produce platelets.</td>
<td>Dr Emma Josefsson, Cancer and Haematology division.</td>
</tr>
<tr>
<td>12 October 2011</td>
<td>The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells.</td>
<td>Dr Erika Cretney, Molecular Immunology division.</td>
</tr>
<tr>
<td>26 October 2011</td>
<td>Examining the requirement of endogenous pro-survival Bcl-2 family members in lymphoma development.</td>
<td>Ms Stephanie Grabow (PhD student), Molecular Genetics of Cancer division.</td>
</tr>
<tr>
<td>28 October 2011</td>
<td>Sequencing and understanding tumour genomes.</td>
<td>Dr Tony Papenfuss, Bioinformatics division.</td>
</tr>
<tr>
<td>2 November 2011</td>
<td>Identification of signalling pathways modulating <em>Toxoplasma</em> host cell invasion.</td>
<td>Dr Chris Tonkin, Infection and Immunity division.</td>
</tr>
<tr>
<td>9 November 2011</td>
<td>Smc3d1 is a novel epigenetic modifier involved in X chromosome inactivation that also behaves as a tumour suppressor.</td>
<td>Ms Huei San Leon (PhD student), Molecular Medicine division.</td>
</tr>
<tr>
<td>16 November 2011</td>
<td>Autoinflammation: diseases of the innate immune system.</td>
<td>Dr Seth Masters, Inflammation division.</td>
</tr>
<tr>
<td>23 November 2011</td>
<td>The role of Polycomb Repressive Complex 2 (PRC2) in tumourigenesis.</td>
<td>Mr Stanley Lee (PhD student), Cancer and Haematology division.</td>
</tr>
<tr>
<td>Date</td>
<td>Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5 December 2011</td>
<td>Deciphering the role of IRF4 in transcription and chromatin regulation during T cell differentiation using RNA and ChIP sequencing.</td>
<td>Dr Axel Kallies, Molecular Immunology division, and Dr Wei Shi, Bioinformatics division.</td>
</tr>
<tr>
<td>14 December 2011</td>
<td>Vascular regression and the role of endothelial cell apoptosis.</td>
<td>Dr Leigh Coultas, Cancer and Haematology division.</td>
</tr>
<tr>
<td>21 December 2011</td>
<td>Characterisation of novel Bcl-2 family member, Bcl-G.</td>
<td>Ms Maybelline Giam (PhD student), Molecular Genetics of Cancer division.</td>
</tr>
<tr>
<td>7 March 2012</td>
<td>Bridging histone acetylation and ubiquitination during development and in stem cells.</td>
<td>Mr Bilal Sheikh (PhD student), Molecular Medicine division.</td>
</tr>
<tr>
<td>14 March 2012</td>
<td>The important role of dendritic cells in autoimmune type 1 diabetes.</td>
<td>Mr Chin-Nien Lee (PhD student), Molecular Immunology division.</td>
</tr>
<tr>
<td>28 March 2012</td>
<td>Transcriptional regulation of CTL differentiation: more than one way to be a killer.</td>
<td>Ms Annie Xin (PhD student), Molecular Immunology division.</td>
</tr>
<tr>
<td>2 April 2012</td>
<td>Overview of malaria parasite virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Dr Jake Baum, Infection and Immunity division.</td>
</tr>
<tr>
<td>11 April 2012</td>
<td>Unlike CD4 T cell help, co-stimulation is necessary for effective primary CD8 T cell influenza-specific immunity.</td>
<td>Ms Shirley Seah (PhD student), Immunology division.</td>
</tr>
<tr>
<td>2 May 2012</td>
<td>Following T cell fate using an interleukin-21 reporter mouse.</td>
<td>Dr Katja Lüthje, Immunology division.</td>
</tr>
<tr>
<td>9 May 2012</td>
<td>Making models of systemic inflammatory disease.</td>
<td>Dr Ben Croker, Inflammation division.</td>
</tr>
<tr>
<td>16 May 2012</td>
<td>SOCS box proteins: regulation of inflammation and immunity.</td>
<td>Dr Sandra Nicholson, Inflammation division.</td>
</tr>
<tr>
<td>23 May 2012</td>
<td>Role of cell death signalling in inflammation.</td>
<td>Dr James Vince, Cell Signalling and Cell Death division.</td>
</tr>
<tr>
<td>30 May 2012</td>
<td>The role of HoxB8 in myeloid cell immortalisation.</td>
<td>Ms Marika Salmanidis (PhD student), Cell Signalling and Cell Death division.</td>
</tr>
<tr>
<td>6 June 2012</td>
<td>Soluble glycoprotein CD52 mediates suppression by antigen-activated regulatory CD4+ T cells.</td>
<td>Dr Esther Bandala Sanchez, Immunology division.</td>
</tr>
<tr>
<td>13 June 2012</td>
<td>The role of HBO1 during embryonic development.</td>
<td>Mr Andrew Kueh (PhD student), Molecular Medicine division.</td>
</tr>
<tr>
<td>14 June 2012</td>
<td>The Ion Torrent sequencing platform: options for WEHI researchers for high-throughput sequencing.</td>
<td>Ms Doreen Agyapomaa, Systems Biology and Personalised Medicine division.</td>
</tr>
<tr>
<td>20 June 2012</td>
<td>BH3-only proteins in apoptosis.</td>
<td>Dr Philippe Bouilliet, Molecular Genetics of Cancer division.</td>
</tr>
<tr>
<td>27 June 2012</td>
<td>Haematopoietic transcription factors in acute leukaemia genesis and therapy.</td>
<td>Dr Ross Dickins, Molecular Medicine division.</td>
</tr>
<tr>
<td>Date</td>
<td>Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>4 July 2011</td>
<td>Cancer immunoediting.</td>
<td>Professor Mark Smyth, Cellular Immunity, Peter MacCallum Cancer Centre, Australia.</td>
</tr>
<tr>
<td>18 July 2011</td>
<td>Xenograft models of pediatric acute leukaemia: insights into biology and treatment.</td>
<td>Associate Professor Richard Lock, Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of NSW, Australia.</td>
</tr>
<tr>
<td>20 July 2011</td>
<td>The role of antibodies in protecting children from <em>Plasmodium falciparum</em> malaria.</td>
<td>Dr Jack Richards, Centre for Immunology, Burnet Institute, Australia.</td>
</tr>
<tr>
<td>27 July 2011</td>
<td>Weight loss surgery provides insights into immune mechanisms of metabolic disease.</td>
<td>Professor Paul O’Brien, Centre of Obesity Research and Education, Monash University, Australia.</td>
</tr>
<tr>
<td>1 August 2011</td>
<td>Antigen presentation in bone marrow transplantation: where and when?</td>
<td>Professor Geoff Hill, Division of Immunology, Bone Marrow Transplant Lab, Queensland Institute of Medical Research, Australia.</td>
</tr>
<tr>
<td>18 August 2011</td>
<td>Modelling cell fate transitions and determinants of cell type.</td>
<td>Dr Jessica Mar, Albert Einstein College of Medicine, US.</td>
</tr>
<tr>
<td>19 August 2011</td>
<td>Stat3: the secret ingredient to turn lysosomes deadly?</td>
<td>Dr Peter Kreuzaler, Trinity College, Department of Pathology, University of Cambridge, UK.</td>
</tr>
<tr>
<td>14 September 2011</td>
<td>IAP antagonists induce conformational changes in cIAP1 that promote dimerisation and auto-ubiquitination.</td>
<td>Dr Wayne Fairbrother, Protein Engineering Department, Genentech Inc US.</td>
</tr>
<tr>
<td>5 October 2011</td>
<td>Minor class mRNA splicing comes into focus: Rnpc3 shapes the developing transcriptome and is deregulated in cancer.</td>
<td>Associate Professor Joan Heath, Colon Biology Lab, Ludwig Institute for Cancer Research, Australia.</td>
</tr>
<tr>
<td>10 October 2011</td>
<td>Non-invasive optical imaging: an established tool for studying disease progression, mechanism and therapy.</td>
<td>Dr Vivek Shinde Patel, Technical Applications, Caliper Life Sciences, Australia.</td>
</tr>
<tr>
<td>18 October 2011</td>
<td>Pipetting, ergonomics and you: an overview of ergonomics, pipetting risk factors, methods for reducing the risk of injury and recommended solutions.</td>
<td>Mr Jason Smith, Mettler Toledo Limited, Australia.</td>
</tr>
<tr>
<td>19 October 2011</td>
<td>Devil facial tumor disease: a cancer of ignorance.</td>
<td>Associate Professor Greg Woods, Menzies Research Institute, Tasmania, Australia.</td>
</tr>
<tr>
<td>20 October 2011</td>
<td>Genetics and evolution of clonally transmissible cancers in dogs and Tasmanian devils.</td>
<td>Dr Elizabeth P Murchison, Wellcome Trust Sanger Institute, UK.</td>
</tr>
<tr>
<td>28 October 2011</td>
<td>Sequencing and understanding tumour genomes.</td>
<td>Mr Dale Garsed, Peter MacCallum Cancer Centre, Australia.</td>
</tr>
<tr>
<td>4 November 2011</td>
<td>Making blood: <em>in vitro</em> production of human red cells for transfusion therapy.</td>
<td>Professor David Anstee, Bristol Institute for Transfusion Sciences, UK.</td>
</tr>
<tr>
<td>7 November 2011</td>
<td>The common gamma chain family of cytokines: from human disease to transcriptional regulation of critical immune pathways.</td>
<td>Dr Warren J Leonard, Laboratory of Molecular Immunology, National Heart Lung and Blood Institute, National Institutes of Health, US.</td>
</tr>
<tr>
<td>18 November 2011</td>
<td>Immune evasion by Tasmanian devil facial tumour.</td>
<td>Dr Hannah Siddle, Department of Pathology, University of Cambridge, UK.</td>
</tr>
<tr>
<td>Date</td>
<td>Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>22 November 2011</td>
<td>Death receptors and ubiquitin in cancer and inflammation.</td>
<td>Professor Henning Walczak, Tumour Immunology, Department of Medicine, Imperial College London, UK.</td>
</tr>
<tr>
<td>22 November 2011</td>
<td>The modular organisation of dynamic signalling networks - why bad is good.</td>
<td>Professor Anthony J Pawson, Department of Medical Genetics and Microbiology, University of Toronto, Canada.</td>
</tr>
<tr>
<td>22 November 2011</td>
<td>Early events in adaptive immunoresponse: from single molecule to in vivo.</td>
<td>Professor Facundo Batista, Lymphocyte Interaction Laboratory, London Research Institute, UK.</td>
</tr>
<tr>
<td>29 November 2011</td>
<td>Drug discovery and development in academia: the Sloan-Kettering experience.</td>
<td>Dr Hakim Djaballah, Memorial Sloan-Kettering Cancer Center, US.</td>
</tr>
<tr>
<td>16 December 2011</td>
<td>Inflammasomes in health and homeostasis in the intestines and beyond.</td>
<td>Professor Richard A Flavell FRS, Howard Hughes Medical Institute, US, and Yale School of Medicine, US.</td>
</tr>
<tr>
<td>19 December 2011</td>
<td>Peeking into the secret life of neutrophils.</td>
<td>Dr Lai Guan Ng, Singapore Immunology Network at A*Star, Singapore.</td>
</tr>
<tr>
<td>7 February 2012</td>
<td>Ubiquitin-mediated regulation of innate immune signaling.</td>
<td>Associate Professor Mads Gyrd-Hansen, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.</td>
</tr>
<tr>
<td>8 February 2012</td>
<td>Functional genomics, experimental models and cancer.</td>
<td>Associate Professor William Hahn, Dana-Farber Cancer Institute, US.</td>
</tr>
<tr>
<td>9 February 2012</td>
<td>Advances in monoclonal antibody purification and protein characterisation.</td>
<td>Mr Oscar Yamasaki, Tosoh Bioscience, Japan.</td>
</tr>
<tr>
<td>13 February 2012</td>
<td>BCR-ABL-independent factors which prevent the control of chronic myelogenous leukaemia.</td>
<td>Associate Professor Sin Tiong Ong, Duke-National University of Singapore Graduate Medical School, Singapore.</td>
</tr>
<tr>
<td>13 February 2012</td>
<td>The use of p53 as a tool for cancer therapy.</td>
<td>Dr Jean-Christophe Marine, VIB Laboratory for Molecular Cancer Biology, KU Leuven, Belgium.</td>
</tr>
<tr>
<td>13 February 2012</td>
<td>Using mouse models to improve cancer therapy.</td>
<td>Dr Michael Hemann, The David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, US.</td>
</tr>
<tr>
<td>14 February 2012</td>
<td>Deconstructing p53 pathways in vivo using mouse models.</td>
<td>Associate Professor Laura Attardi, Department of Radiation and Cancer Biology, Stanford University, US.</td>
</tr>
<tr>
<td>15 February 2012</td>
<td>Kuru: the science and the sorcery.</td>
<td>Professor Michael Alpers, Centre for International Health, Curtin University, Australia.</td>
</tr>
<tr>
<td>20 February 2012</td>
<td>Some like it hot: biomolecule analytics using microscale thermophoresis (MST).</td>
<td>Dr Jan Griesbach, NanoTemper Technologies GmbH, Germany.</td>
</tr>
<tr>
<td>29 February 2012</td>
<td>Immune modulation of vertebrate regeneration.</td>
<td>Professor Nadia Rosenthal, Australian Regenerative Medicine Institute and European Molecular Biology Laboratory Australia, Monash University, Australia.</td>
</tr>
<tr>
<td>Date</td>
<td>Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>29 February 2012</td>
<td>Two issues relevant to how new knowledge is generated: the process for allocating NHMRC project grants; and the strange organisation of universities.</td>
<td>Professor Nicholas Graves School of Public Health and Institute for Health and Biomedical Innovation, Queensland University of Technology, Australia.</td>
</tr>
<tr>
<td>5 March 2012</td>
<td>Breast cancer subtypes: biology, biomarkers and therapeutic targets.</td>
<td>Professor Rob Sutherland AO FAA, Cancer Research Program, Garvan Institute of Medical Research, Australia.</td>
</tr>
<tr>
<td>21 March 2012</td>
<td>Molecular targeted therapy for childhood cancer.</td>
<td>Professor Michelle Haber AM, Children’s Cancer Institute, Australia.</td>
</tr>
<tr>
<td>22 March 2012</td>
<td>Gene regulatory control of entry into the T cell developmental pathway.</td>
<td>Professor Ellen Rothenberg, Division of Biology, California Institute of Technology, US.</td>
</tr>
<tr>
<td>26 March 2012</td>
<td>PerkinElmer/Caliper in vivo roadshow.</td>
<td>Dr Wael Yared, Life Science and Technology, PerkinElmer, Australia, and Dr Kevin Francis</td>
</tr>
<tr>
<td>29 March 2012</td>
<td>The H19 lincRNA is a developmental reservoir of miR-675 which suppresses growth and Igf1r.</td>
<td>Dr Andrew Keniry, The Babraham Institute, UK.</td>
</tr>
<tr>
<td>4 April 2012</td>
<td>Dissecting the dynamics of antiviral T cell responses in the skin during herpes simplex virus infection.</td>
<td>Dr Scott Mueller, Microbiology and Immunology, University of Melbourne, Australia.</td>
</tr>
<tr>
<td>11 April 2012</td>
<td>The fattening and sweetening of haematopoietic stem cells: effects on monocyte production and atherosclerosis.</td>
<td>Dr Andrew Murphy, Molecular Medicine, Department of Medicine, Columbia University, US.</td>
</tr>
<tr>
<td>18 April 2012</td>
<td>Working towards an integrated research platform.</td>
<td>Associate Professor Peter Gibbs, Colorectal Cancer Biomarkers Laboratory, Ludwig Institute for Cancer Research; The Royal Melbourne Hospital and Western Health; and BioGrid Australia.</td>
</tr>
<tr>
<td>27 April 2012</td>
<td>Immunomodulatory effects of vitamin D during antituberculous therapy and HIV/Mycobacterium tuberculosis (MTE) co-infection.</td>
<td>Dr Anna Coussens, Division of Mycobacterial Research, National Institute for Medical Research, UK.</td>
</tr>
<tr>
<td>30 April 2012</td>
<td>Genes, mechanisms, and intervention in autoimmune diabetes.</td>
<td>Dr Anna Coussens, Division of Mycobacterial Research, National Institute for Medical Research, UK.</td>
</tr>
<tr>
<td></td>
<td>Professor John Todd, Cambridge Institute for Medical Research, Cambridge University, UK.</td>
<td>Professor Tania Sorell, Centre for Infectious Diseases and Microbiology, The University of Sydney at Westmead Millennium Institute for Medical Research, Australia.</td>
</tr>
<tr>
<td>11 May 2012</td>
<td>Rejuvenating apoptosis.</td>
<td>Professor Atan Gross, Department of Biological Regulation, Weizman Institute of Science, Israel.</td>
</tr>
<tr>
<td>18 May 2012</td>
<td>Telomeres and other DNA breaks in autoimmunity.</td>
<td>Professor Cornelia Weyand, Stanford University, US.</td>
</tr>
<tr>
<td>29 May 2012</td>
<td>Transcriptional regulation of complex genetic loci during vertebrate development.</td>
<td>Professor Peter Rigby, The Institute of Cancer Research, UK.</td>
</tr>
<tr>
<td>29 May 2012</td>
<td>A global perspective on developing a non-dietary treatment for coeliac disease.</td>
<td>Dr Bob Anderson, Walter and Eliza Hall Institute, Australia, and ImmusanT Inc, US; Dr Evan Newnham, Angliss Hospital, Monash University, and Box Hill Hospital, Australia; Ms Leslie Williams, ImmusanT Inc, US.</td>
</tr>
<tr>
<td>14 June 2012</td>
<td>The Ion Torrent sequencing platform: options for researchers for high-throughput sequencing.</td>
<td>Dr Ken McGrath, Australian Genome Research Facility, Australia.</td>
</tr>
</tbody>
</table>
## 2012 postgraduate lecture series: infection and inflammation

The institute’s postgraduate lecture series provides students, postdoctoral fellows and staff with the opportunity to learn from experts from many institutions across the nation. Following the lecture, the students have the opportunity to pursue further discussions over lunch with the speaker.

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 March 2012</td>
<td>Overview of <em>E.coli</em> and intracellular bacteria virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Professor Elizabeth Hartland, Department of Microbiology and Immunology, University of Melbourne.</td>
</tr>
<tr>
<td>26 March 2012</td>
<td>Overview of Group A <em>Streptococcus</em> virulence and resistance mechanisms and disease pathogenesis, with implications for indigenous health.</td>
<td>Professor Mark Walker, Australian Infectious Disease Research Centre, University of Queensland.</td>
</tr>
<tr>
<td>2 April 2012</td>
<td>Overview of malaria parasite, virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Dr Jake Baum, Infection and Immunity division, Walter and Eliza Hall Institute.</td>
</tr>
<tr>
<td>16 April 2012</td>
<td>Overview of <em>Leishmania</em> parasites, virulence and resistance mechanisms and human disease pathogenesis.</td>
<td>Professor Malcolm McConville, Bio21 Institute.</td>
</tr>
<tr>
<td>23 April 2012</td>
<td>Overview of helminths, virulence and resistance mechanisms and human disease pathogenesis.</td>
<td>Dr Aaron Jex, Faculty of Veterinary Science, University of Melbourne.</td>
</tr>
<tr>
<td>30 April 2012</td>
<td>Overview of fungi, virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Professor Tania Sorell, director, Centre for Infectious Diseases and Microbiology, University of Sydney at Westmead Millennium Institute for Medical Research.</td>
</tr>
<tr>
<td>7 May 2012</td>
<td>Latent viral infections, mechanism of latency, pathogenesis and oncogenesis.</td>
<td>Dr Jamie Nourse, Clinical Immunohaematology division, Queensland Institute of Medical Research.</td>
</tr>
<tr>
<td>14 May 2012</td>
<td>Dengue: a case of once bitten, twice shy.</td>
<td>Professor Paul Young, Australian Infectious Diseases Research Centre, University of Queensland.</td>
</tr>
<tr>
<td>21 May 2012</td>
<td>Overview of hepatitis viruses, virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Associate Professor Joseph Torresi, Department of Infectious Diseases, Austin Hospital.</td>
</tr>
<tr>
<td>28 May 2012</td>
<td>Overview of HIV, virulence and resistance mechanisms and disease pathogenesis.</td>
<td>Professor Steve Wesselingh, South Australian Health and Medical Research Institute.</td>
</tr>
<tr>
<td>4 June 2012</td>
<td>Overview of human prions and disease pathogenesis.</td>
<td>Associate Professor Andrew Hill, Department of Biochemistry and Molecular Biology, Bio21 Institute.</td>
</tr>
<tr>
<td>18 June 2012</td>
<td>Overview of epidemiology and determining modes of transmission/acquisition, e.g. multi-drug resistant <em>Staphylococcus aureus</em> (MRSA) and vancomycin-resistant <em>Enterococcus</em> (VRE) in the hospital and community.</td>
<td>Professor Lindsay Grayson, Department of Infectious Diseases, Austin Hospital.</td>
</tr>
<tr>
<td>25 June 2012</td>
<td>Science of predicting, preparing, preventing for the next potential pandemic.</td>
<td>Professor Raina MacIntyre, School of Public Health and Community Medicine, University of New South Wales.</td>
</tr>
<tr>
<td>2 July 2012</td>
<td>Overview of host sensing of pathogens and innate immunity.</td>
<td>Dr Antje Blumenthal, Epithelial Cancer division, University of Queensland Diamantina Institute.</td>
</tr>
<tr>
<td>Date</td>
<td>Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9 July 2012</td>
<td>Overview of how new epidemic pathogens are recognised and identified, e.g. Nipah/Hendra virus and epidemiological surveillance and detection of emerging infectious disease threats.</td>
<td>Dr Peter Daniels, Australian Animal Health Laboratory, CSIRO.</td>
</tr>
<tr>
<td>16 July 2012</td>
<td>New vaccines for the old enemy: the challenge of tuberculosis.</td>
<td>Professor Warwick Britton, Discipline of Infectious Diseases Immunology and Mycobacterial Research Program at the Centenary Institute of Cancer Medicine Cell Biology, University of Sydney.</td>
</tr>
<tr>
<td>23 July 2012</td>
<td>Overview of host determinants of infectious diseases outcomes, e.g. HCV and IL-28.</td>
<td>Dr Alex Thompson, Hepatology Research, St Vincent’s Hospital.</td>
</tr>
<tr>
<td>30 June 2012</td>
<td>Can vaccines contribute to the malaria eradication agenda?</td>
<td>Associate Professor Louis Schofield, Infection and Immunity division, Walter and Eliza Hall Institute.</td>
</tr>
<tr>
<td>6 August 2012</td>
<td>Overview of septicaemia, pathogenesis of sepsis/SIRS, and the role of pathogens and host factors in pathogenesis.</td>
<td>Dr Christopher MacIsaac, Intensive Care Unit, The Royal Melbourne Hospital.</td>
</tr>
<tr>
<td>13 August 2012</td>
<td>Overview of post Group A Streptococcal immune complications.</td>
<td>Professor Ian Wicks, Inflammation division, Walter and Eliza Hall Institute.</td>
</tr>
<tr>
<td>20 August 2012</td>
<td>The gut microbiota, immunity and human disease.</td>
<td>Professor Charles Mackay, Immunology Department, School of Biomedical Sciences, Monash University.</td>
</tr>
<tr>
<td>27 August 2012</td>
<td>Global equality in infectious diseases control.</td>
<td>Sir Gustav Nossal, Professor Emeritus, University of Melbourne</td>
</tr>
<tr>
<td>3 September 2012</td>
<td>Overview of major Indigenous health infectious diseases issues and problems.</td>
<td>Professor Jonathan Carapetis, Telethon Institute of Child Health Research.</td>
</tr>
</tbody>
</table>
The Burnet Prize

Malaria researcher Dr Jake Baum was the 2011 recipient of the Burnet Prize, the Walter and Eliza Hall Institute’s top award, for his work to understand the ‘motor’ that drives movement of the malaria parasite.

The Burnet Prize is awarded annually to early-career scientists and was established in 1987 through a bequest from Sir Macfarlane Burnet (institute director 1944-65).

Dr Baum’s research aims to identify crucial parasite proteins that are involved in infection and transmission of malaria parasites, including the most virulent strain that infects humans, *Plasmodium falciparum*. Such proteins could serve as important targets for development of new antimalarial drugs.

Dr Baum said he was honoured to receive the Burnet Prize. “The award is wonderful recognition for my research group,” Dr Baum said. “It is humbling, if not a little terrifying, to look at the list of previous winners and see the impact they have had, particularly in translating their research to real human health outcomes. It is my greatest hope that we might see the same impact from our work in the future.”

There is still a lot that is not understood about the processes that regulate how malaria parasites move, Dr Baum said. “The holy grail of malaria research has been to find a vaccine or drug that is effective against all stages of malaria parasite infection,” he said. “Since the parasite must keep moving at all times, we are trying to take apart the motor to understand every process involved, to find a target that meets this criteria. We hope to develop a complete ‘toolkit’ for drug development against motility to identify new targets in the malaria parasite.”

The institute’s other award winners were:

**Best seminar:** The 2011 Seminar Prize was awarded to Dr Ingela Vikstrom from the Immunology division for her presentation, ‘Resolving the stage-specific contribution of the anti-apoptotic proteins to humoral immunity’.

**Best student seminar:** The Student Seminar Prize went to PhD student Mr Oliver Clarke from the institute’s Structural Biology division for his presentation, ‘Domain reorientation and rotation of an intracellular assembly controls conduction in a Kir potassium channel’.

**Art in Science Prize:** Ms Jie Zhou, an honours student from the institute’s Immunology division, won the 2011 Art in Science Prize for her image, *Siblings on Reflection*, showing the symmetry of immune cell fates.

Mr Denis Quilici received an award for 40 years of service to the institute. Eight staff were recognised for 25 years service to the institute: Ms Janice Coventry, Mrs Joan Curtis, Mr Alf Mele, Mrs Brigitte Mesiti, Mr Steven Mihajlovic, Mr Gaetano Naselli, Ms Julie Stanley, Mr Malcolm Williamson.
Engagement

Dr Erinna Lee (right) with a discovery tour participant from the Ashburton Probus Club.
Engagement

The institute is committed to establishing and maintaining awareness and community dialogue about health, medical research and innovation, and the value these offer all Australians.

Our staff and students have participated in a range of activities aimed at reaching these goals, including giving presentations to community groups, hosting laboratory tours, holding positions on scientific boards, organising conferences and participating in the institute’s Open Days.

The institute’s community encompasses school students, donors and bequestors, politicians, colleagues, collaborators, and the public. This year, we welcomed many donors, school groups and organisational representatives to the institute. Throughout the year, these groups toured the laboratories, attended research briefings hosted by our scientific staff, and took part in fundraising activities. We also launched the Walter and Eliza Hall Society to recognise and thank those people who have indicated their intent to leave a gift to the institute in their will.

In 2012 the institute participated in an exhibition organised by the Bio21 Cluster to showcase Victoria’s proud scientific achievements. The Bio21 Cluster is a collaborative network of 22 Melbourne institutions, encompassing universities, tertiary health services, medical research institutes, CSIRO and other member-based organisations. The Innovating for Victoria’s Health exhibition, held at Parliament House in May 2012, has increased awareness of the Bio21 members’ contributions to medical research and initiated discussion among Victorian parliamentarians about the value of medical research to the community.

The Discoveries Need Dollars campaign continues to foster conversations about the value of medical research to the Australian community. In 2011, the federal government commissioned a strategic review of the health and medical research sector (the McKeon Review) in response to community concerns about potential funding cuts in the health and medical research sector. Institute staff prepared three submissions: one on behalf of the institute; one on behalf of the institute’s Gender Equity Committee; and a third on behalf of the Discoveries Need Dollars campaign. The outcomes of the review are due to be released in the second half of 2012.

WEHI.TV animator Ms Etsuko Uno won the Visual Science Award at New York’s Imagine Science Film Festival in October 2011 for her animation Breast stem cells. These achievements of this award-winning team have culminated in the creation of a biomedical animation partnership between WEHI.TV, other biomedical animation studios, and Apple to create online educational resources for biology students. The head of WEHI.TV, Mr Drew Berry, was also the successful recipient of an Inspiring Australia grant, with the Garvan Institute of Medical Research and the CSIRO, to help train three new science animators.

In 2012 we initiated the 10 million and counting campaign to celebrate the contribution of institute researchers to the discovery and development of colony stimulating factors (CSFs). CSFs have been used by more than 10 million cancer patients worldwide to boost their immune systems after chemotherapy or collect stem cells for bone marrow transplants. The initiative aims to expand awareness of our research achievements and establish a community of people who have benefited from this important Australian medical research discovery.

The Hon Justin Madden at the launch of the Innovating for Victoria’s Health exhibition at Parliament House.
The institute’s management is committed to establishing and maintaining collaborative links to help us solve research questions relating to cancer, chronic inflammatory diseases and infectious diseases.

We have a long history of collaborative research into blood cell production and function, with a major focus on stem cells. In November 2011 Stem Cells Australia was launched, linking Australia’s premier life scientists in a seven-year $32 million initiative to position Australia as an international hub for stem cell research.

Stem Cells Australia is a collaboration between the Walter and Eliza Hall Institute, The University of Melbourne, Monash University, University of Queensland, University of New South Wales, Victor Chang Cardiac Research Institute, the Florey Institute of Neuroscience and Mental Health and the CSIRO.

Stem Cells Australia will fast-track efforts to understand how stem cells are controlled and maintained, and what properties and signals allow them to develop into any cell type in the body. The initiative brings together Australia’s leading experts in bioengineering, nanotechnology, stem cell biology, advanced molecular analysis and clinical research to uncover the fundamental mechanisms involved in stem cell regulation and differentiation. We aim to translate the knowledge gained into new biotechnological and therapeutic applications.

The institute makes research collaborations a high priority and is dedicated to establishing partnerships that allow us to develop our laboratory research into new treatments and diagnostics.

We were one of the founding members of Cancer Trials Australia, a leading provider of early-phase cancer clinical trials. Established in 1993, Cancer Trials Australia is a Melbourne-based not-for-profit organisation that helps member investigators evaluate new medicines conceived in their laboratories, in addition to running clinical trials for investigators and research organisations.

Cancer Trials Australia was the local coordinator of a worldwide phase Ia clinical trial of the anti-cancer agent ABT-199 (GDC-0199/RG7601) in patients with chronic lymphocytic leukaemia which began in early 2011. Professor Andrew Roberts, head of the institute’s Clinical Translation Centre, was one of the investigators leading the trial.

Sector-wide collaboration showcases research to Victoria’s politicians

Collaboration has been important to the institute’s successes. Over the past several decades many of our collaborators have been based at neighbouring universities, hospitals and medical research institutes.

In 2001 some of these relationships were formalised when the institute became one of three founding members of the Bio21 Cluster. The cluster was formed to support the development of Victoria’s fledgling biotechnology industry. Today it has 22 members from across Melbourne, all working collaboratively to advance health and medical research in Victoria.

A focus of the cluster, and the institute, over the past 12 months has been engaging Victoria’s parliamentarians in discussion about the contribution health and medical research has, and will, make to Victoria.

One of the central pillars of this was an exhibition of health and medical research organised by the Bio21 Cluster and held in May 2012 to showcase the strength and value of the sector in Victoria. The institute was one of more than 70 organisations represented through displays that profiled the economic benefits the sector has brought to Victoria, the discoveries that have saved and improved lives and the contribution our scientists have made to Victoria’s global profile.

The exhibition was held in Queens Hall, Parliament House, during a parliamentary sitting week, ensuring maximum exposure to Victoria’s politicians. The exhibition is now being seen by a broader audience, with the displays featuring at venues across Victoria.


Strategic partners

51
Many of the institute's researchers contribute to the scientific and medical community both nationally and internationally. One such contribution is serving on conference organising committees. Throughout the year five conferences were organised by institute staff, with a total of 783 delegates attending.

In October 2011, the Malaria in Melbourne meeting was held to facilitate the development of collaborative links among young researchers from various institutes, strengthening the common goal to develop new ways to control malaria. Institute scientists Dr Alyssa Barry (co-chair) and Dr Melanie Rug were on the organising committee, which held a successful conference for 150 young malaria researchers. Also in October 2011, Professor Mike Lawrence chaired the organising committee for the IGF-Oz conference, which brought together Australian researchers interested in the IGF (insulin-like growth factor) system and related proteins in development and disease. Eighty delegates attended this two-day meeting.

Dr Arthur Hsu from the institute’s Bioinformatics division chaired the organising committee for the BioInfoSummer Symposium. This week-long meeting was held in December 2011 and introduced 107 students and early-career researchers from mathematical and biological sciences to state-of-the-art bioinformatics research. Institute scientists were also involved in the Computational Immunology conference in April 2012. Dr Cameron Wellard (chair) and Professor Phil Hodgkin were part of the organising committee, which brought together 30 practitioners from overseas and interstate to present their latest research and apply new techniques to important problems in immunology.

Institute researchers also contribute to the scientific and medical community by serving on review panels, boards and committees, undertaking editorial work for scientific and medical journals, conference organisation and attendance, and involvement with biotechnology, clinical advisory groups and public health programs. A full list of staff service to the scientific and medical community can be found on the CD that accompanies this annual report.

The week-long BioInfoSummer Symposium featured the latest state-of-the-art bioinformatics research.
Championing malaria on the global stage

Continuing its tradition of championing malaria research on the global stage, the Walter and Eliza Hall Institute again played principal host to the quadrennial Molecular Approaches to Malaria (MAM) international conference.

MAM2012 took place in Lorne, Victoria, on 19-23 February 2012. The conference was chaired by Dr Jake Baum from the institute’s Infection and Immunity division and Dr Kevin Saliba from the Australian National University. More than 400 delegates registered with more than half travelling from overseas, including many from regions where malaria remains a major human health problem. Conference speakers gave 62 scientific talks, and the science presented crossed all disciplines, all scales of investigation and every facet of the parasite lifecycle and malaria disease.

The conference heralded an era that places this major global disease centre-stage for biomedical science. By bringing the world’s experts in malaria and parasitic disease to Australia every four years, the MAM conferences continue to take the lead in showcasing how science is tackling one of mankind’s greatest diseases.

Charting the course of Australian health and medical research into the next decade

In 2011, the federal government commissioned a strategic review of health and medical research in Australia.

The government announced the review in the aftermath of widespread community concern that funding of health and medical research would be cut in the May 2011 federal budget. Institute director Professor Doug Hilton prepared a submission to the review on behalf of the Walter and Eliza Hall Institute. The submission highlighted the significant contributions Australian researchers have made to improving health and wellbeing, and outlined the challenges facing the medical research sector in the next decade. Many institute staff and students also made individual contributions to the review.

Professor Hilton said the review was necessary to ensure that Australia’s health and medical research efforts were optimised in the next decade. “Australia is fortunate to have a fantastic pool of talent and significant infrastructure committed to health and medical research,” Professor Hilton said. “We look forward to the McKeon Review providing a ‘road map’ that ensures these resources are best applied to improve the health of Australians.”

The review, chaired by 2011 Australian of the Year Mr Simon McKeon AO, will recommend a 10-year plan for health and medical research in Australia, proposing how the sector can best address Australia’s future health needs, and ways that government funding and policy can be used to strengthen Australian health and medical research.

Institute staff also prepared a submission to the McKeon Review from the Gender Equity Committee and another on behalf of the Discoveries Need Dollars campaign, which has been run by the institute since February 2011. The review is expected to make its recommendations to the government in late 2012.
More than 1000 people visited the institute in 2011-12 as part of the institute’s public engagement program.

The institute has a strong commitment to sharing its medical research discoveries with the community. Two public lectures were held during the year, with more than 450 attendees, a 40 per cent increase in attendance from 2010-11.

In February 2012, Professor Rob Sutherland from the Garvan Institute of Medical Research gave a presentation on the latest in biology, biomarkers and therapeutic targets in breast cancer research. In May 2012, a public lecture on developing non-dietary treatments for coeliac disease was presented by Dr Bob Anderson, honorary associate of the institute and chief scientific and medical officer of ImmusanT Inc; Ms Leslie Williams, president and chief executive officer of ImmusanT Inc; and Dr Evan Newnham, director of Angliss Hospital. The lecture outlined the development and progress of Nexvax2®, a potential therapeutic vaccine for coeliac disease.

The institute’s discovery tours are an opportunity for the public to visit our laboratories, meet our scientists and learn about our many discoveries. In 2011-12, 75 of our scientists volunteered their time to showcase their research at the institute, and more than 650 people attended the 26 tours which were held throughout the year. These tours consisted of both public and private groups and included school students, Probus and community groups, and partner and business organisations. Thirteen schools attended our discovery tours, including students from John Monash Science School, Nagle College, Rosehill Secondary School, Scotch College and Woodleigh School.

In June 2012, more than 380 Year 7-10 students from 44 schools attended a lecture at the institute by Nobel laureate Professor Elizabeth Blackburn. Professor Blackburn inspired the students with her story of the passion, struggles and successes along her scientific journey.

As part of the CSIRO Scientists in Schools program, six institute scientists partnered with schools to engage and motivate students in their learning of science. The schools included Wesley College, Our Lady of Victories and Mill Park Primary School. Our students also volunteered their time at the Gene Technology Access Centre as part of the Insights into Medical Research day in June. They undertook experiments with 60 Year 9 students from schools such as Norwood Secondary College, Assumption College and University High School. Our students also gave career talks, emphasising the diversity of careers in biomedical research.
Supporting talented school students

Encouraging school students of all ages to explore and develop their passion for science is a critical part of the Walter and Eliza Hall Institute’s community outreach and engagement program.

The institute has proudly supported the Science Talent Search, run by the Science Teachers’ Association of Victoria, since 2001. In 2011 our sponsorship provided more than 30 bursaries that were awarded to students across many categories.

The Science Talent Search is open to all primary and secondary school students in Victoria. Students prepare essays, conduct experiments, take photographs, design posters and create videos for the judges’ consideration.

Among the winners of the institute’s bursaries in 2011 were Jessica Jong and Nhu Quynh Quach from Santa Maria College. Jessica and Nhu won a bursary for their scientific poster titled ‘Drugs As Friends & Foes’.

Mr Jules Nisperos, a Year 8 student from Caroline Chisholm Catholic College, was awarded a bursary for his experimental research report titled ‘Is it safe for my teeth?’. Jules examined the effect of applying different colas to animal bone, and concluded that one cola in particular had a markedly heavier impact on bone disintegration.

Jules said he encountered many challenges working on his project and was on the verge of giving up. “My parents encouraged me to finish what I had started,” he said. “I spent many hours experimenting at the school’s laboratory after school, many days of the school holidays continuing my experiments at home and many nights typing up my experimental report.

“My teachers said this was the first time that a student from my school had received an award from this prestigious competition. My parents, teachers and I were extremely proud and excited once we knew that my entry had won a minor bursary.”

Jessica Jong (left) and Nhu Quynh Quach from Santa Maria College display their poster ‘Drugs As Friends & Foes’.

WEHI.TV animation wins New York award

In October 2011, a biomedical animation of breast stem cells and breast development was screened at New York’s Imagine Science Film Festival. The animation, created by WEHI.TV’s Ms Etsuko Uno and Mr Drew Berry, won the festival’s Visual Science Award.

The animation depicts breast stem cells and their role in producing breast milk during pregnancy. Breast stem cells were discovered by researchers in the institute’s ACRF Stem Cells and Cancer division, and have been implicated in the development of certain types of breast cancer.

Ms Uno said she was thrilled to receive the award. “It is great to see our film recognised for its ability to depict highly complex biological processes in an accurate and visually appealing way for the general public,” she said.

WEHI.TV’s latest animation, X Inactivation and Epigenetics, was launched at the Walter and Eliza Hall Institute annual general meeting in October 2011. X inactivation is a vital process that occurs in all DNA-containing cells of the female body. It is also an important research model and tool for studying epigenetics. The animation has attracted almost 7000 views on YouTube.

We continue to receive a large number of requests for the animations from media, science institutes, art galleries, schools and students. Visits to the WEHI.TV YouTube channel WEHImovies have risen by 150 per cent in the past year.

Also in the past year, Mr Berry and Ms Uno have joined a partnership between E. O. Wilson’s Biodiversity Foundation and Apple to create scientifically accurate animations for use in a digital textbook called Life on Earth for students in kindergarten through to late high school. Mr Berry also created an animation for well-known singer and artist Björk for the song Hollow.

“A still from the WEHI.TV animation X Inactivation and Epigenetics.”
GTAC: The Gene Technology Access Centre

GTAC is a specialist science education centre with a focus on engaging students, teachers and the broader community in cell and molecular biology. Collaboration between the Walter and Eliza Hall Institute, The University of Melbourne, University High School and the Victorian Government’s Department of Education and Early Childhood Development, enables the centre to deliver programs that immerse students and their teachers in contemporary science investigations. More than 11,000 school students participated in GTAC programs this year, supported by PhD scientists who mentor and inspire small groups of students while demystifying science.

Specialist GTAC programs in 2012 facilitated student and teacher interaction with prominent scientists such as Sir Gustav Nossal and Professor Phil Hodgkin who presented historical and contemporary perspectives on disease and immunology, Dr David Piedrafita who revealed the amazing world of parasites, and Professor Tony Bacic and Professor Bronwyn Kingwell who provided insights into carbohydrates and our health.

During the year GTAC launched a new DNA barcoding program in which students extract and amplify DNA for sequencing and analysis. GTAC staff and scientists also visited primary schools, facilitating investigations for 2500 students in the fields of forensic microscopy, genetics and the environment.

New GTAC director Ms Jacinta Duncan described the GTAC model as a state treasure. “We have a highly qualified education staff dedicated to designing programs that enhance student engagement in contemporary science working alongside our 70-plus scientist mentors,” Ms Duncan said. “These mentors are engaging students in real science and opening pathways to a career in science. The ongoing support provided by the Walter and Eliza Hall Institute and other research institutes in the Bio21 precinct is invaluable to our success.”

Australian politicians visit the institute

The Walter and Eliza Hall Institute benefits greatly from Victorian and Australian Government support of medical research. We were delighted to welcome a number of state and federal politicians to the institute over the past year. They toured the facilities and met with our researchers to learn more about their work.

Our guests in 2011-12 included former speaker of the House of Representatives, Mr Harry Jenkins MP, and Mr Kelvin Thomson MP, Federal Member for Wills.
Donor and bequestor engagement

This past year has provided a welcome opportunity for us to cement existing relationships with our supporters in the community while building new ones.

We have been humbled by the generosity of our supporters, who have donated almost $6 million to the institute in the past year. In an uncertain financial climate, where competition is intensifying for the limited government funding available for research, this support is more valuable than ever. As we move towards our centenary celebrations in 2015, we hope to build even stronger relationships with our supporters.

The belief our donors and bequestors have shown in us through their ongoing support means a great deal to our scientists and is directly responsible for advancing the institute’s research program.

This year we continued the program of research briefings that introduces our supporters to institute scientists. The feedback from our visitors is that they value the chance to see firsthand the work their donations support.

Bequests have been an important and valued support for the institute’s scientists over the past 97 years, and we are indebted to past bequestors for their generous choice to support our research. In the past year we have established the Walter and Eliza Hall Society to recognise those members of the community who have indicated that they wish to leave a gift to the institute in their will, and give them the opportunity to attend briefings and events at the institute.

For those donors who are unable to visit us due to distance or other restraints we extend our thanks, and hope to be able to welcome you to the institute in the coming years.

Official launch of the Walter and Eliza Hall Society

Institute director Professor Doug Hilton hosted the launch of the Walter and Eliza Hall Society in April 2012, on the 97th birthday of the institute.

The society is named in recognition of Walter and Eliza Hall. Following the death of Walter Hall in 1911, his widow Eliza set up a charitable trust to benefit the community, using part of his estate. An early grant made by the trust established the Walter and Eliza Hall Institute of Medical Research.

The Walter and Eliza Hall Society is a special events program giving bequestors unique opportunities to hear about recent research developments from our key scientists.

Professor Hilton said the society was a way for the institute community to thank those who have indicated their intention to leave a gift to the institute in their will.

“The society acknowledges the vital contribution bequestors have made to the institute's development over the past 97 years,” he said. “The gift they have made in their wills to our medical research is a wonderful gesture which provides hope for the development of new and better treatments that will have a real impact on human health.”
Breakfast with the Cure Cancer Australia Foundation and Can Too

In June 2012 institute director Professor Doug Hilton had the pleasure of hosting a ‘meet the researchers’ breakfast for the Cure Cancer Australia Foundation and its major fundraising arm, Can Too.

Each year Cure Cancer Australia chooses one institute in each state to showcase to their supporters and donors. We were delighted to be the Victorian host in 2012.

Cure Cancer Australia provides funding for early-career medical researchers around Australia. Institute researchers Dr Ashley Ng and Dr Rachael Rutkowski have both benefited from this funding and, with Associate Professor Clare Scott, were at the breakfast to meet the supporters, talk about their research, and host tours of the laboratories.

During the tours the Cure Cancer Australia and Can Too supporters met with Professor Don Metcalf, renowned for leading the research team that discovered colony stimulating factors (CSFs). CSFs have helped more than 10 million people worldwide recover from their cancer treatments.

Professor Hilton said it was a pleasure to welcome the supporters to the institute. “The support of groups such as Cure Cancer Australia and Can Too provides financial security for our early-career researchers as they pursue their research goals,” he said. “This sort of support is vital if young researchers are to produce a body of work on which to firmly establish their research careers.”

Institute researchers raise money in World’s Greatest Shave

The Leukaemia Foundation has been a great supporter of medical research at the Walter and Eliza Hall Institute, providing funding for many of our research staff from students to senior researchers.

For many years, institute staff have participated in the Leukaemia Foundation’s World’s Greatest Shave, an annual event in which people shave or colour their hair to raise money for people with blood cancers such as leukaemia, lymphoma and myeloma. The money is used by the Leukaemia Foundation to provide free services for people with blood cancers and to fund their multi-million dollar research investment each year.

Thirteen staff members took part in the World’s Greatest Shave on Thursday 15 March 2012, including both research and support service staff. The team raised $12,500 for the Leukaemia Foundation, the 11th highest amount of money raised by a team in Tasmania and Victoria.

This year’s team was led by PhD student Ms Hannah Vanyai, who said she was proud to take part in the fundraising event. “My hair was so long – more than 70 centimetres – so I thought it would be great to raise money for the World’s Greatest Shave and donate my hair to make wigs for people who are undergoing chemotherapy,” she said. “This fundraising venture is very personal on two levels: at work I see the amazing research that can be done with funding from events like the World’s Greatest Shave, and a dear friend of mine is also a leukaemia survivor.”
Service to the scientific and wider community

Service to biotechnology boards, committees and consultancies

Warren Alexander, MuriGen Therapeutics Scientific Advisory Board, Co-chair

Marie-Liesse Asselin-Labat, Victorian Comprehensive Cancer Centre Lung Research Collaborative Working Group, Member

Jonathan Baell, Bionomics, Consultant

Melanie Bahlo, MacTel consortium, Scientific consultant

Gabrielle Belz, Australian Government Gene Technology Technical Advisory Committee, Member

Gabrielle Belz, CSL Limited, Consultant

Chris Burns, YM BioSciences, Chief scientific advisor

Peter Colman, Bio21 Australia Ltd, Alternate board member to Professor Doug Hilton

Lynn Corcoran, CSL Limited, Collaborative research project, Project leader

Ross Dickens, Victorian Centre for Functional Genomics Scientific Advisory Committee, Member

Mark Hinds, Bio21 NMR Strategic Committee, Member

David Huang, Bio21 Scientific Advisory Council, Council member

Benjamin Kile, MuriGen Therapeutics, Chief scientific and operating officer

Michael Lawrence, Australian Association of Medical Research Institutes, Proposal advisor for the Australian Synchrotron

Geoff Lindeman, Australian Cancer Research Foundation Medical Research Advisory Committee, Committee member

Anthony Papenfuss, University of Melbourne e-Research Advisory Group, Member

Marc Pellegrini, Cytheris, Inc, Preclinical research advisor

Louis Schofield, Ancora Pharmaceuticals Inc, Scientific Board, Board member

Clare Scott, BioGrid Australia, Breast Stream, Head

Clare Scott, BioGrid Australia Management Committee, Institute representative

Clare Scott, BioGrid Australia, Rare Tumour Stream, Head

Clare Scott, Melbourne Health Expert Scientific Review Panel, Panel member

Clare Scott, Melbourne Health Research Week committee, Institute representative

Clare Scott, Victorian Comprehensive Cancer Centre Seminar Series Committee, Institute representative

Clare Scott, Walter and Eliza Hall Institute of Medical Research Victorian Comprehensive Cancer Centre Gynaecologic Oncology Research Collaborative, Member

John Silke, Cooperative Research Centre for Biomarker Translation, Project leader

John Silke, Scientific Advisory Board, TetraLogic Pharmaceuticals, Pennsylvania, Board member

John Silke, Victorian Comprehensive Cancer Centre Education and Training Committee, Member

Gordon Smyth, Australasian Genomic and Associated Technologies Association (AMATA), President

Gordon Smyth, Australasian Genomic and Associated Technologies Association (AMATA), Committee member

Terry Speed, Bionovo Scientific Advisory Board, Board member

Terry Speed, Pathwork Diagnostics Scientific Advisory Board, Board member

Terry Speed, Veracyte Inc Scientific Advisory Board, Board member

Andreas Strasser, Genentech, Inc., Consultant

Andreas Strasser, Pfizer Inc., Consultant

Andreas Strasser, Walter and Eliza Hall Institute/The Royal Melbourne Hospital Clinical Advisory Group, Member

Ian Street, Children’s Cancer Institute Australian Drug Discovery Scientific Advisory Board, Board member

Ian Street, New South Wales Cancer Institute Research Review Committee, Committee member

David Tarlinton, CSL Limited, Consultant

David Tarlinton, Ozgene Pty Ltd, Consultant

Jason Tye-Din, ImmusaniT, Inc., Consultant

Jason Tye-Din, Nexpep Pty Ltd, Consultant

David Vaux, Scientific Advisory Board, Mochtar Riady Institute of Nanotechnology, Indonesia, Board member

David Vaux, Scientific Advisory Board, TetraLogic Pharmaceuticals, Pennsylvania, Board member

Jane Visvader, Cancer Council Victoria Medical and Scientific Committee, Member

Jane Visvader, International Society for Stem Cell Research, Translational Science Advisory Committee, Member

Jane Visvader, National Breast Cancer Foundation Research Advisory Committee, Member

Service on clinical working or advisory boards

Warren Alexander, Children’s Cancer Institute Australia Scientific Advisory Board, Member

Phil Hodgkin, Bio21 Cluster Scientific Advisory Council, Institute representative

Phil Hodgkin, RMIT Biomedical Science Program Advisory Committee, Member

Benjamin Kile, Australian Cancer Research Foundation Translational Haematology Laboratory Management Committee, Member

Geoff Lindeman, Australian Cancer Research Foundation Centre for Therapeutic Target Discovery, Clinical director

Geoff Lindeman, Australian New Zealand Breast Cancer Trials Group, Board member

Geoff Lindeman, Australian New Zealand Breast Cancer Trials Group Scientific Advisory Committee, Member

Geoff Lindeman, Department of Health Implementation Committee for the Victorian Family Cancer Genetics Service, Member

Geoff Lindeman, Implementation Committee for the Royal Melbourne Hospital Familial Cancer Centre, Chair

Geoff Lindeman, Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Committee member
Geoff Lindeman, Kathleen Cunningham Foundation for Research into Familial Breast Cancer (kConFab) Executive, Member

Geoff Lindeman, Melbourne Health Clinical Advisory Group for Victorian Comprehensive Cancer Centre, Member

Geoff Lindeman, Melbourne Health Research Advisory Group for Victorian Comprehensive Cancer Centre, Member

Geoff Lindeman, Melbourne Health Tissue Bank Implementation Committee, Chair

Geoff Lindeman, New South Wales Breast Cancer Tissue Bank Scientific Advisory Panel, Member

Geoff Lindeman, Royal Melbourne Hospital Familial Cancer Centre, Director

Geoff Lindeman, Sanofi-Aventis International Steering Committee for Sanofi-Aventis PARP inhibitor (BSI-201) Study TCD11418, Member

Geoff Lindeman, Victorian Cancer Biobank Consortium Committee, Member

Geoff Lindeman, Victorian Comprehensive Cancer Centre Research Advisory Group - Tissue Bank Subcommittee, Chair

Geoff Lindeman, Victorian Comprehensive Cancer Centre Working Party - Research, Member

Geoff Lindeman, Victorian Cooperative Oncology Group, Genetics Advisory Committee, The Cancer Council Victoria, Member

Kylie Mason, Victorian Comprehensive Cancer Centre Emergency Admissions Committee, Member

Ivo Mueller, Papua New Guinea National Malaria Control program, Temporary advisor

Ivo Mueller, World Health Organisation Expert Group on Malaria Rapid Diagnostic Tests, Temporary advisor

Ivo Mueller, World Health Organisation Malaria Vaccine Advisory Committee, Temporary advisor

Marc Pellegrini, National Centre in HIV Epidemiology and Clinical Research, Combined Working Group in Immunotherapies, Consultant

Clare Scott, Australia & New Zealand Breast Cancer Trials Group Scientific Advisory Committee, Expert consultant

Clare Scott, BioGrid Australia Scientific Advisory Committee, Member

Clare Scott, Clinical Trials Australia (CTA) Breast Stream, Principal investigator

Clare Scott, Clinical Trials Australia (CTA) Gynaecologic Tumour Stream, Principal investigator

Clare Scott, Clinical Trials Australia (CTA) Phase I Trials Group, Clinical advisor

Clare Scott, Kathleen Cunningham Foundation for Research in Familial Breast Cancer (kConFab) Translational Research Committee, Member

Clare Scott, Victorian Consensus Data Sets Committee, Member

Jason Tye-Din, Coeliac Australia Clinical Advisory Committee, Chair

Jane Visvader, Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) review committee, Member

Service to editorial boards

Jerry Adams, Genes & Development, Member

Jerry Adams, Oncogene, Member

Jerry Adams, Proceedings of the National Academy of Sciences of the United States of America, Invited editor

Warren Alexander, Growth Factors, Editorial board member

Jonathan Baell, Future Medicinal Chemistry, Editorial board member

Melanie Bahlo, Faculty of 1000, Medical Genetics, Associate editor

Melanie Bahlo, Statistical Applications in Genetics and Molecular Biology, Associate editor

Alyssa Barry, The Open Parasitology Journal, Member

Jacob Baum, Frontiers in Microbiology, Review editor

Jacob Baum, Malaria Journal, Editorial board member

Gabrielle Belz, Frontiers in Immunology - Immunological Memory, Editorial board member and guest editor

Gabrielle Belz, Immunology and Cell Biology, Editor-in-Chief

Philippe Bouillet, Cell Death & Differentiation, Associate editor

Geoff Lindeman, Differentiation News & Commentaries, Editorial board member

Philipp Bouillet, Apoptosis, Associate editor

Mark Chong, MicroRNAs in Diabetes and Obesity, Editorial advisory board member

Suzanne Cory, Proceedings of the National Academy of Sciences of the United States of America, Review editor

Alan Cowman, Science, Board of reviewing editors

Paul Ekert, BioMedCentral Cancer, Associate editor

Paul Ekert, Cell Death & Disease, Editorial board member

Daniel Gray, Frontiers in Immunology, Editorial board member

Diana Hansen, ISRN Parasitology, Editorial board member

Len Harrison, Current Diabetes Reports, Editorial board member

Len Harrison, Current Diabetes Reports, Editorial board member

Len Harrison, Diabetes Metabolism Reviews, Editorial board member

Len Harrison, Diabetes Nutrition and Metabolism, Associate editor

Len Harrison, Diabetes Prevention and Therapy, Editorial board member

Len Harrison, Diabetes research and clinical practice, Editorial board member

Len Harrison, Human Vaccines and Immunotherapeutics, Associate editor

Len Harrison, International Journal of Experimental Diabetes Research, Editorial board member

Len Harrison, Journal of Autoimmunity, Editorial board member

Len Harrison, Molecular Medicine, Contributing editor

Len Harrison, Pediatric diabetes, Editorial board member

Mark Hinds, Journal of Biological Chemistry, Editor

Phil Hodgkin, Frontiers in B Cell Biology, Editorial board member

Phil Hodgkin, Immunology and Cell Biology, Editorial board member

David Huang, Cell Death & Differentiation, Editorial board member

David Huang, Cell Death & Differentiation News & Commentaries Network, Editorial board member

David Huang, Cell Death & Disease, Editorial board member
David Huang, Molecular & Cellular Pharmacology, Editorial board member
Nick Huntington, Clinical and Translational Immunology, Editorial board member
Eugene Kapp, Journal of Proteomics & Computational Biology, Member
Eugene Kapp, Molecular and Cellular Proteomics, Member
Ruth Kluck, Cell Death & Disease, Member
Michael Lawrence, Frontiers in Molecular and Structural Endocrinology, Associate editor
Andrew Lew, Frontiers in Molecular Antigen Presenting Cell Biology, Editorial board member
Seth Masters, Stem Cell Research, Member
Seth Masters, Dataset Papers in Cell Biology, Editorial board member
Seth Masters, Frontiers in Inflammation, Editorial review board
Seth Masters, The Open Inflammation Journal, Editorial board member
Donald Metcalf, Cell Cycle, Editorial board member
Donald Metcalf, International Journal of Hematology, Editorial board member
Donald Metcalf, Leukemia, Editorial board member
Donald Metcalf, Stem Cells, Editorial board member
Ivo Mueller, PLoS Medicine, Academic Editor
Ivo Mueller, PLoS One, Editor
Nicos Nicola, Growth Factors, Editorial board member
Nicos Nicola, Open Biotechnology, Editorial board member
Nicos Nicola, Principle Investigator Advisor, Editorial board member
Nicos Nicola, Stem Cells, Editorial board member
Nicos Nicola, Technology Transfer Tactics, Editorial board member
Stephen Nutt, F1000 Research, Editorial board member
Stephen Nutt, Frontiers in Immunological Memory, Editorial board member
Stephen Nutt, Frontiers in NK Cell Biology, Editorial board member
Stephen Nutt, Immunology and Cell Biology, Editorial board member
Marc Pellegrini, Clinical and Translational Immunology, Editorial board member
Marc Pellegrini, F1000 Research, Editorial board member
Louis Schofield, Cellular Microbiology, Editorial board member
Ken Shortman, Frontiers in Molecular Antigen Presentation, Review editor
Ken Shortman, International Immunology, Executive editor
John Silke, Cell Death & Differentiation, Editorial board member
John Silke, Open Cell Signalling Journal, Editorial board member
Gordon Smyth, BioMedCentral Bioinformatics, Editor (Transcriptomics)
Terry Speed, Australian and New Zealand Journal of Statistics, Editorial board member
Terry Speed, Journal of Computational Biology, Editorial board member
Andreas Strasser, Cell Death & Differentiation, Associate editor
Andreas Strasser, Current Opinion in Immunology, Associate editor
Andreas Strasser, Genes to Cells, Associate editor
Andreas Strasser, International Journal of Molecular Medicine, Associate editor
Andreas Strasser, Journal of Cell Biology, Associate editor
Andreas Strasser, Journal of Experimental Medicine, Associate editor

Service to learned scientific societies

Jerry Adams, Australian Society of Biochemistry and Molecular Biology Awards Committee, Member
Jerry Adams, Australian Society of Biochemistry and Molecular Biology National Advisory Council, Member
Mark Chong, Immunology Group of Victoria, Institute representative
Lynn Corcoran, American Association of Immunologists, Member
Lynn Corcoran, Australasian Society for Immunology, Member
Lynn Corcoran, National Association of Research Fellows, Member
Suzanne Cory, Australian Academy of Science, President

Andreas Strasser, Protein Reviews on the Web, National Institutes of Health, Reviewer
Andreas Strasser, University of California, San Diego Nature Signaling Gateway Molecule Pages, Member
Robyn Sutherland, Molecular Immunology, Invited reviewer
David Tarlinton, Faculty of 1000, Editorial board member
David Tarlinton, Frontiers in Immunology, Review editor
David Tarlinton, Immunology and Cell Biology, Editorial board member
David Tarlinton, Immunology Letters, Editorial board member
David Tarlinton, International Immunology, Transmitting editor
Tim Thomas, PLoS One, Editorial board member
David Vaux, Apoptosis, Editorial board member
David Vaux, Cancer Medicine, Editorial board member
David Vaux, Cell Death & Differentiation, Editorial board member
David Vaux, Disease Models and Mechanisms, Editorial board member
David Vaux, EMBO Reports, Editorial board member
Jane Visvader, Breast Cancer Research, Editorial board member
Jane Visvader, Cancer Cell, Editorial board member
Jane Visvader, Cancer Research, Senior editor
Jane Visvader, Cell Stem Cell, Editorial board member
Jane Visvader, Molecular Oncology, Editorial board member
Li Wu, Molecular and Cellular Immunology, Editorial board member
Alan Cowman, Australian Academy of Science Sectional Committee, Member
Grant Dewson, Faculty of 1000, Associate member
Diana Hansen, Victorian Infection and Immunity Network Executive Committee, Member

Walter and Eliza Hall Institute Annual Report 2011-2012
Supplementary information 111
<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Role/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susanne Heinzel</td>
<td>Australasian Society of Immunology</td>
<td>Honorary secretary</td>
</tr>
<tr>
<td>Julia Marchingo</td>
<td>Australasian Society of Immunology</td>
<td>Student representative</td>
</tr>
<tr>
<td>Ivo Mueller</td>
<td>American Society of Tropical Medicine</td>
<td>Member</td>
</tr>
<tr>
<td></td>
<td>and Hygiene</td>
<td></td>
</tr>
<tr>
<td>David Tarlinton</td>
<td>Australasian Society of Immunology</td>
<td>President</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Vaux</td>
<td>Australian Academy of Science</td>
<td>Fellow</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Amgen</td>
<td>2011</td>
</tr>
<tr>
<td></td>
<td>Breast Cancer Scientific</td>
<td>Advisory Board, Member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Australian New</td>
<td>Zealand Breast Cancer Trials</td>
</tr>
<tr>
<td></td>
<td>Group, Board member</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Australian New</td>
<td>Zealand Breast Cancer Trials</td>
</tr>
<tr>
<td></td>
<td>Group, scientific advisory committee</td>
<td>Member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Breast Cancer</td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td>- American Association</td>
<td>for Cancer Research Grants</td>
</tr>
<tr>
<td></td>
<td>- for Translational Breast Cancer</td>
<td>Research Committee</td>
</tr>
<tr>
<td></td>
<td>- Cancer Research Grants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Scientific Review Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Member</td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Israeli Science</td>
<td>Foundation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Member</td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Sanofi-Aventis</td>
<td>International Steering Committee for Sanofi-Aventis</td>
</tr>
<tr>
<td></td>
<td>PARP inhibitor (BSI-201) Study</td>
<td>TCD11418, Member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Sanofi-Aventis</td>
<td>International Steering Committee for Sanofi-Aventis</td>
</tr>
<tr>
<td></td>
<td>PARP inhibitor (BSI-201) Study</td>
<td>TCD11418, Member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>L’Oréal Australia and</td>
<td>Scientific advisor</td>
</tr>
<tr>
<td></td>
<td>Austrian Science Fund</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Medical Research</td>
<td>Council (UK), Panel member</td>
</tr>
<tr>
<td></td>
<td>Council</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>James Murphy</td>
<td>Marsden Fund</td>
<td>New Zealand grant review panel, Member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nick Nicola</td>
<td>Asia-Pacific International</td>
<td>Molecular Biology Network, research advisory board,</td>
</tr>
<tr>
<td></td>
<td>Molecular Biology Network</td>
<td>Board member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nick Nicola</td>
<td>Leukaemia &amp; Lymphoma Research</td>
<td>(UK) Grant Reviews, Panel member</td>
</tr>
<tr>
<td></td>
<td>Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruth Kluck</td>
<td>Faculty of 1000</td>
<td>Contributions, Section head</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eugene Kapp</td>
<td>Informatics Proteomics Research Group</td>
<td>of the Association of Biomolecular Resource</td>
</tr>
<tr>
<td></td>
<td>of the Association of Biomolecular</td>
<td>Facilities Committee</td>
</tr>
<tr>
<td></td>
<td>Resource</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Nutt</td>
<td>Austrian Science Fund</td>
<td>Grant Reviews, Panel member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Nutt</td>
<td>European Research</td>
<td>Council Grant Reviews, Panel member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Nutt</td>
<td>Foundation for</td>
<td>Scientific Research Belgium</td>
</tr>
<tr>
<td></td>
<td>Scientific Research Belgium</td>
<td>Grant Reviews, Panel member</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Nutt</td>
<td>Institut National de la santé et de</td>
<td>Grant Reviews, Panel member</td>
</tr>
<tr>
<td></td>
<td>la recherche médicale</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Service on international committees, councils, boards and foundations, including grant review panels**

- **Gabrielle Belz**, Health Research Council of New Zealand Grant Reviews, Panel member
- **Gabrielle Belz**, Howard Hughes Medical Institute International Review Panel, International Grant Reviews, Panel member
- **Gabrielle Belz**, Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek - Vlaanderen, FWO) Grant Reviews, Panel member
- **Gabrielle Belz**, Welcome Trust UK Grant Reviews, Panel member
- **Marnie Blewitt**, Wellbeing of Women UK Grant Reviews, Panel member
- **Chris Burns**, Health Research Council of New Zealand Grant Reviews, Panel member
- **Sebastian Carotta**, Medical Research Council (UK) Grant Reviews, Panel member
- **Peter Colman**, Institute of Biology and Chemistry of Proteins, CNRS, France, Scientific Advisory Board, BCL-2 Family Database, Scientific advisor
- **Peter Colman**, International Union of Crystallography (IUCr) Executive Committee, Vice President
- **Peter Colman**, Japan Proton Accelerator Research Complex, Macromolecular Crystallography Beamline, International advisor
- **Lynn Corcoran**, Swiss Cancer League Grant Review, Panel member
- **Suzanne Cory**, BioMedical Science International Advisory Council, Member
- **Suzanne Cory**, Cancer Research UK Council Research Strategy Committee, Member
- **Suzanne Cory**, Duke-NUS Graduate Medical School, Singapore, scientific advisory board, Board member
- **Suzanne Cory**, Francis Crick Institute Science Assessment Panel, Member
- **Suzanne Cory**, Gairdner Foundation Medical Advisory Board, Board member
- **Suzanne Cory**, Institute of Medical Biology (A*STAR BMRC) Scientific Advisory Board, Board member
- **Suzanne Cory**, International Human Frontiers Science Program Organization Council of Scientists, Council member
- **Suzanne Cory**, Leukaemia & Lymphoma Research grant review panel, Member
- **Suzanne Cory**, Pasteur Institute, scientific advisory board, Board member
- **Suzanne Cory**, University of Auckland Maurice Wilkins Centre for Molecular Biodiscovery Scientific Advisory Board, Board member
- **Alan Cowman**, Howard Hughes Medical Institute Early Career Scientist Selection Committee, Member
- **Alan Cowman**, World Parasite Foundation, President
- **Erika Cretney**, L’Oréal Australia and New Zealand For Women in Science Fellowships, Jury member
- **Jacqui Gulbis**, Biotechnology and Biological Sciences Research Council (UK) Grant Reviews, Panel member
- **Jacqui Gulbis**, Israeli Science Foundation Grant Reviews, Panel member
- **David Huang**, Biomedical Assessing Committee 3 (BMAC) Health Research Council of New Zealand, Panel member
- **David Huang**, Cancer Research UK Grant Reviews, Panel member
- **David Huang**, Health Research Council of New Zealand Grant Reviews, Panel member
- **David Huang**, Health Research Council of New Zealand, Biomedical Assessing Committee, Panel Member
- **Eugene Kapp**, Informatics Proteomics Research Group of the Association of Biomolecular Resource Facilities Committee, Member
- **Ruth Kluck**, Faculty of 1000, Contributing member
- **Geoff Lindeman**, Amgen 2011 Breast Cancer Scientific Advisory Board, Member
- **Geoff Lindeman**, Australian New Zealand Breast Cancer Trials Group, Board member
- **Geoff Lindeman**, Australian New Zealand Breast Cancer Trials Group, scientific advisory committee, Member
- **Geoff Lindeman**, Breast Cancer Foundation - American Association for Cancer Research Grants for Translational Breast Cancer Research Scientific Review Committee, Member
- **Geoff Lindeman**, Israeli Science Foundation, Member
- **Geoff Lindeman**, Sanofi-Aventis International Steering Committee for Sanofi-Aventis PARP inhibitor (BSI-201) Study TCD11418, Member
- **Geoff Lindeman**, Sanofi-Aventis International Steering Committee for Sanofi-Aventis PARP inhibitor (BSI-201) Study TCD11418, Member
- **Ivo Mueller**, Fonds zur Förderung der wissenschaftlichen Forschung (FWF - Austrian Science Fund), Panel member
- **Ivo Mueller**, Medical Research Council (UK), Panel member
- **James Murphy**, Marsden Fund (New Zealand) grant review panel, Member
- **Nick Nicola**, Asia-Pacific International Molecular Biology Network, research advisory board, Board member
- **Nick Nicola**, Leukaemia & Lymphoma Research (UK) grant review panel, Member
- **Stephen Nutt**, Austrian Science Fund Grant Reviews, Panel member
- **Stephen Nutt**, European Research Council Grant Reviews, Panel member
- **Stephen Nutt**, Foundation for Scientific Research Belgium Grant Reviews, Panel member
- **Stephen Nutt**, Institut National de la santé et de la recherche médicale Grant Reviews, Panel member
- **Stephen Nutt**, Wellcome Trust (UK) Grant Reviews, Panel member
Anthony Papenfuss, The Muscular Dystrophy Campaign Grant Reviews, Panel member

Louis Schofield, Australasian College of Tropical Medicine, Convener

Clare Scott, Australia New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting 2012, organising committee, Member

Clare Scott, Australia New Zealand Gynaecological Oncology Group (ANZGOG) Annual Scientific Meeting 2013, organising committee, Member

Clare Scott, Gynaecologic Cancer Inter-Group, Translational Committee, Member and co-chair

Clare Scott, Gynaecologic Cancer Inter-Group, Translational Committee, Member and co-chair

Clare Scott, Health Research Council of New Zealand Grant Reviews, Member

Clare Scott, Mayo Clinic Rochester, Ovarian Specialized Program of Research Excellence, external advisory board, External advisor

Clare Scott, Mayo Clinic Rochester, Ovarian SPORE (Specialized Program of Research Excellence) External Advisory Board, External advisor

Clare Scott, The Gynaecological Oncology Research Collaborative of the Victorian Comprehensive Cancer Centre and the European Network for Translational Research in Ovarian Cancer (EUTROC), Symposium on Ovarian Cancer, organising committee, Member

Wei Shi, The MicroArray/Sequencing Quality Control Consortium (MAQC/SEQC), Investigator

Ken Shortman, International Society for Dendritic Cell and Vaccine Science, scientific advisory committee, Member

Ken Shortman, International Union of Immunological Societies Nomenclature of Monocytes and Dendritic Cells in Blood Sub-committee, Member

Ken Shortman, National University of Singapore Immunology Program, scientific advisory board, Board member

John Silke, Israel Science Foundation Grant Reviews, Panel member

John Silke, Research Foundation Flanders Grant Reviews, Panel member

Terry Speed, Cambridge Research Institute, scientific advisory board, Board member

Terry Speed, Wellcome Trust Centre for Human Genetics, Oxford, scientific advisory board, Board member

Andreas Strasser, Academia Sinica IMB Performance Review Committee, Member

Andreas Strasser, Dr Josef Steiner Cancer Research Foundation Prize Committee, Advisor

Andreas Strasser, Faculty of 1000 Biology Advisory Board, Board member

Andreas Strasser, Faculty of 1000 Medical Research Advisory Board, Board member

Andreas Strasser, German Science Foundation (DFG Sonderforschungsbereich) Program Grant Assessment Committee, Member

Andreas Strasser, Heineken Prize Committee, Advisor

Andreas Strasser, Highlights Advisory Panel for Nature Reviews Immunology, Panel member

Andreas Strasser, Japanese Society for Promotion of Science, Large Grants Committee, Advisor

Andreas Strasser, Marcel Benoist Prize Committee, Advisor

Andreas Strasser, MIT Promotions and Recruitment Committee, Advisor

Andreas Strasser, The European Research Institute for Integrated Cellular Pathology, International advisory member

Jason Tye-Din, Australasian Society of Parenteral and Enteral Nutrition project grant reviews, Panel member

Jason Tye-Din, Coeliac Australia, clinical advisory committee, Chair

David Vaux, Committee on Freedom and Responsibility in the Conduct of Science (CFRS) of the International Council for Science (ICSU), Member

Jane Visvader, Human Genome Organisation Awards Selection Committee, Member

Jane Visvader, Stinehart-Reed Awards Selection Committee, Stanford University, Member

Service on international conference organising committees

Warren Alexander, The International Society for Stem Cell Research Tenth Annual Meeting, Abstract reviewer

Alyssa Barry, Malaria in Melbourne, Co-chair

Alyssa Barry, Molecular Approaches to Malaria, Committee member

Jacob Baum, Molecular Approaches to Malaria, Chair

Diana Hansen, Molecular Approaches to Malaria, Session chair

Diana Hansen, Lorne Infection and Immunity Meeting Organising Committee, Member

Phil Hodgkin, 41st Australasian Society of Immunology Annual Scientific Meeting, Member

Phil Hodgkin, Quantitative Immunology: Experiments meet modelling program, Kavli Institute for Theoretical Physics, Member

David Huang, Cold Spring Harbor Asia: Translational Approaches to Cancer, organising committee, Member

David Huang, Lorne Cancer Conference Organising Committee, Member and co-convener

David Huang, New Directions in Leukaemia Research Organising Committee, Member

Kurt Lackovic, Australian High Content Screening Group, Co-convener

Erinna Lee, 37th Lorne Conference on Protein Structure and Function, Lorne Protein Conference Program and Organising Committee, Member

Geoff Lindeman, 5th PacRim Breast and Prostate Cancer Meeting International Advisory Committee, Member

Matthew McCormack, New Directions in Leukaemia Research Organising Committee, Member

Ivo Mueller, 4th Vivax Conference, Convener

Clare Scott, International Gynecologic Cancer Society (IGCS) 2014, Organising Committee, Member

John Silke, 13th International TNF Conferences, Advisory committee

Andreas Strasser, 15th International Congress of Immunology Organising Committee, Member
Service on national (Australian) committees, councils, boards and foundations, including grant review panels

Jerry Adams, Australian Cancer Research Foundation Medical Research Advisory Committee, Member

Jerry Adams, Australian Cancer Research Foundation Medical Research Advisory Committee, Member

Jerry Adams, John Curtin School of Medical Research Advisory board member

Jerry Adams, National Health and Medical Research Council Academy, Member

Jerry Adams, National Health and Medical Research Council Assigner’s Academy, Grant review assinger

Jerry Adams, National Health and Medical Research Council Project Grants Review Panel, Member

Warren Alexander, National Health and Medical Research Council Academy, Member

Warren Alexander, National Health and Medical Research Council program grant review panel, Chair and member

Warren Alexander, National Health and Medical Research Council Project Grants Review Panel, Chair and member

Warren Alexander, The University of Melbourne Cancer Research Domain, Haematological Subdomain, Coordinator

Warren Alexander, Victorian Cancer Biobank Consortium Committee, Independent member

Jeff Babon, Australian Research Council Grant Review Panel, Member

Jeff Babon, National Health and Medical Research Council Project Grants Review Panel, Member

Jonathan Baell, National Health and Medical Research Council Project Grants Review Panel, Member

Melanie Bahlo, Australian Research Council Grant Review Panel, Member

Melanie Bahlo, National Health and Medical Research Council Project Grants Review Panel, Member

Jacob Baum, Australian Research Council Grant Review Panel, Member

Jacob Baum, Australian Society for Parasitology Grant Review Panel, Member

Jacob Baum, Borrowman Trust, Member

Jacob Baum, National Health and Medical Research Council Project Grants Review Panel, Member

Gabrielle Belz, Australian Research Council Grant Review Panel, Reviewer

Gabrielle Belz, National Health and Medical Research Council Academy, Member

Gabrielle Belz, National Health and Medical Research Council Project Grants Review Panel, Member

Marnie Blewitt, National Health and Medical Research Council Project Grants Review Panel, Member

Philippe Bouillet, National Health and Medical Research Council Project Grants Review Panel, Member

Chris Burns, Monash University Bachelor of Pharmaceutical Sciences Review Committee, Member

Chris Burns, National Health and Medical Research Council Project Grants Review Panel, Member

Chris Burns, Royal Australian Chemical Institute Biomolecular Division Committee, Member

Matthew Call, Australian Research Council Grants Review Panel, Member

Melissa Call, National Health and Medical Research Council Project Grants Review Panel, Member

Melissa Call, The Australian Society for Medical Research Judging Panel for the Merck Millipore Award for Medical Research 2011, Member

Sebastian Carotta, Australian Research Council Grants Review Panel, Member

Sebastian Carotta, National Health and Medical Research Council Project Grants Review Panel, Member

Peter Colman, Australian Centre for HIV and Hepatitis Virology Research (ACH2) Scientific Advisory Committee, Member

Peter Colman, Australian Research Council Grant Review Panel, Member

Peter Colman, Australian Synchronton Company Limited, Board of directors

Peter Colman, Bragg Institute, Australian Nuclear Science and Technology Organisation Advisory Committee, Member

Peter Colman, Burnet Institute, Board of directors

Peter Colman, National Health and Medical Research Council Project Grants Review Panel, Member

Peter Colman, Prime Minister’s Prizes for Science Secretariat Scientific Prizes Committee, Member

Lynn Corcoran, Australian Research Council OzReader, Reviewer

Lynn Corcoran, National Health and Medical Research Council Project Grants Review Panel, Member

Suzanne Cory, Australian Synchronton National Science Colloquium, Committee member

Suzanne Cory, Australian Synchronton National Science Colloquium, Committee member

Suzanne Cory, Festival of Ideas 2013 Advisory Group, Member

Suzanne Cory, Gene Technology Access Centre Board of Management, Chair

Suzanne Cory, L’Oréal Australia For Women in Science Fellowships Selection Committee, Member
<table>
<thead>
<tr>
<th>Name</th>
<th>Role and Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Ekert</td>
<td>Leukaemia Foundation Australia Grants Review Panel, Panel member</td>
</tr>
<tr>
<td>Paul Ekert</td>
<td>Leukaemia Foundation Australia Medical and Scientific Advisory Committee, Committee member</td>
</tr>
<tr>
<td>Paul Ekert</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Paul Ekert</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Daniel Gray</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Jacqui Gulbis</td>
<td>National Health and Medical Research Council Career Development Fellowship Committee, Panel member</td>
</tr>
<tr>
<td>Jacqui Gulbis</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Jacqui Gulbis</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Diana Hansen</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Diana Hansen</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Melinda Hardy</td>
<td>Macpherson Smith Rural Foundation, Mentor for undergraduate science student</td>
</tr>
<tr>
<td>Len Harrison</td>
<td>Juvenile Diabetes Research Foundation Grant Reviews, Panel member</td>
</tr>
<tr>
<td>Len Harrison</td>
<td>National Health and Medical Research Council Academy, Member</td>
</tr>
<tr>
<td>Susanne Heinzel</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Marco Herold</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Phil Hodgkin</td>
<td>National Health and Medical Research Council Academy, Member</td>
</tr>
<tr>
<td>Phil Hodgkin</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>David Huang</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>David Huang</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>David Huang</td>
<td>South Australian Cancer Research Collaborative Grants Review Panel, Panel member</td>
</tr>
<tr>
<td>David Huang</td>
<td>South Australian Research Collaborative Fellowship Review Panel, Member</td>
</tr>
<tr>
<td>Kim Jacobson</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Emma Joseffson</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Benjamin Kile</td>
<td>Australian Genome Research Facility, Board member</td>
</tr>
<tr>
<td>Benjamin Kile</td>
<td>Australian Phenomics Network Executive Management Committee, Chair</td>
</tr>
<tr>
<td>Benjamin Kile</td>
<td>Heart Foundation Grants Review Panel, Panel member</td>
</tr>
<tr>
<td>Benjamin Kile</td>
<td>National Health and Medical Research Council Career Development Fellowships Grants Review Panel, Chair</td>
</tr>
<tr>
<td>Benjamin Kile</td>
<td>National Health and Medical Research Council Community Observers Working Committee, Member</td>
</tr>
<tr>
<td>Ruth Kluck</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Ruth Kluck</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Kate Lawlor</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Australian Cancer Research Foundation Medical Research Advisory Committee, Member</td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>Australian Cancer Research Foundation Medical Research Advisory Committee, Member</td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Geoff Lindeman</td>
<td>New South Wales Cancer Institute Grants Review Panel, Member</td>
</tr>
<tr>
<td>Matthew McCormack</td>
<td>Australian Research Council Grants Review Panel, Member</td>
</tr>
<tr>
<td>Matthew McCormack</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
<tr>
<td>Matthew McCormack</td>
<td>National Health and Medical Research Council Scholarships grant review panel, Member</td>
</tr>
<tr>
<td>Lisa Mielke</td>
<td>National Health and Medical Research Council Project Grants Review Panel, Member</td>
</tr>
</tbody>
</table>
Ivo Mueller, National Health and Medical Research Council Project Grants Review Panel, Member
James Murphy, Australian Research Council Discovery Grant Scheme, Reviewer
James Murphy, National Health and Medical Research Council Project Grants Review Panel, Member
Thomas Nebi, National Health and Medical Research Council Project Grants Review Panel, Member
Nicos Nicola, Australian Research Council Grants Review Panel, Member
Nicos Nicola, Institute for Molecular Biosciences Advisory Board, Member
Nicos Nicola, Institute for Molecular Biosciences Scientific Advisory Committee, Chair
Nicos Nicola, Kathleen Cunningham Consortium Foundation for Research in Familial Breast Cancer (kConFab) Appeals Committee, Member
Nicos Nicola, National Health and Medical Research Council Project Grants Review Panel, Member
Nicos Nicola, National Health and Medical Research Council Review of Development Grants Funding Scheme Outcomes Steering Committee, Member
Nicos Nicola, Victorian Comprehensive Cancer Centre Research Advisory Committee, Member
Nicos Nicola, Virtual Pharma, Member
Stephen Nutt, Australian Research Council Grants Review Panel, Member
Stephen Nutt, Diabetes Australia Research Trust Grants Review Panel, Member
Stephen Nutt, Multiple Myeloma Research Foundation Grants Review Panel, Panel member
Stephen Nutt, National Health and Medical Research Council Project Grants Review Panel, Member
Anthony Papenfuss, Australian Research Council Grants Review Panel, Member
Anthony Papenfuss, National Health and Medical Research Council Project Grants Review Panel, Member
Thomas Scerri, National Health and Medical Research Council Project Grants Review Panel, Member
Louis Schofield, National Health and Medical Research Council Project Grants Review Panel, Member
Louis Schofield, National Health and Medical Research Council Training Awards, Co-chair
Louis Schofield, Queensland Tropical Health Alliance, Director
Clare Scott, Cancer Australia Grants Review Committee, Member
Clare Scott, Cure Cancer Australia Foundation Board, Member
Clare Scott, Cure Cancer Australia Foundation Research Committee, Chair
Clare Scott, Melbourne Health Research Week Organising Committee, Member
Clare Scott, National Breast Cancer Foundation Postdoctoral Fellow Grants Review Panel, Member
Clare Scott, National Health and Medical Research Council Project Grants Review Panel, Member
John Silke, National Health and Medical Research Council Project Grants Review Panel, Member
Brad Sleebs, National Health and Medical Research Council Project Grants Review Panel, Member
Gordon Smyth, Australian Statistics Conference 2012 Programming Committee, Member
Gordon Smyth, National Health and Medical Research Council Assigner’s Academy, Assigner
Gordon Smyth, National Health and Medical Research Council Project Grants Review Panel, Member
Andreas Strasser, National Health and Medical Research Council Academy, Member
Andreas Strasser, National Health and Medical Research Council Project Grants Review Panel, Member
Andreas Strasser, Victorian Prostate Cancer Research Consortium, Panel member
Ian Street, National Health and Medical Research Council Project Grants Review Panel, Member
Robyn Sutherland, Diabetes Australia Research Trust Grants Review Panel, Member
David Tarlinton, Australian Research Council OzReader, Reviewer
Tim Thomas, National Health and Medical Research Council Project Grants Review Panel, Member
Tim Thomas, National Health and Medical Research Council Project Grants Review Panel, Member
Tim Thomas, National Health and Medical Research Council Development grant review panel, Member
Jason Tye-Din, Diabetes Australia Research Trust Grants Review Panel, Member
Cassandra Vandenberg, National Health and Medical Research Council Project Grants Review Panel, Member
David Vaux, ANZ Trustees Medical Research Grant Award Panel, Member
David Vaux, Australian & New Zealand Association for the Advancement of Science, Federal Council Member and Victorian committee member
David Vaux, Australian Academy of Science, National Committee for International Council for Science, Member
David Vaux, National Health and Medical Research Council Project Grants Review Panel, Member
David Vaux, Victorian Premier’s Medical Research Award Selection Panel, Member
Jane Visvader, Medical and Scientific Committee of The Cancer Council Victoria Standing Research Subcommittee, Member
Jane Visvader, National Breast Cancer Foundation National Collaborative Breast Cancer Research Program Selection Committee, Member
Jane Visvader, National Breast Cancer Foundation Research Advisory Committee, Member
Jane Visvader, National Health and Medical Research Council Assigner’s Academy, Assigner
Jane Visvader, National Breast Cancer Foundation Concept Awards 2011 Review Panel, Chair
Anne Voss, National Health and Medical Research Council Project Grants Review Panel, Member
Anne Voss, The University of Melbourne Research Higher Degree Committee, Member
Service on national conference organising committees

Jonathan Baell, Royal Australian Chemical Institute Biomolecular Division Conference Biomolecular @ The Beach, Committee member

Gabrielle Belz, Australasian Vaccine and Immunotherapeutics Development Meeting, Conference chair

Chris Burns, Royal Australian Chemical Institute Biomolecular Division Conference Biomolecular @ The Beach, Convenor

Stephane Chevrier, International Day of Immunology Committee, Melbourne, Member

Mark Chong, International Day of Immunology Committee, Melbourne, Member

Grant Dewson, Australian Workshop on Cell Death, organising committee, Member

Paul Ekoert, Australian Workshop on Cell Death, organising committee, Member

Phil Hodgkin, Computational Immunology Conference, Chair

Phil Hodgkin, Shortman 75th Birthday Celebration Symposium, Co-chair

Ruth Kluck, AussieMit 2012, Scientific Program Committee, Member

Ruth Kluck, ComBio 2012, Member

Ruth Kluck, First Australian Workshop on Cell Death: Death on the Reef, organising committee, Member

Michael Lawrence, IGF-Oz 2011, program committee, Chair

Michael Lawrence, IGF-Oz 2011, organising committee, Chair

Guillaume Lessene, Royal Australian Chemical Institute Biomolecular Division Conference Biomolecular @ The Beach, Committee member

Andrew Lew, Shortman 75th Birthday Celebration Symposium, Member

Julia Marchingo, Australian Society for Immunology Student Function Subcommittee for the 42nd Annual Scientific Meeting of the Australasian Society for Immunology, Co-chair

Lucille Rankin, International Day of Immunology Committee, Melbourne, Member

Louis Schofield, National Science Conference, scientific organising committee, Member

John Silke, Australian Workshop on Cell Death, organising committee, Member

Andreas Strasser, First Australian p53 Workshop, June 2012, Conference organiser

Robyn Sutherland, Immunology Group of Victoria, Member

Robyn Sutherland, International Day of Immunology Committee, Melbourne, Member

Anne Voss, Hunter Cell Biology Meeting, organising committee, Member

Anne Voss, Lorne Genome Conference, organising committee, Member

Cameron Wellard, Computational Immunology Conference, Member
The eastern wing of the institute has been redeveloped to have a similar layout to the new western wing.
The Board

The directors of the Walter and Eliza Hall Institute of Medical Research board

**Mr Leon A Davis**  AO Dip Prim Metallurgy SAIT Hon DSc Curtin Hon DSc Qld Hon DUniv UniSA FRACI FAIMM

**President**

Appointed: February 2001  
Term expires: May 2013

Mr Davis became chief executive of Rio Tinto Ltd and Rio Tinto plc on 1 January 1997 and retired from the position in 2000. Previously he had been deputy chief executive and chief operating officer of RTZ-CRA.

Mr Davis joined the CRA Group in 1958 as a metallurgical cadet. In 1989 he was appointed a group executive of CRA Limited. Until joining RTZ in 1991 as mining director, his appointments included chairman of Argyle Diamond Mines, Dampier Salt, Wimmera Industrial Minerals and Kalimantan Gold.

In December 2000 Mr Davis became chairman of Westpac Banking Corporation, stepping down from the position in 2007.

**Mr Steven M Skala**  AO BA LLB (Hons) Qld BCL Oxon

**Vice-President**

Appointed: June 1999  
Term Expires: June 2014

Mr Skala is vice chairman Australia & New Zealand of Deutsche Bank AG and a former senior partner of Arnold Bloch Leibler lawyers.

He is chairman of Wilson HTM Investment Group Ltd and a director of the Australian Broadcasting Corporation and Hexima Limited. He is deputy chairman of The General Sir John Monash Foundation, a director of the Centre for Independent Studies and a member of the International Council of New York’s Museum of Modern Art.

Mr Skala is a member of the advisory council of the Australian Innovation Research Centre, the Global Foundation and the Grievance Tribunal of Cricket Australia. He is the immediate past chairman of Film Australia Limited and the Australian Centre for Contemporary Art.

**Mr Roger E Male**  LLB Adelaide Dip Acctg Swinburne

**Honorary Treasurer**

Appointed: June 1998  
Term Expires: May 2013

Mr Male was a partner of Coopers & Lybrand for more than 20 years and retired from the firm as a member of its national committee and Melbourne office managing partner in 1998.

He is a director of Goldman Sachs Australia Managed Funds Limited, and the Uniting Church Funds Management Ltd. Mr Male is also a member of the Almond Orchards Limited compliance committee and the Nillumbik Shire Council audit advisory committee.
**Professor James Angus** AO BSc Syd PhD Syd FAA

**Appointed:** November 2003
**Term expires:** at the discretion of The University of Melbourne

Professor Angus is dean of the Faculty of Medicine, Dentistry and Health Sciences at The University of Melbourne. He was president of the university's academic board and has served on the university's council as well as the council of the Australian Academy of Science. He currently serves on the boards of Melbourne Health, the Mental Health Research Institute, the Victorian Institute of Forensic Medicine, and the Victorian Comprehensive Cancer Centre. He is a past president of Medical Deans Australia and New Zealand, and is honorary secretary to the Victorian Rhodes Scholarship Committee. Professor Angus was awarded the Gottschalk Medal in 1984, the Centenary Medal in 2003 and the Australian Citation Laureate Award for Pharmacology in 2004. He was appointed Officer of the Order of Australia in June 2010.

---

**Mr Mike C Fitzpatrick** BA (Hons) Oxon BEng (Hons) UWA

**Appointed:** February 2001
**Term Expires:** February 2013

Mr Fitzpatrick is chairman of the Australian Football League, Treasury Group Limited, Infrastructure Capital Group, and a non-executive director of Rio Tinto plc. He is the founder and former managing director of Hastings Funds Management Limited. In that role, Mr Fitzpatrick was a director of a number of Hastings-managed investments including Pacific Hydro Limited, Global Renewables Limited, Utilities of Australia, Australian Infrastructure Fund and Airdsia Development Group Pty Ltd (Perth Airport).

Mr Fitzpatrick was a premiership captain (1981, 1982) with the Carlton Football Club in the Australian Football League and a first-grade cricketer. He was formerly a member of the Melbourne Park Tennis Centre Trust, a director of the Carlton Football Club, chairman of the Australian Sports Commission and, in the early 1980s, vice-president of the AFL Players’ Association.

---

**Professor Jim McCluskey** BMedSc MB BS MD UWA FRACP FRCPA FAA

**Appointed:** April 2011
**Term expires:** at the discretion of The University of Melbourne

Professor Jim McCluskey is the deputy vice-chancellor (research) at The University of Melbourne. Prior to this he was the pro vice-chancellor (research partnerships), chair of Microbiology and Immunology and deputy head of that department. Professor McCluskey has an international reputation for his research in genetics and immunity. He has consulted for the Australian Red Cross for more than 20 years and is editor-in-chief of the international immunogenetics journal *Tissue Antigens*.

He is a member of the board of directors of The Florey Institute of Neuroscience and Mental Health, Bionics Institute, UoM Commercial and chair of the Nossal Institute for Global Health council.
Dr Graham F Mitchell  AO RDA BVSc Syd FACVSc PhD Melb FTSE FAA
Appointed:  July 2007  
Term Expires:  June 2013

Dr Mitchell has detailed knowledge of the academia-industry interface and completed his PhD at the Walter and Eliza Hall Institute in the late 1960s. In 1973, after postdoctoral experience in the US, UK and Switzerland, Dr Mitchell returned to the institute and established a program on the immunology of parasitism.

In 1990, Dr Mitchell was appointed director of the Royal Melbourne Zoological Gardens but returned to biomedical research in 1993 as director of research in the R&D division of CSL Limited. Dr Mitchell is an adviser on innovation to the Victorian, Tasmanian, Northern Territory and Federal Governments and jointly acts as chief scientist for the Victorian Government departments of Primary Industries and Sustainability and Environment. He is a non-executive director of Antisense Therapeutics Limited, Compumedics Limited, AgVic Services Pty Ltd, Adelaide Research and Innovation Pty Ltd and Avipep Pty Ltd.

Mrs Linda B Nicholls  AO BA(Econ) Cornell MBA Harvard Hon FAICD
Appointed:  February 2001  
Term Expires:  February 2013

Mrs Nicholls is a corporate adviser and a director of a number of leading Australian companies and organisations. She is chairman of KDR (Yarra Trams), and a director of Sigma Pharmaceutical Group, Fairfax Media, and retired as a director of the Australian Institute of Company Directors in July. Previously Mrs Nicholls was chairman of Healthscope and Australia Post, and a director of St George Bank. She is also vice-president and a member of the Harvard Business School Alumni board. She runs her own corporate advisory practice specialising in business strategy in financial services and health care. Mrs Nicholls has more than 30 years experience as a senior executive and company director in Australia, New Zealand and the United States.

Ms Kate J Redwood  BA BSW (Hons) Monash
Appointed:  August 2009  
Term Expires:  August 2012

Ms Redwood has held a number of senior management positions including CEO of the Australian Physiotherapy Association, executive director of Australian Red Cross Victoria, and executive director of the Victorian Council of Social Service.

A former councillor for the City of Melbourne, Ms Redwood has chaired a number of standing committees as well as the Yarra/Melbourne Regional Library Board, the Melbourne Disability Advisory Committee and for many years was president of the Carlton Senior Citizens’ Centre.

Ms Redwood is a member of the Melbourne Health board and chairs the Melbourne Health community advisory committee. In 2010, she became a director of Hepburn Wind. Ms Redwood was awarded the Centenary Medal in 2001 for services to local government and the community.
Mr Christopher W Thomas  BCom (Hons) MBA Melb FAICD

Appointed: February 2001
Term Expires: February 2013

Mr Thomas joined executive search firm Egon Zehnder International in 1979 and was managing partner of the Melbourne office from 1986 to 2003. He was also leader of the firm’s global Board Consulting Practice Group (1998–2006) and chaired the firm’s twice-yearly international partners’ meetings from 1997 to 2007.

Mr Thomas is a fellow of the Australian Institute of Company Directors. He has served on the board of the Corps of Commissionaires (Victoria) and the council of the Australian Film, Television and Radio School. He was a board member of the Heide Museum of Modern Art for nine years (and its chairman for three years), chairman of the Victorian Community Foundation and president of the Melbourne Business School Alumni.

Ms Catherine M Walter  AM LLB (Hons) LLM MBA Melb FAICD

Appointed: February 2001
Term Expires: February 2013

Ms Walter is a non-executive director of Australian Foundation Investment Company, the Reserve Bank’s Payment Systems Board, Victorian Funds Management and Victorian Opera and chairman of the Australian Synchrotron.

She practised law for 20 years as a commercial lawyer, which included a term as managing partner of Clayton Utz in Melbourne. Ms Walter is a former commissioner of the City of Melbourne.

In 2003, Ms Walter was appointed a Member of the Order of Australia for her service to business, particularly as a director of a number of public companies, to the arts, to the law, and to the community through the City of Melbourne. She was awarded a Centenary Medal in the same year.

Professor Ingrid Winship  MB ChB MD Cape Town FRACP FACD

Appointed: June 2007
Term Expires: June 2013

Professor Ingrid Winship is the inaugural chair of adult clinical genetics at The University of Melbourne and executive director of research for Melbourne Health.

A medical graduate of the University of Cape Town, she completed postgraduate training in genetics and dermatology. In 1994, Professor Winship took up an academic position at the University of Auckland and later became Professor of Clinical Genetics and associate dean for research in the Faculty of Medicine and Health Sciences.

Professor Winship is a member of the Victorian Cancer Action Plan implementation committee, NHMRC Human Genetics Advisory Committee, and Victorian Life Sciences Computation Initiative steering committee.
Chief Operating Officer’s report

This year has seen the near completion of the building works that have occupied the minds and hearts of staff for close to five years. The works have meant a doubling in size of the institute, allowing for the recruitment of new research teams and the establishment of new infrastructure and advanced technologies.

They have also provided the opportunity to create spaces dedicated to acknowledging our donors and supporters and celebrating our scientists and scientific achievements since the institute was established in 1915. Staff across all areas of the institute have made this possible, including divisional coordinators, researchers, research assistants, administration, facilities, marketing, communications and fundraising, IT, bioservices, safety, laboratory operations and scientific services. I would like to take this opportunity to thank everyone for their valuable contributions during the year.

Financial sustainability

Ensuring the institute’s financial sustainability has become part of the day-to-day operations of the institute. We are currently facing opportunities and challenges that we have not seen for more than 25 years: a significant expansion in space and people, and an increased need for funding for research, equipment, infrastructure and operating costs.

To be financially sustainable in the longer term requires the institute to meet its current needs while planning for the future. This requires income growth and diversification, efficient administration and our own income generation.

Income growth and diversification

The institute’s 2011-12 fundraising results have been encouraging, with applications to trusts and foundations resulting in philanthropic grants of $1.152 million. The results for donations and bequests have also been positive, with $5.892 million raised. Significant work has gone into attracting new donors, through an awareness-raising newspaper campaign, building relationships with existing donors and in growing our new bequest society, the Walter and Eliza Hall Society.

Strategies are currently being developed to diversify our sources of funding, including entering the newly emerging market of private ancillary funds and developing a corporate partnership program. Planning is also underway to identify fundraising opportunities leading up to our centenary in 2015.

The marketing and communications team have continued to show strong leadership over the past year, building on the success of the Discoveries Need Dollars campaign. While continuing to focus on raising the profile of the institute in the media and general community, they also played a key role in developing the institute’s submission to the Strategic Review of Health and Medical Research in Australia, chaired by Simon McKeon.
Efficient operations

Over the past three months we have been piloting the 5S Lean System to improve efficiency by building smarter, simpler and sustainable processes and ways of working. The pilot has been run in the Bioservices facility and has been enthusiastically embraced by the team. We plan to progressively roll out the system to other areas of the institute following the pilot. A review of our procurement function is also underway using value stream mapping to improve efficiencies and reduce costs, with collaborative purchasing and e-procurement as key elements.

Meanwhile we are continuing with reviews of scientific services. Reviews of FACS and Bioservices have been completed and review reports on Histology and Imaging are currently under consideration. The reviews are being led by institute researchers. We also participated in a National Health and Medical Research Council audit during the year.

Risk and compliance

Risk management has evolved at the institute over recent years to include fraud prevention, internal control, corporate governance and integration of operational risk management functions.

This broadening of the risk management portfolio means it is no longer confined to staff involved in insurance, loss prevention, safety and audit, but involves IT, human resources, finance, laboratory operations, facilities, research divisions and other areas. The institute’s compliance with policies, procedures and legal and regulatory obligations is regularly examined by the institute’s internal auditor, who reports through to the Audit and Risk Committee, a sub-committee of the board.

To add rigor, a new management-level Risk and Compliance Committee has been established. This committee has commenced reviewing and updating the institute’s risk policy, risk profile, risk register, business continuity plan, critical incident plan, and emergency procedures. It is also developing a ‘risk champions’ program, which will assist with integrating and sustaining risk management in operational areas.

Ludwig Institute for Cancer Research, Parkville

Early in 2012 the Ludwig Institute for Cancer Research announced it was closing its Parkville node. This presented an opportunity for us to recruit more than 60 outstanding staff and students to the institute.

Researchers, divisional coordinators, management, and staff from human resources, finance, business development, grants, facilities, IT, laboratory operations, safety and bioservices from the Ludwig Institute and the Walter and Eliza Hall Institute have worked closely to develop a funding agreement, negotiate leases, intellectual property assignment, transfer of research grants, relocation of equipment, animal and human ethics committee approvals, while also integrating Ludwig facilities into our operations and setting up laboratories and IT for the new laboratory groups.

Staff changes

At the end of 2012 Murray Jeffs, the institute’s chief financial officer and company secretary, will retire after 16 years. Murray has made an outstanding contribution to the institute. His role in managing the endowment fund, and assisting donors and bequestors, leaves the institute in a strong financial position. We are fortunate that the incoming chief financial officer, Kim Tsai, who commences at the institute on 1 November 2012, comes to the institute with extensive experience in the medical research sector.
Building redevelopment

Over the past year the institute’s focus has been on settling into the new west wing of the building while refurbishing the existing east wing to create an integrated research facility. It has been a long but exciting process and in November 2012 we will be celebrating the formal opening of our new building.

The success of the project, which was achieved on time and on budget, was made possible by the strong partnerships between the institute and the architects (Denton Corker Marshall and S2F/ SKM), the builders (Baulderstone BPL) and the consultant team (Aurecon, Donald Cant Watts Corke and others). The support of the institute’s internal project team, user planning teams, divisional coordinators and researchers was invaluable during the building and refurbishment periods.

The project couldn’t have occurred without the generous support of the Australian Government ($50 million), the Victorian Government ($50 million), and The Atlantic Philanthropies ($30 million) who made this $185 million expansion and redevelopment possible. We are extremely grateful for their generous grants and for the strong support of other granting bodies including The Ian Potter Foundation, the Australian Cancer Research Foundation and the Drakensburg Trust who all generously provided funding for fit-out of the new facilities.

We were very pleased to be advised that the land lease for the institute’s expanded site had been fully executed by the Victorian Minister for Environment and Climate Change on 23 November 2011, for a period of 99 years less one day. This marked a major milestone in the life of the project and was achieved through strong collaboration between two state government departments (Health and Innovation), Melbourne Health and the institute.

Supporting women in science

In 2010 the institute established a Gender Equity Committee, seeking to address the lack of female researchers progressing to become independent research scientists.

The committee is developing and implementing initiatives that promote equity, social inclusion and awareness of the obstacles encountered by women in their career development.

One of the programs developed by the Gender Equity Committee is a ‘Women in Science’ lecture series, which showcases the careers and challenges of outstanding female scientists.

During the year the lecture series featured two highly regarded and prominent women scientists: Professor Nadia Rosenthal, director of the Australian Regenerative Medicine Institute at Monash University who is acclaimed for her research on the genetics of muscle and cardiac development; and Professor Michelle Haber, director of the Children’s Cancer Institute Australia who is known for her research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children.

Each lecture was followed by a lunch, providing an opportunity for female scientists at postdoctoral, PhD and junior laboratory head levels to meet the speakers, hear about their experiences as female scientists and discuss their advice for a successful career in science.

“I walked out of the lunches pumped up and full of ambition and motivation,” said postdoctoral fellow Dr Erika Cretney from the institute’s Molecular Immunology division. The Gender Equity Committee will continue to host this successful series, with four seminars scheduled for 2012–13.

Professor Nadia Rosenthal speaking with women scientists at the institute.
Supporters and donors

The support the institute receives from government, private donors, trusts, foundations and industry is vital to helping our researchers make the discoveries necessary to advance the understanding, prevention and treatment of cancers, chronic inflammatory diseases and infectious diseases.

We are grateful for the trust our supporters have awarded us and are committed to honouring that trust.

Government support

The institute is thankful for the support of the Victorian and Australian Governments.

This year we received $34 million in grants and $9.5 million in fellowships through the National Health and Medical Research Council. A further $412,000 in grants and $2.5 million in fellowships was received from the Australian Research Council. The institute also received $1.7 million in support from the Australian Phenomics Network, Australian Stem Cell Centre, Australia-Europe Malaria Research Cooperation (OzEMalaR), CRC for Cancer Therapeutics, CSIRO, and HEARing CRC.


We are also grateful for the support provided through the following international government agencies: Canadian Institutes of Health Research (Canada), National Cancer Institute (US), National Institutes of Health (US) and Swiss National Science Foundation (Switzerland).

Trusts and foundations

Philanthropic grants provide crucial support for our research by contributing funding to purchase equipment, to fund salaries and projects and to provide the dollars to build laboratories and buildings.

These grants provide a much-needed subsidy for projects that may not qualify for federal or state funding and provide investment in, and support to, our researchers.

This year we welcomed new trusts and foundations to our supporter list and also continue to appreciate long-standing relationships with existing supporters. It is through this sustained support we can initiate new methods of tackling research problems, build stronger collaborative partnerships and continue to produce high-impact research.

We thank the following trusts and foundations that have provided support to the institute through successful competitive and non-competitive grants over the past 12 months:


Private donors

The institute is fortunate to receive support from individuals, companies and community organisations. Support includes donations from golf clubs Australia-wide, community-based organisations, family trusts and workplace giving and matched giving programs. One particular highlight was the establishment of a three-year partnership with Coeliac Australia which will provide more than $500,000 for the institute’s coeliac disease research (see page 25).
Recognising the support of The J.H.A. Munro Foundation

The J.H.A. Munro Foundation has been a generous supporter of the Walter and Eliza Hall Institute since 2009.

Funding from the foundation has supported various areas of research at the institute, particularly type 1 diabetes and coeliac disease research.

In 2012 the institute was advised that The J.H.A. Munro Foundation Ltd had decided to go into voluntary deregistration and that the directors had chosen to donate more than $580,000 in residual funds to support our medical research.

Institute director Professor Doug Hilton met with Professor Terry Nolan, Mr Andrew J. Crozier-Durham, Mr Simon Stuart and Mr Bob Munro to discuss how the generous donation from the foundation could be best used to support institute researchers.

“Bob was adamant that the funds be used at the discretion of the director,” Professor Hilton said. “Untied philanthropic funding is crucial to the success of our institute as it allows us to take risks on smart young researchers.

In discussion with Bob, we decided that the funds would be kept invested in perpetuity, with the interest funding a fellowship for researchers. Given Bob’s interest in diabetes and coeliac disease we thought it made sense for the funding to initially support Dr Jason Tye-Din, one of our star clinician researchers who is spear-heading our coeliac disease research program.”

Dr Tye-Din will become the inaugural J.H.A. Munro Fellow, in honour of Mr Bob Munro’s uncle Mr James Harry Alexander Munro (Alex). “It is a pleasure to name the fellowship in recognition of Mr Munro’s uncle, who was renowned as a person of high principles and morals and donated generously to charity,” Professor Hilton said. “The J.H.A. Munro Fellowship will allow us to attract, retain and support the brightest researchers of each generation and will be a wonderful testament to the generosity and foresight of Bob and Alex Munro.”

Mr Bob Munro has been a generous supporter of the institute’s research.

Remembering Bev Gray

Mrs Bev Gray was a passionate supporter of ovarian cancer research.

Bev was diagnosed with ovarian cancer in 2003. When she was diagnosed, Bev’s tests revealed that the cancer had spread beyond her ovaries. As with many women who have ovarian cancer, Bev had some symptoms, but they were not recognised as early signs of ovarian cancer.

Bev passed away in February 2012, after nine years living with ovarian cancer. She is survived by her husband Tony, and daughters Katya and Miranda.

Katya said Bev’s greatest hope was to see better early-warning markers identified to screen for ovarian cancer and help in detecting the disease before it spreads and is harder to treat. “In the weeks before she passed away, mum wanted to know what she could do to help make this happen,” Katya said. “Rather than sending flowers, mum asked her friends and family to donate money to ovarian cancer research in the hopes that one day, better early markers, treatments and perhaps a cure, could be found.”

Katya works at the Walter and Eliza Hall Institute, and – in accordance with Bev’s wishes – the Gray family chose to give the donations to the institute’s ovarian cancer research program, led by Associate Professor Clare Scott. The money was used to set up the Bev Gray Scholarship, which will help to support a student training with Associate Professor Scott.

Bev’s daughter Miranda gave birth to a son four months before Bev passed away. “She was overjoyed to be able to spend time with her first grandchild, even though that time was so short,” Bev’s husband Tony said.

He said Bev was extremely touched to think she was able to contribute to future ovarian cancer research. “Bev was always thinking of others and gave a lot to other people,” Tony said. “Until the very end she was a giver of herself and still thinking of how she could help people, particularly other women with ovarian cancer.”

Katya works at the Walter and Eliza Hall Institute, and – in accordance with Bev’s wishes – the Gray family chose to give the donations to the institute’s ovarian cancer research program, led by Associate Professor Clare Scott. The money was used to set up the Bev Gray Scholarship, which will help to support a student training with Associate Professor Scott.

Bev’s daughter Miranda gave birth to a son four months before Bev passed away. “She was overjoyed to be able to spend time with her first grandchild, even though that time was so short,” Bev’s husband Tony said.

He said Bev was extremely touched to think she was able to contribute to future ovarian cancer research. “Bev was always thinking of others and gave a lot to other people,” Tony said. “Until the very end she was a giver of herself and still thinking of how she could help people, particularly other women with ovarian cancer.”

Katya works at the Walter and Eliza Hall Institute, and – in accordance with Bev’s wishes – the Gray family chose to give the donations to the institute’s ovarian cancer research program, led by Associate Professor Clare Scott. The money was used to set up the Bev Gray Scholarship, which will help to support a student training with Associate Professor Scott.

Bev’s daughter Miranda gave birth to a son four months before Bev passed away. “She was overjoyed to be able to spend time with her first grandchild, even though that time was so short,” Bev’s husband Tony said.

He said Bev was extremely touched to think she was able to contribute to future ovarian cancer research. “Bev was always thinking of others and gave a lot to other people,” Tony said. “Until the very end she was a giver of herself and still thinking of how she could help people, particularly other women with ovarian cancer.”

The late Mrs Bev Gray with her grandson Ryan J Bailey.
Supporting the next generation of scientists

A generous donation by Mr Michael and Mrs Kelli Harris will help support the next generation of scientists training at the Walter and Eliza Hall Institute.

Mr Harris is the son of former institute researcher and cell biologist Dr Alan Harris, who passed away in 2006. The Alan W Harris Honours Scholarship was established in honour of his contribution to the institute and is awarded to students who are accepted into the institute’s honours program. The award provides $5000 to each honours student.

Mr Harris said his father had demonstrated a lifelong commitment to encouraging students and young scientists in the early phase of their research careers. “Dad gave a lot of his time to his students,” Mr Harris said. “Having been honours students ourselves, my wife Kelli and I know how difficult it can be financially. To honour dad, we decided to donate to a scholarship that supports talented students who are making their own contribution to science.”

During his 36-year research career at the institute Dr Harris made contributions to the fields of genetics, immunology, cancer biology and histopathology. Mr Harris and his wife Kelli work in the health sector and have a particular interest in research that benefits developing countries.

Mr Harris visited the institute in 2012 to meet two Alan W Harris Honours Scholarship recipients, current Honours student Ms Jie Zhou and former Honours student Mr Simon Preston, who is now undertaking a PhD at the institute. “I enjoyed meeting them and learning about their research,” Mr Harris said. “It was satisfying to know that this is what dad would appreciate.”

Ms Zhou said the scholarship made her life much easier. “Having moved out of home, every cent counts. It helps me worry less and focus more on my studies,” she said.

Mr Preston agreed. “The scholarship lightens the financial burden placed on honours students, and allows us to focus on what is most important, our research,” he said.

Golf clubs tee off for medical research

For several decades golf clubs around Australia have organised charity days to support the Walter and Eliza Hall Institute’s research, raising more than $1.6 million. Women in golf clubs have contributed significantly to this achievement.

In 1976 women golfers at Victoria Golf Club in Cheltenham, Melbourne, decided to change the way they made donations to charities. Instead of giving a little to many good charities, the women’s committee of the day decided they would raise one piece of equipment for the Walter and Eliza Hall Institute.

Mrs Norma Wilkinson, president of the Women’s Committee from 1992 to 1994, said that each year the institute’s scientists were invited to select what equipment was a priority for the next year. “Many women members then worked tirelessly towards its purchase, and great friendships were made,” she said.

Over 36 years, 400 women members at Victoria Golf Club have raised more than $136,000 to purchase equipment for the institute’s medical research.

The most recent acquisition was a dissecting microscope for Dr Marie-Liesse Asselin-Labat’s laboratory in the institute’s ACRF Stem Cells and Cancer division. Dr Asselin-Labat has worked to understand how breast cancer starts. She was part of the institute team that identified breast stem cells, a discovery that caused a major shift in the way scientists thought breast cancer developed. Dr Asselin-Labat is now focusing on lung cancer, looking at how lung stem cells are regulated and what drives tumour initiation in the lungs.

Mrs Jan Tootell, Lady President of Victoria Golf Club, said that members continue their commitment to supporting community projects. “We are not just a golf club, we are part of the community and we like to contribute when we can,” she said.

Ms Jie Zhou (left), Mr Simon Preston (centre) and Mr Michael Harris.
Celebrating a remarkable gift

A hundred years ago the most significant donor in the institute’s history, the Walter and Eliza Hall Trust, was established.

Both Walter Hall and his wife Eliza were active philanthropists during their life together. In 1912, the year following Walter’s death, Eliza set up a charitable trust, calling it the Walter and Eliza Hall Trust, as a means of assisting those in need. Her gift of £1,000,000 to establish the trust was the largest charitable gift in Australian history up to that time, the equivalent of approximately $107.5 million today.

In the first years of the Walter and Eliza Hall Institute it was financed solely by an annual donation of £2500 (about $220,000) from the trust. That support has continued until the present day, with the trust’s total donations to the institute amounting to approximately $10.1 million in today’s terms.

Mr John Chatterton, chairman of The Walter and Eliza Hall Trust, said the tenacity and vision of the men who were its first trustees were crucial to the establishment of the institute.

“The trust’s Melbourne-based trustee, Richard Gardiner Casey, was instrumental in highlighting to trustees the need for research into cancer in 1914,” Mr Chatterton said. “Following several meetings with medical professors from The University of Melbourne and the then new Melbourne Hospital an agreement was struck to establish the Walter and Eliza Hall Institute of Research in Pathology and Medicine.”

Mr Chatterton said it was in 1924, under the second director Dr Charles Kellaway, that the institute began to take off in the way Richard Gardiner Casey had envisioned.

“Casey would be very pleased with what his idea has become. The institute has gone from strength to strength and we are delighted to have been there from the beginning.”

Fraser, Kay. (2012). A Remarkable Gift, 100 Years of the Walter & Eliza Hall Trust. Queensland, Australia: The University of Queensland Press.

The institute acknowledges the support of the following organisations

[List of organisations and logos]
Donations of $1000 and over

Anonymous – NSW
Anonymous – NSW
Anonymous – TAS
Anonymous – VIC
Anonymous – VIC
Anonymous – VIC
Anonymous – VIC
Anonymous – VIC
Anonymous – VIC
Anonymous – VIC
Hazel & Pip Appel Fund
The Pierce Armstrong Foundation
Ms Katherine I Behrend
Bell Charitable Fund
Berwick Opportunity Shop
Mr Angelo Bladeni
Bonegilla Old Time Dances
Cardinia Beaconsills Golf Links
John Frederick Bransden Charitable Trust
Thomas, Annie and Doris Burgess Charity Trust
Coeliac Australia
George Collie Trust
Coolah Lady Golfers
Corcoran Parker Pty Ltd
Dr Andrew Cuthbertson
Professor Howard D’Abrera
Mrs June Danks
Mr Gordon Darling AC CMG
Mr and Mrs Patrick N Devlin
Mrs Helen M Diamond
Drakensberg Trust
Dr Janice D Dudley
Estate of Audrey Evelyn McNeill
Estate of Patricia Mary Pearl
Estate of Hazel Jean Phillips
Estate of Joyce Sainsbury
Estate of Lorraine Florence Williams
Estate of Emily Vera Winder
Estate of Florence Mary Young
Mrs Geraldine Eckersley
Mr James R Gill
Google Matching Gifts Program
Mrs Andrea Gowors
Frederick and Winifred Grassick Memorial Fund
Mr Peter Greening
Mrs Jean T Hadges
Mr and Mrs Michael A Harris
Heathbury Pty Ltd
H & L Hecht Trust
Helpmann Foundation
Mrs Jane Hemstritch
Amelia Eliza Holland Trust
Mr Graham B Jackson
Ms and Mr Caroline Johnston
Mrs Chlorine Kluck
Dr Darren Lockie
Albert H Maggs Charitable Trust
Professor Bruce Mann
Dr Neville McCarthy AC and Mrs Margaret McCarthy
Mrs Christine and Mr Denis McConnell
Miriam Vale Golf Club Lady Members
Dame Elisabeth Murdoch AC DBE
Mrs Anne E Naylor
Ms Carolyn O’Byrne
Orange Ex-Services Golf Club
Mrs Marion Page
Pambula-Merimbula Golf Club
Philanthropic Services, Perpetual Trustees
Miss Heather M Phiddian
GT & L Potter Charitable Trust
Mr John B Prescott AC and Mrs Jennifer Prescott
Mrs Edith Qualtrough
Ramaciotti Award
John T Reid Charitable Trusts
Agnes Maude Reilly Charitable Trust
Margaret Lewis Reilly Charitable Trust
Mr Dieter and Mrs Maxine Rinke
RobMeree Foundation
Mrs Margaret S Ross AM
Rotary Club of Point Geelong Williamstown
S.T.A.F. - Rupert, Ethel & Ronald Fraser & Ruby Thomas
Mrs Sam Sharman
Ms Pauline Speedy
Strathmore Community Services Ltd
Ms Jenny Tatchell
Tathra Beach Country Club Ladies Golf
The Angior Family Foundation
The William Angliss (Victoria) Charitable Fund
The Baldy Trust Fund
The C.H. Boden Memorial Trust
The Frank Broadhurst Memorial Charitable Fund
The Decor Corporation Pty Ltd
The Dyson Bequest
The Thomas William Francis & Violet Coles Trust
The Goldschlager Family Charitable Foundation
The Isabel & John Gilbertson Charitable Trust
The Walter and Eliza Hall Trust
The J.H.A. Munro Foundation Ltd
The Ruse Family Trust
The Harry Secomb Foundation
The Jack and Robert Smorgon Families Foundation
The Lady Tata Memorial Trust
The Scobie and Claire MacKinnon Trust
The Hugh Williamson Foundation
The Woodend Foundation
Mr Christopher and Mrs Cheryl Thomas
Mr and Mrs Ralph Thomas
Mrs Olive Thurlby
Mrs Margaret and Mr Peter Tse
Vincentia Golf Club Lady Members
Mr John C Warburton
Ms Marjorie E J Wilks
Mr David A Williamson
Yarra Yarra Golf Club

New donations of capital received in the 2011–12 financial year

Anonymous seminar award
Tim Bates Memorial Diabetes Research Fund
DA Craven Memorial Fund
JE Craven & MA Shearer Estates
Alan Harris Scholarship Fund
David Mann Memorial Research Fund
Nossal Family Trust
Paddy Pearl Fund
Qualtrough Research Fund
Sidwell OB Estate
The full list of the institute’s permanent named capital funds is on the accompanying CD.
Members of the institute
during the financial year to 30 June 2012

The University of Melbourne
The Royal Melbourne Hospital
Dr Susan M Alberti AO
Professor Emeritus Robin Anders
Professor James A Angus AO
Mr Donald Argus AC
Sir James Balderson AC
Mrs Ann D Bates
Mr Robert Bates
Mr Lance H J Bauer
Professor Claude C A Bernard
Mr Marc Besen AO
Dr Gytha W Bitheras
Dr Peter Brennan
Mrs Beverley A Brownstein
Mr Edward G Brownstein
Dr Margaret N Brumby AM
Professor Tony Burgess
Mr Leon A Davis
Mrs Annette Davis
Mr Stephen Daley
Mr John C Dahlsen
Professor Christopher J D de Kretser
Mr Ronald F Diamond
Mrs Helen M Diamond
Mr Mick Dexter
Mrs Marion O Page
Mr Erich A Mayer
Mrs Lousje Skala
Mrs Sam M Sharman
Dr Neville J McCarthy
Mr Jack Smorgon
Professor Nicholas M Gough
Mrs Andrea Gowers
Mr John P Grace
Mr John Greig
Sir Andrew Grimaud OBE
Mrs Anne Grindrod
Mrs Jean T Hadges
Dr Emanuela Handman
Mr Harry M Hearn AM
Professor David Hill
Dr Margaret C Holmes
Dr Margo C Honeyman
Dr Thomas H Hurley AO OBE
Mr Darvell M Hutchinson AM
Ms Helen Kennan
Mr Warwick G Kent AO
Professor Emeritus Priscilla Kincaid-Smith AC OBE
Professor Frank Larkins AM
Professor Richard G Larkins AO
Mr Gary W Liddell
Mr Sean Luk
Professor Emeritus Athol W J Lykke Deceased 4 February 2012
Professor Emeritus lan R Mackay AM
Mrs Avvis L Macphee AM
Ms Eve Mahlab AO
Mrs Robyn G Male
Mr Roger E Male
Mrs Lorrie Mandel
Ms Nerissa L Mapes
Professor Emeritus Thomas J Martin AO
Professor Ray Martin AO
Mr Erich A Mayer AM
Dr Neville J McCarthy AO
Mrs Jean M McCaughey AO
Professor Jim McCluskey
Professor John A McKenzie AM
Professor Frederick Mendelsohn AO
Professor Jacques Miller AC
Professor John Mills
Mr Robert C Minter
Trustee, the Walter and Eliza Hall Trust
Professor Christina Mitchell
Dr Graham F Mitchell AO
Dr Judith A Mitchell
Mr Barry Moore
Mrs Barbara R Morgan
Mr Hugh M Morgan AC
Dr George Morstyn
Mr Bob I Munro
Dame Elisabeth Murdoch AC DBE
Mr Anthony P Murphy
Ms Linda B Nicholls AO
Lady Lyn Nossal
Mr Tom J R O’Brien AM
Dr Peter P H Eng
Dr Andrew Gearing
Professor Emeritus Jim Pittard AM
Lady Primrose Potter AC
Mr John B Prescott AC
Mrs Edith Qualtrough
Ms Lesley Qualtrough
Professor Peter Ratnjen
Mr Kate J Redwood
Mr John B Reid AO
Mr Dieter O Rinke
Associate Professor Ken Roberts AM
Mr Michael B Robinson AO
Ms Linda Rodger
Mrs Mary Rodger
Mrs Margaret S Roos AM
Mr Fergus D Ryan
Professor Graeme B Ryan AC
Professor Nick Samaras
Mrs Pam J Sargood
Professor Carl B Schedvin
Ms Carol J Schwartz AM
Dr Roland Scollay
Mr Andrew Scott
Professor John F Scott AO
Dr Paul W Scown
Mrs Sam M Sharmen
Mrs Louise Skala
Mr Steven M Skala AO
Mr Jack Smorgon AO
Mr Robert Smorgon AM
Ms Linda Sorrell
Ms Pauline Speedy
Miss Ann A Sprague
Mr Geoffrey J Stewardson
Dr John Stocker AO
Mr John W Stratton
Ms Helen Sykes
Ms Jenny Tatchell
Mr Bruce B Teele
Mrs Cheryl F Thomas
Mr Christopher Thomas
Mr John C Walker QC
Mr Stanley Wallis AC
Ms Catherine Walter AM
Mr John M Walter
Mr John C Warburton
Mr Robert Warren
Ms Marion J Webster OAM
Mr Kevin J Weight
Professor Emeritus Jim Pittard AM
Dr Senga Whittingham
Mr David A Williamson
Professor Robert Williamson AO
Professor Ingrid Winship
Mr Peter A Worcester

Sir Arvi Parbo AC
Professor David G Penington AC
Professor Roger Pepperell
Mr David R Percival
Professor Emeritus Jim Pittard AM
Lady Primrose Potter AC
Mr John B Prescott AC
Mrs Edith Qualtrough
Ms Lesley Qualtrough
Professor Peter Ratnjen
Ms Kate J Redwood
Mr John B Reid AO
Mr Dieter O Rinke
Associate Professor Ken Roberts AM
Mr Michael B Robinson AO
Ms Linda Rodger
Mrs Mary Rodger
Mrs Margaret S Roos AM
Mr Fergus D Ryan
Professor Graeme B Ryan AC
Professor Nick Samaras
Mrs Pam J Sargood
Professor Carl B Schedvin
Ms Carol J Schwartz AM
Dr Roland Scollay
Mr Andrew Scott
Professor John F Scott AO
Dr Paul W Scown
Mrs Sam M Sharmen
Mrs Louise Skala
Mr Steven M Skala AO
Mr Jack Smorgon AO
Mr Robert Smorgon AM
Ms Linda Sorrell
Ms Pauline Speedy
Miss Ann A Sprague
Mr Geoffrey J Stewardson
Dr John Stocker AO
Mr John W Stratton
Ms Helen Sykes
Ms Jenny Tatchell
Mr Bruce B Teele
Mrs Cheryl F Thomas
Mr Christopher Thomas
Mr John C Walker QC
Mr Stanley Wallis AC
Ms Catherine Walter AM
Mr John M Walter
Mr John C Warburton
Mr Robert Warren
Ms Marion J Webster OAM
Mr Kevin J Weight
Professor Emeritus Jim Pittard AM
Dr Senga Whittingham
Mr David A Williamson
Professor Robert Williamson AO
Professor Ingrid Winship
Mr Peter A Worcester
Staff list

Director
Doug Hilton, BSc Monash BSc(Hons) Melbourne PhD Melbourne FAA

Assistant director
Dave Vaux, BMedSc Melbourne MB BS Melbourne PhD Melbourne FAA

Director’s office
Keely Bumsted O’Brien, BSc Simmons College PhD Washington, scientific education officer (from 07/11)
Pamela Dewhurst, personal assistant
Kelly Rodger, executive assistant (administrative)
Linda Scott, personal assistant to president of the Australian Academy of Science
Fenny Wiradjaja, BSc Monash PhD Monash, executive assistant (scientific)

Chief operating officer
Maureen O’Keefe, BSc(Hons) Monash DipEd Melbourne MBA Melbourne GAICD WCLP

Chief operating officer’s office
Sue Cameron-Codognotto, administrative officer
Jenna Kelley, administrative assistant

Internal audit
Stanley Balbata, CPA, internal auditor

Research Grants
Julie Mercer, BSc Melbourne DipEd Monash PhD Monash, grants manager
Annette Wilson, BA(Hons) Monash MA Monash GradDipSocSci Swinburne, grants administrative assistant

Bioservices
Catherine O’Brien, BVSc Melbourne, veterinarian
Gavina Bailey, animal ethics committee and regulatory compliance officer

Angela Milligan, head, Bioservices – Parkville
Sophie Allan
Kim Birchall
Amanda Bradfield (to 02/12)
Rebecca Cole
Danniele Cooper
Jessica Coughlin
Faye Dabrowski
Merle Dayton
Kris Dennenosser (to 09/11)
Heather Donatucci
Emma Dunstan (from 02/12)
Michelle Fornito
Carmen Gatt
Jaclyn Gilbert
Katya Gray
Megan Hailay (from 08/11 to 11/11)
Melissa Hobbs, BSc Monash
Krystal Hughes
Nadia Iannarelli
Meagan James (to 02/12)
Elizabeth Kyran
Emma Lanera
Jamie Leahy
Silvana Liburdi
Nicoe Lynch
Liana Mackiewicz
Kate McKenzie
Julie Merryfull
Glen Monagle
Andrea Morcom
Gary Morgan
Danny Noriel
Stephanie O’Connor
Melissa Pritchard
Lisa Reid
Alice Renkema (to 04/12)
Kristen Siciluna (from 07/11)
Giovanni Siciliano
Catherine Smith
Chryistal Smith
Keti Stoev
Emily Sutherland (to 09/11)
Paul Trajevski
Kelly Trueman
Kristy Vella
Kelly Walker (from 08/11)
Lauren Wilkins
Jian Xiao
Catherine Yates

Gillian Carter, head, Bioservices – Kew
Andrea Baldwin
Fiona Berryman
Kerry Betts
Peter Coffman
Rhiannan Crawley (from 01/12)
Carmen Epifanio (from 01/12)

Jackie Fisher
Sharen Hennessy
Wendy Intrepido
Jess Janssen
Terese Johns, education and training manager
Melissa Keeble
Con Kouloukas
Kelly Lane, BSc Melbourne
Teisha Mason
Cameron McKenzie
Lyciah Mounsey (from 08/11)
Sohrab Partow
Bec Poppleton
Liz Reddie
Laanne Scott
Blanca Sinaranda
Silvia Stoef (from 11/11)
Cheryl Thorp, administrative assistant
Collette Turfrey
Sarah Vivian
Melinda Watts (from 10/11)
Kelly Wilson

Elaine Major, head, Bioservices – Biotechnology Centre
Loretta Allen (to 01/12)
Kathy Barber
Denise Barker
Rebecca Bowyer (to 07/11)
Sheree Brown
Tara Carle
Cassandra D’Alessandro (from 02/12)
Christopher Evans
Katie Franks
Theresa Gibbs
Stephanie Green
Aida Herrera
Melanie Howell
Priscilla Kennedy
Lyn Lowe
Vicki Marshall, BSc LaTrobe
Dang Nguyen (to 03/12)
Shauna Ross
Mathew Salzone (to 04/12)
Emilia Simankowicz (from 11/11)
Julie Stanley
Christina Tsatsoulis
Jayne Vella (from 11/11)
Fiona Waters, BSc LaTrobe
Magda Wilk

Eren Loza, Head, Bioservices – LaTrobe
Louise Inglis
Jose Jimenez
Tracey Kemp
Tony Trajevski, animal attendant coordinator
Business Development Office

Julian Clark, BSc(Hons) Flinders PhD
Glasgow, head, business development

Patricia Diggie, BSc(Hons) Monash PhD
Bristol, business development officer

James Dromey, BSc(Hons) London PhD
London, business development associate

Gabrielle Hirsch, BSc(Hons) Monash LLB
Monash, IP/legal officer (from 12/11)

Carmela Monger, BSc(MIT)
Monash, patents administrator

Building and Engineering Services

Steve Droste, BEng Melbourne, facilities manager

Geoff Cravino, engineering supervisor
Nick Basalaj, essential safety measures technician

Mahbub Bhuiyan, MPICt Macquarie, security and compliance supervisor

Peter Brown, maintenance technician
Marek Grostal, BEng(Technology)
Warsaw, electronics technician

Cipriano Maligasy, BEng Manila, electrical/mechanical technician

Af Mele, trades assistant
Greg Menzies, engineering purchasing officer

Onker Singh, maintenance technician
Derek Wates, refrigeration technician

Graham Pratt, engineering supervisor, Bundoora

Darren Goodwin, workshop technician
Jeffrey Langley, maintenance technician

Patrick Makiatea, trades assistant
Robert Mitrevski, workshop technician

Graham Thornbury, maintenance technician

Clinical Translation Centre

Andrew Roberts, MB BS Qld PhD
Melbourne FRACP FRCPA, head, clinical translation centre

Jenni Harris, BSc(Nursing)
Ballarat GradDipCC(ICU) Monash
GradDipSc(Nursing) VUT, clinical project officer

Cathy Quilici (from 09/11), research assistant

Naomi Sprigg, visiting tissue coordinator
Lina Laskos, BSc(Hons) Monash PhD
Monash, clinical project officer

Community Relations

Deb Cutts, BSc Monash, fundraising manager (to 12/11)

Penny Fannin, BSc(Hons) Melbourne GradDipJourn Murdoch, strategic communications and marketing manager

Drew Berry, BSc(Hons) Monash MSc Melbourne, biomedical animations manager

Elizabeth Bravo, catering supervisor

Rachel Bucknall, BVC(Hons) Monash, graphics officer (from 02/12)

Richard Burleigh, database officer (from 05/12)

Lee Byrne, BA South Australia MA Deakin, web communications manager (from 04/12)

Jacqui Church, community relations coordinator (to 03/12)

Madhu Dass, catering assistant

Rosie Falcone, reception coordinator

Maureen Grant, BA UTS CEM, conference and events manager

Renee Jowett, receptionist

Lauren McCluskey, BA RMIT, development officer (from 08/11)

Peter Maltezos, graphics officer

Dany Maneely, BBiomedSc Durham MSc Imperial College, web content manager (to 04/12)

Czesia Markiewicz, photographer

Brigitte Mesiti, graphics officer

Alice Robinson, BA Flinders LLB Flinders, communications officer (from 08/11)

Vanessa Solomon, BSc(Hons) UTAS PhD Melbourne, communications advisor

Simon Taplin, production manager

Julie Tester, BA Melbourne BSW Melbourne, donor development manager

Jane Turner, BA Monash, trusts and foundations manager (from 07/11)

Etsuko Uno, BSc(Hons) UWA MA Rockefeller, biomedical animator

Cameron Wells, graphics officer

Elizabeth Williams, BSc(Hons) UWA GradDipSciComm UWA, media and publications manager

Finance

Murray Jeffs, BBus(Accounting) RMIT CPA FCIS SF Fin, financial controller

Malcolm Williamson, BBus(Accounting)
Swinburne, financial operations manager

Yesar Al-Hashimi, BBus(Administration)
Yarmouk, accounts officer

Gordana Barkovic, accounts officer

Kaye Bates, accounts officer

Michelle Birrell, BBus(Administration)
Monash, accounts/grants officer

Peter Chen, BCom Deakin, accounts payable officer

Barbara Groves, accounts officer

Justine Koutsoupias, BCom RMIT, accountant (from 08/11)

Adrian Turvey, assistant accountant

Procurement and Logistics

Todd Jasper, procurement and logistics coordinator

Luke Baltrunas, storeperson

Oscar Canedo, storeperson

Mario Florides, stores and inventory clerk

Brigitte Jordanidis, administration assistant

Claudia Kerstovitch, administration coordinator

Stella Kyetos, shipping officer

Jim McDonagh, shipping officer

Dorothy Pilarinos, purchasing officer

Richard Reeve, stores supervisor

John Sapazovski, storeperson

Boris Trajevski, purchasing officer

Human Resources

Paul Fraser, BSc(Hons) Melbourne DipEd Melbourne MEdAdmin New England, human resources manager

Catherine Axiq, BBus Swinburne, human resources administrator

Frank Draffen, academic administration officer

Mabel Kiang, BBus Swinburne, payroll/HR administrator

Vanessa Linde, BHealthSc Deakin, human resources officer

Yvonne Sirinotis, BBus LaTrobe, human resources officer

Rita Tiziani, senior human resources officer
Information Technology Services

John Wastell, BSc(Hons) Melbourne PhD Melbourne, head, Information Technology Services
Adrian Colomitchi, BSc Bachareast, software engineer (from 10/11)
Janice Coventry, BSc Melbourne DipEd Melbourne, VMS systems manager
Jason Cutler, BInfTech Monash, helpdesk engineer
Miffy Edwards, BA Monash, DBA/senior applications programmer
Chris Fitzgerald, helpdesk engineer
David Hardy, BA(Hons) De Montfort, Macintosh systems manager
Edy Huynh, computer technician
Norm King, computer technician
Khoi Le, software engineer
Tri Le, BSc(Hons) Monash, PC systems manager
John McFarlane, GradDipAppInfSys RMIT, IT services manager
Austin McLaughlin, BSc(Hons) LaTrobe, application services manager (from 07/11)
John Nguyen, BECompEng Melbourne, desktop systems support engineer
Jakub Szarlat, BESoftEng(Hons) Melbourne, Unix/Linux systems manager
Phi Tang, BComp(Hons) Adelaide, software engineer (from 10/11)
Dung Tran, BEComp Monash, networks manager
Qui Tran, BAppSc Chisholm, Microsoft server applications support engineer
Rodney Van Cooten, BSc(Hons) Melbourne, CTx computer systems engineer

Laboratory Services and Operations

Helene Martin, BSc(Hons) Melbourne MBB RMIT PhD Melbourne, laboratory operations manager
Michael Rubira, BAppSc RMIT, laboratory operations manager
Wendy Carter, ARMIT RMIT

Flow Cytometry Laboratory

Frank Battye, BSc(Hons) LaTrobe PhD LaTrobe, head, flow cytometry
David Baloyan, BSc(Hons) Javakhishvili Tbilisi State MSc(Hons) Javakhishvili Tbilisi State
Adrian Binek, BSc Swinburne (from 02/12)
Sandy Fung, BSc Melbourne (to 01/12)
Angela Hind (to 03/12)
Dora Kaminaris, BSc Monash
Padmini Nanda, BSc Bangalore MSc Bangalore
Chayanica Nasa, BSc Delhi MSc Delhi Rumbi Tichawangana, BSc Deakin BSc(Hons) Melbourne
Lankesha Yapa, BSc Auckland MSc Auckland

Gene Targeting Service

Jacob Sarkis, BSc RMIT
Elizabeth Viney, BAppSc RMIT

Histology

Ellen Tsui, head of Histology
Vera Babo
Salam Hasanein
Yuyin Hoang
Steven Mihajlovic, BSc Sydney
MSLA Zagreb
Kevin Weston

Imaging Facility

Kelly Rogers, BSc(Hons) Deakin PhD Griffith, head, imaging facility
Lachlan Whitehead, BA Melbourne BSc(Hons) Melbourne PhD Melbourne (from 04/12)

Media

Wendy Dietrich, BAppSc Monash BAppSc(Hons) RMIT, head, Central Services
Kelly Arnott
Goran Arsovski
Balwinder Kaur, BA Bunjab
Linda Minter (to 01/12)
Carolyn Sperrey
Dora Vasiadis, media supervisor

Monoclonal Antibody laboratory

Kaye Wycherley, head, Monoclonal Antibody services
Ridouan Boubhoub
Monica Brown
Mytha Huynh
Karen Mackwell, BAppSc RMIT
Paul Masendycz, BAppSc RMIT, laboratory coordinator

Preparation Services

Lary Juatan
Dianne Mathews
Heather Orange
Josephine Pink
Wendy Ross
Anna Rymer
Denise Stephen

Radiation and Instrument Services

Denis Quilici, ARMIT RMIT, radiation safety
Thomas Nikolaou

Library and Information Management

Josephine Marshall, head, library and information management
Richard Burt, BA LaTrobe MIMS Swinburne GradDipEd Monash, records officer
Wendy Hertan, BA VUT GradDiplLib Melbourne, assistant librarian

Safety

Tony Hendy, BAgSc(Hons) Melbourne GCertIndHygSc Deakin, safety systems manager
Grant Thomas, BAppSc RMIT, chemical safety officer
Board Committees

Audit and Risk Committee
Ms Linda B Nicholls AO, Chair
Mr Peter Caldwell (Deloitte)
Professor Doug Hilton
Mr Murray Jeffs
Mr Roger Male
Ms Maureen O’Keefe
Mr Steven Skala AO
Mr Malcolm Williamson
Mr Stan Balbata (Minutes)

Commercialisation Committee
Dr Graham Mitchell, Chair
Mr Leon Davis AO
Dr James Dromey
Dr Julian Clark
Professor Peter Colman
Professor Doug Hilton
Dr George Morstyn
Professor Nick Nicola AO
Ms Maureen O’Keefe
Dr John Raff
Ms Carmela Monger (Minutes)

Financial Sustainability Committee
Mr Christopher Thomas, Chair
Mrs Sally Bruce
Mr Greg Camm
Mr Michael Daddo
Mr Leon Davis
Mr John Dyson
Ms Penny Fannin
Ms Jane Hemstritch
Professor Doug Hilton
Ms Caroline Johnston
Mr Rowan Kennedy
Ms Maureen O’Keefe
Mr Steven Skala
Mr Robert Wylie
Ms Sue Cameron (Minutes)

Human Research Ethics Committee
Associate Professor Rufus Black, Chair
Dr Bob Anderson (to 12/11)
Dr John Bonacci
Associate Professor Paul Ekert (from 01/2)
Reverend Father Michael Elligate, Deputy Chair
Mr David Freeman
Observer: Dr Lina Laskos
Professor Geoff Lindeman
Mrs Netta McArthur
Mr Paul McCaffrey
Dr Rachel Nowak
Ms Maureen O’Keefe
Professor Louis Schofield
Professor Ingrid Winship
Ms Sue Cameron (Minutes)

Investment Committee
Mr Roger Male, Chair
Mr Steven Daley
Professor Doug Hilton
Mr Murray Jeffs
Mr Stephen Merlicek
Mr Stephen Milburn-Pyle
Ms Maureen O’Keefe
Mr John Stratton
Ms Fiona Trafford-Walker
Ms Catherine Walter AM
Mr Peter Worcester
Mr Andrew Scott (Minutes)

New Building Sub-Committee
Mr Michael Fitzpatrick, Chair
Mr Leon Davis AO
Professor Doug Hilton
Mr Tony Murphy
Ms Maureen O’Keefe
Professor Nick Nicola AO
Professor David Vaux
State Government Observers:
Mr Simon Rabl, DPI
Mr Steven Skala AO
Ms Sue Cameron (Minutes)
Advisory Committees

Appointment and Promotion Review Committee
Professor James Angus,
The University of Melbourne, Chair
Professor Jerry Adams
Professor Warren Alexander
Professor Peter Colman
Professor Alan Cowman
Professor Len Harrison
Professor Doug Hilton
Professor Phil Hodgkin
Professor David Huang
Professor Geoff Lindeman
Professor Nick Nicola
Dr Stephen Nutt
Professor Liam O’Connor
Professor Andrew Roberts
Professor Terry Speed
Professor Andreas Strasser
Professor David Vaux
Professor Jane Visvader
Professor Ian Wicks
Mr Paul Fraser,
Human Resources Manager (Minutes)

International Scientific Advisory Council
Dr David Baltimore,
California Institute of Technology
Professor Christophe Benoist,
Joslin Diabetes Center
Professor Anton Berns,
Netherlands Cancer Institute
Dr Alan Bernstein,
Global HIV Vaccine Enterprise
Professor Elizabeth Blackburn,
University of California San Francisco
Professor Dr Meinrad Busslinger,
Research Institute of Molecular Pathology
Professor Peter Doherty,
The University of Melbourne
Professor Richard Flavell,
Yale University
Professor Christopher Goodnow,
John Curtin School of Medical Research,
Australian National University
Dr Diane Mathis,
Joslin Diabetes Center
Professor Philippe Sansonetti,
Institut Pasteur
Professor Tom Steitz,
Howard Hughes Medical Institute,
Yale University
Professor Bruce Stillman,
Cold Spring Harbor Laboratory
Professor James Wells,
Small Molecule Discovery Center,
University of California San Francisco
Director’s Office,
Walter and Eliza Hall Institute (Minutes)

Senior Scientific Advisory Committee
Professor Doug Hilton, Chair
Professor Jerry Adams
Professor Warren Alexander
Dr Chris Burns
Professor Peter Colman
Professor Alan Cowman
Professor Len Harrison
Professor Phil Hodgkin
Professor David Huang
Professor Geoff Lindeman
Professor Nick Nicola
Dr Stephen Nutt
Professor Liam O’Connor
Professor Andrew Roberts
Professor Ken Shortman
Professor Gordon Smyth
Professor Terry Speed
Professor Andreas Strasser
Professor David Vaux
Professor Jane Visvader
Professor Ian Wicks
Ms Kelly Rodger (Minutes)
### Standing Committees and Sub-Committees

#### Animal Ethics Committee
- Professor Colin Chapman, Chair
- Dr Marnie Blewitt (Scientist)
- Dr Alan Bolton (The Lost Dogs Home)
- Mr Terence Flanagan (Representing the public interest)
- Dr Daniel Gray (Scientist)
- Dr Carlotta Kellaway (Representing the public interest)
- Associate Professor Andrew Lew (Veterinarian/Scientist)
- Ms Julie Merryful (Senior Animal Technician)
- Dr Matthew McCormack (Scientist)
- Ms Angela Milligan (Senior Animal Technician)
- Dr Catheryn O’Brien (Veterinarian)
- Mr Tony Pyman (Representing the public interest)
- Mrs Gavina Bailey (Minutes)

#### Clinical Translation Standing Committee
- Professor Andrew Roberts, Chair
- Dr Bob Anderson
- Dr Chris Burns
- Dr Julian Clark
- Dr Ross Dickins
- Associate Professor Paul Ekert
- Professor Len Harrison
- Dr Susanne Heinzel
- Dr Lina Laskos
- Professor Geoffrey Lindeman
- Associate Professor Clare Scott
- Ms Monique Topp
- Dr Jason Tye-Din
- Professor Paul Waring, University of Melbourne
- Professor Ian Wicks
- Ms Jenni Harris (Minutes)

#### Biosafety Committee
- Dr Ross Dickins, Chair (from 01/12)
- Dr Stephen Nutt, Chair (to 12/11)
- Ms Wendy Carter
- Mr Tony Hendy (to 02/12)
- Associate Professor Andrew Lew
- Dr Helene Martin
- Professor Marjory Martin (to 02/12)
- Dr Catheryn O’Brien
- Ms Maureen O’Keefe
- Dr Marc Pellegrini, Deputy Chair (from 01/12)
- Professor Andrew Roberts
- Mr Michael Rubira
- Dr Odilia Wijburg
- Ms Marian Cravino (Minutes)

#### Education Committee
- Dr Anne Voss, Chair
- Dr Keely Bumsted-O’Brien
- Dr Matthew Call
- Dr Peter Czabotar
- Dr Grant Dawson
- Mr Frank Daffren
- Associate Professor Paul Ekert
- Ms Penny Fannin
- Mr Paul Fraser
- Dr Nick Huntington
- Dr Ruth Kluck
- Mr James McCoy
- Dr Sandra Nicholson, Deputy Chair
- Dr Marc Pellegrini
- Associate Professor John Silke
- Dr Brad Sleebs
- Professor Terry Speed
- Associate Professor David Tarlinton
- Dr Chris Tonkin
- Ms Jenni Harris (Minutes)

#### Engagement Committee
- Ms Penny Fannin, co-Chair
- Professor David Vaux, co-Chair
- Dr Keely Bumsted-O’Brien
- Miss Lee Byrne
- Ms Gillian Carter
- Mr Jason Corbin
- Dr Leigh Coutsas
- Professor Alan Cowman
- Dr Marlyse Debrincat
- Dr James Dromey
- Dr Krystal Evans
- Ms Angela Georgiou
- Mrs Maureen Grant
- Mr Colin Hockings
- Dr Kurt Lackovic
- Dr Erinna Lee
- Ms Jo Marshall
- Dr Ashely Ng
- Ms Milakra Robati
- Dr Christine White
- Ms Alice Robinson (Minutes)

#### Gender Equity Committee
- Associate Professor Lynn Corcoran, co-Chair
- Professor Terry Speed, co-Chair
- Dr Marie-Liesa Asselin-Labat
- Dr Alyssa Barry
- Professor Sharon Bell
- Keely Bumsted-O’Brien
- Dr Chris Burns
- Dr Kim Jacobson
- Dr Ben Kile
- Carmela Monger
- Associate Professor Clare Scott
- Ms Rita Tiziani
- Ms Hannah Vanayi
- Ms Kelly Rodger (Minutes)
Health, Safety and Environment Committee
Mr Paul Fraser, Chair
Ms Tracey Baldwin
Ms Wendy Carter
Mr Steve Droste
Ms Jessica Janssen
Dr Guillaume Lessene
Dr Kym Lowes
Mr Greg Menzies
Ms Andrea Morcom
Ms Maureen O’Keefe
Mr Denis Quilici
Ms Lucille Rankin
Mr Michael Rubira
Mr Keith Satterley
Ms Rita Tiziani
Ms Ellen Tsui
Mr Tony Hendy (Minutes)

IT Standing Committee
Professor Peter Colman, co-Chair
Dr John Wastell, co-Chair
Ms Lee Byrne
Dr Hendrik Falk
Professor Phil Hodgkin
Professor David Huang
Professor Liam O’Connor
Ms Maureen O’Keefe
Dr Tony Papentjuss
Dr Kelly Rogers
Ms Jie Zhou
Ms Helen Barry (Minutes)

Mouse Management Committee
Associate Professor Andrew Lew, Chair
Professor Warren Alexander
Dr Ben Croker
Mr Paul Fraser
Dr Diana Hansen
Dr Axel Kailies
Dr Kylie Mason
Ms Angela Milligan
Dr Sandra Nicholson
Dr Catheryn O’Brien
Professor Andreas Strasser
Associate Professor David Tarlinton
Professor Jane Visvader
Dr Anne Voss
Mrs Gavina Bailey (Minutes)

Senior Technology Planning Group
Professor Nick Nicola AO, Chair
Professor Warren Alexander
Dr Jake Baum
Professor Peter Colman
Dr Leigh Coultas
Professor David Huang
Dr Ben Kile
Professor Liam O’Connor
Ms Maureen O’Keefe
Professor Andrew Roberts
Associate Professor David Tarlinton
Ms Jane Turner (from 03/12)
Professor Jane Visvader
Dr Sabine Kelly (Minutes)

Scientific Services
Professor Warren Alexander, co-Chair
Ms Maureen O’Keefe, co-Chair
Dr Gabrielle Belz
Professor David Huang
Mr Michael Rubira
Dr Chris Tonkin
Mr Malcolm Williamson
Dr Sabine Kelly (Minutes)

Marketing Committee
Dr Marthe D’Ombrain, Chair (Minutes)
Dr Julian Clark
Dr James Dromey
Ms Penny Fannin
Dr Stephanie Grabow
Professor Doug Hilton
Dr Kurt Lackovic
Ms Maureen O’Keefe
Ms Liz Williams
The year at a glance

Income

- Philanthropic grants, fellowships, donations and bequests – Australian: 10%
- Philanthropic grants and fellowships – overseas: 3%
- Victorian Government: 8%
- Australian Government: 61%
- Other income: 5%
- Income: 72,881
- Income for research (excluding investment income): 70,748
- Donation and bequest investment income: 11,280
- Donation and bequest investment income ($000): 11,486
- Expenditure: 89,109
- Expenditure on research: 79,124
- Net surplus (deficit) from research: (4,948)
- Number of staff and visiting scientists: 608
- Number of postgraduate students: 137
- Total staff and students (EFTs): 745

Expenditure

- Administration: 6%
- Business development: 2%
- Building operation: 7%
- Support laboratories: 23%
- Scientific laboratories: 62%
Statement of comprehensive income for the year ended 30 June 2012

<table>
<thead>
<tr>
<th>Revenue for research activities</th>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Government revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Health and Medical Research Council</td>
<td>4(a)</td>
<td>43,528</td>
<td>39,595</td>
</tr>
<tr>
<td>Cooperative Research Centres</td>
<td>4(b)</td>
<td>2,199</td>
<td>2,185</td>
</tr>
<tr>
<td>Other federal government grants</td>
<td>4(c)</td>
<td>1,706</td>
<td>2,615</td>
</tr>
<tr>
<td>Other federal government fellowships</td>
<td>4(d)</td>
<td>2,529</td>
<td>1,578</td>
</tr>
<tr>
<td>Victorian Government grants</td>
<td>4(e)</td>
<td>7,074</td>
<td>6,842</td>
</tr>
<tr>
<td>Foreign government grants and fellowships</td>
<td>4(f)</td>
<td>359</td>
<td>557</td>
</tr>
<tr>
<td><strong>Total government revenue</strong></td>
<td></td>
<td>57,395</td>
<td>53,372</td>
</tr>
<tr>
<td><strong>Other grant revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Industrial grants and contracts</td>
<td>4(g)</td>
<td>1,114</td>
<td>1,846</td>
</tr>
<tr>
<td>Philanthropic grants and fellowships – Australia</td>
<td>4(h)</td>
<td>5,285</td>
<td>3,830</td>
</tr>
<tr>
<td>Philanthropic grants and fellowships – International</td>
<td>4(i)</td>
<td>2,180</td>
<td>3,235</td>
</tr>
<tr>
<td><strong>Total other grant revenue</strong></td>
<td></td>
<td>8,579</td>
<td>8,911</td>
</tr>
<tr>
<td><strong>Other revenue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>4(j)</td>
<td>11,280</td>
<td>16,236</td>
</tr>
<tr>
<td>Royalty income</td>
<td></td>
<td>810</td>
<td>2,513</td>
</tr>
<tr>
<td>General income</td>
<td></td>
<td>3,054</td>
<td>2,647</td>
</tr>
<tr>
<td>Donations and bequests</td>
<td></td>
<td>3,043</td>
<td>3,305</td>
</tr>
<tr>
<td><strong>Total other revenue</strong></td>
<td></td>
<td>18,187</td>
<td>24,701</td>
</tr>
<tr>
<td><strong>Total revenues for research activities</strong></td>
<td></td>
<td>84,161</td>
<td>86,984</td>
</tr>
</tbody>
</table>

The financial statements are to be read in conjunction with the notes to, and forming part of, the financial statements.
<table>
<thead>
<tr>
<th>Expenditure on research activities</th>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scientific laboratories</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td></td>
<td>41,421</td>
<td>36,793</td>
</tr>
<tr>
<td>Apparatus and equipment</td>
<td></td>
<td>2,044</td>
<td>2,000</td>
</tr>
<tr>
<td>Consumable supplies</td>
<td></td>
<td>9,664</td>
<td>8,671</td>
</tr>
<tr>
<td>Other expenses</td>
<td></td>
<td>2,223</td>
<td>2,539</td>
</tr>
<tr>
<td><strong>Total scientific laboratories</strong></td>
<td></td>
<td>55,352</td>
<td>50,003</td>
</tr>
<tr>
<td><strong>Support laboratories</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td></td>
<td>13,287</td>
<td>11,988</td>
</tr>
<tr>
<td>Apparatus and equipment</td>
<td></td>
<td>2,075</td>
<td>862</td>
</tr>
<tr>
<td>Consumable supplies</td>
<td></td>
<td>2,477</td>
<td>2,556</td>
</tr>
<tr>
<td>Other expenses</td>
<td></td>
<td>2,088</td>
<td>1,658</td>
</tr>
<tr>
<td><strong>Total support laboratories</strong></td>
<td></td>
<td>19,927</td>
<td>17,064</td>
</tr>
<tr>
<td><strong>Building operation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td></td>
<td>1,434</td>
<td>1,328</td>
</tr>
<tr>
<td>Operating costs and repairs</td>
<td></td>
<td>4,877</td>
<td>4,353</td>
</tr>
<tr>
<td><strong>Total building operation</strong></td>
<td></td>
<td>6,311</td>
<td>5,681</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td></td>
<td>4,540</td>
<td>3,890</td>
</tr>
<tr>
<td>Equipment</td>
<td></td>
<td>75</td>
<td>73</td>
</tr>
<tr>
<td>Fundraising and marketing expenditure</td>
<td></td>
<td>192</td>
<td>139</td>
</tr>
<tr>
<td>Other expenses</td>
<td></td>
<td>936</td>
<td>790</td>
</tr>
<tr>
<td><strong>Total administration</strong></td>
<td></td>
<td>5,743</td>
<td>4,892</td>
</tr>
<tr>
<td><strong>Business development</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td></td>
<td>877</td>
<td>800</td>
</tr>
<tr>
<td>Patents</td>
<td></td>
<td>572</td>
<td>360</td>
</tr>
<tr>
<td>Other expenses</td>
<td></td>
<td>327</td>
<td>324</td>
</tr>
<tr>
<td><strong>Total business development</strong></td>
<td></td>
<td>1,776</td>
<td>1,484</td>
</tr>
<tr>
<td><strong>Total expenditure on research activities</strong></td>
<td></td>
<td>89,109</td>
<td>79,124</td>
</tr>
<tr>
<td><strong>Surplus (deficit) from research activities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other income</td>
<td>2</td>
<td>25,369</td>
<td>3,098</td>
</tr>
<tr>
<td>Impairment write-down of available-for-sale assets</td>
<td>12(f)</td>
<td>(2,333)</td>
<td>(2,945)</td>
</tr>
<tr>
<td>Write back of prior years’ implementation costs</td>
<td></td>
<td>744</td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>21</td>
<td>(5,681)</td>
<td>(6,375)</td>
</tr>
<tr>
<td><strong>Net surplus before capitalised bequests and grants for capital works</strong></td>
<td></td>
<td>12,407</td>
<td>2,382</td>
</tr>
<tr>
<td>Capitalised bequests and grants for capital works</td>
<td>3</td>
<td>16,757</td>
<td>52,765</td>
</tr>
<tr>
<td><strong>Net surplus for the year</strong></td>
<td>12(a)</td>
<td>29,164</td>
<td>55,147</td>
</tr>
<tr>
<td><strong>Other comprehensive income</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain/(loss) on available-for-sale investments taken to equity</td>
<td>12(f)</td>
<td>(10,905)</td>
<td>4,850</td>
</tr>
<tr>
<td>Transfers to (gain) or loss on sale of financial assets</td>
<td>12(f)</td>
<td>(1,154)</td>
<td>(6,944)</td>
</tr>
<tr>
<td>Transfer impairment write-down of available-for-sale financial assets</td>
<td>12(f)</td>
<td>2,333</td>
<td>2,945</td>
</tr>
<tr>
<td><strong>Total comprehensive income for the year</strong></td>
<td></td>
<td>19,438</td>
<td>55,998</td>
</tr>
</tbody>
</table>

The financial statements are to be read in conjunction with the notes to, and forming part of, the financial statements.
Statement of financial position as at 30 June 2012

<table>
<thead>
<tr>
<th>Assets</th>
<th>Note</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td>$'000</td>
<td>$'000</td>
</tr>
<tr>
<td>Cash</td>
<td>17(a)</td>
<td>14,994</td>
<td>23,876</td>
</tr>
<tr>
<td>Current tax assets</td>
<td>7(a)</td>
<td>2,117</td>
<td>3,580</td>
</tr>
<tr>
<td>Receivables</td>
<td>7(b)</td>
<td>11,804</td>
<td>11,554</td>
</tr>
<tr>
<td>Other financial assets</td>
<td>7(c)</td>
<td>17,000</td>
<td>26,000</td>
</tr>
<tr>
<td>Prepaid operating lease</td>
<td>11</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td></td>
<td>45,947</td>
<td>65,042</td>
</tr>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other financial assets</td>
<td>8</td>
<td>157,716</td>
<td>155,122</td>
</tr>
<tr>
<td>Property, plant and equipment – at deemed cost</td>
<td>21</td>
<td>193,398</td>
<td>155,675</td>
</tr>
<tr>
<td>Prepaid operating lease</td>
<td>11</td>
<td>2,752</td>
<td>2,784</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td></td>
<td>353,866</td>
<td>313,581</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td></td>
<td>399,813</td>
<td>378,623</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade payables</td>
<td></td>
<td>6,322</td>
<td>7,591</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>9</td>
<td>8,222</td>
<td>7,756</td>
</tr>
<tr>
<td>Unearned grants and fellowships</td>
<td>10</td>
<td>13,164</td>
<td>11,798</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td></td>
<td>27,708</td>
<td>27,145</td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employee benefits</td>
<td>9</td>
<td>7,676</td>
<td>6,487</td>
</tr>
<tr>
<td><strong>Total non-current liabilities</strong></td>
<td></td>
<td>7,676</td>
<td>6,487</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td></td>
<td>35,384</td>
<td>33,632</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td></td>
<td>364,429</td>
<td>344,991</td>
</tr>
<tr>
<td><strong>Funds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanent invested funds</td>
<td>12(b)</td>
<td>139,073</td>
<td>134,457</td>
</tr>
<tr>
<td>General funds</td>
<td>12(c)</td>
<td>162,909</td>
<td>138,752</td>
</tr>
<tr>
<td>Royalty fund</td>
<td>12(d)</td>
<td>17,079</td>
<td>16,788</td>
</tr>
<tr>
<td>Leadership fund</td>
<td>12(e)</td>
<td>16,282</td>
<td>16,182</td>
</tr>
<tr>
<td>Investment revaluation reserve</td>
<td>12(f)</td>
<td>29,086</td>
<td>38,812</td>
</tr>
<tr>
<td><strong>Total funds</strong></td>
<td></td>
<td>364,429</td>
<td>344,991</td>
</tr>
</tbody>
</table>

The financial statements are to be read in conjunction with the notes to, and forming part of, the financial statements.
## Statement of cash flows for the year ended 30 June 2012

<table>
<thead>
<tr>
<th>Notes</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations and bequests</td>
<td>3,043</td>
<td>3,305</td>
</tr>
<tr>
<td>General income</td>
<td>3,054</td>
<td>2,646</td>
</tr>
<tr>
<td>Receipts from granting bodies</td>
<td>65,605</td>
<td>60,012</td>
</tr>
<tr>
<td>Payments to suppliers and employees</td>
<td>(88,562)</td>
<td>(84,353)</td>
</tr>
<tr>
<td>Royalty receipts</td>
<td>810</td>
<td>2,513</td>
</tr>
<tr>
<td>Dividends received</td>
<td>7,363</td>
<td>8,695</td>
</tr>
<tr>
<td>Interest and bill discounts received</td>
<td>5,460</td>
<td>6,205</td>
</tr>
<tr>
<td><strong>Net cash provided by/(used in) operating activities</strong></td>
<td>(3,228)</td>
<td>(977)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payment for other financial assets</td>
<td>(26,522)</td>
<td>(16,150)</td>
</tr>
<tr>
<td>Proceeds on sale of other financial assets</td>
<td>14,252</td>
<td>32,319</td>
</tr>
<tr>
<td>Sale(Purchase) of bills of exchange</td>
<td>9,000</td>
<td>11,853</td>
</tr>
<tr>
<td>Grants and Donations for Property, Plant and Equipment</td>
<td>25,006</td>
<td>37,719</td>
</tr>
<tr>
<td>Payment for property, plant and equipment</td>
<td>(30,753)</td>
<td>(53,523)</td>
</tr>
<tr>
<td><strong>Net cash provided by/(used in) investing activities</strong></td>
<td>(9,017)</td>
<td>12,218</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from financing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations and bequests to permanent invested funds</td>
<td>3,363</td>
<td>1,566</td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>3,363</td>
<td>1,566</td>
</tr>
<tr>
<td><strong>Net (decrease) increase in cash held</strong></td>
<td>(8,862)</td>
<td>12,807</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents at the beginning of the financial year</td>
<td>23,876</td>
<td>11,069</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at the end of the financial year</strong></td>
<td>14,994</td>
<td>23,876</td>
</tr>
</tbody>
</table>

The financial statements are to be read in conjunction with the notes to and forming part of the financial statements.
Statement of changes in equity

<table>
<thead>
<tr>
<th></th>
<th>Permanent funds</th>
<th>General funds</th>
<th>Royalty funds</th>
<th>Leadership funds</th>
<th>Investment revaluation reserve</th>
<th>Total funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at 1 July 2011</td>
<td>129,802</td>
<td>90,534</td>
<td>14,823</td>
<td>15,873</td>
<td>37,961</td>
<td>288,993</td>
</tr>
<tr>
<td>Surplus for the year</td>
<td>4,655</td>
<td>48,218</td>
<td>1,965</td>
<td>309</td>
<td></td>
<td>55,147</td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>851</td>
<td>851</td>
</tr>
<tr>
<td>Total comprehensive income for the year</td>
<td>4,655</td>
<td>48,218</td>
<td>1,965</td>
<td>309</td>
<td>851</td>
<td>55,998</td>
</tr>
<tr>
<td>Balance at 30 June 2011</td>
<td>134,457</td>
<td>138,752</td>
<td>16,788</td>
<td>16,182</td>
<td>38,812</td>
<td>344,991</td>
</tr>
<tr>
<td>Surplus for the year</td>
<td>4,616</td>
<td>24,157</td>
<td>291</td>
<td>100</td>
<td>-</td>
<td>29,164</td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(9,726)</td>
<td>(9,726)</td>
</tr>
<tr>
<td>Total comprehensive income for the year</td>
<td>4,616</td>
<td>24,157</td>
<td>291</td>
<td>100</td>
<td>(9,726)</td>
<td>19,438</td>
</tr>
<tr>
<td>Balance at 30 June 2012</td>
<td>139,073</td>
<td>162,909</td>
<td>17,079</td>
<td>16,282</td>
<td>29,086</td>
<td>364,429</td>
</tr>
</tbody>
</table>

The financial statements are to be read in conjunction with the notes to and forming part of the financial statements.
Notes to the annual accounts 2011-2012

1. Statement of significant accounting policies

The Walter and Eliza Hall Institute of Medical Research (‘the institute’) is incorporated in Victoria as a company limited by guarantee. The institute has 170 members and the guarantee is limited to two dollars per member. The financial report is a general purpose financial report prepared in accordance with the Corporations Act 2001, Accounting Standards and complies with other requirements of the law. Accounting Standards include Australian equivalents to International Financial Reporting Standards (A-IFRS). The institute is exempt from taxation. The institute is a not-for-profit entity.

The financial statements were authorised for issue by the directors on 13 September 2012.

The financial report has been prepared on the basis of historical cost except for the revaluation of certain non-current assets and financial instruments. Cost is based on the fair values of the consideration given in exchange for assets.

The institute is a company of the kind referred to in ASIC Class Order 98/0100, dated 10 July 1998, and in accordance with that Class Order amounts in the financial report are rounded off the nearest thousand dollars, unless otherwise indicated.

Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.

The following significant accounting policies have been adopted in the preparation and presentation of the financial report:

(a) Property, plant and equipment

Property, plant and equipment held for use in research, or for administrative purposes, are stated in the statement of financial position at cost, less any subsequent accumulated depreciation.

Depreciation is provided on property, plant and equipment including freehold buildings. Depreciation is calculated on a straight-line basis so as to write off the net cost of each asset over its expected useful life. Leasehold improvements are depreciated over the period of the lease or the estimated useful life, whichever is shorter, using the straight-line method.

A regular review of useful lives, depreciation rates and residual values is conducted at each year end, with the effect of any changes in estimate accounted for on a prospective basis.

The following estimated useful lives are used in the calculation of depreciation: buildings (20 to 40 years); plant and equipment (5 to 20 years); and furniture and fittings (5 to 15 years).

Land leased at Parkville is recognised as part of Property, Plant and Equipment at fair value. Subsequent measurement will be under the cost method, whereby the asset will not be revalued.

(b) Acquisition of assets

Assets acquired are recorded at the cost of acquisition, being the purchase consideration determined as at the date of acquisition plus costs incidental to the acquisition. Items of property, plant and equipment are recorded at cost less accumulated depreciation, with the exception of land which is not depreciated.

(c) Source of capital funds

(i) The institute is a company limited by guarantee and as such has no issued capital. General Funds consist of the net accumulation of surpluses and deficits of prior years.

(ii) Permanent Invested Funds originate from gifts and bequests, the income from which is applied as stipulated by the donor, or to general research where there is no specific stipulation. These gifts and bequests are appropriated to Funds in the statement of financial position.

(iii) The Royalty Fund consists of the balance of royalties received in respect of patented inventions and not expended.

(iv) The Leadership Fund consists of donations and income earned thereon. The Leadership Fund was established in honour of Professors Gustav Nossal, Donald Metcalf and Jacques Miller to provide named fellowships to nurture the development of outstanding young scientists with the potential to be future leaders of biomedical research.

(v) The Investment Revaluation Reserve consists of gains and losses recognised through movement in the fair value of Investments and other financial assets.

(d) Income recognition

Grants

Revenue from grants is recognised when the company is entitled to receive the grant. However, reciprocal grants received or receivable for specific projects during the year but unspent at the end of the financial year, are carried forward to the next financial year.

Sale of goods and disposal of assets

Revenue from the sale of goods and disposal of assets is recognised when goods are delivered and legal title has passed.

Rendering of services

Revenue from a contract to provide services is recognised by reference to the stage of completion of the contract.

Royalties

Royalty income is recognised when received.

Contributions of assets

Revenue arising from the contribution of assets is recognised when the company gains control of the contribution.

Donations and Bequests

Donation and bequest income is disclosed as part of revenue for research activities, except for, where stipulated by the donor or bequestor, certain amounts are treated as capitalised donations and bequests and appropriated to Permanent Funds.
(e) Investments and other financial assets

All investments are initially recognised at fair value plus transaction costs. After initial recognition, investments are measured at fair value. Gains or losses on investments held are recognised in the Investment Revaluation Reserve. For assets that are actively traded in organised financial markets, fair value is determined by reference to the Stock Exchange quoted market bid prices at the close of business on balance date.

(i) Available-for-sale financial assets

Shares and other investments held by the company are classified as being available-for-sale and are stated at fair value. Fair value is determined in the manner described in note 20. Gains and losses arising from changes in fair value are recognised directly in the investment revaluation reserve with the exception of impairment losses which are recognised directly in profit or loss. Where the investment is disposed of or is determined to be impaired, the cumulative gain or loss previously recognised in investments revaluation reserve is included in profit or loss for the period.

(ii) Impairment of financial assets

Financial assets, other than those at fair value through profit or loss, are assessed for indicators of impairment at each balance sheet date. Financial assets are impaired where there is objective evidence that as a result of one or more events that occurred after initial recognition of the financial asset the estimated future cash flows of the investment have been impacted. Financial assets held below cost, by 20% or more, or for greater than 12 months are considered impaired and adjusted through profit and loss.

(iii) Bills of exchange are recorded at amortised cost, with revenue recognised on an accruals basis.

(iv) Dividend revenue is recognised on a receivable basis. Interest revenue is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.

(f) Cash and cash equivalents

Cash comprises cash on hand and demand deposits. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash, which are subject to an insignificant risk of changes in value and have a maturity of six months or less at the date of acquisition.

(g) Accounts payable

Trade payables and other accounts payable are recognised when the company becomes obliged to make future payments resulting from the purchase of goods and services.

(h) Research costs

Research costs are recognised as an expense when incurred, except to the extent that such costs, together with unamortised deferred costs in relation to that project, are expected, beyond any reasonable doubt, to be recoverable.

Grants received or receivable in relation to research costs, which are recognised as an expense during the current or previous periods, are recognised as revenue in net surplus or deficit.

(i) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST except:

(i) where the amount of GST incurred is not recoverable from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense; or

(ii) for receivables and payables which are recognised inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables. Cash flows are included in the statement of cash flows on a gross basis. The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

(j) Employee benefits

Provision is made for benefits accruing to employees in respect of annual leave and long service leave, when it is probable that settlement will be required and they are capable of being measured reliably.

Provisions made in respect to annual leave and long service leave expected to be settled within 12 months, are measured at their nominal values, using the remuneration rate expected to apply at the time of settlement.

Provisions made in respect to long service leave which are not expected to be settled within 12 months are measured as the present value of the estimated future cash outflows to be made by the company in respect of services provided by employees up to the reporting date.

(k) Foreign currency

All foreign currency transactions during the financial year are brought to account using the exchange rate in effect at the date of the transaction. Foreign currency monetary items at reporting date are translated at the exchange rate existing at that date. Exchange differences are recognised in the net surplus or deficit in the period in which they arise, except that exchange differences which relate to assets under construction for future productive use are included in the cost of those assets.

(l) Leased assets

Operating lease payments are recognised as an expense on a straight-line basis which reflects the pattern in which economic benefits from the leased asset are consumed.

(m) Impairment of non-financial assets

All non-financial assets are assessed annually for indications of impairment. If there is an indication of impairment, the assets concerned are tested as to whether their carrying value exceeds their possible recoverable amount. Where an asset’s carrying value exceeds its recoverable amount, the difference is written-off as an expense. The recoverable amount for most assets is measured at the higher of value in use and fair value less costs to sell. Depreciated replacement cost is used to determine value in use. Depreciated replacement cost is the current replacement cost of an item of plant and equipment less, where applicable, accumulated depreciation to date, calculated on the basis of such cost.
(n) Critical accounting judgements and key sources of estimation uncertainty
In the application of the institute’s accounting policies, which are described above, management may from time to time make judgements, estimates and assumptions about carrying values of assets and liabilities that may not be readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the result of which form the basis of making the judgement.

(o) Impact of revised standards
In the current year, the institute has adopted all of the new and revised standards and interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective for the current annual reporting period.
- AASB 2010-4 ‘Further Amendments to Australian Accounting Standards arising from the Annual Improvements Project’
- AASB 2010-5 ‘Amendments to Australian Accounting Standards’
- AASB 1054 ‘Australian Additional Disclosures’
- AASB 124 ‘Related Part Disclosures’

(p) Standards and interpretations issued not yet effective
At the date of authorisation of the financial report, the standards and interpretations that are relevant to the institute, listed below, were on issue but not yet effective.
Initial application of the following standard will not affect any of the amounts recognised in the financial report, but will change the disclosures presently made in relation to the company’s financial report:

<table>
<thead>
<tr>
<th>Standard</th>
<th>Effective for annual reporting periods beginning on or after</th>
<th>Expected to be initially applied in the financial year ending</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASB 9 Financial Instruments, AASB 2009-11 Amendments to Australian Accounting Standards arising from AASB 9</td>
<td>1-Jan-13</td>
<td>30-Jun-14</td>
</tr>
<tr>
<td>AASB 13 Fair Value Measurement</td>
<td>1-Jan-13</td>
<td>30-Jun-14</td>
</tr>
<tr>
<td>AASB 119 Employee Benefits</td>
<td>1-Jan-13</td>
<td>30-Jun-14</td>
</tr>
<tr>
<td>AASB 2011-9 Presentation of items of Other Comprehensive Income</td>
<td>1-Jul-12</td>
<td>30-Jun-13</td>
</tr>
<tr>
<td>AASB 2012-5 Amendments to Australian Accounting Standards arising from Annual Improvements 2009-2011 Cycle</td>
<td>1-Jan-13</td>
<td>30-Jun-14</td>
</tr>
</tbody>
</table>

(q) Comparative amounts
Certain comparatives have been reclassified where appropriate.
4. Income analysis

The following has been prepared in support of the items of income shown in the statement of comprehensive income. The institute ensures all grants are expended as stipulated.

(a) Australian Government grants

Department of Health and Ageing
National Health and Medical Research Council

– Research grants 26,718 25,065
– Research fellowships 7,177 5,881
– Infrastructure grant 7,283 6,518
– Postdoctoral fellowships and scholarships 2,350 2,131

Total as per statement of comprehensive income 43,528 39,595

(b) Cooperative Research Centres

CRC for Cancer Therapeutics 1,593 1,440
HEARing CRC 606 745

Total as per statement of comprehensive income 2,199 2,185

(c) Other Australian Government grants

Australia and New Zealand Breast Cancer Trials Group - 11
Australian Phenomics Network 796 1,180
Australian Research Council 412 293
Australian Stem Cell Centre 23 941
Cancer Australia - 140
CSIRO 450 -
Department of Innovation, Industry, Science and Research - 50
OzEMalaR 25 -

Total as per statement of comprehensive income 1,706 2,615

(d) Other Australian Government fellowships

Australian Research Council 2,529 1,578

Total as per statement of comprehensive income 2,529 1,578

(e) Victorian Government grants

Department of Business and Innovation

– Operational Infrastructure Support program 5,340 5,666
Victorian Breast Cancer Research Consortium 875 659
Victorian Cancer Agency 637 380
Victorian Comprehensive Cancer Centre 6 -
Victorian Endowment for Science, Knowledge and Innovation fellowship 111 62
Victorian Life Sciences Computation Initiative 17 -
Victorian Neurotrauma Initiative 88 75

Total as per statement of comprehensive income 7,074 6,842

(f) Foreign government grants and fellowships

Canadian Institutes of Health Research postdoctoral fellowship 41 -
National Cancer Institute, US 112 319
National Institutes of Health, US 210 181
Swiss National Science Foundation fellowship, Switzerland (3) 57 -

Total as per statement of comprehensive income 359 557
Financial statements

(g) Industrial grants and contracts

<table>
<thead>
<tr>
<th>Organization</th>
<th>2012 $'000</th>
<th>2011 $'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ancora Pharmaceuticals</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>BACE Therapeutics</td>
<td>-</td>
<td>11</td>
</tr>
<tr>
<td>Bayhill Therapeutics</td>
<td>15</td>
<td>36</td>
</tr>
<tr>
<td>Bionomics Ltd</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>CSL Ltd</td>
<td>973</td>
<td>1,068</td>
</tr>
<tr>
<td>Drugs for Neglected Diseases Initiative</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>28</td>
<td>-</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme</td>
<td>35</td>
<td>12</td>
</tr>
<tr>
<td>NexPep Pty Ltd</td>
<td>-</td>
<td>100</td>
</tr>
<tr>
<td>Pfizer Global Pharmaceuticals</td>
<td>-</td>
<td>154</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>54</td>
<td>445</td>
</tr>
</tbody>
</table>

Total as per statement of comprehensive income

1,114 $'000 1,846 $'000

(h) Philanthropic grants and fellowships – Australia

Brought forward from previous year

1,667 $'000 1,614 $'000

Received and owing (net)

<table>
<thead>
<tr>
<th>Organization</th>
<th>2012 $'000</th>
<th>2011 $'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anonymous grant</td>
<td>25</td>
<td>-</td>
</tr>
<tr>
<td>Hazel &amp; Pip Appel Fund</td>
<td>80</td>
<td>81</td>
</tr>
<tr>
<td>Arthritis Foundation of Australia</td>
<td>45</td>
<td>43</td>
</tr>
<tr>
<td>Arthritis Foundation of Australia Allan and Beryl Stephens Fund</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Australian Academy of Science (Ron Rickards Fellowship)</td>
<td>- 12</td>
<td></td>
</tr>
<tr>
<td>Australian Friends of the Hebrew University, Jerusalem Limited</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Australian Kidney Foundation</td>
<td>17</td>
<td>-</td>
</tr>
<tr>
<td>Cancer Council Victoria</td>
<td>513</td>
<td>324</td>
</tr>
<tr>
<td>Centenary Institute</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Coeliac Australia Project</td>
<td>110</td>
<td>-</td>
</tr>
<tr>
<td>Cure Cancer Australia</td>
<td>133</td>
<td>90</td>
</tr>
<tr>
<td>Diabetes Australia Research Trust</td>
<td>88</td>
<td>30</td>
</tr>
<tr>
<td>Diabetes Vaccine Development Centre</td>
<td>56</td>
<td>101</td>
</tr>
<tr>
<td>Thomas William Francis and Violet Coles Trust</td>
<td>13</td>
<td>26</td>
</tr>
<tr>
<td>Dr Eric Guiler Tasmanian Devil Research Grant</td>
<td>27</td>
<td>-</td>
</tr>
<tr>
<td>H &amp; L Hecht Trust</td>
<td>59</td>
<td>-</td>
</tr>
<tr>
<td>Leukaemia Foundation of Australia</td>
<td>619</td>
<td>529</td>
</tr>
<tr>
<td>Leukaemia Foundation of Queensland</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Lions Sponsored Cancer Research Fund</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Ludwig Institute for Cancer Research</td>
<td>1,154</td>
<td>-</td>
</tr>
<tr>
<td>R. G. Menzies Fellowship</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Harold Mitchell Foundation Fellowship</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>National Breast Cancer Foundation</td>
<td>257</td>
<td>227</td>
</tr>
<tr>
<td>National Heart Foundation Fellowship</td>
<td>174</td>
<td>109</td>
</tr>
<tr>
<td>Ophthalmic Research Institute of Australia Research Grant</td>
<td>50</td>
<td>-</td>
</tr>
<tr>
<td>Prostate Cancer Foundation of Australia</td>
<td>31</td>
<td>31</td>
</tr>
<tr>
<td>Ramaciotti Award</td>
<td>32</td>
<td>-</td>
</tr>
<tr>
<td>The Angior Family Foundation</td>
<td>22</td>
<td>-</td>
</tr>
<tr>
<td>The Jack Brockhoff Foundation</td>
<td>-</td>
<td>25</td>
</tr>
<tr>
<td>The William Buckland Foundation</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>The CASS Foundation</td>
<td>32</td>
<td>105</td>
</tr>
<tr>
<td>The Rebecca L. Cooper Medical Research Foundation</td>
<td>61</td>
<td>11</td>
</tr>
<tr>
<td>The Dyson Fellowship</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
The Scobie & Claire MacKinnon Trust  25  -  
The Royal Australasian College of Physicians Fellowship  15  -  
The Royal College of Pathologists of Australasia  10  -  
The Royal Melbourne Hospital - Department of Diabetes and Endocrinology  10  -  
The Royal Melbourne Hospital Home Lottery Grant  -  10  
The Harry Secombe Foundation  100  -  
The Trust Company (The Woodend Foundation)  50  -  
The Sylvia and Charles Viertel Charitable Foundation  820  536  
Thomas Family Fund (Melbourne Community Foundation)  -  10  
Fellowships and scholarships internal  1,540  1,364  
Institutional allowances and miscellaneous adjustments  57  (26)  

<table>
<thead>
<tr>
<th></th>
<th>2012 $’000</th>
<th>2011 $’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>5,285</td>
<td>3,830</td>
</tr>
<tr>
<td>Less: carried forward to next financial year</td>
<td>(2,801)</td>
<td>(1,667)</td>
</tr>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>2,180</td>
<td>3,235</td>
</tr>
</tbody>
</table>

(i) Philanthropic grants and fellowships – international

Brought forward from previous year  391  1,061  
American Australian Association (Keith Murdoch Fellowship)  6  10  
Association for International Cancer Research  80  87  
CONRAD, US  -  70  
Human Frontier Science Program Organisation, France  250  -  
Japan College of Rheumatology  4  -  
Juvenile Diabetes Research Foundation, US  194  467  
Kay Kendall Leukaemia Fund Fellowship, UK  34  -  
Susan G. Komen for the Cure, US  -  18  
Multiple Myeloma Research Foundation, US  131  36  
PATH Malaria Vaccine Initiative, US  485  286  
Papua New Guinea Institute of Medical Research, PNG  265  -  
The Bill & Melinda Gates Foundation, US  1,223  417  
The Leukemia & Lymphoma Society of America, US  -  1,032  
The Publishing Group, US  43  -  
The Lady Tata Memorial Trust, UK  9  41  
The University of Alabama at Birmingham, US  69  -  
The Wellcome Trust, UK  95  53  
Institutional allowances and miscellaneous adjustments  (2)  48  

<table>
<thead>
<tr>
<th></th>
<th>2012 $’000</th>
<th>2011 $’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>3,277</td>
<td>3,626</td>
</tr>
<tr>
<td>Less carried forward to next financial year</td>
<td>(1,097)</td>
<td>(391)</td>
</tr>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>2,180</td>
<td>3,235</td>
</tr>
</tbody>
</table>

(j) Investment income from investments received during the year, prior to adjustments for amounts carried forward:

Recognised in surplus or deficit  
Dividends and distributions income on available-for-sale financial assets  7,510  12,405  
Interest income on available-for-sale financial assets  5,460  5,367  
Amortisation of investment premiums  (150)  (172)  

<table>
<thead>
<tr>
<th></th>
<th>2012 $’000</th>
<th>2011 $’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>12,820</td>
<td>17,600</td>
</tr>
<tr>
<td>Less transfer to grants and fellowships</td>
<td>(1,540)</td>
<td>(1,364)</td>
</tr>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>11,280</td>
<td>16,236</td>
</tr>
</tbody>
</table>

Interest income from financial assets held at amortised cost attributable to Building funds  

<table>
<thead>
<tr>
<th></th>
<th>2012 $’000</th>
<th>2011 $’000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total as per statement of comprehensive income</td>
<td>11,710</td>
<td>136</td>
</tr>
</tbody>
</table>
(k) Fellowships and scholarships

Investment income was received during the year for specific fellowships and scholarships. The following fellowships and scholarships, include those supported by Permanent Invested Funds. This income is brought to account in the year of receipt and is shown below net of sums unexpended and carried forward.

The income concerned was:

From investment income:

- Tim Bates Memorial Diabetes Research Fund 5,000
- E M Carty Fund 14,000
- Gideon Goldstein Lectureship 45,000
- Dr Ian Mackay Fellowship Fund 17,000
- Gordon Clunes Mathison Fund 7,000
- Paddy Pearl Fund 7,000
- John T Reid Charitable Trusts 414,000
- Lyndal & Jean Skea Leukaemia Fund 36,000
- The Alooa of Australia Fellowship 27,000
- The Macfarlane Burnet Award 6,000
- The Leadership Fund 1,003,000
- The Edith Moffatt Scholarship Fund 132,000
- The Colin Syme Fellowship Fund 113,000
- The Edward Wilson Memorial Fellowship 89,000

Total 1,915,000

Less Included in appropriation to permanent funds (375,000)

Total expended during year 1,540,000

5. Operating expenses

The following items of expense are included in the net surplus.

Remuneration of auditors
Auditing the financial report: $56,000 (2011: $56,000)
Other regulatory audit services: $8,990 (2011: $6,006)

Employee entitlement expense
Long service leave 1,682,000
Annual leave 752,000

Depreciation
Depreciation of non-current property, plant and equipment 5,881,000

Operating lease
Operating lease expense 32,000

6. Directors’ remuneration

The directors of the Walter and Eliza Hall Institute of Medical Research during the year were:

LA Davis  J Angus  J McCluskey  CW Thomas
SM Skala  MC Fitzpatrick  LB Nicholls  CM Walter
RE Male  GF Mitchell  CJ Redwood  IM Winship

The aggregate income paid or payable, or otherwise made available, in respect of the financial year, to all directors of the company, directly or indirectly, by the company or by any related party was nil (2011: nil).

Aggregate retirement benefits paid to all directors of the company, by the company or by any related party was nil (2011: nil).
7. Current assets

(a) Current tax assets
Franking credits receivable  1,936  3,580
GST Refundable  181 - 2,117 3,580

(b) Current receivables at amortised cost
Sundry debtors and prepayments*  3,829  2,535
Grants receivable  7,066  8,103
Accrued income  909  916
11,804 11,554
*Terms of payment are 30 days

(c) Other current financial assets at amortised cost
Bills of exchange  17,000  26,000

8. Other non-current financial assets
Non-quoted available-for-sale Investments at fair value
Fixed interest securities  27,882  35,020
Shares  213  264
Quoted available-for-sale investments at fair value
Shares  113,879  113,610
Unit trusts  862  955
Perpetual floating rate securities  14,879  5,273
157,716 155,122

(a) Fair value measurements recognised in the statement of financial position

The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into levels 1 to 3 based on
- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 fair value measurements are those derived from inputs other than those quoted prices included within level 1 that are observable for the asset, either directly (i.e. as prices) or indirectly (i.e. derived from prices)
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset that are not based on observable market data

<table>
<thead>
<tr>
<th></th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>30/06/12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available for sale financial assets</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
</tr>
<tr>
<td>Quoted shares</td>
<td>113,880</td>
<td>-</td>
<td>-</td>
<td>113,880</td>
</tr>
<tr>
<td>Fixed interest securities</td>
<td>-</td>
<td>27,882</td>
<td>-</td>
<td>27,882</td>
</tr>
<tr>
<td>Perpetual floating rate securities</td>
<td>-</td>
<td>14,879</td>
<td>-</td>
<td>14,879</td>
</tr>
<tr>
<td>Unit trusts</td>
<td>-</td>
<td>862</td>
<td>-</td>
<td>862</td>
</tr>
<tr>
<td>Unquoted shares</td>
<td>-</td>
<td>-</td>
<td>213</td>
<td>213</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>113,880</td>
<td>43,623</td>
<td>213</td>
<td>157,716</td>
</tr>
</tbody>
</table>
(b) Reconciliation of level 3 fair value measurements of financial assets

<table>
<thead>
<tr>
<th>Available-for -sale unquoted equities</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening balance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases</td>
<td>264</td>
<td>239</td>
</tr>
<tr>
<td>Transfers out of level 3</td>
<td>(14)</td>
<td>-</td>
</tr>
<tr>
<td>Revaluation</td>
<td>(37)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Closing balance</strong></td>
<td>213</td>
<td>264</td>
</tr>
</tbody>
</table>

9. Employee benefits

The aggregate employee benefit liability recognised and included in the financial statements is as follows:

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>8,222</td>
<td>7,756</td>
</tr>
<tr>
<td>Non-current</td>
<td>7,676</td>
<td>6,487</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>15,898</td>
<td>14,243</td>
</tr>
</tbody>
</table>

Prepaid wages and salaries are included in the current receivables balance.

Number of employees at end of financial year (full time equivalents)

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff</td>
<td>597</td>
<td>569</td>
</tr>
<tr>
<td>Visiting scientists</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>607</td>
<td>585</td>
</tr>
</tbody>
</table>

10. Unearned grants and fellowships

Grants and fellowships already committed and applicable to future periods:

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants</td>
<td>9,742</td>
<td>8,356</td>
</tr>
<tr>
<td>Fellowships</td>
<td>3,422</td>
<td>3,442</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>13,164</td>
<td>11,798</td>
</tr>
</tbody>
</table>

11. Operating leases

Operating leases relate to research facilities with lease terms of between 5 to 99 years, with an option to extend. All operating lease contracts contain market review clauses in the event that the company exercises its option to renew. The company does not have an option to purchase the leased asset at the expiry of the lease period. The operating leases are prepaid.

Non-cancellable operating leases

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not longer than 1 year</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Longer than 1 year and not longer than 5 years</td>
<td>128</td>
<td>128</td>
</tr>
<tr>
<td>Longer than 5 years</td>
<td>2,624</td>
<td>2,656</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>2,784</td>
<td>2,816</td>
</tr>
</tbody>
</table>

12. Capital movements

(a) The net surplus for the financial year is $29,164 (2011 - $55,147)

This has been appropriated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfer to Permanent Invested Funds 12(b)</td>
<td>4,616</td>
<td>4,655</td>
</tr>
<tr>
<td>Transfer to General Funds 12(c)</td>
<td>24,157</td>
<td>48,218</td>
</tr>
<tr>
<td>Transfer to Royalty Fund 12(d)</td>
<td>291</td>
<td>1,965</td>
</tr>
<tr>
<td>Transfer to Leadership Fund 12(e)</td>
<td>100</td>
<td>309</td>
</tr>
<tr>
<td><strong>Total appropriations to funds</strong></td>
<td>29,164</td>
<td>55,147</td>
</tr>
</tbody>
</table>
(b) Permanent Invested Funds

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>134,457</td>
<td>129,802</td>
</tr>
<tr>
<td>Surplus for year transferred from statement of comprehensive income</td>
<td>4,616</td>
<td>4,655</td>
</tr>
<tr>
<td><strong>Total Permanent Invested Funds</strong></td>
<td><strong>139,073</strong></td>
<td><strong>134,457</strong></td>
</tr>
</tbody>
</table>

(c) General Funds

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>138,752</td>
<td>90,534</td>
</tr>
<tr>
<td>Surplus for year transferred from statement of comprehensive income</td>
<td>24,157</td>
<td>48,218</td>
</tr>
<tr>
<td><strong>Total General Funds</strong></td>
<td><strong>162,909</strong></td>
<td><strong>138,752</strong></td>
</tr>
</tbody>
</table>

(d) Royalty Fund

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>16,788</td>
<td>14,823</td>
</tr>
<tr>
<td>Surplus for year transferred from statement of comprehensive income</td>
<td>291</td>
<td>1,965</td>
</tr>
<tr>
<td><strong>Total Royalty Fund</strong></td>
<td><strong>17,079</strong></td>
<td><strong>16,788</strong></td>
</tr>
</tbody>
</table>

(e) Leadership Fund

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>16,182</td>
<td>15,873</td>
</tr>
<tr>
<td>Surplus for year transferred from statement of comprehensive income</td>
<td>100</td>
<td>309</td>
</tr>
<tr>
<td><strong>Total Leadership Fund</strong></td>
<td><strong>16,282</strong></td>
<td><strong>16,182</strong></td>
</tr>
</tbody>
</table>

(f) Investment revaluation reserve

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>38,812</td>
<td>37,961</td>
</tr>
<tr>
<td>Valuation gain/(loss) recognised for the year</td>
<td>(10,905)</td>
<td>4,850</td>
</tr>
<tr>
<td>Transfers to gain or loss on sale of investment</td>
<td>(1,154)</td>
<td>(6,944)</td>
</tr>
<tr>
<td>Transfers due to loss on impairment</td>
<td>2,333</td>
<td>2,945</td>
</tr>
<tr>
<td><strong>Total investment revaluation reserve</strong></td>
<td><strong>29,086</strong></td>
<td><strong>38,812</strong></td>
</tr>
</tbody>
</table>

**Total funds** | **364,429** | **344,991** |

13. Joint projects

At 30 June 2012, the institute was no longer committed to a project with the Ludwig Institute for Cancer Research for the joint operation of the Joint Protein Structure Laboratory. This ceased at 30 June 2011.

Expenditure for the year ended 30 June

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries</td>
<td>-</td>
<td>139</td>
</tr>
<tr>
<td>Equipment</td>
<td>-</td>
<td>232</td>
</tr>
<tr>
<td>Consumables and other</td>
<td>-</td>
<td>81</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>-</td>
<td><strong>452</strong></td>
</tr>
</tbody>
</table>

These amounts are included in provision of scientific services and represent the institute’s half share in this project. Total liability on this project amounted to zero at 30 June 2012 (2011 – $12,346) which is included in Trade Payables. There are no contingent liabilities associated with this project.

14. Economic dependency

The company is reliant upon grants from the Australian Government National Health and Medical Research Council for 48.9% of operating expenditure (2011 - 49.9%) and the Victorian Government Department of Business and Innovation for 6% of operating expenditure (2011 - 7.2%) for support of its basic research activities.

15. Segment information

The company operates predominantly in medical research in Australia.

16. Capital expenditure commitments

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not longer than 1 year</td>
<td>6,933</td>
<td>42,097</td>
</tr>
<tr>
<td>After 1 year but not more than 5 years</td>
<td>-</td>
<td>8,911</td>
</tr>
<tr>
<td><strong>Total commitments</strong></td>
<td><strong>6,933</strong></td>
<td><strong>51,008</strong></td>
</tr>
</tbody>
</table>

Refer note 22 building project
17. Notes to statement of cash flows

(a) Reconciliation of cash

For the purposes of the statement of cash flows, cash includes cash on hand, cash at bank and investments in money market instruments, net of outstanding bank overdrafts.

Cash at the end of the financial year as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>441</td>
<td>238</td>
</tr>
<tr>
<td>Deposits at call</td>
<td>14,553</td>
<td>23,638</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>14,994</strong></td>
<td><strong>23,876</strong></td>
</tr>
</tbody>
</table>

(b) Reconciliation of net surplus to net cash flows from operating activities

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net surplus</td>
<td>29,164</td>
<td>55,147</td>
</tr>
<tr>
<td>Depreciation</td>
<td>5,681</td>
<td>6,375</td>
</tr>
<tr>
<td>Contribution Income</td>
<td>(12,782)</td>
<td>-</td>
</tr>
<tr>
<td>Loss on Disposal of Property Plant and Equipment</td>
<td>131</td>
<td>-</td>
</tr>
<tr>
<td>Donations and bequests</td>
<td>(3,363)</td>
<td>(1,566)</td>
</tr>
<tr>
<td>Gain on sale of available-for-sale financial assets</td>
<td>(877)</td>
<td>(2,962)</td>
</tr>
<tr>
<td>Write down of available-for-sale investments</td>
<td>2,333</td>
<td>2,945</td>
</tr>
<tr>
<td>Increase in Investments – dividend reinvestment plans</td>
<td>(1,557)</td>
<td>(1,737)</td>
</tr>
<tr>
<td>Grants and donations for capital works</td>
<td>(25,006)</td>
<td>(37,719)</td>
</tr>
<tr>
<td>Amortisation of investment premiums</td>
<td>149</td>
<td>545</td>
</tr>
<tr>
<td>Donated Financial Assets</td>
<td>(98)</td>
<td></td>
</tr>
</tbody>
</table>

Changes in net assets and liabilities:

(Increase)/decrease in assets:

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tax assets</td>
<td>1,463</td>
<td>(1,973)</td>
</tr>
<tr>
<td>Sundry debtors and prepayments</td>
<td>(197)</td>
<td>(1,243)</td>
</tr>
<tr>
<td>Income receivable</td>
<td>(53)</td>
<td>327</td>
</tr>
<tr>
<td>Other – prepaid operating lease</td>
<td>32</td>
<td>199</td>
</tr>
</tbody>
</table>

Increase/(decrease) in liabilities:

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade payables</td>
<td>(1,270)</td>
<td>(7,749)</td>
</tr>
<tr>
<td>Current provisions</td>
<td>466</td>
<td>765</td>
</tr>
<tr>
<td>Other current liabilities(Grants)</td>
<td>1,367</td>
<td>(13,169)</td>
</tr>
<tr>
<td>Non-current provisions</td>
<td>1,189</td>
<td>838</td>
</tr>
</tbody>
</table>

Net cash from operating activities

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net cash from operating activities</strong></td>
<td><strong>(3,228)</strong></td>
<td><strong>(977)</strong></td>
</tr>
</tbody>
</table>

(c) Non-cash financing and investing activities

During the financial year:

Dividends of $1,567,000 (2011-$1,737,000) were reinvested as part of dividend and distribution reinvestment plans.

Shares of $98,000 (2011-nil) were donated to the institute during the year

18. Key management personnel compensation

The aggregate compensation of the key management personnel of the institute is set out below:

<table>
<thead>
<tr>
<th>Item</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term employee benefits</td>
<td>1,141,675</td>
<td>1,076,609</td>
</tr>
<tr>
<td>Post-employment benefits</td>
<td>201,345</td>
<td>174,887</td>
</tr>
</tbody>
</table>

**Total**                      | **1,343,020** | **1,251,496** |
19. Superannuation commitments

(a) Institute employees are members of a range of superannuation funds, which are divided into the following categories:

Those operative and open to membership by new employees:
UniSuper – Accumulation Super (1)
Other superannuation funds chosen by employees.

Those closed to future membership by institute employees:
UniSuper – Defined Benefit Division
UniSuper – Accumulation Super (2)

(b) UniSuper plans

UniSuper is a multi employer superannuation fund operated by UniSuper Limited as the corporate trustee and administrated by UniSuper Management Pty Ltd, a wholly owned subsidiary of UniSuper Limited. The operations of UniSuper are regulated by the Superannuation Industry (Supervision) Act 1993.

(i) The UniSuper schemes known as the Defined Benefit Division or Accumulation Super (2) were only available to contributing members of the Walter and Eliza Hall Institute of Medical Research Superannuation Fund (1979) which closed in 2003.

(ii) The maximum contribution rate to the schemes is 21% of member’s salary of which the member contributes 7% and the institute 14%.

(iii) UniSuper has advised that the Accumulation Super (2) and Defined Benefit Division plans are defined as multi-employer defined contribution schemes in accordance with AASB 119 Employee Benefits. AASB 119 Employee Benefits states that this is appropriate for a defined benefit plan where the employer does not have access to the information required and there is no reliable basis for allocating the benefits, liabilities, assets and costs between employers.

(iv) The number of members of the Walter and Eliza Hall Institute of Medical Research Superannuation Fund (1979) who became members of the UniSuper – Defined Benefit Division when the fund closed in 2003 was 204. The number of institute employees who are members of the Defined Benefit Division as at 30 June 2012 was 121 (2011 – 126).

(v) New employees who commenced after 1 July 2003 have a minimum contribution 9% of their annual salary contributed by the institute to accumulation super (1) or to a fund of their choice prescribed under the Superannuation Guarantee Charge Act (1992).

(c) The total superannuation contributions by the institute during the year in respect to the above plans were:

<table>
<thead>
<tr>
<th>Plan Description</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>UniSuper – Defined Benefit Division</td>
<td>1,856</td>
<td>1,831</td>
</tr>
<tr>
<td>UniSuper – Accumulation Super (2)</td>
<td>400</td>
<td>392</td>
</tr>
<tr>
<td>UniSuper – Accumulation Super (1)</td>
<td>3,890</td>
<td>3,485</td>
</tr>
<tr>
<td>Other superannuation funds</td>
<td>122</td>
<td>97</td>
</tr>
<tr>
<td>Total</td>
<td>6,268</td>
<td>5,805</td>
</tr>
</tbody>
</table>

20. Financial instruments

(a) Significant accounting policies

Details of the significant accounting policies and methods adopted, including the criteria for recognition, the basis of measurement and the basis on which revenues and expenses are recognised, in respect of each class of financial asset, financial liability and equity instruments are disclosed in note 1 to the financial statements.

(b) Significant terms, conditions and objectives of derivative financial instruments

The company does not enter into or trade derivative financial instruments.

(c) Capital risk management

The company manages its capital to ensure it will be able to continue as a going concern whilst maximising its return on investment within the risk profile maintained by the company. The capital structure consists of permanent funds, retained earnings and reserves.
(d) Financial risk management
The company minimises financial risk through the charter given to the investment committee. In line with this charter, the company invests short term funds in a appropriate combination of fixed and floating instruments.

(e) Interest rate risk management
The company is exposed to interest rate risk as it invests funds at both fixed and floating interest rates. The majority of financial assets in this class are bank accounts, bank bills and fixed interest securities with varying interest rates.

(f) Interest rate sensitivity analysis
The sensitivity analysis below has been determined based on the exposure to interest rates at the reporting date and the stipulated change taking place at the beginning of the financial year and held constant throughout the reporting period. A 25 basis point decrease was used as the minimum point and 100 basis point decrease as the maximum point. This consistent with the management’s view of interest rate sensitivity. A net decrease in interest rates translates into a fall in net surplus as investment income is reduced. The investment revaluation reserve would increase mainly as a result of the changes in the fair value of available-for-sale fixed rate instruments.

<table>
<thead>
<tr>
<th>Interest rate risk</th>
<th>Minimum 25bp</th>
<th>Maximum 100bp</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2012 $000's</td>
<td>2011 $000's</td>
</tr>
<tr>
<td>Effect on surplus</td>
<td>106 $000's</td>
<td>138 $000's</td>
</tr>
<tr>
<td>Effect on reserve</td>
<td>64 $000's</td>
<td>81 $000's</td>
</tr>
</tbody>
</table>

(g) Equity price sensitivity analysis
The sensitivity analysis below has been determined based on the exposure to equity price risks at the reporting date. At reporting date, if the equity prices had been 5% higher or lower:
- net surplus for the year ended 30 June 2012 would have been unaffected as the equity investments are classified as available-for-sale; and
- investment revaluation reserve would decrease/increase by $5.7 million (2011: $5.7 million) mainly as a result of the changes in fair value of available-for-sale shares.

The company’s sensitivity to equity prices has not changed significantly from the prior year.

(h) Credit risk management
Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the company. The company has adopted a policy of only dealing with creditworthy counter parties as a means of mitigating the risk of financial loss from defaults. The company’s exposure is continuously monitored and reviewed. Trade receivables consist of a large number of customers including granting bodies. The company does not have a significant credit exposure to any single party or any group of counter parties having similar characteristics. The carrying amount of financial assets recorded in the financial statements represents the company’s maximum exposure to credit risk.

(i) Liquidity risk management
Ultimate responsibility for liquidity risk management rests with the board of directors, who have built an appropriate risk management framework for the management of the company’s short, medium and long-term funding and liquidity management. The company manages the liquidity risk by maintaining adequate cash reserves, and by continuously monitoring forecast and actual cash flows while matching the maturity profiles of financial assets. Given the current surplus cash assets, liquidity risk is minimal. The company does not have any interest bearing liabilities. The remaining contractual maturity for its non-interest-bearing financial liabilities is $6,322 thousand payable within 3 months of 30 June 2012 (2011: $7,592 thousand).

(j) Fair value
The carrying amount of the institute’s financial assets and financial liabilities recorded in the financial statements approximates their fair values. The fair value of financial assets and financial liabilities with standard terms and conditions and traded on active liquid markets are determined with reference to quoted market prices.
(k) Interest rate risk

The following table details the Institute’s exposure to interest rate risk as at 30 June 2011 and 30 June 2012.

<table>
<thead>
<tr>
<th></th>
<th>Average interest rate</th>
<th>Variable interest rate</th>
<th>Less than 1 year</th>
<th>1 to 5 years</th>
<th>More than 5 years</th>
<th>Non-Interest Bearing</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
<td>$'000</td>
</tr>
<tr>
<td><strong>30-Jun-12</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Financial assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>3.22%</td>
<td>14,553</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,553</td>
<td>14,553</td>
</tr>
<tr>
<td>Tax assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,117</td>
<td>2,117</td>
</tr>
<tr>
<td>Sundry debtors and prepayments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,829</td>
<td>3,829</td>
<td></td>
</tr>
<tr>
<td>Accrued income</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>909</td>
<td>909</td>
</tr>
<tr>
<td>Bills of exchange</td>
<td>4.77%</td>
<td>-</td>
<td>17,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,000</td>
</tr>
<tr>
<td>Fixed interest securities</td>
<td>8.21%</td>
<td>-</td>
<td>1,887</td>
<td>140</td>
<td>262</td>
<td>-</td>
<td>113,879</td>
</tr>
<tr>
<td>Shares</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>113,879</td>
</tr>
<tr>
<td>Unit trusts</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>862</td>
<td>862</td>
</tr>
<tr>
<td>Perpetual floating rate securities</td>
<td>6.86%</td>
<td>-</td>
<td>-</td>
<td>10,261</td>
<td>-</td>
<td>-</td>
<td>10,261</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14,553</td>
<td>18,887</td>
<td>10,401</td>
<td>262</td>
<td>121,596</td>
<td>165,699</td>
<td></td>
</tr>
<tr>
<td><strong>Financial liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade payables*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,322</td>
<td>6,322</td>
</tr>
<tr>
<td>Grants carried forward</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13,164</td>
<td>13,164</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6,322</td>
<td>6,322</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19,486</td>
</tr>
<tr>
<td><strong>30-Jun-11</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Financial assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>3.54%</td>
<td>23,876</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23,876</td>
<td>23,876</td>
</tr>
<tr>
<td>Tax assets</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,887</td>
<td>4,887</td>
</tr>
<tr>
<td>Sundry debtors and prepayments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,535</td>
<td>2,535</td>
<td></td>
</tr>
<tr>
<td>Accrued income</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>916</td>
<td>916</td>
</tr>
<tr>
<td>Bills of exchange</td>
<td>5.86%</td>
<td>-</td>
<td>26,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>26,000</td>
</tr>
<tr>
<td>Fixed interest securities</td>
<td>8.40%</td>
<td>-</td>
<td>2,930</td>
<td>32,090</td>
<td>-</td>
<td>-</td>
<td>113,610</td>
</tr>
<tr>
<td>Shares</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>955</td>
<td>955</td>
</tr>
<tr>
<td>Unit trusts</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,798</td>
<td>11,798</td>
</tr>
<tr>
<td>Perpetual floating rate securities</td>
<td>7.23%</td>
<td>-</td>
<td>-</td>
<td>5,273</td>
<td>-</td>
<td>-</td>
<td>5,273</td>
</tr>
<tr>
<td></td>
<td>23,876</td>
<td>28,930</td>
<td>37,363</td>
<td>-</td>
<td>122,903</td>
<td>213,072</td>
<td></td>
</tr>
<tr>
<td><strong>Financial liabilities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade payables*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,592</td>
<td>7,592</td>
</tr>
<tr>
<td>Grants carried forward</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,798</td>
<td>11,798</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7,592</td>
<td>7,592</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19,390</td>
</tr>
</tbody>
</table>

*payment terms 30 days
### 21. Property, plant and equipment

<table>
<thead>
<tr>
<th></th>
<th>Buildings $'000</th>
<th>Work in progress $'000</th>
<th>Plant and equipment $'000</th>
<th>Furniture and fittings $'000</th>
<th>Land Lease $'000</th>
<th>Total $'000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gross carrying amount</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at 30 June 2010</td>
<td>20,238</td>
<td>86,114</td>
<td>31,005</td>
<td>1,418</td>
<td></td>
<td>138,775</td>
</tr>
<tr>
<td>Additions at cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Balance at 30 June 2011</strong></td>
<td><strong>135,833</strong></td>
<td><strong>19,873</strong></td>
<td><strong>33,544</strong></td>
<td><strong>1,610</strong></td>
<td></td>
<td><strong>190,860</strong></td>
</tr>
<tr>
<td>Additions at cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Balance at 30 June 2012</strong></td>
<td><strong>176,697</strong></td>
<td><strong>3,091</strong></td>
<td><strong>35,313</strong></td>
<td><strong>1,610</strong></td>
<td><strong>16,200</strong></td>
<td><strong>232,911</strong></td>
</tr>
<tr>
<td><strong>Accumulated depreciation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance at 30 June 2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additions at cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additions at cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disposals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Carrying amounts</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As at 30 June 2011</td>
<td>123,827</td>
<td>19,873</td>
<td>11,629</td>
<td>346</td>
<td></td>
<td>155,675</td>
</tr>
<tr>
<td>As at 30 June 2012</td>
<td>161,836</td>
<td>3,091</td>
<td>11,851</td>
<td>420</td>
<td>16,200</td>
<td>193,398</td>
</tr>
</tbody>
</table>

*$133.3M of building project works was funded from building grants and the balance from interest earned thereon and institute funds – refer note 22.

An independent valuation of the land leased at Parkville was completed in May 2012. Land leased was valued by Mr Peter Volakos AAPI of the firm Colliers International. The valuation was based on an adopted market value.

Aggregate depreciation allocated, whether recognised as an expense or capitalised as part of the carrying amount of other assets during the year:

<table>
<thead>
<tr>
<th></th>
<th>2012 $'000</th>
<th>2011 $'000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buildings</td>
<td>2,910</td>
<td>3,767</td>
</tr>
<tr>
<td>Plant and equipment</td>
<td>2,661</td>
<td>2,527</td>
</tr>
<tr>
<td>Furniture and fittings</td>
<td>110</td>
<td>81</td>
</tr>
<tr>
<td><strong>Total depreciation</strong></td>
<td>5,681</td>
<td>6,375</td>
</tr>
</tbody>
</table>
22. Building project

The institute was committed to expansion of its Parkville facilities and funding totalling $130 million was secured from three parties, the Australian Government, the Victorian Government and The Atlantic Philanthropies. A further three grants were obtained to substantially complete the project this financial year. Amounts expended to date are shown in note 21 as Property, Plant & Equipment. The following table indicates amounts that have been received and expended up to the financial years ended on 30 June.

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$000's</td>
<td>$000's</td>
</tr>
<tr>
<td>Australian Government</td>
<td>50,000</td>
<td>50,000</td>
</tr>
<tr>
<td>The Atlantic Philanthropies</td>
<td>30,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Victorian Government</td>
<td>50,000</td>
<td>50,000</td>
</tr>
<tr>
<td>Australian Cancer Research Foundation</td>
<td>2,000</td>
<td>-</td>
</tr>
<tr>
<td>The Ian Potter Foundation</td>
<td>1,000</td>
<td>-</td>
</tr>
<tr>
<td>Drakensburg Trust</td>
<td>300</td>
<td>-</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>133,300</td>
<td>130,000</td>
</tr>
</tbody>
</table>

Expended on building project (133,300) (120,910)
Transferred to Walter and Eliza Hall Institute project facility trust (49,000) (49,000)
Transferred from Walter and Eliza Hall Institute project facility trust 49,000 39,910

**Funds held on deposit**

- -

(included in deposits at call note 17(a))

The financial impacts of the transactions on the institute have been disclosed in the statement of cash flows and in note 10 grants committed to future periods.

During 2006 the ‘Walter and Eliza Hall Institute project facility trust’ was established to hold funds granted from the Victorian Government for the expansion of Parkville facilities. $49 million has been transferred to this trust from amounts received to date. At 30 June 2012 $49 million has been returned for expenditure on the building project (30 June 2011 $37.7 million).

Interest earned on building funds refer note 4(j)
Governance statement:
The Walter and Eliza Hall Institute of Medical Research is a public company limited by guarantee. Ultimate responsibility for the governance of the company rests with the board of directors. This governance statement outlines how the board meets that responsibility.

Achieving the mission:
The board’s primary role is to ensure that the institute’s activities are directed towards achieving its mission of ‘Mastery of Disease through Discovery’. The board must ensure that this mission is achieved in the most efficient and effective way.

Specific responsibilities of the board:
The board fulfils its primary role by:
• selecting, appointing, guiding and monitoring the performance of the chief executive;
• formulating the institute’s strategic plan in conjunction with the chief executive and senior management;
• approving operating and capital budgets formulated by the chief executive and management;
• monitoring management’s progress in achieving the strategic plan;
• monitoring management’s adherence to operating and capital budgets;
• ensuring the integrity of internal control, risk management and management information systems;
• ensuring stakeholders receive regular reports, including financial reports;
• ensuring the company complies with relevant legislation and regulations; and
• acting as an advocate for the institute whenever and wherever possible.

Management’s responsibility:
The Board has formally delegated responsibility for the institute’s day-to-day operations and administration to the chief executive and executive management.

Board oversight:
The board oversees and monitors management’s performance by:
• meeting at least four times during the year;
• receiving detailed financial and other reports from management at these meetings;
• receiving additional information and input from management when necessary; and
• assigning to the Audit and Risk, Commercialisation, Investment and Remuneration committees of the board responsibility to oversee particular aspects of the institute’s operations and administration.

Each board committee operates under a charter approved by the board. These charters are reviewed annually and updated as necessary.

Board members:
All board members are non-executive directors and receive no remuneration for their services. The company’s constitution specifies:
• there must be no less than 12 and no more than 18 directors;
• directors (except those appointed by The University of Melbourne) are appointed for a maximum of four terms of three years each, after which directors may be reappointed annually with the unanimous agreement of all other board members; and
• the president or vice president may hold office for an additional period or periods not exceeding six years.

Appointments to the board are made to ensure the board has the right mix of skills, experience and expertise. Board members are appointed by the company’s founding members, The University of Melbourne and The Royal Melbourne Hospital (Melbourne Health) – two each and up to a further 14 by the board.

Board and committee members receive written advice of the terms and conditions of their appointment. Board and committee members’ knowledge of the business is maintained by visits to the institute’s operations and management presentations.

The performance of individual board and committee members and the board and board committees is assessed annually.

Risk management:
The board oversees the institute’s risk management system, which is designed to protect the organisation’s reputation and manage those risks that might preclude it from achieving its goals.

Management is responsible for establishing and implementing the risk management system, which assesses, monitors and manages operational, financial reporting and compliance risks. The Audit and Risk Committee is responsible for monitoring the effectiveness of the risk management system between annual reviews.

Ethical standards and code of conduct:
Board members, senior executives and staff are expected to comply with relevant laws and the codes of conduct of relevant professional bodies, and to act with integrity, compassion, fairness and honesty at all times when dealing with colleagues, and others who are stakeholders in our mission.

Involving stakeholders:
The institute has many stakeholders, including our donors and benefactors, our staff, and students, the broader community, the government agencies who provide us funds and regulate our operations, and our suppliers.

We adopt a consultative approach in dealing with our stakeholders. We get involved in industry forums to ensure governments at all levels are aware of our concerns and our achievements and to remain abreast of industry developments.

Indemnification and insurance:
The institute insures directors (and the company secretary and executives) against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of director (or company secretary or executive) of the company, other than conduct involving a wilful breach of duty in relation to the company.
Financial statements

Directors’ report

The directors of the Walter and Eliza Hall Institute of Medical Research submit herewith the annual financial report of the company for the year ended 30 June 2012. In order to comply with the provisions of the Corporations Act 2001, the directors report as follows:

Directors and board meetings

The names and particulars of the directors of the company during or since the end of the financial year and attendance at board meetings in the year to 30 June 2012 are:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Joined Board</th>
<th>Age</th>
<th>Meetings held while a Director</th>
<th>Meetings Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonard A Davis</td>
<td>Chairman and President of the Institute</td>
<td>2001</td>
<td>72</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Stéphane David</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael C Fitzpatrick</td>
<td></td>
<td>2001</td>
<td>59</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Roger E Male</td>
<td>Honorary Treasurer</td>
<td>1998</td>
<td>69</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>James A Angus</td>
<td></td>
<td>2003</td>
<td>63</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Gareth J Goodfellow*</td>
<td></td>
<td>2012</td>
<td>61</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>James McCluskey</td>
<td></td>
<td>2011</td>
<td>61</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Graham F Mitchell</td>
<td></td>
<td>2007</td>
<td>71</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Linda B Nicholls</td>
<td></td>
<td>2001</td>
<td>64</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Catherine J Redwood†</td>
<td></td>
<td>2009</td>
<td>63</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Christopher W Thomas</td>
<td></td>
<td>2001</td>
<td>66</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Catherine M Walter</td>
<td></td>
<td>2001</td>
<td>60</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Ingrid M Winship</td>
<td></td>
<td>2007</td>
<td>54</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

The Audit and Risk Committee

The role of the Audit and Risk Committee is to assist the board in fulfilling its statutory and fiduciary responsibilities with regard to accounting and financial reporting practices and internal control systems of the company. The committee met three times during the year.

Appreciation

The board wishes to extend its appreciation to the members of the various committees (Appointments and Promotions Committee, Ethics Committee, Investment Committee, Commercialisation Advisory Committee, Financial Sustainability Committee, and the New Building Steering Committee) as well as the many other people including the director, staff, students, overseas visitors and honorary workers, who work so tirelessly to advance the company’s world-wide reputation for excellence in medical research.

Principal activities

The company’s principal activity in the course of the financial year was medical research and there has been no significant change in that activity during the financial year.

Financial results

The financial result from research activities was a net deficit of $4,948,000 (2011 surplus of $7,860,000). After allowing for the surplus arising from, contribution income, gains from the sale of investments and other grants, donations and bequests, depreciation and amortisation the overall result for the year was a surplus of $29,164,000 (2011 – $55,147,000). Tax is not applicable. The company is limited by guarantee, has no share capital and declares no dividends.

Operations

A review of operations of the company is included in the detailed scientific reports.

Environmental regulations

The institute aims to achieve a high standard in environmental matters. The institute complies with the Environmental Protection Act in respect of its operations. Discharges to air and water are below specified levels of contaminants and solid waste is disposed of in an appropriate manner. Biomedical waste and sharps are disposed of through appropriately licensed contractors. The directors have not received notification nor are they aware of any breaches of environmental laws by the institute.
Auditors’ independence declaration

The Auditors’ independence declaration is included on page 165 of the financial report.

Other Matters

(a) During the financial year there was no significant change in the company’s state of affairs other than that referred to in the accounts or the notes thereto.

(b) There has not been any other matter or circumstance that has arisen since the end of the financial year, that has significantly affected, or may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

(c) The company is in the process of expansion and redevelopment of the Parkville premises which will significantly increase its capacity and operations in the coming years. Disclosure of information regarding likely developments in the operations of the company in future years and the expected results of those operations is likely to result in unreasonable prejudice to the company. Accordingly, this information has not been disclosed in this report.

(d) During the financial year the company paid a premium in respect of a contract insuring the directors and officers of the company against liability incurred as such a director or officer to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium. The company has not otherwise, during or since the financial year, indemnified or agreed to indemnify an officer or auditor of the company or any related body corporate against a liability incurred as such an officer or auditor.

(e) The company is a company of the kind referred to in ASIC Class Order 98/100, dated 10 July 1998, and in accordance with that Class Order amounts in the directors’ report and the financial report are rounded off to the nearest thousand dollars.

Signed in accordance with a resolution of the directors made pursuant to s.298(2) of the Corporations Act 2001.

On behalf of the directors

Leon Davis
President
Melbourne, 13 September 2012

Roger Male
Treasurer

Directors’ declaration

The directors declare that:

(a) The attached financial statements and notes thereto comply with accounting standards;

(b) The attached financial statements and notes thereto give a true and fair view of the financial position and performance of the company;

(c) In the directors’ opinion, the attached financial statements and notes thereto are in accordance with the Corporations Act 2001; and

(d) In the directors’ opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the directors made pursuant to s.295(5) of the Corporations Act 2001.

On behalf of the directors

Leon Davis
President
Melbourne, 13 September 2012

Roger Male
Treasurer
Financial statements

The Board of Directors
The Walter and Eliza Hall Institute of Medical Research
IG Royal Parade
Parkville VIC 3052

13 September 2012

Dear Board Members

The Walter and Eliza Hall Institute of Medical Research

In accordance with section 307C of the Corporations Act 2001, I am pleased to provide the following declaration of independence to the directors of The Walter and Eliza Hall Institute of Medical Research.

As lead audit partner for the audit of the financial statements of The Walter and Eliza Hall Institute of Medical Research for the financial year ended 30 June 2012, I declare that to the best of my knowledge and belief, there have been no contraventions of:

(i) the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and

(ii) any applicable code of professional conduct in relation to the audit.

Yours sincerely,

DELOITTE TOUCHE TOHMATSU

Peter Caldwell
Partner
Chartered Accountants

Liability limited by a scheme approved under Professional Standards Legislation
Member of Deloitte Touche Tohmatsu Limited
Independent Auditor’s Report
to the Members of The Walter and Eliza Hall
Institute of Medical Research

We have audited the accompanying financial report of The Walter and Eliza Hall Institute of Medical Research, which comprises the statement of financial position as at 30 June 2012, the statement of comprehensive income, the statement of cash flows and the statement of changes in equity for the year ended on that date, notes comprising a statement of significant accounting policies and other explanatory information, and the directors’ declaration as set out on pages 141 to 161 and 163 to 164.

Directors’ Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control, relevant to the entity’s preparation of the financial report that gives a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Auditor’s Independence Declaration

In conducting our audit, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Walter and Eliza Hall Institute of Medical Research, would be in the same terms if given to the directors as at the time of this auditor’s report.

Opinion

In our opinion, the financial report of The Walter and Eliza Hall Institute of Medical Research is in accordance with the Corporations Act 2001, including:

(a) giving a true and fair view of the company’s financial position as at 30 June 2012 and of its performance for the year ended on that date; and

(b) complying with Australian Accounting Standards and the Corporations Regulations 2001.

DELOITTE TOUCHE TOHMATSU

Peter Caldwell
Partner
Chartered Accountants
Melbourne, 13 September 2012
Statistical summary for the year ended 30 June

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australian Government</td>
<td>49,962</td>
<td>45,973</td>
<td>39,291</td>
<td>37,409</td>
<td>33,446</td>
</tr>
<tr>
<td>Victorian Government</td>
<td>7,074</td>
<td>6,842</td>
<td>7,638</td>
<td>7,355</td>
<td>8,229</td>
</tr>
<tr>
<td>Foreign governments</td>
<td>359</td>
<td>557</td>
<td>953</td>
<td>543</td>
<td>443</td>
</tr>
<tr>
<td><strong>Government revenue</strong></td>
<td>57,395</td>
<td>53,372</td>
<td>47,882</td>
<td>45,307</td>
<td>42,118</td>
</tr>
<tr>
<td>Industrial grants and contracts</td>
<td>1,114</td>
<td>1,846</td>
<td>3,518</td>
<td>3,722</td>
<td>3,847</td>
</tr>
<tr>
<td>Philanthropic grants and fellowships – Australia</td>
<td>5,285</td>
<td>3,830</td>
<td>3,644</td>
<td>3,440</td>
<td>2,370</td>
</tr>
<tr>
<td>Philanthropic grants and fellowships – international</td>
<td>2,180</td>
<td>3,235</td>
<td>4,399</td>
<td>6,551</td>
<td>6,208</td>
</tr>
<tr>
<td>Investment income 12</td>
<td>11,280</td>
<td>11,486</td>
<td>9,278</td>
<td>10,007</td>
<td>8,561</td>
</tr>
<tr>
<td>Royalty income</td>
<td>810</td>
<td>2,513</td>
<td>1,071</td>
<td>1,356</td>
<td>1,443</td>
</tr>
<tr>
<td>General revenue</td>
<td>3,054</td>
<td>2,647</td>
<td>2,761</td>
<td>3,140</td>
<td>2,238</td>
</tr>
<tr>
<td>Donations and bequests</td>
<td>3,043</td>
<td>3,305</td>
<td>958</td>
<td>1,178</td>
<td>927</td>
</tr>
<tr>
<td><strong>Non-government revenue</strong></td>
<td>26,766</td>
<td>28,862</td>
<td>25,629</td>
<td>29,394</td>
<td>26,144</td>
</tr>
<tr>
<td><strong>Total revenue for research</strong></td>
<td>84,161</td>
<td>82,234</td>
<td>73,511</td>
<td>74,701</td>
<td>68,262</td>
</tr>
<tr>
<td><strong>Research expenditure and financial results</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staff costs</td>
<td>61,559</td>
<td>54,799</td>
<td>48,938</td>
<td>45,419</td>
<td>42,903</td>
</tr>
<tr>
<td>Laboratory operating costs</td>
<td>16,452</td>
<td>15,424</td>
<td>16,310</td>
<td>15,817</td>
<td>15,068</td>
</tr>
<tr>
<td>Laboratory equipment</td>
<td>4,119</td>
<td>2,862</td>
<td>2,474</td>
<td>2,591</td>
<td>2,271</td>
</tr>
<tr>
<td>Building operations</td>
<td>4,877</td>
<td>4,353</td>
<td>4,366</td>
<td>4,551</td>
<td>4,152</td>
</tr>
<tr>
<td>Administration</td>
<td>1,203</td>
<td>1,002</td>
<td>1,225</td>
<td>1,485</td>
<td>1,375</td>
</tr>
<tr>
<td>Business development</td>
<td>899</td>
<td>684</td>
<td>879</td>
<td>1,410</td>
<td>1,109</td>
</tr>
<tr>
<td><strong>Total research expenditure</strong></td>
<td>89,109</td>
<td>79,124</td>
<td>74,182</td>
<td>71,273</td>
<td>66,878</td>
</tr>
<tr>
<td><strong>Results from research activities</strong></td>
<td>-4,948</td>
<td>3,110</td>
<td>-671</td>
<td>3,428</td>
<td>1,364</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Profit on sale of long-term investments 2</td>
<td>877</td>
<td>7,712</td>
<td>1,151</td>
<td>1,372</td>
<td>5,260</td>
</tr>
<tr>
<td>Contribution Income for recognition of land lease</td>
<td>12,782</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Donations and bequests</td>
<td>3,461</td>
<td>1,566</td>
<td>2,120</td>
<td>9,879</td>
<td>34,738</td>
</tr>
<tr>
<td>Grants and donations for capital works 1</td>
<td>906</td>
<td>117</td>
<td>428</td>
<td>492</td>
<td>2,547</td>
</tr>
<tr>
<td><strong>Total other income</strong></td>
<td>18,026</td>
<td>9,395</td>
<td>3,699</td>
<td>11,743</td>
<td>42,545</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss on impairment write down of long-term investments</td>
<td>-2,333</td>
<td>-2,945</td>
<td>-203</td>
<td>-8,417</td>
<td>-9,336</td>
</tr>
<tr>
<td>Depreciation and amortisation</td>
<td>-5,681</td>
<td>-6,375</td>
<td>-3,877</td>
<td>-3,025</td>
<td>-2,834</td>
</tr>
<tr>
<td><strong>Total other expenses</strong></td>
<td>-8,014</td>
<td>-9,320</td>
<td>-4,080</td>
<td>-11,442</td>
<td>-12,170</td>
</tr>
<tr>
<td><strong>Net operating surplus</strong></td>
<td>5,064</td>
<td>3,185</td>
<td>-1,052</td>
<td>3,729</td>
<td>31,759</td>
</tr>
</tbody>
</table>

1. Excluding funds for Walter and Eliza Hall Institute redevelopment project
2. Income excludes share buy back dividends in 2011 ($4.75M)
3. Income includes share buy back dividends in 2011 ($4.75M)

**Capital funds**
- Permanent invested capital funds: 139,073, 134,457, 129,802, 128,475, 115,072
- General funds: 162,909, 138,752, 90,534, 35,998, 25,814
- Royalty fund: 17,079, 16,788, 14,823, 14,294, 14,142
- Leadership fund: 16,282, 16,182, 15,873, 15,672, 15,226
- Asset revaluation reserve: 29,086, 38,812, 37,961, 25,952, 42,297
- **Total funds**: 364,429, 344,991, 288,993, 218,391, 212,551

**Capital expenditure**
- Property, plant and equipment: 43,348, 53,579, 64,516, 17,286, 10,712

**Staff numbers: (equivalent full-time) at 30 June**
- 2012: 64, 64, 52, 52, 50
- 2011: 160, 147, 143, 156, 130
- 2010: 10, 16, 14, 28, 24

**Scientific research staff:**
- Senior faculty: 64, 64, 52, 52, 50
- Other: 160, 147, 143, 156, 130
- Visiting scientists: 10, 16, 14, 28, 24

**Supporting staff:**
- Laboratories and all services: 374, 358, 349, 323, 315
- **Total staff and visiting scientists**: 608, 565, 558, 559, 519
- **Students** (equivalent full-time): 137, 135, 103, 68, 67
- **Papers published** (equivalent): 284, 250, 249, 246, 224
Capital Funds

Permanent Named Capital Funds

The following is a complete listing of all permanent funds held and invested by the institute at 30 June, 2012. In 2011-12 the aggregate profit/loss on sale of investments was apportioned to individual fund accounts.

*New donations of capital received in current financial year.

*JE Craven & MA Shearer Estates

<table>
<thead>
<tr>
<th>Fund Name</th>
<th>2012 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adair John Bequest (ex DW)</td>
<td>311,202</td>
</tr>
<tr>
<td>Adair John Bequest (ex MF)</td>
<td>59,086</td>
</tr>
<tr>
<td>Alexander R Estate</td>
<td>124,088</td>
</tr>
<tr>
<td>Allison-Levick J &amp; H</td>
<td>69,650</td>
</tr>
<tr>
<td>Amey AM Estate</td>
<td>29,964</td>
</tr>
<tr>
<td>Anderson KA Estate</td>
<td>222,735</td>
</tr>
<tr>
<td>Anderson NM Estate</td>
<td>13,498</td>
</tr>
<tr>
<td>Angus Dorothy Irene Estate</td>
<td>219,187</td>
</tr>
<tr>
<td>Anonymous – Victoria</td>
<td>47,925</td>
</tr>
<tr>
<td>Anonymous – Victoria</td>
<td>155,328</td>
</tr>
<tr>
<td>Anonymous – Victoria</td>
<td>5,771</td>
</tr>
<tr>
<td>Amel Florence Janet</td>
<td>45,328</td>
</tr>
<tr>
<td>Arter Myra G Estate</td>
<td>69,690</td>
</tr>
<tr>
<td>Ashford Ivy A Estate</td>
<td>27,587</td>
</tr>
<tr>
<td>Attwell Samuel E Estate</td>
<td>53,975</td>
</tr>
<tr>
<td>Ayteo George &amp; Isabel Fund</td>
<td>39,650</td>
</tr>
<tr>
<td>Baker Alice Lillian Estate</td>
<td>65,702</td>
</tr>
<tr>
<td>Ballantyne JW Estate</td>
<td>628,301</td>
</tr>
<tr>
<td>Bartfield WG Estate</td>
<td>42,650</td>
</tr>
<tr>
<td>Bartlett Mary V Estate</td>
<td>30,223</td>
</tr>
<tr>
<td>Bates Tim Memorial Diabetes Research Fund</td>
<td>99,022</td>
</tr>
<tr>
<td>Charles L Bartholomew Estate</td>
<td>125,410</td>
</tr>
<tr>
<td>Bauer Dr Franz Estate</td>
<td>51,620</td>
</tr>
<tr>
<td>Bell Valerie Amy</td>
<td>73,122</td>
</tr>
<tr>
<td>Benjamin EG Estate</td>
<td>48,374</td>
</tr>
<tr>
<td>Bennett LM Estate</td>
<td>30,595</td>
</tr>
<tr>
<td>Berry Ruby C Estate</td>
<td>129,084</td>
</tr>
<tr>
<td>Biderman Cyla Estate</td>
<td>61,610</td>
</tr>
<tr>
<td>Blain BE Estate</td>
<td>98,654</td>
</tr>
<tr>
<td>Bland RT Estate</td>
<td>296,685</td>
</tr>
<tr>
<td>Bock Lindsay William Estate</td>
<td>26,117</td>
</tr>
<tr>
<td>Boothman Alva Estate</td>
<td>606,369</td>
</tr>
<tr>
<td>Borrett M A Estate</td>
<td>471,286</td>
</tr>
<tr>
<td>Bran EG Estate</td>
<td>171,540</td>
</tr>
<tr>
<td>Brennan EM Estate</td>
<td>53,547</td>
</tr>
<tr>
<td>The Ruby Bryan Memorial Fund</td>
<td>585,034</td>
</tr>
<tr>
<td>Brittain W &amp; Vi Mem Fund</td>
<td>63,102</td>
</tr>
<tr>
<td>Brockhoff Nyon Trust</td>
<td>198,165</td>
</tr>
<tr>
<td>Brough AV Estate</td>
<td>68,169</td>
</tr>
<tr>
<td>Brown Isabelle A Estate</td>
<td>71,002</td>
</tr>
<tr>
<td>Bruce RH Estate</td>
<td>31,140</td>
</tr>
<tr>
<td>Buckland W Foundation Fund</td>
<td>182,683</td>
</tr>
<tr>
<td>Buckman Olive Estate</td>
<td>21,642</td>
</tr>
<tr>
<td>Bulk C G Estate</td>
<td>394,588</td>
</tr>
<tr>
<td>Brumloop LAA Estate</td>
<td>67,969</td>
</tr>
<tr>
<td>Burley Stanley Estate</td>
<td>55,354</td>
</tr>
<tr>
<td>Burnt Sir Macfarlane Estate</td>
<td>86,387</td>
</tr>
<tr>
<td>Burns JC Estate</td>
<td>146,049</td>
</tr>
<tr>
<td>Cahill JL Estate</td>
<td>20,233</td>
</tr>
<tr>
<td>Callaway LJ Estate</td>
<td>38,725</td>
</tr>
<tr>
<td>Cambridge Beresford Estate</td>
<td>160,401</td>
</tr>
<tr>
<td>Carlin Freda Evelyn Estate</td>
<td>79,342</td>
</tr>
<tr>
<td>Carling DM Estate</td>
<td>141,749</td>
</tr>
<tr>
<td>Carlson Catherine Estate</td>
<td>71,168</td>
</tr>
<tr>
<td>Carlson Elizabeth F Estate</td>
<td>80,435</td>
</tr>
<tr>
<td>Carty LEW Charitable Fund</td>
<td>34,209</td>
</tr>
<tr>
<td>Cato EA Estate</td>
<td>701,831</td>
</tr>
<tr>
<td>Cato MC Estate</td>
<td>570,448</td>
</tr>
<tr>
<td>Chaifield SL Estate</td>
<td>96,285</td>
</tr>
<tr>
<td>Claridge John PG Estate</td>
<td>28,699</td>
</tr>
<tr>
<td>Clark Lindsayay Fund</td>
<td>778,776</td>
</tr>
<tr>
<td>Cockburn Clarice BP Estate</td>
<td>21,580</td>
</tr>
<tr>
<td>Cole DE Estate</td>
<td>618,668</td>
</tr>
<tr>
<td>Coles GO Estate</td>
<td>30,091</td>
</tr>
<tr>
<td>Collie Barbara Estate</td>
<td>119,812</td>
</tr>
<tr>
<td>Collie Betty Rae</td>
<td>168,000</td>
</tr>
<tr>
<td>Collie George Estate</td>
<td>1,879,968</td>
</tr>
<tr>
<td>Colliver Len Estate</td>
<td>44,283</td>
</tr>
<tr>
<td>Connolly Grace C Estate</td>
<td>101,972</td>
</tr>
<tr>
<td>Cormack Margaret Mary</td>
<td>76,074</td>
</tr>
<tr>
<td>Cory Joy &amp; Desmond Cancer Research Fund</td>
<td>103,022</td>
</tr>
<tr>
<td>Coultaa Hylda M Estate</td>
<td>102,221</td>
</tr>
<tr>
<td>Courtney Gwendoline Vara Estate</td>
<td>218,809</td>
</tr>
<tr>
<td>Couatts Dr ELA Estate</td>
<td>102,631</td>
</tr>
<tr>
<td>Couatts IBM Estate</td>
<td>21,763</td>
</tr>
<tr>
<td>*Craven DA Memorial Fund</td>
<td>883,940</td>
</tr>
<tr>
<td>*JE Craven &amp; MA Shearer Estates</td>
<td>38,806,418</td>
</tr>
<tr>
<td>Crawford Duncan Estate</td>
<td>13,385</td>
</tr>
<tr>
<td>Criswick R M Estate</td>
<td>408,173</td>
</tr>
<tr>
<td>Critchlow Ronald P Estate</td>
<td>238,842</td>
</tr>
<tr>
<td>Crowley MM Estate</td>
<td>166,896</td>
</tr>
<tr>
<td>Cubbins SG Estate</td>
<td>71,057</td>
</tr>
<tr>
<td>Cummings ED Estate</td>
<td>126,512</td>
</tr>
<tr>
<td>Cutter BE Estate</td>
<td>13,149</td>
</tr>
<tr>
<td>Darbyshire EJ (Ted) Estate</td>
<td>275,175</td>
</tr>
<tr>
<td>Davey Dorothy Estate</td>
<td>243,476</td>
</tr>
<tr>
<td>Davidson BI Estate</td>
<td>20,662</td>
</tr>
<tr>
<td>Davidson EE Estate</td>
<td>23,450</td>
</tr>
<tr>
<td>Davis FLG Estate</td>
<td>46,885</td>
</tr>
<tr>
<td>Dawson Anne Marie Estate</td>
<td>6,268</td>
</tr>
<tr>
<td>Del Cott RAM Estate</td>
<td>206,683</td>
</tr>
<tr>
<td>Deryk SD Estate</td>
<td>55,900</td>
</tr>
<tr>
<td>Sir Harold Dew and Family Estate</td>
<td>655,859</td>
</tr>
<tr>
<td>Dick MRK (Ray) Estate</td>
<td>173,443</td>
</tr>
<tr>
<td>Dickie Phoebe Estate</td>
<td>35,542</td>
</tr>
<tr>
<td>Dirmsy WE Estate</td>
<td>178,878</td>
</tr>
<tr>
<td>Dobbie Myrtle M Estate</td>
<td>32,647</td>
</tr>
<tr>
<td>Dodgshun GM Estate</td>
<td>129,759</td>
</tr>
<tr>
<td>Dossetor Catherine L Estate</td>
<td>28,229</td>
</tr>
<tr>
<td>Dowie S Estate</td>
<td>18,327</td>
</tr>
<tr>
<td>Drakensberg Trust</td>
<td>1,970,345</td>
</tr>
<tr>
<td>Duncan PH Estate</td>
<td>77,449</td>
</tr>
<tr>
<td>East James Douglas Estate</td>
<td>147,414</td>
</tr>
<tr>
<td>Edwards Allen Richard Estate</td>
<td>155,041</td>
</tr>
<tr>
<td>Edwards HW Estate</td>
<td>197,549</td>
</tr>
<tr>
<td>Eisner KR</td>
<td>76,286</td>
</tr>
<tr>
<td>Ellis GM Estate</td>
<td>2,995,228</td>
</tr>
<tr>
<td>Emery Harriet Anne Estate</td>
<td>17,005</td>
</tr>
<tr>
<td>Eva Michael Ross Estate</td>
<td>3,565,880</td>
</tr>
<tr>
<td>Facey Mary Bethune Estate</td>
<td>13,028</td>
</tr>
<tr>
<td>Fagg Maude V Estate</td>
<td>81,055</td>
</tr>
<tr>
<td>Farrant John Estate</td>
<td>151,302</td>
</tr>
<tr>
<td>Fields Ernest Estate</td>
<td>227,686</td>
</tr>
<tr>
<td>Findlay Winifred Gertrude Estate</td>
<td>113,825</td>
</tr>
<tr>
<td>Fitzgerald Sheila Mary Estate</td>
<td>34,854</td>
</tr>
<tr>
<td>Ford Ada Joyce Estate</td>
<td>15,974</td>
</tr>
<tr>
<td>Fraser K Estate</td>
<td>1,650,971</td>
</tr>
<tr>
<td>Galbraith DA &amp; DV Estate</td>
<td>90,015</td>
</tr>
<tr>
<td>Gerdiis Sheila Lesley G Estate</td>
<td>54,050</td>
</tr>
<tr>
<td>Gibbs Geo &amp; Bennett Wm A</td>
<td>333,927</td>
</tr>
<tr>
<td>Gilbert Augusta Estate</td>
<td>301,743</td>
</tr>
<tr>
<td>Gilder CH Estate</td>
<td>13,307</td>
</tr>
<tr>
<td>Gillon AM Estate</td>
<td>2,516,795</td>
</tr>
<tr>
<td>Girdwood J Estate</td>
<td>198,333</td>
</tr>
<tr>
<td>Goldman Sachs</td>
<td>20,912</td>
</tr>
<tr>
<td>Gray Bessie Mavis Fund</td>
<td>20,912</td>
</tr>
<tr>
<td>Gray Clara Estate</td>
<td>60,063</td>
</tr>
<tr>
<td>Greig Harry Douglas Estate</td>
<td>419,583</td>
</tr>
</tbody>
</table>

Walter and Eliza Hall Institute
Annual Report 2011-2012
Supplementary Information
<table>
<thead>
<tr>
<th>Name of Estate</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grubb Walter Joseph Estate</td>
<td>31,048</td>
</tr>
<tr>
<td>Guest Doris Rose Estate</td>
<td>13,059</td>
</tr>
<tr>
<td>Hackett Dorothy Estate</td>
<td>5,376</td>
</tr>
<tr>
<td>Hadfield RCS Estate</td>
<td>94,721</td>
</tr>
<tr>
<td>Hadley AN Estate</td>
<td>945,011</td>
</tr>
<tr>
<td>Hamilton M Estate</td>
<td>37,814</td>
</tr>
<tr>
<td>Harrap FM Estate</td>
<td>111,912</td>
</tr>
<tr>
<td>Harrap LM Estate</td>
<td>24,132</td>
</tr>
<tr>
<td>*Harris Alan Scholarship Fund</td>
<td>38,894</td>
</tr>
<tr>
<td>Harris John D &amp; Lyla Foundation</td>
<td>709,948</td>
</tr>
<tr>
<td>Hartlett K Estate</td>
<td>815,853</td>
</tr>
<tr>
<td>Haydon Michael JM Memorial Fund</td>
<td>49,917</td>
</tr>
<tr>
<td>Hearse JD</td>
<td>992,693</td>
</tr>
<tr>
<td>Hemphill Olive May Estate</td>
<td>54,974</td>
</tr>
<tr>
<td>Henderson AN Estate</td>
<td>20,962</td>
</tr>
<tr>
<td>Henderson Joan Estate</td>
<td>107,139</td>
</tr>
<tr>
<td>Henry MA Estate</td>
<td>526,816</td>
</tr>
<tr>
<td>Heron Thelma Hope Estate</td>
<td>78,197</td>
</tr>
<tr>
<td>Highton GAN Estate</td>
<td>449,424</td>
</tr>
<tr>
<td>Hill Ramon Bruce Estate</td>
<td>126,543</td>
</tr>
<tr>
<td>Hind Ruby F Estate</td>
<td>27,298</td>
</tr>
<tr>
<td>Hocking Helen Estate</td>
<td>298,695</td>
</tr>
<tr>
<td>Holmes EM Estate</td>
<td>66,797</td>
</tr>
<tr>
<td>Hope Irene Estate</td>
<td>351,571</td>
</tr>
<tr>
<td>Hooper Nancy Hilda</td>
<td>92,834</td>
</tr>
<tr>
<td>Hosier MM Estate</td>
<td>125,319</td>
</tr>
<tr>
<td>Hurry M Estate</td>
<td>25,358</td>
</tr>
<tr>
<td>Inglis Dulcie M Estate</td>
<td>93,834</td>
</tr>
<tr>
<td>Ironside WH Estate</td>
<td>55,354</td>
</tr>
<tr>
<td>Jackson Catherine M Estate</td>
<td>159,850</td>
</tr>
<tr>
<td>Johnson Daphne Adele Estate</td>
<td>6,517</td>
</tr>
<tr>
<td>Johnson Ethel Grace Estate</td>
<td>37,907</td>
</tr>
<tr>
<td>Johnson Sydney Robert Estate</td>
<td>43,247</td>
</tr>
<tr>
<td>Johnstone Reginald Ben Estate</td>
<td>11,542</td>
</tr>
<tr>
<td>Judd Anita Estate</td>
<td>49,891</td>
</tr>
<tr>
<td>Kayler-Thomson Marion Estate</td>
<td>43,201</td>
</tr>
<tr>
<td>Keating L Estate</td>
<td>1,125,422</td>
</tr>
<tr>
<td>Keats LCA Estate</td>
<td>1,064,186</td>
</tr>
<tr>
<td>Kallock TH Estate</td>
<td>1,499,737</td>
</tr>
<tr>
<td>Kendall Nanyce Douglas</td>
<td>39,131</td>
</tr>
<tr>
<td>Kerr HM Estate</td>
<td>90,071</td>
</tr>
<tr>
<td>King DM Estate</td>
<td>34,343</td>
</tr>
<tr>
<td>Knight FF Estate</td>
<td>25,074</td>
</tr>
<tr>
<td>Lang John Murray Estate</td>
<td>616,415</td>
</tr>
<tr>
<td>Lantéri Gwen Estate</td>
<td>1,281,044</td>
</tr>
<tr>
<td>Larard DV Estate</td>
<td>10,659</td>
</tr>
<tr>
<td>Leckie Winifred Estate</td>
<td>179,917</td>
</tr>
<tr>
<td>Liford VM Estate</td>
<td>394,565</td>
</tr>
<tr>
<td>Lins RD Estate</td>
<td>22,142</td>
</tr>
<tr>
<td>Little Mabel B Estate</td>
<td>54,012</td>
</tr>
<tr>
<td>Lyddon Pauline M Estate</td>
<td>993,084</td>
</tr>
<tr>
<td>Lyell Alexia Bequest</td>
<td>359,590</td>
</tr>
<tr>
<td>MacAekill WG &amp; I</td>
<td>22,142</td>
</tr>
<tr>
<td>Mace Nina May Estate</td>
<td>239,425</td>
</tr>
<tr>
<td>MacDonald Elsie May Estate</td>
<td>149,383</td>
</tr>
<tr>
<td>Macindoe Jock &amp; Diana Fund</td>
<td>33,213</td>
</tr>
<tr>
<td>Macintosh Elizabeth H Estate</td>
<td>19,946</td>
</tr>
<tr>
<td>Mackie-Smith CM Estate</td>
<td>303,399</td>
</tr>
<tr>
<td>Macleay The Lillian &amp; Kenneth Bequest</td>
<td>347,690</td>
</tr>
<tr>
<td>Mahoney Florence Cancer Fund</td>
<td>139,917</td>
</tr>
<tr>
<td>Malcolm Phyllis Elizabeth Estate</td>
<td>224,212</td>
</tr>
<tr>
<td>Maloney Kathleen Margaret Estate</td>
<td>18,454</td>
</tr>
<tr>
<td>*Mann David Memorial Research Fund</td>
<td>20,000</td>
</tr>
<tr>
<td>Mansfield Trevor Geoffrey Estate</td>
<td>8,242</td>
</tr>
<tr>
<td>Marguccio R Estate</td>
<td>11,071</td>
</tr>
<tr>
<td>Mariner Barry Leonard Estate</td>
<td>51,154</td>
</tr>
<tr>
<td>McArthur Nellie M Estate</td>
<td>88,061</td>
</tr>
<tr>
<td>McCooke Miss MH Estate</td>
<td>278,115</td>
</tr>
<tr>
<td>McDonald Charles Thomas</td>
<td>15,093</td>
</tr>
<tr>
<td>McDouall Phyllis Mable Estate</td>
<td>104,646</td>
</tr>
<tr>
<td>McGhee ME Estate</td>
<td>60,282</td>
</tr>
<tr>
<td>McGregor Amy VK Estate</td>
<td>101,940</td>
</tr>
<tr>
<td>McGregor Elvira Ruth Estate</td>
<td>18,784</td>
</tr>
<tr>
<td>McGregor KB Estate</td>
<td>147,384</td>
</tr>
<tr>
<td>McKinnon Sheila May Estate</td>
<td>37,166</td>
</tr>
<tr>
<td>McLean Ada Myee</td>
<td>4,105</td>
</tr>
<tr>
<td>Dutton Estate</td>
<td>316,941</td>
</tr>
<tr>
<td>McNab M Estate</td>
<td>4,737</td>
</tr>
<tr>
<td>McNeill Sir James Fund</td>
<td>17,220</td>
</tr>
<tr>
<td>McRorie Ruby A Estate</td>
<td>64,744</td>
</tr>
<tr>
<td>Menagh Thelma Marie Estate</td>
<td>15,065</td>
</tr>
<tr>
<td>Miller Lorna May Estate</td>
<td>722,527</td>
</tr>
<tr>
<td>Miller MA Estate</td>
<td>51,817</td>
</tr>
<tr>
<td>Miller Violet Isabella Estate</td>
<td>60,301</td>
</tr>
<tr>
<td>Minney DW &amp; NR Fund</td>
<td>11,071</td>
</tr>
<tr>
<td>Mitchell, Bettye Victoria Fund</td>
<td>3,633,135</td>
</tr>
<tr>
<td>Mitchell Doris Georgina Mildred</td>
<td>55,354</td>
</tr>
<tr>
<td>Mitchell G Fund</td>
<td>42,907</td>
</tr>
<tr>
<td>Modern FHW Estate</td>
<td>106,705</td>
</tr>
<tr>
<td>Moody E Vaughan Estate</td>
<td>1,057,635</td>
</tr>
<tr>
<td>Moon Ida Alice Estate</td>
<td>41,802</td>
</tr>
<tr>
<td>Mooney Carmel Mary, Estate of</td>
<td>139,135</td>
</tr>
<tr>
<td>Moore Phyllis Estate</td>
<td>11,071</td>
</tr>
<tr>
<td>Morgan DM Estate</td>
<td>326,472</td>
</tr>
<tr>
<td>Morris Foundation of Medical Research</td>
<td>139,931</td>
</tr>
<tr>
<td>Moss EE Estate</td>
<td>213,568</td>
</tr>
<tr>
<td>Muller FG Estate</td>
<td>15,807</td>
</tr>
<tr>
<td>Murray Alan Ambrose Estate</td>
<td>28,459</td>
</tr>
<tr>
<td>Murray Gwendoline Mary Fund</td>
<td>987,209</td>
</tr>
<tr>
<td>Must Mary Kathleen Bequest</td>
<td>865,189</td>
</tr>
<tr>
<td>Myer Dame Merlyn Estate</td>
<td>11,926</td>
</tr>
<tr>
<td>Myer Pam Sallmann Foundation</td>
<td>24,143</td>
</tr>
<tr>
<td>Nevill Melanie Joy</td>
<td>66,551</td>
</tr>
<tr>
<td>Newton Evelyn</td>
<td>15,470</td>
</tr>
<tr>
<td>Newton EM Estate</td>
<td>15,038</td>
</tr>
<tr>
<td>Nicholas Harold George Estate</td>
<td>264,006</td>
</tr>
<tr>
<td>Norins Leslie Fund</td>
<td>225,505</td>
</tr>
<tr>
<td>Norton M Estate</td>
<td>700,381</td>
</tr>
<tr>
<td>*Nossal Sir Gustav Fund</td>
<td>241,563</td>
</tr>
<tr>
<td>Nottingham SG Estate</td>
<td>28,633</td>
</tr>
<tr>
<td>Palmer DE Estate</td>
<td>21,609</td>
</tr>
<tr>
<td>Palmer Ethel Fund</td>
<td>260,206</td>
</tr>
<tr>
<td>Parker Barbara Memorial Fund</td>
<td>59,310</td>
</tr>
<tr>
<td>Parker Mabel V Estate</td>
<td>66,815</td>
</tr>
<tr>
<td>Parsons Kathleen FB Estate</td>
<td>33,827</td>
</tr>
<tr>
<td>Patten Ralph &amp; Etty Bequest</td>
<td>251,688</td>
</tr>
<tr>
<td>Patterson Gerard A Estate</td>
<td>15,817</td>
</tr>
<tr>
<td>Paulin Leukaemia Fund</td>
<td>182,506</td>
</tr>
<tr>
<td>Paulin SC Estate</td>
<td>22,921</td>
</tr>
<tr>
<td>Payne Henry and Charlotte Fund</td>
<td>788,802</td>
</tr>
<tr>
<td>Peterson Vera Estate</td>
<td>472,808</td>
</tr>
<tr>
<td>Petley Francis Estate</td>
<td>125,599</td>
</tr>
<tr>
<td>Pierce John Lindsay Estate</td>
<td>1,008,690</td>
</tr>
<tr>
<td>Petsch Dr CH Fund</td>
<td>168,310</td>
</tr>
<tr>
<td>Porter Florence JA Estate</td>
<td>108,154</td>
</tr>
<tr>
<td>Prater Mabel Edward</td>
<td>11,479</td>
</tr>
<tr>
<td>Pritchard DG Estate</td>
<td>28,415</td>
</tr>
<tr>
<td>Pyke MA Estate</td>
<td>13,285</td>
</tr>
<tr>
<td>*Quattrough Research Fund</td>
<td>2,000,000</td>
</tr>
<tr>
<td>Rae Olive Estate</td>
<td>924,480</td>
</tr>
<tr>
<td>Reeves Jessie Estate</td>
<td>51,911</td>
</tr>
<tr>
<td>Reid Charitable Trusts</td>
<td>5,256,194</td>
</tr>
<tr>
<td>Reiser Erwin Estate</td>
<td>22,142</td>
</tr>
<tr>
<td>Richardson DLK Estate</td>
<td>70,797</td>
</tr>
<tr>
<td>Ricker EM Fund</td>
<td>63,700</td>
</tr>
<tr>
<td>Roberts JI Charitable Fund</td>
<td>6,753</td>
</tr>
<tr>
<td>Robertson AT Estate</td>
<td>11,071</td>
</tr>
<tr>
<td>Rose Norma J Estate</td>
<td>11,192</td>
</tr>
<tr>
<td>Ruppel FE Estate</td>
<td>128,332</td>
</tr>
<tr>
<td>Salemann CW Estate</td>
<td>11,071</td>
</tr>
<tr>
<td>Sallmann L &amp; E Memorial Fund</td>
<td>21,609</td>
</tr>
<tr>
<td>Santos TS Estate</td>
<td>716,970</td>
</tr>
<tr>
<td>Schack Elsie Edith Estate</td>
<td>104,766</td>
</tr>
<tr>
<td>Scott Annie May Estate</td>
<td>136,551</td>
</tr>
<tr>
<td>Sharp II Estate</td>
<td>17,403</td>
</tr>
<tr>
<td>Shaw Eileen Coryn Estate</td>
<td>19,386</td>
</tr>
<tr>
<td>Shelton Edgar Estate</td>
<td>679,526</td>
</tr>
<tr>
<td>*Sidwell OB Estate</td>
<td>1,596,984</td>
</tr>
<tr>
<td>Skinner Phyllis Maye Estate</td>
<td>70,180</td>
</tr>
</tbody>
</table>
### Leadership Fund

The Leadership Fund was established in honour of Professors Gustav Nossal, Donald Metcalf and Jacques Miller to provide named Fellowships to nurture the development of outstanding young scientists with the potential to be future leaders of biomedical research.

The Leadership Fund at 30 June 2012 included the following permanent funds ($10,000 and over):

- Sir Harold Dew and Family Estate 3,855,317
- Chugai Pharmaceutical Co Ltd 802,473
- The Ian Potter Foundation 802,473
- L M Archibald Estate 534,982
- Albert H Maggs Charitable Trust 523,296
- Helen Macpherson Smith Trust 320,989
- Anonymous 267,491
- Anonymous 267,491
- E Vaughan Moody Estate 267,491
- The Broken Hill Proprietary Company Limited 267,491
- J B Were & Son Charitable Fund 267,491
- Eunice L Lambert Estate 263,134
- Betty Eunice Stephens Estate 180,154
- National Australia Bank 160,495
- Victor Smorgon Charitable Fund 117,696
- The Sidney Myer Fund 96,297
- Leslie D W Stewart Estate 78,730
- Joe White Bequest 72,758
- Krongold Foundation Pty Limited 53,498
- Professor Sir Gustav Nossal 53,498
- The Scobie and Claire Mackinnon Trust 53,498
- The R & J Law-Smith Gift 32,099
- National Mutual Holdings Limited 32,099
- Pacific Dunlop Ltd 32,099
- Sheila R White Estate 31,650
- Coles Myer Ltd 26,749
- James Kirby Foundation 26,749
- Arthur Andersen & Co Foundation 21,399
- Arthur Robinson & Hedderwicks 21,399
- H B Kay Estate 10,700
- Stephelle Pty Ltd 10,700
- C M Walter 10,700

### Fellowship and Scholarship Funds

<table>
<thead>
<tr>
<th>Fund Name</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoa Australia Fellowship</td>
<td>446,954</td>
</tr>
<tr>
<td>Carty EM</td>
<td>274,400</td>
</tr>
<tr>
<td>Mackay Dr Ian Fellowship Fund</td>
<td>219,709</td>
</tr>
<tr>
<td>Mathison G C Research Scholarship</td>
<td>137,018</td>
</tr>
<tr>
<td>Moffatt Edith Scholarship Fund</td>
<td>1,615,909</td>
</tr>
<tr>
<td>*JHA Munro Foundation</td>
<td>586,806</td>
</tr>
<tr>
<td>*Paddy Pearl Fund</td>
<td>919,956</td>
</tr>
<tr>
<td>Skea Lyndal and Jean Leukaemia Fund</td>
<td>769,909</td>
</tr>
<tr>
<td>Syne Colin Fellowship Fund</td>
<td>1,626,028</td>
</tr>
<tr>
<td>Wilson Ed Memorial Fellowship</td>
<td>1,434,817</td>
</tr>
</tbody>
</table>

### Other Funds

- *Anonymous Seminar Award 12,890
- Gideon Goldstein Fund 891,212
- Mckay C N Fund 218,269

The following Estates in which the institute had an interest, were managed during the year by Trustees. (Income received by the institute in the financial year is treated similarly to donations and bequests):

- The Baldry Trust Fund
- CH Boden Memorial Trust
- John Frederick Bransden Memorial Fund
- Frank Broadhurst Estate
- Thomas, Annie & Doris Burgess Charity Trust
- George Colle Estate
- Miss EM Drummond Estate
- Frederick and Winifred Grassick Memorial Fund
- The Helpman Family Foundation
- The Mackie Bequest
- Ireland and Ronald MacDonald Foundation
- Albert H Maggs Charitable Trust
- Mrs AM Reilly
- Miss ML Reilly
- The Stang Bequest
- Emily Vera Winder Estate
- Florence Mary Young Charitable Trust

### Financial statements

#### thrift

- **Supplementary information**
A gift in your will to medical research

Medical research is vital to improving healthcare and quality of life.

Researchers at the Walter and Eliza Hall Institute of Medical Research have made many discoveries that have improved health outcomes for millions of people.

A gift in your will to the Walter and Eliza Hall Institute is a lasting gift that will support our research efforts to improve human health with better prevention, detection and treatment of disease.

For a confidential discussion, please contact our Community Relations department by emailing donationenquiries@wehi.edu.au or calling 03 9345 2555.

Do you want to help the fight against disease?

Volunteers needed to donate blood for research

The Volunteer Blood Donor Registry collects a small amount of blood from healthy volunteers for use in research into diseases such as cancer, inflammatory and blood diseases, infectious diseases, heart and vascular disease, and brain diseases.

If you are aged between 18 and 80 you can contribute to research to help us better understand these diseases.

All information will be treated with strict confidentiality.

Please contact the Volunteer Blood Donor Registry for more information:

Dr Lina Laskos or Ms Naomi Sprigg
P: (03) 9345 2304 or (03) 9342 3174
E: info@blooddonorregistry.org
A: Walter and Eliza Hall Institute, 1G Royal Parade, Parkville VIC 3052
W: blooddonorregistry.org